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Thesis 
 
 
Primary Hypothesis 
A randomised controlled trial of sertraline versus placebo, to treat Major Depressive 
Disorder in patients on haemodialysis, is feasible. 
 
Secondary Objectives 
To determine data in relation to the following factors to facilitate the design of a 
definitive randomised controlled trial of antidepressant medication in patients on 
haemodialysis with Major Depressive Disorder: 
• The prevalence of depression symptoms and Major Depressive Disorder in 
patients on haemodialysis 
• The relationships between depression and fatigue in haemodialysis patients 
• Current practice patterns in the use of antidepressant medication in 
haemodialysis patients 
 
        Ayman Guirguis (2017) 
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Abstract 
Depression is common in haemodialysis (HD) patients and is often unrecognised and 
undertreated, though associated with excess morbidity and mortality. Diagnosis is 
challenging due to symptom overlap with kidney failure, with fatigue being the most 
common overlapping symptom. Research on the effectiveness of antidepressant 
medication in this setting is sparse. A recent systematic review advocated well-
designed Randomised Controlled Trials (RCTs) in this setting. 
The studies reported in this thesis had a number of aims. The main aim was to 
undertake a multicentre feasibility randomised, double blind, placebo-controlled trial 
of sertraline in patients on HD with Major Depressive Disorder (MDD). To identify 
suitable patients for this, a screening phase was required, which also allowed 
determination of the prevalence of depression in this setting and of the relative 
effectiveness of screening tools Patient Health Questionnaire-2 (PHQ-2), Patient 
Health Questionnaire-9 (PHQ-9), and Beck Depression Inventory-II (BDI-II). It also 
allowed examination of the relationships of fatigue in this setting (assessed mainly 
by the Multidimensional Fatigue Inventory (MFI), including those with a diagnosis, 
and management of depression. The finding, during screening, that a large proportion 
of the HD cohort was already on antidepressant treatment, presented the opportunity 
to study ‘real-life’ practice patterns in the management of antidepressant treatment in 
this setting. 
Recruitment into the RCT was difficult. 1,355 patients in five HD centres were 
considered for screening, but 243 of these were excluded, mainly because of their 
inability to read and understand English. Of the remaining 1,110 patients, 709 
consented to screening. 231 of these screened positive for high depression symptoms 
but 130 were not considered for the trial phase, mainly because of concurrent 
treatment for depression (68 patients), and other contraindicated conditions and 
medication. In addition, 38 patients declined to take part in the psychiatric interview 
necessary for diagnosis of MDD.  
Of the 63 who underwent the diagnostic interview, 37 (58.7%) were diagnosed with 
MDD and 30 consented to enter the RCT and were randomised into sertraline or 
placebo groups. This was half of the anticipated recruitment into the RCT. Twenty-
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one patients (70%) completed the six-month study, eight of 15 in the sertraline group 
and 13 of 15 in the placebo group (p<0.05). Drop out was mainly due to adverse or 
serious adverse events. Depression scores (BDI-II and Montgomery-Åsberg 
Depression Rating Scale (MADRS)) improved significantly in both the sertraline and 
placebo groups over six months but there were no significant differences between the 
treatment groups. There was a slight suggestion of more rapid improvement over the 
first two months on sertraline, but this was not significant.  
Fatigue scores were high in all sub-domains – with only a weak relationship with age 
and comorbidity. Mental fatigue was the strongest independent predictor of high 
depressive symptoms (BDI-II ≥16, PHQ-9 ≥8), while physical fatigue had the 
strongest relationship with dialysis recovery time, and survival. Distinguishing 
between these components of fatigue may have a role in refining the diagnosis and 
management of MDD.  
Forty-one of the 76 patients on antidepressant medication at screening were followed 
up for a mean of 14±5 months. Ten different antidepressant agents were being taken 
– the most common being Citalopram (39%). Most had been prescribed by GPs. 
Two-thirds of patients either deteriorated or failed to improve in terms of BDI-II 
scores during follow-up, many of whom had had no adjustment of medication during 
this time. Diagnostic evaluation at follow-up showed 37% to be suffering from 
current or recurrent major depressive episodes (MDE), 48% to have evidence of past 
MDE, and 15% to have no evidence of ever having been depressed.  
These empirical studies confirm that depression is very common in HD patients. Its 
diagnosis is complicated due to symptom overlap with the uraemic syndrome. 
Fatigue seems to be a key area of overlap with symptoms of depression with a 
complex relationship. There was no obvious benefit from antidepressants in this 
feasibility RCT and there was a high drop-out rate due to adverse events, particularly 
in the sertraline group. These findings raise concerns about the benefits and risks of 
antidepressants in patients on HD. Current practice patterns may be subjecting 
patients to substantial risk for little or no benefit. Identifying whether antidepressant 
medication is effective in this context is a major clinical need, hence the requirement 
for a definitive study. There is no doubt that to undertake a definitive study would 
pose considerable recruitment challenges. The findings presented here emphasise the 
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importance of finding ways to overcome these challenges that might include efforts 
to incorporate patients already taking antidepressants. 
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Thesis Structure and Prelude 
In order to defend the thesis offered here the following work are organised into four 
main sections. First, introductory chapters describe 1- the nature, consequences and 
treatment of kidney failure. 2- an overview of depression- in the general population; 
in patients with End Stage Renal Disease, including its prevalence, complications 
and the challenges involved in the diagnosis of Major Depressive Disorder in this 
setting due to the overlapping symptoms of depression and the uraemic syndrome. 3- 
a review of fatigue in particular in End Stage Renal Disease including its 
measurement and its overlap with depression symptoms.  Following this, the second 
section is presented and concerns the consideration of the applied methodology. This 
includes the measurement of depression symptoms by the Beck Depression 
Inventory -II and the Patient Health Questionnaire 9, and fatigue by the Multi-
Dimensional Fatigue Inventory and Short Form 36(SF-36) energy/fatigue subscale. 
The Mini-International Neuropsychiatric Interview (MINI) version 6.0 is also 
described including the Folstein Mini Mental Status Examination as a means of 
making a formal Diagnostic and Statistical Manual of Mental Disorders, Fourth 
Edition (DSM-IV) diagnosis of major depressive disorder. The Montgomery-Asberg 
Depression Scale (MADRS) is described as a measure of the severity of depressive 
episodes in patients with mood disorders and is more sensitive to the changes 
brought on by antidepressant treatment. The third empirical section concerns a series 
of studies covering depression and fatigue in haemodialysis patients. These include a 
screening study to identify patients with high depressive symptoms and fatigue 
scores, a feasibly randomised controlled trial in patients diagnosed with depression 
and treated with either sertraline or placebo for 6 months, and a study of practice 
patterns on the use of antidepressants in haemodialysis patients. At the end of each of 
these studies there is an independent discussion highlighting the major findings. The 
fourth and final section presents an overarching discussion and the recommendations 
of the thesis. 
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Chapter 1 
The Kidney 
The kidneys are the waste filtering and disposal system of the body. Up to one-third 
of all blood leaving the heart passes into the kidneys to be filtered before flowing to 
the rest of the body’s tissues. A person can live with only one functioning kidney but 
loss of both kidneys leads to rapid accumulation of wastes and death within a few 
days. The paired organs lie retro-peritoneally along the posterior muscular wall of the 
abdominal cavity. Each contains around 1 million individual nephrons, the 
microscopic functional units that filter blood, to produce urine. Each nephron is 
made of two main parts: the glomerulus, which filters the blood, and the tubule, 
which is responsible for modification of the composition of the filtrate according to 
bodily needs.  
 
1.1 Function of the Kidney 
The main functions of the kidney are summarised in Table 1. 
Table 1: Main kidney functions 
Function of the kidney 
Excretion of waste products Electrolyte homeostasis  
Water homeostasis Blood pressure homeostasis 
Acid/base homeostasis Hormone production 
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1.1.2 Excretion of Waste Products 
The primary function of the kidneys is the excretion of waste products, including 
those resulting from metabolic activity, protein metabolism, and bacterial action in 
the intestine. Many of these products are toxic to the body if they accumulate 
because of kidney failure. These ‘uraemic toxins’ (Table 2) can be classified into 
three main groups: 
 Small water-soluble molecules: often the product of metabolic activity, e.g. 
urea, creatinine, and uric acid 
 Middle molecules: often low molecular weight proteins, some with structural 
functions, e.g. beta-2-microglobulin 
 Protein bound compounds: some of which are produced in the intestine, e.g. 
p-cresol 
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Table 2: Uraemic toxins (3)  
Small water-soluble solutes Middle molecules Protein-bound solutes  
Asymmetric 
dimethylarginine 
Degranulation-inhibiting     
protein I 
3-Deoxyglucosone 
Benzylalcohol Atrial natriuretic peptide CMPF 
-Guanidinopropionic acid 2-Microglobulin Fructoselysine 
-Lipotropin -Endorphin Glyoxal 
Creatinine Cholecystokinin Hippuric acid 
Cytidine Clara cell protein Homocysteine 
Guanidine Complement factor D Hydroquinone 
Guanidinoacetic acid Cystatin C Indole-3-acetic acid 
Guanidinosuccinic acid Adrenomedullin Indoxyl sulfate 
Hypoxanthine Delta-sleep-inducing peptide Kinurenine 
Malondialdehyde Endothelin Kynurenic acid 
Methylguanidine Hyaluronic acid Methylglyoxal 
Myoinositol Interleukin 1  N-carboxymethyllysine 
Orotic acid Interleukin 6 P-cresol 
Orotidine Kappa-Ig light chain Pentosidine 
Oxalate Lambda-Ig light chain Phenol 
Pseudouridine Leptin P-OHhippuric acid 
Symmetric dimethylarginine Methionine-enkepahlin Quinolinic acid 
Urea Neuropeptide Y Spermidine 
Uric acid Parathyroid hormone Spermine 
Xanthine Retinol binding protein  
  Tumournecrosis factor alpha  
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The glomerulus filters small and middle molecule solutes, allowing excretion in the 
urine. The composition of the filtrate is further modified by tubular absorption or 
secretion. For instance, urea reabsorption by the tubules has a role in the medullary 
counter-current system, which is important in urinary concentration mechanisms. 
Low molecular weight proteins in the filtrate, e.g. beta-2-microglobulin, are 
catabolised by tubular cells and the constituent amino acids are reabsorbed. Protein-
bound solutes are poorly filtered and tubular secretion may be an important route of 
elimination.  
 
1.1.3 Fluid Haemostasis 
The kidneys are able to control the fluid volume of the body by varying the tubular 
handling of salt and water according to bodily needs. In healthy individuals, around 
180 litres of fluid are filtered daily and all but around 2 litres are reabsorbed, mostly 
in association with sodium (Na
+
) and chloride (Cl
-
), passively, in the proximal 
tubule, and distally, regulated by aldosterone. Atrial natriuretic peptide (ANP) may 
also have a role in increasing the excretion of Na
+
 and Cl
-
 ions in response to fluid 
overload. 
When the body is relatively water-depleted, plasma osmolality is increased, 
triggering an increase in antidiuretic hormone (ADH) release from the posterior 
pituitary gland. ADH stimulates the formation of water channel proteins in the 
collecting ducts of the nephrons, thus permitting water to pass from urine into the 
tubule cells and on into the blood. In states of water-excess, ADH secretion is 
suppressed, allowing excretion of the excess water. 
  
1.1.4 Acid/Base Haemostasis 
The kidneys regulate the pH of the blood by controlling the excretion of hydrogen 
ions (H
+
) and bicarbonate ions (HCO3
-
). Hydrogen ions accumulate when proteins 
are metabolised in the liver and when carbon dioxide in the blood reacts with water 
to form carbonic acid (H2CO3), a weak acid that partially dissociates in water to form 
hydrogen ions and bicarbonate ions. Both ions are filtered by the glomerulus but 
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HCO3
- 
undergoes tubular reabsorption, unlike H
+
, which is excreted. The tubule cells 
may also actively secrete H
+
 during acidosis. Reabsorbed HCO3
-
 can neutralise H
+ 
to 
form carbonic acid, which in the capillaries of the lungs dissociates into carbon 
dioxide and water, allowing carbon dioxide to be exhaled. 
 
1.1.5 Electrolyte Homeostasis 
The kidneys maintain the homeostasis of important electrolytes by controlling their 
urinary excretion. 
 Sodium (Na+): Sodium is vital for the regulation of extracellular volume and 
pressure and for normal neuromuscular function. Over 99% of filtered Na
+
 is 
reabsorbed. Mechanisms are briefly discussed above in section 1.1.3. 
 Potassium (K
+
): Potassium is the main intracellular cation and is vital for 
neuromuscular function. Unlike sodium, only about 60% to 80% of filtered K
+ 
is 
reabsorbed. Most K
+
 reabsorption occurs in the proximal tubule and ascending 
loop of Henle. 
 Chloride (Cl
-
): Chloride is the most prevalent anion in the body. Chloride is vital 
for the regulation of factors such as pH and extracellular fluid balance and helps 
to establish the electrical potential of neurons and muscle cells. The proximal 
tubule and ascending loop of Henle reabsorb about 90% of filtered Cl
-
. 
 Calcium (Ca
2+
): Calcium is an important structural element in bones and teeth, 
and is also essential for the contraction of muscle tissue, the release of 
neurotransmitters by neurons, and the stimulation of cardiac muscle tissue in the 
heart. The proximal convoluted tubule and the ascending loop of Henle reabsorb 
most of the filtered Ca
2+
. Fine tuning takes place in the distal tubule, where 
parathyroid hormone (PTH) is an important regulator. 
 Magnesium (Mg
2+
): Magnesium is essential for the proper function of enzymes 
that work with phosphate compounds such as ATP, DNA and RNA. The 
proximal convoluted tubule and loop of Henle reabsorb most of the filtered Mg
2+
. 
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1.1.6 Blood Pressure Homeostasis 
The kidneys help to control blood pressure by regulating the volume of the 
extracellular fluid by the excretion of Na
+
 ions and water, as discussed above, and by 
producing the enzyme renin, part of the renin-angiotensin system (RAS), which has 
many important roles, including the regulation of vascular tone and control of 
aldosterone secretion.  
 
1.1.7 Hormone Production 
The kidneys maintain a small but important endocrine function by producing the 
hormones calcitriol and erythropoietin. 
 Calcitriol is the active form of vitamin D in the body. Proximal tubular cells 
produce calcitriol from 25 hydroxy vitamin D which is the major circulating 
form of vitamin D. Calcitriol has many actions, including increasing 
intestinal calcium absorption and suppressing parathyroid hormone secretion.  
 Erythropoietin (EPO) is produced by the cells of the peritubular capillaries 
in response to hypoxia. EPO stimulates the cells in the bone marrow to 
increase their output of red blood cells. 
Several hormones produced elsewhere in the body help to control the function of the 
kidneys. 
 Antidiuretic hormone (ADH), also known as vasopressin, is produced by the 
neuro-secretory cells in the hypothalamus. These cells extend into the posterior 
pituitary, which stores and releases ADH in response to a decrease in blood 
volume or increased blood osmolarity. ADH increases the number of water 
channels in collecting duct cells, allowing increased water reabsorption.  
 Angiotensin II is a hormone synthesised in the liver and activated by the 
enzyme renin and angiotensin-converting enzyme (ACE). Angiotensin II is 
highly vasoactive. It has important actions in the control of blood pressure, and 
it also increases the reabsorption of Na
+
 and Cl
-
 ions in the proximal tubule. 
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 Aldosterone is produced in the adrenal cortex in response to Angiotensin II. 
Aldosterone acts on the cells of the collecting ducts, promoting Na+ 
reabsorption and K+ excretion. 
 Atrial natriuretic peptide (ANP) is produced by cardiac muscle cells in the 
atria, in response to volume overload. ANP increases the glomerular filtration 
rate and promotes renal salt and water excretion by interfering with counter 
current exchange. 
 
1.2 Kidney Disease 
1.2.1 Acute Kidney Injury 
Acute kidney injury (AKI), previously called acute renal failure (ARF), usually with 
fairly rapid loss of renal function and potentially reversible, is generally 
characterised by oliguria (< 400 ml per day in adults) and fluid and electrolyte 
imbalance. AKI can result from a variety of causes, which are generally classified as: 
1) pre-renal – usually associated with hypotension due to blood loss or dehydration; 
2) intrinsic – due to direct damage to the kidney, e.g. rapidly progressive 
glomerulonephritis; or 3) acute interstitial nephritis, and post-renal due to obstruction 
of urine outflow at any level. The underlying cause must be identified and treated to 
arrest the progress. Dialysis may be necessary to bridge the time gap between renal 
injury and recovery. Acute kidney injury can be present on top of chronic kidney 
disease, a condition called acute-on-chronic renal failure. The acute part of acute-on-
chronic renal failure may be reversible. Like AKI, acute-on-chronic renal failure can 
be difficult to distinguish from chronic kidney disease in the absence of a typical 
history and/or previous chemistry.  
 
1.2.2 Chronic Kidney Disease 
Chronic kidney disease (CKD) implies irreversible loss of kidney function, which 
usually occurs over a period of months or years. Symptoms of worsening kidney 
function tend to occur in the later stages and are non-specific, e.g. feeling generally 
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unwell and experiencing a reduced appetite. CKD is often diagnosed on screening 
people known to be at risk of kidney problems, such as those with high blood 
pressure, diabetes, or those with a family history of the condition. CKD may also be 
identified when it leads to one of its recognised complications, such as hypertension, 
cardiovascular disease, or anaemia. 
 
1.2.2.1 Aetiology 
The aetiology of CKD is varied. In the UK, as in many developed countries, diabetic 
nephropathy is the most prevalent primary renal disease in patients with advanced 
kidney disease (Table 3). 
 
Table 3: Primary renal disease in incident renal replacement therapy patients, 
(1) 
Percentage with Co-morbid Diagnosis in Renal Replacement Therapy Patients 
   
Diagnosis                                        Age <65                                    Age≥65                         All patients 
Diabetes 28.6 22.3 25.6 
Glomerulonephritis 17.3 10.4 14.0 
Pyelonephritis 6.8 6.4 6.6 
Hypertension 6.2 8.8 7.4 
Polycystic kidney 10.1 3.1 6.7 
Renal vascular disease 1.7 10.9 6.1 
Other 17.4 18.0 17.7 
Uncertain aetiology                                             11.8 20.1 15.9 
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1.2.2.2 Stages of CKD 
Stages of chronic kidney disease are shown in Table 4, in which eGFR was estimated 
from serum creatinine measurements using the Modification of Diet in Renal Disease 
(MDRD) study equation (4). Individuals with an estimated glomerular filtration rate 
(eGFR) <60 mL/min/1.73 m
2
 for three months are classified by Kidney Disease 
Outcomes Quality Initiative (K/DOQL) as having moderate to severe CKD (Stages 
3-5). Individuals with evidence of kidney disease (e.g. proteinuria, abnormal renal 
imaging) and higher levels of eGFR are classified as having CKD (Stages 1 or 2) (5). 
 
Table 4: The K/DOQI stages of chronic kidney disease (5) 
 
Stage 
 
Description 
Estimated Glomerular 
Filtration Rate 
(mL/min/1.73m
2
 BSA) 
1 Kidney damage, normal or increased eGFR ≥ 90 
2 Kidney damage, mildly reduced eGFR 60-89 
3 Moderately reduced eGFR 30-59 
4 Severely reduced eGFR 15-29 
5 Kidney failure / Advanced chronic kidney disease <15 (or dialysis) 
 
1.3 End-stage Renal Disease (ESRD) 
End-stage renal disease (ESRD) refers to the state of reduced kidney function when 
the kidneys are unable to sustain life without some form of renal replacement therapy 
(RRT), i.e. Stage 5. 
1.3.1 Incidence of ESRD 
The UK Renal Registry (http://www.renalreg.com) collects standardised data on 
incidence, clinical outcomes, and management of patients with ESRD receiving renal 
replacement therapy from all UK renal services on a quarterly basis. UK Renal 
Registry data shows that 6,891 patients started renal replacement therapy in 2012 (2). 
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The incidence has increased over the last 20 or so years, with some levelling off 
more recently (Figure 1) (1). Incident rates are higher in males and peak in the eighth 
decade of life (Figure 2) (1). 
 
Figure 1: Incidence of RRT from 1990 to 2012, (1) 
 
 
 
 
 
 
 
 
 
 
Figure 2: Incidence rate of RRT by age and gender in 2012, (1) 
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1.3.2 Prevalence of ESRD 
There were 54,824 adult patients receiving RRT in the UK on 31 December 2012 
(UK Renal Registry (1)). Around half of these patients had a functioning transplant, 
with the remainder on dialysis – predominantly HD. There has been a significant 
increase in the RRT population over the last 20 years (Figure 3). There have also 
been significant demographic changes. The median age of prevalent RRT patients in 
2000 was 55 years compared to 58 years in 2012. The percentage of RRT patients 
aged greater than 70 years increased from 19.2% in 2000 to 24.9% in 2012. This 
reflects an aging general population as well as improved survival on RRT. The 
availability of transplantation and HD are continuing to increase, while that of 
peritoneal dialysis (PD) is declining (Figure 3). The reasons for these changes are 
complex. The growth in centre-based HD facilities from the early 1990s, improved 
understanding of the limitations of PD as a long-term therapy, the selection of 
younger and fitter patients with a better prognosis for transplantation, and the growth 
in living donor and pre-emptive (before dialysis) transplantation are important 
factors in understanding these changes. The increasing age has significant 
implications, with higher proportions of the HD population being frail and 
dependent. 
Figure 3: Growth in prevalent patients by treatment modality at the end of each 
year 1997–2012, (1) 
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1.3.3 Uraemic Syndrome   
The effects of impaired renal function are manifested in the clinical syndrome termed 
‘uraemia’. The term was introduced by Priorry and L’Heritier in 1940 and literally 
means ‘urine in blood’. Uraemia is the end result of the retention of all of the various 
substances that are normally excreted in urine. The term uraemia is used to describe a 
complex clinical syndrome that has many interrelated features.  
The syndrome is recognised as a composite problem, involving all of the body’s 
system and reflecting biochemical alterations in all aspects of the constitution of the 
internal environment. Uraemia is considered to be a consequence of the 
accumulation of metabolic end products with associated changes in water, 
electrolyte, acid-base homeostasis, disturbance in hormone and nutritional status, and 
abnormalities in the metabolism of fat, carbohydrates, and protein.  
The syndrome of uraemia resembles systemic poisoning. Many substances 
accumulate in uraemia and some of these substances have been established as 
playing an important role as toxins (Table 2). Many of these metabolites and 
substances appear to act as enzyme inhibitors, with possible cumulative effects.  
 
1.3.3.1 Implication of Uraemic Toxins 
Accumulated uraemic solutes are termed uraemic toxins if they are biologically 
active. The accumulation of uraemic toxins is associated with negative effects on 
almost every organ system, as outlined in Table 5.  
 Cardiovascular system: Heart disease accounts for more than 50% of deaths 
in uraemic patients (6, 7), and more than 60% of patients starting dialysis 
have echocardiographic manifestations, including left-ventricular 
hypertrophy (LVH), left-ventricular enlargement, and/or cardiac dysfunction 
(8). Risk factors in uraemic patients include bacteremia, extracellular fluid 
overload, and glycaemic load. This is in addition to anaemia, proteinuria, 
increases in levels of pro-inflammatory cytokines, oxidative stress, abnormal 
calcium and phosphate metabolism, and the accumulation of uraemic toxins, 
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as well as hypertension, diabetes, and dyslipidaemia as primary comorbidities 
(Figure 4). 
 Fluid and electrolyte imbalance: Salt and water retention are common in 
end-stage renal failure (ESRF) due to loss of excretory function. 
Hyperkalaemia and acidosis are similarly common manifestations of uraemia. 
Damaged kidneys are unable to excrete the 1mg/kg of acid generated by 
metabolism of dietary proteins. Bone buffering of the excess hydrogen ions 
contributes to renal osteodystrophy. 
 Musculoskeletal: Phosphate excretion is impaired in CKD. 
Hyperphosphataemia results in impaired renal activation of vitamin D3 and 
reduced circulating calcitriol levels, leading to reduced intestinal calcium 
absorption and hypocalcaemia. Loss of functioning of renal mass also results 
in reduced secretion of calcitriol. Hyperparathyroidism and bone disease can 
result in bone pain and fractures. Metastatic calcium phosphate deposition 
occurs especially in heart valves and blood vessels – increasing 
cardiovascular risk. Renal osteodystrophy typically presents with bony pain 
and proximal muscle weakness along with spontaneous fractures, which are 
slow to heal. It involves a number of entities, including hyperparathyroidism, 
osteomalacia, adynamic bone disease, osteoporosis, and ectopic calcification. 
It is due to disruption of the complex interplay of calcium, phosphate, vitamin 
D, PTH, and metabolic acidosis.  
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Figure 4: Complex pathogenesis of chronic kidney disease (CKD) and 
cardiovascular disease (CVD) (9) 
 
 
 Haematological: Anaemia is very common in ESRD; the primary cause is 
insufficient production of erythropoietin. Iron deficiency, B12 deficiency, 
haemolysis, short red blood cell life, and/or suppressed bone marrow may 
contribute. The most important effects of anaemia occur within the 
cardiovascular system and include LVH, exacerbation of heart failure, and a 
lowered threshold for angina. Other manifestations include decreased aerobic 
capacity, poor cognition, and diminished overall well-being. Uraemic patients 
have impaired platelet function so bleeding time is prolonged. Symptoms 
may be manifested as petechiae, purpura, and increased bruising. There is 
also an increased risk of bleeding. 
 Endocrine – Endocrine abnormalities include: hyperparathyroidism, and 
increased insulin resistance, which may lead to glucose intolerance. 
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Disturbances of thyroid function (‘sick euthyroidism’) and pituitary function 
may also occur. 
 Neurological: Peripheral neuropathy is very common and related to uraemic 
toxin retention, and, in patients with diabetes, to diabetic neuropathy. 
Disturbed cognitive function is common. Uraemic encephalopathy is a rare 
manifestation of severe uraemia. Symptoms include difficulty in 
concentrating, lethargy, confusion and, eventually, coma if left untreated. 
 Gastrointestinal: Metallic taste and loss of appetite are early symptoms of 
renal failure, and may be followed by nausea, vomiting, anorexia, and weight 
loss. Altered coagulation may lead to gastrointestinal bleeding, gastritis, and 
peptic ulcerations. Hiccups are common.  
 Skin: Uraemia causes pruritis and abnormal skin pigmentation. High plasma 
phosphate levels may exacerbate pruritis. Yellowish skin pigmentation, also 
known as uraemic hue, is noted in many patients. This colour change is a 
result of retained lipochromes and carotenoids. These manifestations are 
often relieved with dialysis and control of serum phosphate levels. 
Table 5 below summarise the manifestation of uraemia complications and 
symptoms, whether occurring directly from uraemia or secondarily from uraemic 
complications. 
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Table 5: Complications and symptoms of uraemic syndrome 
Complications of uraemia 
 
Anaemia Fluid overload Cardiac failure 
Hypertension Insulin resistance Hyperparathyroidism 
Coagulation disorder Osteodystrophy Immune dysfunction 
Inflammation                                      Coordination disorders Loss of strength 
Tremor Pericarditis Polyneuritis 
Vascular disease Skin atrophy  
 
Symptoms of uraemia 
 Loss of appetite 
 Nausea and vomiting 
 Fatigue 
 Weight loss 
 Itchy skin 
 Confusion 
 Trouble concentrating 
 Swelling throughout the body 
 Low urine output 
 Generalized weakness 
 Multiple bruises 
 Numbness and tingling in the extremities 
 Decreased desire for sexual activity 
 Menstrual irregularities 
 Constipation 
 Diarrhoea 
 Muscle cramps and twitches 
 Shortness of breath 
 Chest pain 
 Weak, brittle bones 
 Yellowish-brownish skin tone 
 Headache 
 Frequent hiccups 
 Irritability 
 
1.3.4 Comorbidities 
One of the consequences of the increasing age of the RRT population is their 
increasing comorbid burden, though the burden is high in younger patients too. It can 
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be seen from Table 6 that comorbidities in relation to diabetes and cardiovascular 
disease are particularly common. Smoking is not considered a comorbidity, though it 
contributes to many comorbidities, e.g. malignancy, angina, and chronic obstructive 
pulmonary disease (COPD). 
Table 6: Comorbidities in RRT patients in 2012 (1) 
Comorbidity                                                     Age <65                  Age ≥65                                                   
Overall prevalence                                       N             (%)            N         (%)        p value*       (%) 
 
Any comorbidity present 1,459 (41.6) 2,291 (64.0) <0.0001 52.9 
Angina                                                                                         194 (5.6) 536 (15.2) <0.0001 10.4 
MI in past 3 months                                      42 (1.2) 99 (2.8) <0.0001 2.0 
MI ˃3 months ago                                       208 (6.0) 467 (13.2) <0.0001 9.7 
CABG**/angioplasty                                       176 (5.1) 385 (10.9) <0.0001 8.0 
Cerebrovascular disease                            231 (6.7) 496 (14.0) <0.0001 10.4 
Diabetes (not listed as PRD***)           182 (5.2) 476 (13.5) <0.0001 9.4 
Diabetes listed as PRD                       1,008 (29.1) 765 (21.7) <0.0001 25.4 
COPD                                                    155 (4.5) 345 (9.8) < 0.0001 7.1 
Liver disease                                                     154 (4.4) 68 (1.9) <0.0001 3.2 
Claudication                              142 (4.1) 277 (7.9) <0.0001 6.0 
Ischaemic/ neuropathic ulcers                                           147 (4.2) 123 (3.5) <0.0989 3.9 
Angioplasty/vascular graft                                77 (2.2) 208 (5.9) <0.0001 4.1 
Amputation                                                          110 (3.2) 86 (2.4) <0.06 2.8 
Smoking                                                            516 (15.4) 431 (12.6) <0.0008 14.0 
Malignancy                                                       234 (6.8) 659 (18.6) <0.0001 12.7 
 
∗ p values from Chi-squared tests for differences between age groups in the percentage with the comorbidity 
** Coronary artery by-pass grafting (CABG) 
***Primary renal disease (PRD)  
Depression can also be considered as comorbidity or a consequence of the illness. 
Cognitive impairment is also common in patients with CKD (10)and may complicate 
the diagnosis of depression(11).   
1.4 Management of ESRD 
1.4.1 Diagnosis of ESRD and Dialysis Initiation 
The diagnosis of ESRD is based on the demonstration of severe kidney failure (CKD 
Stage 5) in blood tests and evidence of irreversibility (e.g. history of progressive 
decline in renal function, small kidneys on renal ultrasound, and occasionally renal 
biopsy findings). In general, these criteria are not by themselves an indication for 
dialysis initiation. In most cases the presence of symptoms attributable to uraemia is 
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the trigger to start dialysis (12). In suitable patients, transplantation can be carried out 
pre-emptively, where possible, before symptoms occur. 
1.4.2 Interface of Primary and Secondary Care 
Many patients with early CKD are cared for in primary care. Most kidney units 
provide local guidelines to primary care providers regarding referral of patients with 
CKD to secondary care. Many patients need input from multiple sources in addition 
to the nephrologist, e.g. cardiologist, diabetologists, and vascular surgeons. Clear 
communication between professionals is, therefore, crucially important to avoid 
problems such as duplicated investigations, failure to preserve peripheral vasculature 
for potential arteriovenous (AV) fistula, and potentially nephrotoxic investigations, 
e.g. as in contrast studies.   
 
1.4.3 Referral to Nephrologist 
Most patients (around 80% in the UK) start dialysis in a planned fashion (‘planned 
starters’), having been referred to a nephrologist when their glomerular filtration rate 
(GFR) was around 30 ml/min/1.73 m
2
, followed up over a period of time (usually 
many months or years) until a treatment decision was made. Critically, these patients 
have had time to adapt, seek support, and be educated (13, 14). However, renal 
disease can remain asymptomatic for some individuals until the disease is very 
advanced. Such patients are often termed (‘late presenters’). Other patients may have 
been seen in primary or secondary care with known kidney disease, yet for some 
reason referral to a nephrologist was delayed (‘late referral’). Individuals in both 
categories may present in need of urgent dialysis colloquially referred to as (‘crash 
landers’). In addition, some patients may have been referred and clinically assessed 
by a nephrologist, but go on to need dialysis far sooner than initially expected 
(‘failed planned’). Starting dialysis within 90 days of referral to a nephrologist, and 
without adequate time to plan, can include patients in all of the above categories, and 
is captured by the general term (‘unplanned starters’). Such patients constitute 
around 20% of the incident dialysis population. An unplanned start to dialysis has 
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been shown in several empirical works to have adverse consequences upon patient 
outcome (13, 14).  
Selecting a point at which to start dialysis is a complex issue with no definitive 
answer. Dialysis is currently started when eGFR is at a mean of around 
8ml/min/1.73m
2
 (UK Renal Registry data). K-DOQI guidelines recommend 
considering starting dialysis when eGFR <15ml/min/1.73m
2
 (15) whereas the Renal 
Association (UK) guidelines recommend dialysis consideration when eGFR 
<10ml/min/1.73m
2
 (16). In both guidelines, the absolute need to initiate dialysis is 
dictated by the presence of clinical symptoms, including symptoms of uraemia, fluid 
overload, and declining nutritional status. These symptoms tend to be more important 
indicators of the need for dialysis than the eGFR. While there is little debate about 
the survival disadvantage of late referral (17), there is RCT data suggesting no 
benefit of early planned initiation based on the level of renal function alone (12). 
 
1.4.4 Treatment of ESRD 
1.4.4.1 Conservative Treatment 
Conservative kidney management provides all the aspects of kidney care support 
without the dialysis treatment. Conservative treatment includes medical, emotional, 
social, spiritual, and practical care for both the person with kidney failure and their 
family. The decision to choose conservative care is made in consultation with a renal 
multidisciplinary team. It is an appropriate choice for some people when dialysis is 
very unlikely to improve their quality or length of life and may even reduce aspects 
of overall quality of life. Studies have shown that the conservative care of frail 
elderly patients with ESRD can achieve outcomes comparable to those patients 
receiving HD. Many frail and elderly patients may live just as long being 
conservatively managed as with dialysis treatment (18). 
In such settings, the kidney care team should ensure:  
• A medication review to ensure avoidance of drugs likely to damage kidney 
function such as non-steroidal anti-inflammatory agents. 
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• Advice on an appropriate diet, though as kidney failure worsens and 
appetite deteriorates, adherence to a rigid diet becomes progressively less 
important and/or even feasible.  
• Advice on the avoidance of dehydration e.g. associated with inter-current 
illnesses causing diarrhoea and/or vomiting.  
• Adequate symptomatic treatment, e.g. breathlessness, nausea, poor appetite, 
and itching.  
• Adequate community support, such as home help and district nursing.  
• Referral to a local palliative care service, with the aim of keeping the patient 
active and independent for as long as possible, as well as support in the final 
stages. 
1.4.4.2 Renal Replacement Therapy (RRT) 
Dialysis replaces some aspects of renal function such as the removal of small and 
middle-sized molecules, while also permitting removal of fluid. There are two basic 
types of dialysis: haemodialysis (HD) and peritoneal dialysis (PD). Both modalities 
serve the same purpose, but differ in their application. Figure 5 shows treatment 
modality in prevalent RRT.  
1.4.4.2.1 Haemodialysis 
Haemodialysis is the most common dialysis modality and has been in regular use 
since the 1960s. Haemodialysis can be carried out in a hospital, in a separate clinic, 
in a self-care centre, and even in the patient’s own home. The process normally takes 
between three to five hours thrice weekly. Preparation is necessary by creating access 
to the circulation – the optimal being the arteriovenous fistula (AV fistula). Dialysis 
involves pumping blood from the fistula through the dialyser, where waste products, 
toxins, and excess fluid are removed by diffusion and convection, and back into the 
fistula. Anticoagulation is required usually using systemic low molecular weight 
heparin. Haemodialysis adequacy is assessed by either the urea reduction ratio 
(URR) or normalised urea clearance (Kt/V, where K is the dialyser clearance, t the 
duration of the dialysis session and V the total body water). A sessional URR of 
>65% or sessional Kt/V of 1.2 is the minimum target adequacy for thrice weekly HD 
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(KDOQI, 2002) (5). These adequacy criteria relate to thrice weekly treatments, 
which are currently the norm, though it is thought that significant benefits may 
accrue from more frequent sessions (5). 
1.4.4.2.2 Peritoneal Dialysis (PD) 
Peritoneal dialysis has been in use since the 1980s, and is now a common home-
based treatment for kidney failure patients. PD takes advantage of the peritoneum as 
a natural semi-permeable membrane. Dialysis fluid is introduced to the abdominal 
cavity, where waste products transfer through the peritoneal membrane into the fluid. 
On draining the abdomen, the waste is removed. There are two main versions of 
dialysis: the first is continuous ambulatory peritoneal dialysis (CAPD), where the 
patient is able to ambulate while dialysing; the second is continuous cycler-assisted 
peritoneal dialysis (CCPD), which requires the use of a machine called a cycler to fill 
and drain the abdomen, usually while the patient sleeps. 
 
1.4.4.2.3 Renal Transplantation 
Renal transplantation is the preferred treatment for ESRD, though only a minority of 
patients are suitable. In Europe and the US in 2002/3, only 24-55% of dialysis 
patients under the age of 65 were on the transplant waiting list. The higher 
prevalence of comorbid conditions suggests that the proportion is very much less in 
older patients. This selection coupled with better control of uraemia by means of 
transplantation accounts for the better prognosis compared with dialysis. A 
successful transplant returns renal function to near normal and frees the patient from 
dialysis treatment.  
There are two sources of kidneys: living donors, either blood relative or unrelated 
donors, and non-living (cadaver) donors. To manage the risk of the body rejecting 
the transplant, immunosuppressive medication is required for the duration of the 
transplant. Use of these agents carries risks – particularly of increased susceptibility 
to infection. Nevertheless, the benefits of renal transplantation are well established, 
improving both survival and quality of life. Improved techniques have led to 
transplanted kidneys surviving longer, with around 50% lasting 10 years or more. 
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However, the demand for donor kidneys outweighs the supply, which prolongs the 
patient’s reliance upon dialysis therapies.  
Figure 5: Treatment modality in prevalent RRT patients (1) 
 
 
 
 
 
 
 
 
 
 
1.5 Life on Haemodialysis  
1.5.1 Physical Impact of the Treatment 
 Cardiovascular disease: The prevalence of cardiovascular disease is very 
high in the dialysis population. Cardiovascular mortality is dramatically 
increased in patients on dialysis compared with the aged-matched general 
population. The risk is particularly magnified in younger patients (Figure 6). 
The increased prevalence of cardiovascular disease also contributes to 
morbidity, particularly to increased symptoms of lethargy, breathlessness, and 
chest pain, increased intradialytic symptoms related to hypotension and 
dysrhythmias, and increased admissions and interventions for fluid overload, 
pulmonary oedema, dysrhythmias, and acute myocardial events. Mitral and 
aortic valve calcification as a result of metastatic calcium deposition is 
common among patients with ESRD. Patients with ESRD with indwelling 
haemodialysis catheters are at a particularly increased risk of infective 
endocarditis. Sudden arrhythmic death accounts for approximately half of the 
HD: Haemodialysis, CAPD: 
Continuous Ambulatory 
Peritoneal Dialysis, APD: 
Automated Peritoneal Dialysis 
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cardiovascular disease (CVD) mortality in patients with ESRD (19). There is 
also a well-recognised association between cardiovascular disease and 
depression, both of which are common in dialysis patients (20). 
Figure 6: Cardiovascular mortality defined by death in general population (21)  
 
 
 Hypertension: In patients on HD the management of hypertension is less 
well defined than in the general population. Blood pressure varies throughout 
the dialysis cycle, i.e. pre- and post-dialysis pressures often being markedly 
different. Blood pressure targets are not well defined, there being a ‘U-
shaped’ curve relating blood pressure and mortality. The mainstay of 
treatment is maintenance of a normal extracellular fluid volume by fluid 
removal on dialysis. Assessing the appropriate ‘dry weight’ of a patient is 
difficult. Miscalculations are frequent. Underestimation results in intradialytic 
hypotension, and overestimation in fluid overload, hypertension, and 
pulmonary oedema. Most patients also require antihypertensive agents. 
 Anaemia: Treating a haemoglobin level <11g/dl with erythropoiesis-
stimulating agent therapy improves functional capacity, but a reduction in 
mortality is unproven.  
 Mineral and bone disorders: Reduced intake of phosphate; use of 
phosphate binders, calcium, and calcitriol supplements may all be required. 
 Uraemic symptoms: Many of the symptoms associated with uraemia 
described earlier are incompletely controlled by dialysis therapy. 
Symptomatic treatment is required for these problems. 
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 Comorbid conditions: As described earlier, it is common for dialysis 
patients to suffer from a range of other conditions upon which the dialysis 
treatment has either no impact or perhaps a negative one. These conditions 
need specific management in their own right. Clinical management is either 
pharmacological (antihypertensive, anti-hyperlipidaemia, anaemia, bone and 
minerals, and cardiac) or non-pharmacological (diet, fluid restriction, 
psychological support). The ‘pill-burden’ endured by HD patients is huge, 
averaging around ten different agents (22).  
 Dialysis-related conditions: It is common for patients to suffer from a range 
of symptoms related to the dialysis session. Symptomatic hypotension during 
the session occurs in up to 15% of sessions. Muscle cramps and headaches 
are also common. Recovery following the procedure can be prolonged – the 
mean recovery time being 6-8 hours (23). 
 
1.5.2 Psycho-social Impact 
HD is an intrusive treatment. Figure 7 below summarises the journey of a patient 
receiving HD three times weekly and the challenges they are exposed to. This 
includes spending 3-4 hours on the dialysis machine, but also accompanying pre- and 
post-dialysis impact and burdens and day-to-day life constraints secondary to the 
illness. Additionally, there tend to be multiple hospitalisations, adding to the overall 
burden. 
 
 
 
 
 
 
 
Figure 7 HD life journey 
 
 
 
Dialysis Journey 3 x weeks 
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HD patients have sustained multiple losses, including loss of renal function and 
mobility, loss of their role within the family and the workplace, loss of physical skills 
and cognitive abilities, and loss of sexual function (24, 25). Additionally, stressors in 
the life of a dialysis patient can include dietary and time constraints, functional 
limitation, loss of employment, changes in self-perception, alterations in sexual 
function, general and perceived effects of illness, medication used to treat the illness, 
and fear of death. The demands with HD include potential changes in a patient’s 
status in marital, familial, occupational, and social contexts; the expenses and 
worries associated with the treatment, illness, uncertainty, anxiety, and the costs 
entailed while waiting for transplant. Furthermore, treatment within a unit implies a 
complex relationship with dialysis personnel: physicians, nurses, technicians, and 
other staff. In the absence of adaptive coping, disabilities, and marital and family 
dysfunction can occur. The main psychological impact is depression in response to 
the above losses (25). 
Over the past decade, increasing emphasis has been given to quality of life as 
survival with chronic diseases has increased. The World Health Organisation defines 
quality of life as ‘an individual’s perception of their position in life in the context of 
culture and value systems in which they live and in relation to their goals and 
expectations, standards and concerns. It is a broad ranging concept affected in a 
complex way by a person’s physical health, psychological state, level of 
independence and their relationships to salient features of their environment’ (26)  
In the context of chronic illnesses, the most widely studied aspect of quality of life 
has been Health-related Quality of Life (HRQL). This construct gives insight into the 
patients’ perceptions of the physical and psychosocial impact of the illness and its 
treatment on their lives (27). 
Depression and anxiety are important independent predictors of low quality of life 
across HD patients (28-31). Depression not only undermines the patients’ mental and 
physical health but also alter their subjective perceptions of physical status, 
functional capacity, and social function. It has been proposed that depression and 
anxiety may be more strongly associated with HRQL than clinical and socio-
demographic variables taken together (28, 32). 
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Due to the nature of dialysis, the combination of chronic dialysis with having a job 
appears to be difficult. The Dialysis Outcomes and Practice Patterns Study (DOPPS) 
(33) indicated that the percentage of employed patients was low in the US, Europe, 
and Japan. The study showed that unemployment is common in ESRD patients, 
leading to further burdens such as a loss of social support, and low quality of life and 
reduced self-esteem (34, 35). Moreover, the patient’s financial situation declines.  
Living with a high symptom burden can be debilitating. The prevalence of pain in 
patients treated with haemodialysis is often underappreciated (36, 37). Better pain 
management appears to be a priority to improve QoL. Fatigue is common (38). It 
impacts on physical functioning (38, 39), family and social roles (39), activity levels 
(40), and mental and physical QoL (41). It damages patients’ abilities to manage 
everyday activities (42, 43) resulting in feelings of isolation (42). It impairs memory 
and concentration (43). Some feel too fatigued to communicate and have difficulty 
maintaining close relationships (42). Fatigue symptoms can lead to poor sleep, poor 
physical health, and eventually depression (44). Sleep disturbances are highly 
prevalent (45, 46) and are associated with poor QoL (47-49). Restless leg syndrome 
(RLS) is also common and is associated with insomnia, mortality, and depression 
(50-53). In a large cohort of dialysis and transplant patients, RLS was predictive of 
significant depressive symptoms after controlling for covariates including albumin 
and co-morbidity (54).  
Social support depends on instrumental, emotional, and informational help. Low 
perceived social support, defined by the quality of social relationships, is also a 
strong predictor of depression in ESRD (55, 56). ESRD is also associated with more 
psychological distress in younger patients compared with the elderly as a 
consequence of larger disruptions to their valued activities, lifestyles, and interests 
(57, 58). Thus, the dynamic interplay among these biological, social, and 
psychological factors may intensify or buffer people’s feelings of distress. 
Psychosocial factors and burdens, as highlighted above, may prevent or trigger 
depression at any point during the trajectory of CKD. In the early stages of CKD, 
people may be depressed and anxious because of their changed identity from being 
healthy to sick, the symptom burden, fear of dialysis, the uncertainty of the disease 
outcome, and negative experiences with the healthcare system (59). Those on 
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dialysis often dislike the treatment (or have ambivalent feelings, as it keeps them 
alive), suffer from the lifestyle disruption it causes, which may be linked to financial 
struggles, and feel guilty for the burden they perceive they cause for family members 
(59, 60). Patients’ self-concept and self-esteem may also change due to the changes 
in their physical status, lifestyle, and social roles.  
 
1.5.3 End of Life 
For some patients, who have serious and complex illnesses or who are frail and 
elderly, dialysis treatments may be exceptionally burdensome with little benefit to 
either survival or quality of life. People who find themselves in this situation are 
often worried and unsure about what will happen and how long they will live if they 
choose to stop dialysis treatment. Patients and their families need support in coming 
to the decision about whether to continue with dialysis. If a decision is made to 
discontinue dialysis, they require end-of-life care, which should include detailed 
assessment of preferences for place of care, physical symptoms, psycho-social 
symptoms, family well-being and planning ahead in order to maximise the quality of 
remaining life.  
Traditionally, it was believed that uraemic death was relatively symptom free; 
however, evidence does not support this (61). In studies that looked at end-of-life 
symptoms, it was shown that some patients have a peaceful and symptom-free death; 
however, a significant minority experience severe or distressing symptoms (61). 
Pain, breathlessness, nausea, retained respiratory tract secretions, and terminal 
agitation can all be problematic. These symptoms are relatively well controlled in the 
majority of patients. Agitation usually responds to low doses of anxiolytics such as 
midazolam. Retained respiratory tract secretions can be improved by hyoscine. Pain 
and breathlessness can be effectively managed by low doses of opioid medications.  
 
1.6 Summary 
Kidney disease is complex and has many different stages, and ESRD is the final 
stage. There are different treatment modalities for ESRD, including HD, which 
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usually involves lengthy out-patient treatment sessions three times a week, placing 
significant burdens on the patient and their family or carers. Life on HD is 
challenging, with both physical and psychological challenges. This thesis will 
concentrate on the psychological impact of ESRD and HD, which can include the 
presence of depression and high fatigue levels. The diagnosis of depression is 
complicated by the overlap of the symptoms of uraemia. Additionally, medications 
used to treat patients with ESRD might also cause depression or have side effects 
that mimic its symptomatology. When depression and fatigue are identified, 
alleviation of these symptoms with appropriate management should be attempted.  
In the forthcoming chapters, a comprehensive review of both depression and fatigue 
will be conducted to give a clear understanding of these disorders, as well as an up-
to-date review of the literature in order to identify the gaps upon which the thesis and 
research will be based. 
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Chapter 2 
Depression in End-stage Renal Disease 
In this chapter, I will initially focus on major depressive disorder in the general 
population, then in patients with chronic disease, and finally in ESRD patients on 
HD. 
2.1 Mood Disorder 
Mood is a subjective, pervasive, and sustained feeling that is experienced internally 
and influences a person’s behaviour and perception of the world. The external 
expression of mood is described as ‘affect’. Healthy individuals experience a wide 
range of moods and have an equally large repertoire of affective expression. Mood 
disorders are a group of clinical conditions characterised by the loss of a sense of 
control and a subjective experience of distress. Patients with a disorder of elevated 
mood (mania) present with grandiosity, flight of ideas, decreased sleep, and 
expansiveness.  
Those with a disorder of depressed mood present with loss of energy and interest, a 
sense of guilt, loss of appetite, sleep disturbance, poor concentration, and thoughts of 
suicide and death. These mood disorders result in substantially impaired 
interpersonal, social, and occupational functioning and suicidal activity. Patients who 
are affected with depressive episodes only are said to have major depressive disorder 
or unipolar depression. Other disorders of depressed mood include bipolar affective 
disorder (alternating between severely depressed and elevated moods), cyclothymia 
(a milder form of alternating mood states) and dysthymia (chronic low-grade 
depression). 
The morbidity caused by these disorders is greatly underappreciated. A survey 
conducted by the World Health Organisation (WHO) showed that mood disorders 
currently rank as the world’s fourth greatest cause of illness burden. The report 
estimates these disorders will rank second by 2020 (62). The illness burden 
associated with day-to-day disability is profound. Depression and bipolar disorders 
constitute the world’s leading cause of disability among adults (63).  
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In the UK, mental health problems are the largest single cause of disability, 
accounting for 23% of the total burden of disease. The economic and social costs of 
mental illness in England are estimated to be around £105 billion/year. This includes 
£21.3 billion in health and social care costs, £30.3 billion in lost economic output, 
and £8.4 billion in sickness absence due to mental ill health (62). Depression causes 
more disability than angina, arthritis, asthma, and diabetes. Both acute and chronic 
depressive episodes cause greater day-to-day impairment of quality of life than 
diabetes, high blood pressure, arthritis, or peptic ulcer disease (64). A recent heath 
economic analysis ranked depression as one of the five most costly brain disorders in 
the UK, amounting to £19.3 billion per annum (65), of which the majority of the cost 
was indirect, attributable to illness-related loss of income and revenue.  
 
2.2 Major Depressive Disorder (MDD) 
2.2.1 Classification 
The two major classifications of mental disorder diagnosis used internationally are 
the World Health Organisation’s International Classification of Diseases (ICD) and 
the American Psychiatric Association’s (APA) Diagnostic and Statistical Manual of 
Mental Health (DSM). Currently used versions are the ICD10 (66) and DSM-IV 
(67). 
The ICD-10 was published in 1992 as an aid to the collection of international 
statistics about disease.  
The DSM-IV is specific to mental disorders only and includes a multiaxial system of 
classification with five axes incorporating clinical disorders, personality disorder, 
and intellectual disabilities, and medical, psychosocial, environmental, and childhood 
factors. It is a hierarchical system that provides operationalised criteria for each 
diagnosis. It was underpinned by a comprehensive literature review, analysis of data, 
and field trials to evaluate changes. It has abandoned the psychoses–neuroses 
distinction, and has some minor differences from the ICD-10, which are outlined in 
Table 7. The DSM-5 (68) was published in May 2013, and superseding the DSM IV-
TR. In most respects, DSM-5 does not differ greatly from DSM-IV. Notable changes 
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include dropping Asperger’s syndrome as a distinct classification; loss of subtype 
classifications for variant forms of schizophrenia; dropping the ‘bereavement 
exclusion’ for depressive disorder; a revised treatment and naming of gender identity 
disorder to gender dysphoria; and removing the A2 criterion for post-traumatic stress 
disorder. 
 
Table 7: Differences in the ICD-10 and DSM-IV classification systems  
                                              ICD-10                                                                  DSM-IV 
 
Origin                             International (WHO) 1992                                        American Psychiatric Association (APA) 1994 
 
Presentation        Different versions for different settings                                                   Single document 
 
Languages            Available free in all widely spoken languages                           English only and not ‘licensed’                                
 
Structure         Part of overall ICD framework. Single axis in                                                 Multi-axial                                                            
                          chapter V; separate multiaxial systems available                  All categories defined using operational                                                                                                  
                          Versions use both operational and clinical prototypes         criteria (reliable, easily applied, internationally                                                                                                        
                  accepted, easy-to-design interview for research) 
                             
Content                  Guidelines and criteria do not include social                        Diagnostic criteria usually include significant     
                                        consequences of psychiatric disorder impairment in social functions 
                                   Terms ‘neurotic’ and ‘neurasthenia’ preserved                    Terms ‘neurotic’ and ‘neurasthenia’ discarded 
 
 
DSM-IV and ICD-10 have virtually the same diagnostic features for a ‘clinically 
important’ severity of depression (termed a major depressive episode in DSM-IV or 
a depressive episode in ICD-10). However, their thresholds differ, with DSM-IV 
requiring a minimum of five out of nine symptoms (which must include depressed 
mood and/or anhedonia) and ICD-10 requiring four out of ten symptoms (including 
at least two weeks of depressed mood, anhedonia, and loss of energy). This may 
mean that more people may be identified as depressed using the ICD-10 criteria 
compared with that of DSM-IV (69) , or at least that slightly different populations are 
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identified (70), related to the need for only one of two key symptoms for DSM-IV 
but two out of three for ICD-10. 
Major depressive disorder is a mental disorder characterised by pervasive and 
persistent low mood, accompanied by loss of interest and/or anhedonia (the loss of 
interest in otherwise pleasurable everyday activities, such as hobbies, sex, or work).   
The severity of the disorder is determined by the number and severity of symptoms, 
as well as the degree of functional impairment. These are accompanied by other 
somatic, cognitive, and behavioural symptoms, such as loss of energy, significant 
changes in body weight, insomnia or hypersomnia, agitation, difficulty 
concentrating, feelings of worthlessness, hopelessness, helplessness, excessive guilt, 
and/or thoughts about death and suicide.  
Depression is usually categorised on the basis of the severity, duration, and number 
of symptoms. For example, the Diagnostic and Statistical Manual of Mental 
Disorders of the American Psychiatric Association (DSM IV-TR) classifies 
depressive disorders as Major Depressive Disorder, Dysthymic Disorder, and 
Depressive Disorder Not Otherwise Specified (67) (Table 8). While much attention 
has focused on the management of major depression, less severe forms of depression 
may lead to as much disability as major depression (71). Also, less severe but 
persistent mental stress may develop into major depression if protective factors are 
not mobilised (72).  
Table 8: Symptoms of depressive disorders (based on the Diagnostic and 
Statistical Manual of Mental Disorders, Fourth Edition) 
Major Depressive Episodes 
Five or more of the following symptoms have been present during the same two-week period 
and represent a change from previous functioning; at least one of the symptoms is either 
depressed mood or loss of interest or pleasure. 
(1) Depressed mood 
(2) Markedly diminished interest or pleasure in (almost) all activities 
(3) Significant weight loss when not dieting, or weight gain, or decrease or increase in 
appetite 
(4) Insomnia or hypersomnia 
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(5) Psychomotor agitation or retardation 
(6) Fatigue or loss of energy 
(7) Feelings of worthlessness or excessive or inappropriate guilt 
(8) Diminished ability to think or concentrate, or indecisiveness 
(9) Recurrent thoughts of death, recurrent suicidal ideation, or a suicide attempt  
The symptoms cause significant distress or impairment in social, occupational, or other 
important areas of functioning. 
Dysthymic Disorder 
Depressed mood for at least two years. Presence, while depressed, of two (or more) of the 
following: 
(1) Poor appetite or overeating 
(2) Insomnia or hypersomnia 
(3) Low energy or fatigue 
(4) Low self-esteem 
(5) Poor concentration or difficulty making decisions 
(6) Feelings of hopelessness 
The symptoms cause significant distress or impairment in social, occupational, or other 
important areas of functioning. 
Examples of Depressive Disorders Not Otherwise Specified 
(1) Minor depressive disorder: episodes of at least two weeks of depressive symptoms, but 
with fewer than the five items required for major depressive disorder 
(2) Recurrent brief depressive disorder: depressive episodes lasting from two days up to two 
weeks, occurring at least once a month for 12 months 
(3) Situations in which the clinician has concluded that a depressive disorder is present, but 
is unable to determine whether it is primary, due to a general medical condition, or 
substance-induced 
 
2.2.2 Diagnosis 
Diagnostic approaches rely upon professional evaluation typically by structured or 
semi-structured interviews using diagnostic criteria such as the Diagnostic and 
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Statistical Manual of DSM-IV, as explained above. The Structured Clinical Interview 
for Depression (SCID) is one diagnostic assessment based upon the DSM-IV criteria. 
Other diagnostic methods included, the Diagnostic Interview Schedule (DIS) and the 
Mini-International Neuropsychiatric Interview (MINI). Formal diagnosis has 
implications for the management and treatment of depressive disorders.  
The Mini-International Neuropsychiatric Interview (MINI): The MINI is a short 
diagnostic structured interview (DSI) developed jointly by psychiatrists and 
clinicians in the US and Europe, for DSM-IV and ICD-10 psychiatric disorder. It was 
designed to meet the need for a short but accurate structured psychiatric interview for 
multicentre clinical and epidemiology studies and to be used as a first step in 
outcome tracking in non-research clinical settings. It is fully structured to allow 
administration by non-specialised interviewers. It focuses on the existence of current 
disorders. For each disorder, one or two screening questions rule out the diagnosis 
when answered negatively. Examinations for severity, disability, or medically 
explained symptoms are not explored symptom by symptom (73). Two joint papers 
present the inter-rater and test-retest reliability of the MINI and the validity versus 
the Composite International Diagnostic Interview (CIDI) (74) and the Structured 
Clinical Interview for DSM-III-R patients (SCID) (75). 346 patients (296 psychiatric 
and 50 non-psychiatric) were administered the MINI and the CIDI ‘gold standard’. 
Forty-two were interviewed by two investigators and 42 were interviewed 
subsequently within two days. Interviewers were trained to use both instruments. The 
mean duration of the interview was 21 minutes with the MINI and 92 minutes for 
corresponding sections of the CIDI. Kappa coefficient, sensitivity, and specificity 
were good or very good for all diagnoses with the exception of generalised anxiety 
disorder (GAD) (kappa = 0.36), agoraphobia (sensitivity = 0.59) and bulimia (kappa 
= 0.53). Inter-rater and test-retest reliability were good, with the kappa coefficients 
ranging from 0.88 to 1.0. The main reasons for discrepancies were attributed largely 
to the coexistence of affective and psychotic symptoms. The MINI provided reliable 
DSM-III-R diagnoses within a short time frame. 
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2.2.3 Screening 
Screening for depression in the general medical population remains controversial as 
there is a lack of diagnostic capability and typical self-report scales are used, 
requiring the patient to rate symptom frequency or severity. Such tools assess the 
patient’s mood based upon a continuum, with higher depression scores often 
reflecting greater depressive symptoms. Self-report scales are useful research tools 
that allow depression to be quantified across a population who do, as well as those 
who do not, meet the diagnostic criteria for depression. Given the high prevalence of 
depression and its significant impact on morbidity and mortality, a strong case can be 
made for screening patients with chronic medical conditions, as this could serve to 
identity patients with significant depressive symptoms or to assess the severity of 
depression so that the diagnosis of depression is not missed and the opportunity to 
provide treatment can be considered.  
The Beck Depressive Inventory (BDI) is a 21-item self-report questionnaire that 
uses cut-off levels for depression in the general population: 9, no depression; 10 to 
15, mild depression; 16 to 23, moderate depression; 24, severe depression. The 21 
items are scored on a four-point scale, where 0 signifies no problem and 3 represents 
an extreme problem, with a total score range of 0 to 63 (76). 
The Cognitive Depression Index (CDI) is a subset of the BDI that consists of items 
of affective components and excludes the somatic components of the questionnaire. 
The affective component contains eight items: pessimism, past failures, guilty 
feelings, punishment feelings, self-dislike, self-criticalness, suicidal thoughts or 
wishes, and worthlessness. The somatic component consists of the other thirteen 
items: sadness, loss of pleasure, crying, agitation, loss of interest, indecisiveness, loss 
of energy, change in sleep patterns, irritability, change in appetite, concentration 
difficulties, tiredness and/or fatigue, and loss of interest in sex. The two subscales 
were moderately correlated at 0.57, suggesting that the physical and psychological 
aspects of depression are related rather than totally distinct (77, 78). 
The nine-question Patient Health Questionnaire (PHQ-9) consists of nine 
questions that assess the severity of depression with each question based on a scale 
of 0 to 3. Higher PHQ-9 scores correlate with increased depressive affect. The PHQ-
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9 has a maximum possible score of 27: 0-4, none; 5-9, mild; 10-14, moderate; 15-19, 
moderately severe; 20-27, severe (79, 80).  
The Centre for Epidemiologic Studies Depression Scale (CES-D) consists of 20 
items ranging on a scale of 0 to 60. A CES-D cut-off score of 16 in the general 
population is used as a screening tool for possible depression (81).  
The Zung Self-report Depression Scale (Zung SDS) is a short, self-administered 
survey to quantify the depressed status of a patient. There are 20 items on the scale, 
which rate the affective, psychological, and somatic symptoms associated with 
depression. There are ten positively worded and ten negatively worded questions. 
Each question is scored on a scale of 1 to 4 (based on these replies: ‘a little of the 
time’, ‘some of the time’, ‘good part of the time’, ‘most of the time’). Scores on the 
test range from 20 to 80. The scores fall into four ranges; normal range (20-44), 
mildly depressed (45-59), moderately depressed (60-69), and severely depressed 
(above 70) (82).  
The Hospital Anxiety Depression Scale (HADS) is commonly used to determine 
the levels of anxiety and depression that a patient is experiencing. The HADS is a 
14-item scale. Seven of the items relate to anxiety and seven relate to depression. 
Each item on the questionnaire is scored from 0 to 3 and this means that a person can 
score between 0 and 21 for either anxiety or depression. The cut-off point for 
caseness of anxiety or depression is 8/21 (83, 84). 
Quick Inventory of Depressive Symptomatology Self-report (QIDS-SR) The 16-
item QIDS measures depressive symptom severity derived from the 30-item 
Inventory of Depressive Symptomatology (IDS), and is available in both self-report 
(QIDS-SR(16)) and clinician-rated (QIDS-C(16)) formats. The scoring system for 
the QIDS converts responses to 16 separate items into the nine DSM-IV symptom 
criterion domains. The nine domains comprise: 1) sad mood; 2) concentration; 3) 
self-criticism; 4) suicidal ideation; 5) interest; 6) energy/fatigue; 7) sleep disturbance 
(initial, middle, and late insomnia or hypersomnia); 8) decrease/increase in 
appetite/weight; and 9) psychomotor agitation/retardation. The total score ranges 
from 0 to 27. The cut-off point for depression is ≥10 (85).  
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The Hamilton Rating Scale for Depression (HAMD) is a 17-item clinician-rated 
questionnaire that is used to assess depressive affect. Each item on the questionnaire 
is scored on a three- or five-point scale. A score of 0-7 is considered normal. Scores 
of 20 or higher indicate moderate, severe, or very severe depression, and are usually 
required for entry into a clinical trial. Questions 18-20 may be recorded to give 
further information about the depression (such as whether diurnal variation or 
paranoid symptoms are present), but are not part of the scale (86). 
The Montgomery-Åsberg Depression Rating Scale (MADRS) is a 10-item 
clinician-rated questionnaire used to measure the severity of depressive episodes in 
patients with mood disorder (87). It was designed as an adjunct to the HAMD as it 
seems more sensitive to the changes brought on by antidepressants and other forms 
of treatment than the Hamilton Scale (88). A higher MADRS score indicates more 
severe depression, and each item yields a score of 0 to 6 (89). The overall score 
ranges from 0 to 60. Usual cut-off points are: 0-6, normal/symptom absent; 7-19, 
mild depression; 20-34, moderate depression; >34, severe depression (89, 90). 
MADRS is less biased by anxiety and physical factors (0 items) than HAMD so is 
especially useful in the presence of physical illness (91). 
The Clinical Global Impression (CGI) rating scales are commonly used measures 
of symptom severity, treatment response, and the efficacy of treatments in treatment 
studies of patients with mental disorders (92). Many researchers, while recognising 
the validity of the scale, consider it to be subjective as it requires the user of the scale 
to compare the subjects to typical patients in the clinician’s experience. They are: 
 The Clinical Global Impression – Severity scale (CGI-S) is a seven-point 
scale that requires the clinician to rate the severity of the patient's illness at 
the time of assessment, relative to the clinician's past experience with patients 
who have the same diagnosis. Considering total clinical experience, a patient 
is assessed on severity of mental illness at the time of rating: 1, normal, not at 
all ill; 2, borderline mentally ill; 3, mildly ill; 4, moderately ill; 5, markedly 
ill; 6, severely ill; or 7, extremely ill. 
 The Clinical Global Impression – Improvement scale (CGI-I) is a seven-point 
scale that requires the clinician to assess how much the patient's illness has 
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improved or worsened relative to a baseline state at the beginning of the 
intervention. It is rated as: 1, very much improved; 2, much improved; 3, 
minimally improved; 4, no change; 5, minimally worse; 6, much worse; or 7, 
very much worse. 
 The Clinical Global Impression – Efficacy Index is a four-point × four-point 
rating scale that assesses the therapeutic effect of the treatment as: 1, 
unchanged to worse; 2, minimal; 3, moderate; 4, marked by side effects rated 
as: none; do not significantly interfere with patient's functioning; significantly 
interfere with patient's functioning; or outweigh therapeutic effect. 
 
2.2.4 Epidemiology of MDD 
At least 12% of the adult population will suffer from a mood disorder at some point, 
with some surveys suggesting lifetime prevalence rates as high as 25%. The 
cumulative risks of the specific major mood disorders are 10.2% for major 
depressive disorder and 1.3% for bipolar disorder (93-96). 
Minor or sub-syndromal forms of major depressive disorder include dysthymia 
(persistent, unremitting symptoms for at least two years), sub-syndromal 
symptomatic depression (characterised by neither sufficient duration for dysthymia 
nor sufficient symptom severity for a major depressive episode), and adjustment 
disorders with depressive features (onset following a stressor; less severe and 
persistent than a major depressive episode). The lifetime risk of dysthymia is about 
3-5% (97, 98).  
The modal age of onset of major depressive disorder is between 25 and 35 years (93, 
96, 99), and has decreased over the past four generations (93). Earlier onsets are 
associated with greater lifetime incidence and higher rates of recurrence (99). A later 
onset is associated with the absence of family history of mood disorder, alcohol, and 
antisocial personality disorder. The lifetime risk that someone with dysthymia will 
develop a major depressive episode exceeds 70% (95). Major depressive disorder 
and dysthymia are more common among women, who have a morbid risk 1.5-2 times 
greater than men (93, 96, 99).  
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For a fortunate minority (30-45%), a single lifetime episode of major depression may 
have few long-term sequelae. More often, major depressive episodes recur with 
increasing frequency. After a second lifetime episode, the risk of a third is at least 
70% within three years (without prophylactic treatment) (100). Early withdrawal of 
antidepressant medication before three months results in the return of the symptoms, 
and as the course of the disorder progresses, patients tend to have more frequent 
episodes that last longer. Over a 30-year period, the mean number of episodes is five 
to six (101).  
The average depressive episode lasts about nine to 12 months without treatment, 
although about 20% run a chronic course of two years or longer. Once established, 
chronic episodes last an average of five to eight years (93). Episodes of major 
depressive disorder with dysthymia are called double-depressive syndrome 
(dysthymia plus a superimposed major depressive episode) and are associated with 
the most disability (102).  
Most people who suffer from one episode of depression will develop a recurrence of 
the disorder. Early in the course of illness, it is not uncommon for an apparently 
unipolar disorder to switch to bipolar, especially when the onset of depression is 
before the age of 25 (103). After three or more depressive episodes, however, the 
onset of mania is much less likely (<5% incidence). 
 
2.2.5 Aetiology 
2.2.5.1 Neuro-biological factors  
The classical theory to explain depression is the ‘monoamine hypothesis’, which 
proposes that depression is related to a deficit of monoamines, particularly 
norepinephrine (NE) and serotonin (5-HT), at critical synapses (104). Additional 
neurotransmitters implicated include acetylcholine (105), gaba amino butyric acid 
(106), glutamine, and glycine-N-methyl-d-aspartate (107). 
The monoamine neurotransmitters NE, 5-HT, and dopamine (DA) are the main focus 
of theories and research on the aetiology of depressive disorder. Malfunctioning of 
monoamine pathways has been difficult to document in depression, but the 
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antidepressant actions of currently available drugs (i.e. their ability to reduce or 
eliminate depressive symptoms) are definitely linked to boosting neurotransmission 
in monoamine pathways (108). 
Depression has also been associated with dysfunction of the hypothalamic-pituitary-
adrenal (HPA) axis. This may manifest itself in two ways; firstly, activation of the 
HPA axis and, secondly, blunting of the normal diurnal cortisol profiles. Cortisol is a 
counter-regulatory hormone and in excess induces visceral/central adiposity, insulin 
resistance, dyslipidemia (metabolic syndrome), and hypertension. States of 
depression and stress can result in elevated plasma adreno-corticotrophin hormone 
(ACTH) and cortisol levels, elevated 24-hour urine free cortisol (UFC) levels, 
adrenal gland enlargement, and failure to suppress cortisol in response to the 
dexamethasone suppression test (109). Successful treatment for major depressive 
disorder can restore the suppressive response to dexamethasone (110). 
MDD is also known to be accompanied by clinically significant cognitive functional 
impairment and is associated with poor response to treatment (111). 
Neuropsychological dysfunction is often present in the disorder and has been shown 
to contribute independently to poor functional outcome (112). These  includes 
sustained vigilance and motor functioning (113), visuomotor attention and 
processing (114), ideational fluency (115) short-term and working memory, verbal 
and non-verbal learning (116) and general intelligence (117). It has been proposed 
that executive function may be particularly impaired in individuals with MDD, and 
that problems in other domains, such as memory, attention, and problem-solving, 
may arise because these abilities rely heavily on aspects of executive and prefrontal 
function (118).  
 
2.2.5.2 Psycho-social factors 
There are many psycho-social pathways that may lead to depression. The most 
common involve family relationships, interpersonal relationships, social function, 
and the discrimination an individual might suffer at the hands of others. Psycho-
social factors are: 
Raphe nuclei Regulates: 
Mood, sleep, emotions (anger, aggression), Body temperature, 
Appetite, Memory processing. 
Impairment causes; depression, anxiety and schizophrenia 
 
 
41 
 
 Life events and environmental stress: Stressful life events are associated 
with the onset of episodes of major depression. The response to stressful life 
events is also influenced by genetic factors, which seem to align with those 
that predispose to major depression. The most compelling data indicate that 
losing a parent before the age of 11 is often associated with the development 
of depression (119). Loss of spouse may also precipitate depressive episodes. 
Other risk factors include female gender, unemployment, living alone, and 
older age (120). Depression is related to the normal emotions of sadness and 
bereavement, but it does not remit when the external cause of these emotions 
dissipates, and it is disproportionate to their cause. Classic severe states of 
depression often have no external precipitating cause. It is difficult, however, 
to draw clear distinctions between depressions with and those without 
psychosocial precipitating events (121). 
 Cognitive impairment: Both low mood and cognitive impairment are 
associated with poor psychosocial functioning. Patients usually rated their 
social or occupational functioning as significantly, severely, or totally   
impaired (112). Therefore, the remediation of cognitive impairment and 
alleviation of depressive symptoms each play an important role in improving 
outcome for patients with depression (11). Cognitive impairment represents a 
core feature of depression that cannot be considered an epiphenomenon that 
is entirely secondary to symptoms of low mood .It is widely acknowledged as 
an important aspect of MDD. Indeed, the DSM-IV criteria for MDD include 
“diminished ability to think or concentrate, or indecisiveness”.  Impaired 
cognition has been estimated to occur in around two-thirds of depressed 
patients(122). Impairments in cognition have been found to persist beyond 
acute episodes of depression, and between one-third and one-half of remitted 
depressed patients are thought to be affected by cognitive impairment (123). 
 Personality factors: Certain personality types such as obsessive compulsive 
personality disorder (OCPD), and emotionally unstable (borderline) or 
histrionic personality disorders are at greater risk of depression, compared to 
antisocial or paranoid personality disorders since the latter tend to use 
projection and other externalising defence mechanisms to protect themselves 
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(124). Beck (125) proposed that depression may occur when persons 
experience events that represent a perceived loss in a domain that has 
particular meaning or relevance for them. Thus, for highly sociotropic people 
(those who need positive interchanges with other individuals), depression is 
most likely to occur in response to perceived interpersonal loss or rejection. 
In contrast, highly autonomous people (those who need independence and to 
attain meaningful goals) are most likely to become depressed in response to 
perceived failure or lack of control over the environment. 
 Psychodynamic factors: Sigmund Freud (126) was first to explore the 
psychodynamic understanding of depression. This was later expanded by 
Karl Abraham (101) as the ‘classic view of depression’. This theory involves 
four key points: 1) disturbances in the infant-mother relationship during the 
oral phase (10-18 months) predispose to subsequent vulnerability of 
depression; 2) depression can be linked to a real or imagined object loss; 3) 
introjection of the lost object acts as a defensive mechanism to deal with the 
distress related to the loss; 4) object loss is regarded with a mixture of love 
and hate; feelings of anger are directed inward at the self. 
 Genetics: studies comparing concordance rates for major depression between 
monozygotic and dizygotic twins suggest a heritability of about 37% (127). 
Kendler et al. (128) showed that although depression is due in part to 
heritable depression prone personality traits, it is also the result of heritable 
factors that are independent of personality. Early-onset, severe, and recurrent 
depression may have a higher heritability than other forms of depression 
(129). It is clear from studies of families that major depression is not caused 
by any single gene but is a disease with complex genetic features. Studies of 
pedigrees with multiple cases of major depression have identified 
chromosomal regions with linkage to the disorder, and some of these loci 
have been replicated in more than one study, although no single chromosomal 
region has been replicated in every family study of genetic linkage in 
depression. There is evidence of linkage of recurrent, early-onset depression 
to chromosome 15q25-q26, but the population attributable risk was small. No 
specific molecular risk factor has been reliably identified (130). One common 
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polymorphic variant of the serotonin-transporter-linked polymorphic region 
(5-HTTLPR), which affects the promoter of the serotonin-transporter gene, 
causes reduced uptake of the neurotransmitter serotonin into the presynaptic 
cells in the brain (131). Some studies have shown that this polymorphism 
confers a predisposition to depression (132), but it also confers a 
predisposition to an anxious and pessimistic personality (131). Brain imaging 
reveals functional differences in emotion-related areas of the brain among 
carriers of the different common polymorphisms of 5-HTTLPR (133), 
although a direct relation to depression is unclear. In a large, prospective 
epidemiologic study, Caspi et al. (134) found that 5-HTTLPR predicted 
depression only in association with defined life stresses. Some environmental 
factors could confer a predisposition to depression by affecting the genome 
epigenetically – for example, increased maternal care in rodents causes an 
epigenetic change in the promoter region of the glucocorticoid receptor gene 
(135).  
 Frailty: is a multifactorial geriatric syndrome, which may be influenced by 
pain, mobility and balance problems, weakness, and poor endurance. All of 
these risk factors may lead to disability, or functional dependence, and thus 
lead to depression(136). In a recent meta-analysis there was a “bi-directional 
relationship between frailty and depression”. Approximately 40% of frail 
people with depression have frailty and a similar proportion of those with 
frailty have depression. Frail older people are four times more likely to have 
depression than non-frail people (137). The relationship between depressive 
symptomatology and increased risk of incident frailty was robust, while the 
opposite relationship was less conclusive (138). There is evidence that 
depression is associated with increased weakness, mobility deficits, and 
fatigue, which may thus increase the risk of frailty and increased mortality 
over a period of up to 5 years (139). 
Depression may also predict indicators of frailty due to the decrease in social   
ties, gait speed, and less physical activities, or due to the increase in sedentary 
life, fall risk, weight loss, and malnutrition, which may increase the 
perpetuation of affective symptoms typical of depression including sadness, 
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anhedonia and helplessness (140). Additionally, depression may not only be 
associated with physical frailty, but also with cognitive impairment as 
discussed above, which may be long-lasting and may persist even during 
affective remission (141). Depression related cognitive impairment may 
contribute to the emergence of frailty. It is also possible that there are shared 
risk factors and pathophysiological pathways. These are partly explained by 
overlapping mechanisms such as cerebrovascular disease and sub-clinical 
vascular diseases that cause pre-frontal white-matter hyper-intensities in 
patients with late-life depression have consistently been considered a key 
factor in pre-frailty (142), chronic inflammation, oxidative stress, 
mitochondrial dysfunction (143),  HPA axis dysregulation (144).  
There are approaches to prevent frailty or depression which may protect 
against the other. The potential role of antidepressant medications on frailty 
has not been clear because geriatric characteristics are rarely taken into 
account in trials on antidepressant drugs in late-life depression (145). 
Successful treatment of the depression itself may result in increased 
behavioural and social activation, thereby increasing physical and social 
activity levels, improving muscle mass and strength, and the elder’s overall 
energy levels, thereby, reducing frailty (146). Increasing physical activity is 
an effective intervention for frailty in older adults, and can protect and 
manage depressive symptoms in the elderly through potential neurobiological 
changes and as a consequence of social and physical engagement (147, 148). 
 
2.2.6 Comorbidity 
Patients with major depressive disorder are at increased risk of developing additional 
comorbid mental illness. The most frequent disorders are: alcohol abuse/dependence, 
panic disorder/OCD, and social anxiety (life time prevalence 27%, 10%, 12%, 
respectively) (149).  
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2.2.7 Management of Depression  
Most patients with depressive disorder are managed in primary care. However, lack 
of understanding of the recognition and treatment of depression means not all those 
requiring treatment are recognised (NICE, 2009) (150).  
About 50% of patients having their first depressive episode exhibit significant 
depressive symptoms before the first identifiable full episode (101). Early 
identification and treatment of symptoms may prevent the development of a full 
depressive episode. The incidence of relapse is lower in those on prophylactic 
antidepressants and who had only one or two episodes. However, the more episodes 
of depression, the less the duration between the episodes and the more severe (101).  
Once the diagnosis of clinical depression is made, treatment options need to be 
tailored to the individual needs of the patient and the resources available to the 
clinical team. NICE recommends not using antidepressants routinely to treat 
persistent subthreshold depressive symptoms or mild depression, but rather consider 
psychological intervention, e.g. cognitive behaviour therapy (CBT), because the 
risk–benefit ratio is poor. Antidepressants should be considered for people with a 
past history of moderate or severe depression or initial presentation of subthreshold 
depressive symptoms that have been present for a long period (typically at least two 
years), or subthreshold depressive symptoms or mild depression that persist(s) after 
other interventions. An algorithm depicting a suggested management plan for the use 
of antidepressants is shown in Figure 8. 
There are a variety of treatment options. Firstly, there is pharmacotherapy, which 
includes different groups of antidepressants (Table 9). Secondly, there are 
psychosocial therapies, including CBT, a type of psychotherapy developed by Beck 
(125). CBT is based on the cognitive model, which states that thoughts, feelings, and 
behaviour are all connected, and that individuals can move toward overcoming 
difficulties and meeting their goals by identifying and changing unhelpful or 
inaccurate thinking, problematic behaviour, and distressing emotional responses. 
According to cognitive therapists, depression is maintained by constant negative 
thoughts. These thoughts are known as automatic thoughts, which occur without 
conscious effort, as in depressed patients. CBT involves the individual working 
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collaboratively with the therapist to develop skills for testing and modifying beliefs, 
identifying distorted thinking, relating to others differently, and changing behaviours. 
A course may last from six weeks to six months, with weekly sessions of 45 minutes. 
The duration will depend on the type of problem and progress. The availability of 
CBT varies between different areas. Interpersonal therapy, developed by Gerald 
Klerman (151) is another form of psychosocial therapy. It is time limited (12 to 16 
weeks) and focuses on one or two of a patient’s current interpersonal problems. It 
encourages the patient to regain control of mood and functioning through a treatment 
alliance in which the therapist empathically engages the patient, helps him/her to feel 
understood, arouses affect, presents a clear rationale and treatment ritual, and yields 
success experiences. Somatic therapies are also effective and include 
electroconvulsive therapy (152), vagal nerve stimulation (153), deep brain 
stimulation (154) and trans-cranial magnetic stimulation (155). In severe/resistant 
episodes a combination of one or more of the above is considered, depending on the 
psychiatric assessment and risk. 
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Table 9: Antidepressant pharmacotherapy 
Generic name               Usual 
daily dose 
(mg)           
                  Common side effects            Clinical caveats 
5-HT Reuptake Inhibitor 
Citalopram 
Escitalopram  
Fluoxetine                                          
Fluvoxamine                                      
Paroxetine                                         
Sertraline                                           
 
 
 
20-60                                  
10-20                                   
10-40                                       
100-300 
20-50 
50-200                                                                                                                                                                                                                                                                                             
all SSRIs may cause insomnia agitation, sedation, 
GI distress and sexual dysfunction.                
many SSRIs inhibit 
various cytochrome 
p450 isoenzymes they 
are better tolerated than  
TCA, high safety in 
over dose (OD). Shorter 
half-life SSRIs may be
associated with                                                                                                                                                                                                                                                                                                                                                                                                  
discontinuation 
symptoms if stopped 
abruptly. 
NE Reuptake Inhibitor                                                                                             
Desipramine    75-300                                drowsiness, insomnia, OSH, CA, agitation, 
↑weight, anticholonergic¹ 
dose titration required. 
over dose can be fatal 
Protriptyline 20-60 drowsiness, insomnia   
OSH, CA, agitation, anticholonergic¹                        
dose titration required. 
over dose can be fatal  
Nortriptyline                                                                                                 
 
40-200 drowsiness, insomnia, OSH, CA,↑weight, 
anticholonergic¹ 
dose titration required. 
over dose can be fatal 
Maprotiline 100-225 drowsiness, insomnia, OSH, CA, anticholonergic¹ dose titration required. 
over dose can be fatal 
NE and 5-HT Reuptake 
Inhibitor 
   
Amitriptyline 75-300 drowsiness, OSH,CA, ↑weight, anticholonergic¹ dose titration required. 
over dose can be fatal 
Doxepin 75-300 drowsiness, OSH,CA, ↑weight, anticholonergic¹ over dose can be fatal 
Imipramine 75-300 drowsiness, agitation, insomnia, OSH, CA, 
 anticholonergic¹ 
dose titration required. 
over dose can be fatal 
Trimipramine 75-300 drowsiness, OSH,CA, ↑weight, anticholonergic¹ dose titration required. 
over dose can be fatal 
Venlafaxine       75-375 sleep changes, GI distress,                                                                                                                      
discontinuation syndrome                            
higher dose may cause
hypertension dose 
titration is required.                                                                                                                                        
Abrupt stop may cause 
discontinuation 
symptoms. 
Clomipramine                          75-300                             drowsiness, ↑weight                                            dose titration required 
Duloxetine    30-60 GI distress, discontinuation                                                                                  
Syndrome 
dose titration required
Pre- and post-synaptic agents    
Nefazodone                                   300-600                           Sedation, dose titration required, 
no sexual dysfunction                                                     
Mirtazapine 15-45 sedation, ↑weight dose titration required, 
no sexual dysfunction                                                     
Dopamine Reuptake Inhibitor    
Bupropion                                      
  
200-400                           insomnia, agitation, GIT distress                                              No sexual dysfunction 
Mixed Action Agents    
Trazodon 150-600 drowsiness, OSH, CA, GI distress                              ↑weigh Priapism is possible   
Amoxapine 100-600 drowsiness, insomnia, agitation, OSH,CA, ↑weight, 
anticholonergic¹ 
dose titration required, 
movement disorder 
 
CA: cardiac arrhythmia; 5-HT: serotonin, GI: gastrointestinal; NE: norepinephrine; OSH: orthostatic 
hypotension; SSRI: selective serotonin reuptake inhibitor; 1 dry mouth, blurred vision, constipation, urinary 
urgency.                                           
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Algorithm for the Management of Depression 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
• Make a diagnosis and access severity and risk 
• Select appropriate antidepressant with the patient 
• Assess the need for: hospital treatment, community treatment with or without home treatment team 
• Consider the predisposing and precipitating factors  
• Explain diagnosis, treatment plan, and share decisions/choice with the patients and relatives 
• Effect of treatment (benefits and risk) and provide guidance leaflet 
• Follow up in 2 weeks 
• Review effects and side effects of treatment and provide required reassurance and 
enquires 
• Follow up every 2 weeks 
• Assess the response to treatment at 6 weeks and earlier if the condition worsens 
If better: 
• Continue treatment 
• Review need to modify 
precipitating and 
maintaining factors 
If not better: 
• Review diagnosis 
• Review adherence 
• Review dosage 
If treatment inadequate: 
• Consider changing 
antidepressant 
• Consider specialist 
opinion 
• Consider referral to 
secondary care 
When recovered: 
 Continue antidepressant for 6 
months 
 Consider long-term treatment 
depends on the number of 
episodes( second episode 1 year, 
third episode 2 years) 
If treatment inadequate: 
 Increase the dose and 
review once or twice a 
week 
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Figure 8 Management of depression 
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2.3 Depression in Chronic Physical Illness 
The role of depression in physical illness has been recognised and addressed 
extensively by the National Institute for Health and Clinical Excellence (CG91 
Depression with a Chronic Physical Health Problem: NICE Guideline. National 
Collaborating Centre for Mental Health, London, 2009). Depressive symptoms, 
particularly when persistent and severe, may be associated not only with impaired 
quality of life but also with a reduced survival (156). Patients with chronic physical 
illness who are depressed are at risk because of the difficulty in adhering to 
complicated treatment regimens or because of suicidality. However, although the 
presence of major depression has important clinical implications in medically ill 
patients, the recognition of depression by physicians is poor (157). The failure to 
diagnose depression may be due to uncertainty about the diagnostic validity of many 
of the symptoms of depression in the presence of a medical illness and to pessimism 
regarding the possibilities for therapeutic intervention. Such pessimism may be 
unwarranted (158). 
When depression occurs along with another medical or psychiatric condition, the 
term ‘compound depression’ is often used (159). 
The diagnosis and treatment of depression in patients with physical illness is 
challenging and the disorder is in general more treatment resistant than depression in 
patients without other medical or psychiatric comorbidities (24, 160-162). 
  
2.3.1 Clinical Features 
Psychological symptoms associated with physical illness are very common but do 
not always indicate a depressive illness. Adjustment disorders commonly follow the 
onset of an acute illness. Symptoms of low mood, anxiety, guilt, and hopelessness 
develop in response to an identifiable stressor but are not persistent. The boundary 
between adjustment and depressive disorders is not clear-cut, but the key determinant 
is the severity and duration of symptoms (see next paragraph). Other indicators of a 
possible mood disorder are failure to adjust to the illness, poorer physical 
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functioning, slower recovery than would be expected, and reduced social interaction 
(163).  
Depressive syndromes and medical illnesses may relate through several mechanisms. 
A medical condition may affect self-esteem, body image, or social functioning, or it 
may alter psychodynamic equilibria. These effects may themselves be sources of 
stress that can overwhelm coping mechanisms and hence contribute to depression 
(164). Organic factors in the medically ill may contribute to depression and to 
symptoms that resemble depression. 
Medical conditions may produce both somatic and cognitive-affective symptoms that 
result in false-positive diagnoses of depression. Biologic factors including metabolic 
disturbances and the effects of medications may also result in depressive syndromes 
– referred to as organic affective disorders.  
Five or more symptoms of depression that persist over a two-week period are 
indicative of a depressive illness that warrants specific treatment. Asking about self-
harm is essential as chronic physical illness (particularly cancer, HIV and AIDS, 
renal disease, and chronic pain) is associated with an increased risk of suicide (165).  
 
2.3.2 Epidemiology 
Depressive disorders are 1.5-4 times more prevalent in medically ill patients than in 
the general population (166). Mood disorders can be regarded as the final common 
pathway arising from the interaction between multiple pathophysiological, 
psychological, and socioeconomic stressors that chronic illness imposes on the 
individual (167). 
The diseases with the highest prevalence of major depression (95% CI for MD 
prevalence %) have been reported as follows: chronic fatigue syndrome (32.0-40.7), 
fibromyalgia (19.4-24.9), inflammatory bowel disease (14.6-18.2), asthma (12.4-
14.4), back problems (12.0-13.3), multiple sclerosis (10.9-20.6), epilepsy (10.0-
17.2), cancer (9.7-13.8), COPD (8.8-14.6), migraine (8.2-12.3), rheumatic arthritis 
(9.4-10.6), stroke (6.7- 10.6), diabetes mellitus (6.7 -8.6), heart disease (6.4- 8.2), 
and Parkinson’s disease (2.2-13.7) (168).  
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2.3.3 Aetiology 
Depression in chronic physical illness can occur as a specific consequence of that 
illness or as an adverse effect of drug treatment. Additionally, a psychological 
reaction to physical illness may be precipitated by the exacerbation of an illness or 
the realisation of its serious or disabling nature. Uncertainty about the future, feelings 
of loss of control, and a sense of failure are common responses to illness but do not 
inevitably lead to depression. Risk factors for the development of a mood disorder 
include: a prior history of depression, low social support, substance misuse, and 
additional stressful life events such as marital separation or loss of job (169).  
 
2.3.4 Diagnosis 
The diagnosis of depression in chronic physical illness is the same as in the general 
population. There is also a need to consider the illness presentation and medication. 
There are specific criteria in DSM-IV that need to be taken account in assessing 
patients with chronic physical illness. A prominent and persistent disturbance 
in mood predominates the clinical picture and is characterised by either (or both) of 
the following: 
 Depressed mood or markedly diminished interest or pleasure in all, or almost 
all, activities  
 Elevated, expansive, or irritable mood  
 In addition to: 
o Evidence from the history, physical examination, or laboratory 
findings that the disturbance is the direct physiological consequence 
of a general medical condition 
o Disturbance is not better accounted for by another mental disorder 
(e.g. adjustment disorder with depressed mood in response to the 
stress of having a general medical condition)  
o Disturbance does not occur exclusively during the course of 
a delirium  
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o Symptoms cause clinically significant distress or impairment in 
social, occupational, or other important areas of functioning  
Symptoms such as insomnia and appetite change may also be due to physical illness, 
and in assessing depression there is no evidence that taking account of somatic 
complaints leads to over-diagnosis (170). In fact, depression comorbid with physical 
illness is often missed for reasons such as misattribution of symptoms as a normal or 
realistic response to illness, negative attitudes to a diagnosis of depression, 
unwillingness of patients to report symptoms, and unsuitability of the clinical setting 
for the discussion of emotional problems (171). 
 
2.3.5 Management 
In the management of depression in chronic physical illness, account should be taken 
of the patient’s age, multiple comorbidities, drug therapy, polypharmacy, and 
potential drug interactions.  
 
2.4 Depression in ESRD 
Most people with ESRD who require dialysis treatment report psychological distress, 
and people with CKD identify improving psychosocial aspects of living with their 
illness among their most important research priorities (59, 172). I will discuss the 
contributing factors to depressive disorder in this group of patients in the following 
sections. 
 
2.4.1 Contributing Factors to Depressive Disorders in ESRD 
There are multiple factors that contribute to depression in ESRD. These are 
summarised in the Figure 9 and were explained in the previous kidney chapter.  
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2.4.2 Prevalence of Depression in CKD 
In a systematic review and meta-analysis of observational studies (173), the point 
prevalence of depressive symptoms ranged between 1.4% and 94.9%, with an overall 
meta-analytical prevalence of 34.0%. The point prevalence of depressive symptoms 
when using self-rating scales was statistically different in each stage of CKD, with 
dialysis patients experiencing the highest rate of depressive symptoms. The point 
prevalence of depression was markedly lower when adjudicated by clinical interview 
using specified diagnostic criteria (Table 10). 
 
 
 
Biological factors 
Uraemic toxins (sleep disturbance, fatigue, 
reduced appetite, pain, decreased sexual 
drive) 
Chronic inflammation  
Disturbance of glucose-insulin homeostasis 
HPA axis deregulation 
Changes in hormonal activity 
Psychological factors 
Changes in social roles 
Self-image 
Loss of freedom 
Hopelessness 
Negative body image 
Low self-esteem 
Comorbidities (death/dying) 
Uncertain future 
 
 
 
Socio-economic factors 
Younger age 
Female gender 
Unemployment 
Low income 
Poor social support 
DEPRESSION 
Figure 9 Factors contributing to depression 
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Table 10: Prevalence of depression in CKD, (173) 
 
2.4.3 Prevalence in the Dialysis Setting 
The prevalence of depression in haemodialysis patients as adjudicated by clinical 
interview was 22.8% (Table 11). When assessed using self- or clinician-administered 
questionnaires, the overall estimated prevalence of depressive symptoms was 
statistically higher than reported in interview studies (39.3%). The prevalence of 
depressive symptoms varied by screening tool used in the order of increasing 
prevalence: the HADS, Center for Epidemiological Studies – Depression scale, the 
BDI, the Hamilton Depression Scale, and the Zung SDS (Table 11).  
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Table 11: Prevalence of depressive symptoms in people with ESRD on dialysis, 
(173) 
 
CI, confidence interval; BDI, Beck Depression Inventory; CES-D, Center for Epidemiological Studies 
Depression Scale; HADS, Hospital Anxiety and Depression Scale; Hamilton, Hamilton Depression Scale. 
 
2.4.4 Prevalence in CKD 
In the setting of earlier stages of CKD (Stages 1-5), prevalence of depressive 
symptoms in individuals ranged from 7.0% to 50.0% (Table 12). In reporting 
depression assessed using clinical interview and patient- or clinician-completed 
rating scales, the pooled prevalence was 21.4% and 26.5%, respectively. 
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Table 12: Prevalence of depressive symptoms in people with chronic kidney 
disease Stages 1-5, (173) 
 
 
2.4.5 Prevalence in Transplant 
In the transplant setting, the reported prevalence of depressive symptoms ranged 
between 2.0% and 76.5%. The prevalence of depression assessed by interview was 
25.7% and that assessed by self-rating scales was 26.6% (Table 13). 
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Table 13: Prevalence of depressive symptoms in kidney transplant recipients, 
(173) 
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2.4.6 Screening 
Self- or clinician-completed assessments for depression are generally used in clinical 
settings for screening and in clinical research for pragmatic reasons to reduce time 
and financial costs. In addition, numerous cut-off point scores have been described 
for the available rating scales to identify patients in the ESRD population as having 
clinically relevant depressive symptoms and to estimate sensitivity and specificity of 
cut-off points in this setting. Self-administered diagnostic tools tend to overestimate 
the prevalence of depression in CKD, particularly for patients with ESRD, compared 
with clinical interview. Self-report measures are likely to assign symptoms 
commonly experienced in severe CKD (such as fatigue, sleep disturbance, and poor 
appetite) as indicative of the somatic symptoms of depression and may 
inappropriately classify such patients as depressed. Interviews to adjudicate 
depression based on specific diagnostic criteria such as the DSM-IV may provide a 
more accurate estimate of depression prevalence. Although self-reporting scales are 
efficient and require fewer clinical resources to administer, in the dialysis setting 
particularly, interview-based diagnosis is the most appropriate for the assessment and 
management of depression (173). This is due to the multiple factors, including the 
uraemic syndrome, as previously discussed in the kidney chapter.  
A number of measures have been used to screen for depressive symptoms in patients 
with ESRD, including: BDI version II (BDI-II), 16-item QIDS-SR, CESD, HADS, 
and the PHQ-9, as in Table 14. The optimal screening tool and diagnostic method to 
identify depression and depressive affect in patients with renal disease remain 
unknown, although several studies have been performed to determine the validity 
and accuracy of these tools in the ESRD population (174-176). I will cover 
comprehensively the use of both the BDI-II and PHQ-9 as the screening tools used in 
this empirical study.  
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Table 14: Screening tools used in advanced kidney disease 
Scale No of 
items 
Score , 
range 
Cut-off 
score in 
general 
population                                                                                
Cut-off score in CKD 
(sensitivity, specificity)                                                          
Cut-off score in ESRD 
(sensitivity, specificity)                                             
Ref 
BDI                                     21 0-63                        ≥10                       ≥11 (89%, 88%)                                    ≥14-16 (62-91%, 81 86%)                                                                  (174-178)
QIDS-SR 16                  0-27                        ≥10                       ≥10 (91%, 88%)  (178) 
CESD 20                 
  
0-60 ≥16  ≥18 (69%, 83%) (176) 
PHQ-9            
 
9                  0-27 ≥10                       ≥10 (92%, 92%) (175) 
HADS                                                                                                                            14 0-21 ≥8 ≥12 (81%, 90.2%) (179) 
 
BDI: The BDI-II is a revision of the original BDI-1A to correspond with the 
diagnostic criteria of the Diagnostic and Statistical Manual of Mental Disorder, 
Fourth Edition (DSM-IV) criteria for Major Depressive Disorder. The BDI-II 
includes four new items not present in the BDI-1A: agitation, worthlessness, loss of 
energy, and concentration difficulty. Four items on the BDI-1A (weight loss, body 
image, work difficulty, and somatic preoccupation) are not included in the BDI-II. In 
addition, the BDI-II asks patients to answer questions regarding how they have been 
feeling over the ‘past two weeks, including today’, reflecting the timeframe for 
symptoms described in the DSM-IV. The BDI-II has been found to have good 
reliability (α=0.91) in outpatient samples with various psychiatric disorders (180, 
181).  
The BDI-II was chosen for use in the studies to be presented because it conforms to 
current diagnostic criteria for MDD (DSM-IV) and because its properties in general 
and clinical samples have been well examined (77, 180, 181). Furthermore, the 
original BDI has also been used with the ESRD setting and more recent work has 
shown that the original compares well with diagnostic standards, if cut-off scores are 
adjusted upwards (182). In one of the first empirical studies to test the BDI in ESRD 
patients, Craven et al. (174) evaluated the measure against DSM-III criteria for 
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depression in 99 patients. They found that a BDI ≥15 produced optimal sensitivity 
(0.92) and a negative predictive value (0.99). The authors note that increasing the 
cut-off above ≥15 decreased sensitivity and did not produce a meaningful increase in 
positive predictive value. 
More recent data confirms that the cut-off on the BDI needs to be adjusted upwards 
for use in ESRD patients, presumably due to increased somatic symptoms 
encountered in this population. For example, a BDI cut-off ≥16 was shown to 
compare well with diagnostic standards, revealing 91% sensitivity and 86% 
specificity for depression when compared to the SCID in ESRD patients, and 
revealed utility for the shorter PHQ where a cut-off score of ≥10 was associated with 
92% specificity and sensitivity (175). 
The BDI and CES-D measures were compared against the SCID in 98 HD patients 
(176). A CES-D score >18 gave 69% sensitivity and 83% specificity for depression. 
A BDI cut-off of 14 yielded 62% sensitivity and 81% specificity. A study in UK 
dialysis patients compared the BDI against the ICD-10 diagnostic criteria for MDD 
(182). Analysis of 57 dialysis patients’ BDI scores against the diagnostic criteria 
found that a BDI ≥15 produces 78% specificity and 100% sensitivity, whereas a BDI 
≥20 produces 92% specificity and 71.4% sensitivity. Interestingly, these studies have 
utilised the original BDI and not the BDI-II. Given that the BDI-II leads to slightly 
higher mean total scores compared to the BDI, it could be assumed that a cut-off 
score based on the BDI-II in ESRD would be marginally higher that the 14-15 cut-
off scores reported in studies that used the BDI. However, it should be noted that 
some confusion has been reported within the wider literature regarding the correct 
citation of versions of the BDI (183). For example, in one ESRD study, the authors 
failed to cite the version of the BDI used, instead citing apparent ‘validation’ studies 
(184). The failure to adequately describe the questionnaire version inhibits the 
reliable comparison of scores between studies (and estimated prevalence based upon 
cut-off scores that differ between versions) and may misinform as to which version 
to use in subsequent studies.  
PHQ: The PHQ and subsequent variants (including the Brief PHQ, PHQ-9, PHQ-8, 
and PHQ-2) were developed from the Primary Care Evaluation of Mental Disorders 
(PRIME-MD). The PHQ was validated using 3,000 primary care patients in eight 
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different clinics and 3,000 obstetrics/gynaecology patients in seven different clinics 
(185). Shortened versions combined the two original components into a self-
administered version called the PRIME-MD PHQ (186).  
The PHQ-9 and the shorter PHQ-2 are the depression modules of the PHQ and 
currently the most widely used versions in clinical settings. Another variant, the 
PHQ-8, is used primarily in research studies and includes all items of the PHQ-9 
except the ninth item that pertains to self-harm. The PHQ-9 detects and measures 
depression and severity in medical populations in clinical settings. Higher PHQ-9 
scores correlate with increased depressive affect (79).  
The nine items on the PHQ-9 consist of the nine criteria on which the DSM-IV 
depressive disorder diagnoses are based. Interpretive guidelines for the PHQ-9 as a 
severity measure: 1-4, no depression; 5-9, mild depression; 10-14, moderate 
depression; 15-19, moderately severe depression; and 20-27, severe depression (79). 
A diagnosis of MDD is considered if ≥5 of the nine symptom criteria have been 
present at least ‘more than half the days’ in the past two weeks, and if one of the 
symptoms is depressed mood or anhedonia or the criteria of ‘thoughts that you would 
be better off dead or of hurting yourself in some way’ is present at all. Consideration 
of other depressive disorders is recommended if two, three, or four of the nine 
symptom criteria have been present at least ‘more than half the days’ in the past two 
weeks, and one of the symptoms is depressed mood or anhedonia. The 
recommendation is that a clinical evaluation be the final determination of depressive 
disorder diagnosis (79).  
Severity of depression as measured by the PHQ-9 was found to be highly correlated 
with scores on the BDI in the general population (r= 0.73). Strong associations were 
also found between the PHQ-9 and 20-item Short-form Health Survey (SF-20) 
scores, particularly those scales most strongly related to depression (e.g. mental 
health), as well as with self-reported disability days, clinic visits, and the amount of 
difficulty self-attributed to symptoms (187). Similarly strong correlations were found 
between PHQ-2 and SF-20 scores, with the strongest correlation again with mental 
health (range 0.63-0.70) (188). Test characteristics (sensitivity, specificity, likelihood 
ratio, and area under the receiver operator characteristic (ROC) curve) were found to 
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be similar for the PHQ-2 in comparison to the Symptom-Driven Diagnostic System 
for Primary Care (SDDS-PC), Medical Outcomes Study (MOS), CES-D, 10-item 
CES-D, BDI, and 13-item BDI-II (189). 
 
2.4.7 Complexity of Diagnosing Depression in ESRD Population 
A distinction must be made between depressive affect, as assessed by self-report 
questionnaires, and a psychiatric diagnosis of depressive disorder based on DSM-IV 
criteria (176, 190). High levels of somatic/uraemic symptoms, such as fatigue, poor 
appetite, and sleep disturbance reported by chronically ill ESRD patients on self-
administered depression scales may be misclassified as symptoms of depression and 
lead to a false diagnosis of depressive disorder (25, 191-193). Cognitive impairment 
is common in depression and ESRD and impairments in cognition have been found 
to persist beyond acute episodes of depression, and between one-third and one-half 
of remitted depressed patients are thought to be affected by cognitive deficits (123). 
Patients who had cognitive impairment while depressed continued to experience 
deficits in cognition when remitted from depression(194). Formal diagnosis of 
depression requires a structured clinical interview based on agreed criteria, e.g. 
MINI. 
 
2.4.8 Association and Consequences of Depression in ESRD 
Population 
As mentioned earlier, depression has been associated with the response to a loss of 
some kind (195). ESRD patients have sustained multiple losses, including loss of 
role within the family and workplace, loss of renal function and mobility, loss of 
physical health and cognitive abilities, and loss of sexual function (24). Medications 
used to treat patients with ESRD might also cause depression or have side effects 
that mimic its symptomatology.  
 Quality of Life (QoL): Over the past decade, increasing emphasis has been 
given to quality of life as survival with chronic diseases has increased. The 
World Health Organisation defines quality of life as ‘an individual’s 
63 
 
perception of their position in life in the context of culture and value systems 
in which they live and in relation to their goals and expectations, standards 
and concerns. It is a broad ranging concept affected in a complex way by a 
person’s physical health, psychological state, level of independence and their 
relationships to salient features of their environment’ (26). Clinical and socio-
demographic factors in the context of HD, such as the presence and severity 
of anaemia, malnutrition, inflammation, sleep disorders, sexual dysfunction, 
unemployment, and low socio-economic status, have been shown to be 
associated with impaired quality of life (196). Importantly, however, these 
clinical and socio-demographic factors account for only a fraction of the 
variance in HRQL scores (28).  
Depression and anxiety are important independent predictors of low quality 
of life across all RRT modalities. Depression not only undermines the 
patient’s mental and physical health but also alters their subjective perception 
of physical status, functional capacity, and social function. It has been 
proposed that depression and anxiety may be more strongly associated with 
HRQL than clinical and socio-demographic variables taken together (28-32). 
In the context of chronic illnesses, the most widely studied aspect of quality 
of life has been Health-related Quality of Life (HRQL). This construct gives 
insight into the patient’s perception of the physical and psychosocial impact 
of the illness and its treatment on their lives. Due to each patient’s 
idiosyncratic perception of his/her illness, skills for adaptation, and 
socioeconomic background, people with the same health status may have 
very different HRQL.  
 Treatment and dietary adherence: As with most chronic illnesses, non-
adherence to a prescribed medical treatment regimen is pervasive in patients 
receiving HD (197). In addition, dialysis patients need to adhere to a 
multifaceted treatment regimen, undergo regularly scheduled and time-
consuming dialysis treatments, as well as follow a strict medication and 
dietary regimen. Regular doses of phosphate-binding medication are required 
to reduce intestinal absorption of phosphorus-rich foods (e.g., dairy products) 
due to the body's inability to excrete phosphorus (P). Sustained elevations in 
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serum P are associated with a variety of complications, including 
hypocalcaemia, hyperparathyroidism, and vascular calcification. 
There are also major limitations on the amount of fluid that can be safely 
consumed due to the intermittent nature of haemodialysis. Prolonged fluid 
overload is associated with hypertension and heart failure, and is potentially 
life-threatening. Interdialytic weight gain is typically used to define 
adherence to the fluid-intake restrictions (198). Higher values are interpreted 
as reflecting poorer patient adherence, with values over 2.5 kg (or over 4% of 
the patient's body weight) generally indicative of problematic adherence 
(199). High interdialytic weight gains lead to increased requirement for 
ultrafiltration during dialysis and can result in cramps and hypotension (200). 
Studies examining the prevalence of non-adherence among renal dialysis 
patients have typically observed that between 30% and 50% of dialysis 
patients do not adhere to diet, fluid-intake, and medication regiments (199, 
201-204). 
 Mortality and hospitalisation: Though depression has been associated with 
increased mortality in the general medical population (205-210), the 
relationship between depression and mortality in CKD patients has proved 
difficult to clarify. Early studies with relatively small sample sizes, using a 
variety of self-report questionnaires for cross-sectional assessment of 
depressive symptoms, did not find any association (211-215) in contrast to 
others (193, 216-219). Such studies have often compared means between 
groups of deceased and surviving patients without accounting for potentially 
confounding medical and demographic factors. However, in a large 
multinational sample in the DOPPS I, ESRD patients treated with 
haemodialysis who were classified as depressed and those who reported 
frequent depressive affect had higher risk of mortality, withdrawal from 
therapy, and hospitalisation (220). Persistent or worsening depressive 
symptoms over repeated assessments (rather than a single depressive episode) 
also predicted long-term CKD mortality (221). Kimmel et al. assessed 
depressive symptoms in 295 chronic HD patients over 20 to 60 months, and 
found that though baseline depressive affect did not predict mortality over 
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this period, changes of depressive symptoms did (211). Also, physician-
diagnosed clinical depression may predict mortality more strongly than self-
reported depressive symptoms (221).  
Boulware and colleagues evaluated baseline and longitudinal data from the 
Choices for Healthy Outcomes in Caring for End-stage Renal Disease 
(CHOICE) study, with a large cohort of 1,041 incident patients starting 
peritoneal dialysis and haemodialysis (222). They determined that levels of 
depressive affect at the beginning of their study were not associated with 
increased overall mortality. However, using several different time-dependent 
analyses, they demonstrated that persistently higher levels of depressive 
affect over time were associated with increased risk of death and 
cardiovascular events in both adjusted and unadjusted analyses. A recent 
meta-analysis has supported the relationship between depression and 
mortality in CKD (223). 
Haemodialysis patients with depression are twice as likely to require 
hospitalisation within a year compared with those without depression (221). 
They had a 30% increase in both number of hospitalisations and cumulative 
hospital days (224). In a prospective observational cohort study of 267 
consecutively recruited patients with Stage 2-5 CKD pre-dialysis patients, a 
diagnosis of current major depressive episode at baseline was associated with 
an increased risk (adjusted hazard ratio 1.86) of a composite of death, 
hospitalisation, or progression to dialysis, independent of comorbidities and 
kidney disease severity (225). 
 Fatigue: Fatigue is a symptom commonly experienced in the general 
population. Although fatigue is often a consequence of medical or psychiatric 
illness, many people experience fatigue related to lifestyle or situational 
factors, such as lack of sleep or stress. Fatigue is a psychosomatic syndrome 
that is also common in HD patients, and a key area of overlap with 
depression. Its prevalence ranges from 42% to 89% according to treatment 
modality and assessment instruments employed (226). Fatigue was as 
common as depressed mood in 62 patients on HD interviewed and followed 
for a mean of 29 months, as shown in Figure 10 (29). There is a joint 
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relationship between fatigue and frailty mediated by the common biomedical 
determinants shared by frailty and  fatigue (227). Forty percent of individuals 
with depression have frailty and a similar proportion of those with frailty 
have depression (137). A full review of fatigue in ESRD will be covered in 
the fatigue chapter.  
Figure 10 Symptoms frequency in HD patients, (29) 
 
 
2.4.9 Management 
Despite the high prevalence of depressive symptoms as well as depressive disorder 
among patients with ESRD and its association with poor outcomes, only a minority 
of chronic dialysis patients receive adequate diagnosis and treatment for depression 
(176, 184, 228). For example, in a retrospective analysis of the African American 
Study of Kidney Disease and Hypertension Cohort Study, only 20% of CKD 
participants with a BDI score of >14 (above the threshold validated for depression) 
were prescribed antidepressant medications (229). Similarly, Watnick et al. (184) 
reported that only 16% of ESRD patients initiating chronic HD with BDI scores of 
≥15 were on antidepressants. In a prospective observational cohort of 98 prevalent 
HD patients, nephrologists were informed about a current diagnosis of depressive 
disorder based on DSM-IV diagnostic criteria in 26% of cases (221). However, 
interventions were carried out in less than a quarter of these patients.  
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Once the diagnosis of clinical depression is made, treatment options need to be 
tailored to the individual needs of the patient and the resources available to the 
clinical team or dialysis facility. There are a variety of treatment options available. 
NICE recommends that chronically ill patients with comorbid depression be treated 
with CBT and/or SSRIs (150). Despite their proven efficacy among the physically 
well population, there are factors that may prevent SSRIs from being effective in the 
ESRD population. NICE recommends conducting a placebo-controlled trial of at 
least six months duration in patients with COPD because of the dearth of published 
data (150). Similar comments have been made with respect to ESRD (230). 
 
2.4.9.1 Antidepressant Pharmacotherapy in ESRD 
Antidepressant medications are generally highly protein bound and not removed 
significantly by the dialysis procedure (231). They commonly undergo hepatic 
metabolism, but many have active metabolites that are renally excreted, leading to 
accumulation of potentially toxic metabolites in patients with decreased glomerular 
filtration rates (232). In addition, there is a significant risk of drug–drug interactions 
in ESRD patients who, because of a large burden of comorbidities and metabolic 
derangements, may already be taking other medications.  
Several classes of antidepressants such as serotonin modulators, tricyclics, and 
tetracyclics have cardiac side effects such as QTc prolongation, arrhythmias, and 
orthostatic hypotension. Given that a large proportion of patients with ESRD suffer 
from CVD, use of such medications without clinical trials to advocate safety must be 
carefully considered. Central nervous system depression is also a common adverse 
event. Increased bleeding risk was reported in association with SSRIs (231), which 
may become problematic in ESRD due to underlying platelet dysfunction related to 
uraemia. Finally, the serotonergic gastrointestinal activity of SSRIs, one of the most 
commonly used antidepressant classes, can result in nausea and vomiting, which 
again may exacerbate these symptoms in patients with ESRD (61, 232).  
A preferred group of antidepressant medications from the clinicians view was 
developed, as outlined in Table 15 (233, 234), and the appropriate medication 
selected after discussion with the nephrologist 
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Table 15: Preferred antidepressants in patients with chronic physical illness 
Antidepressant  
 
Initial dose in mg/day   Usual dose in mg/day Most common side effects 
SSRIs    
Sertraline 25  25-150 Gastrointestinal symptoms, 
central nervous system 
symptoms, sexual dysfunction   
Citalopram 10 10-40 Gastrointestinal symptoms, 
central nervous system 
symptoms, sexual dysfunction   
Paroxetine                 10 10-20 Gastrointestinal symptoms, 
central nervous system 
symptoms, sexual dysfunction   
Tricyclic drugs    
Nortriptyline 10-25 50-100 Cardiac arrhythmia, central 
nervous system symptoms, 
orthostasis 
Other drugs    
Buptopion                                        75          300 Central nervous system 
symptoms 
Nefazodone 300 600 Gastrointestinal symptoms, 
central nervous system symptoms 
 
There are insufficient data to clearly suggest that treatment of major depressive 
disorder is either efficacious or changes outcomes in ESRD patients (235, 236). Few 
studies have examined this issue and are fraught with serious limitations, including 
small sample sizes (237-241), lack of placebo control (236-239, 241, 242), and lack 
of DSM-IV-based criteria for major depressive disorder (239, 240).  
Only a few studies have examined the potential utility of pharmacologic therapy for 
depression in ESRD patients (237, 238, 240, 243). Streltzer (244) reviewed his 
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experience with tricyclic antidepressants in five HD patients; three of these patients 
had a good clinical response. Kennedy et al. (238) identified 10 dialysis patients with 
major depressive illness. Treatment with desipramine or mianserin was instituted in 
eight of these patients; two patients were felt to have medical contraindications to 
therapy. Six of the eight treated patients had a clinical response and two patients 
discontinued therapy.  
Blumenfield et al. (240) organised a randomised trial of fluoxetine therapy in 14 HD 
patients with major depressive illness. Six of seven patients treated with fluoxetine 
completed a course of therapy and reported no significant side effects. Depressive 
symptoms were improved at four and eight weeks after the start of therapy, but the 
difference was only statistically significant at four weeks. No patients discontinued 
the study drug because of adverse events, all of which were reported as minor. 
Furthermore, all patients in the intervention arm had serum plasma concentrations of 
fluoxetine and norfluoxetine <250 ng/ml at eight weeks, similar to reported levels in 
patients with normal renal function. Although this study suggests promise for use of 
SSRIs in HD patients, the short duration and small sample size did not allow for 
adequate assessment of adverse effects.  
Atalay et al. (245) reported that treatment with SSRI sertraline at 50mg per day for 
12 weeks was associated with a decrease in depressive symptoms in 25 chronic 
peritoneal dialysis patients, with BDI scores decreasing from 22 to 15 (P<0.001). 
Lack of a control group and the small sample size were major limitations. In 
addition, mean post treatment BDI score was still above the cut-off for depression.  
Koo et al. (241) reported treatment of 34 dialysis patients with another SSRI, 
paroxetine, at 10mg per day for eight weeks concurrently with psychotherapy. 
Although the authors reported a statistically significant decrease in Hamilton 
Depression Rating Scale scores (from 16.6±7.0 to 15.1±6.6, P<0.01), the clinical 
relevance of a 1.5 unit decrease in score is unclear. This study also suffered from the 
lack of a placebo control group and short-term follow-up.  
Non-randomised observational studies of antidepressant medications in ESRD 
patients on chronic peritoneal dialysis reported some improvement in depressive 
symptoms; however, major limitations included the lack of a control group, selection 
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and refusal bias, and a 50% medication discontinuation rate. Of a total of 136 
patients with ESRD on chronic peritoneal dialysis who scored ≥11 on the BDI 
depression questionnaire were studied, only 51% agreed to be further evaluated, and 
of those, only 72% agreed to have pharmacologic treatment. Finally, merely 23 of 44 
(52%) of patients who agreed to treatment completed a 12-week course of 
antidepressant medications. Although a mean decrease in BDI scores from 17.1±6.9 
to 8.6±3.2 was reported in completers, this study does underline the fact that even 
when ESRD patients were given a diagnosis of depression and treatment was 
recommended, not all agreed to medical management (236, 237).  
Until more data are available for treatment of depression in ESRD, nephrologists are 
left with the challenge of adding another medication to the growing list prescribed to 
patients with ESRD, considering non-pharmacologic therapy, or worse yet, 
dismissing depressive symptoms as nonspecific symptoms of chronic disease or 
uraemia. However, data clearly suggest that both depression diagnosis and 
depressive symptoms independently predict poor outcomes in these patients. 
Therefore, such symptoms should not be ignored. Based on the data available, if a 
trial of medication is considered, SSRIs would likely be a prudent choice because of 
established safety in patients with CVD (246). 
 
2.4.9.2 Non-pharmacotherapy 
Given the concerns and potential problems with pharmacologic treatment of 
depression in patients with ESRD, potential non-pharmacologic interventions have 
been considered. These approaches, however, are likely to challenge healthcare 
providers given the organisation and structure in ESRD care and mental health 
services in most countries (that is, the limited resources available for and limited 
recognition of the significance of providing psychosocial support). Importantly, 
several studies have now suggested an improvement in depressive symptoms in 
ESRD patients treated with various non-pharmacologic regimens.  
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2.4.9.2.1 CBT  
In a six-month randomised trial of CBT versus the wait lists from two centres in New 
York, 59 HD patients were assigned to the treatment-first group (n=33) or the wait-
list control group (n=26) (247). In the intervention phase, CBT was administered 
during dialysis treatments for three months; participants were assessed three and six 
months after randomisation. Compared with the wait-list group, the treatment-first 
group achieved larger reductions in BDI-II (self-reported, P=0.03) and HDRS 
(clinician-reported, P= 0.001) scores at three months. The BDI scores did not decline 
any further at the six-month follow-up. Among participants with depression 
diagnosed at baseline, 89% in the treatment-first group were not depressed at the end 
of treatment compared with 38% in the wait-list group (Fisher’s exact test, P=0.01). 
The treatment group experienced greater improvements in quality of life, assessed 
with the Kidney Disease Quality of Life Short Form (KDQOL-SF) (P=0.04), and 
interdialytic weight gain (P=0.002) than the wait-list group, although no effect on 
compliance was evident at the six-month follow-up.  
In another nine-month randomised trial of CBT in Brazil, 85 HD patients with a 
major depressive disorder on standardised interviewing were randomised to receive 
standard care (control group) or CBT with a trained psychologist (248). Group 
sessions were held weekly for 12 weeks, and then monthly maintenance sessions 
were continued. Baseline BDI scores decreased from 25 in both groups to 10.8±8.8 
in the treatment group versus 17.6±11.2 in the control group (between-group 
comparison P<0.002) at nine months. These significant improvements in depressive 
symptoms in the treatment group were confirmed with standardised patient 
interviews.  
 
2.4.9.2.2 Alterations in the Dialysis Treatment 
Trials have focused attention on the impact of alterations in the dialysis treatment 
regimen on depressive symptoms in HD patients (249, 250). The Following 
Rehabilitation, Economics and Everyday-Dialysis Outcome Measurements 
(FREEDOM) study is an observational cohort study of patients changing to six times 
per week HD with the NxStage machine with targeted standardised weekly KT/V of 
72 
 
a minimum of 2.1 (251). In all, 239 participants were enrolled (intention-to-treat 
cohort), but only 128 completed the study (per-protocol cohort). In the per-protocol 
group’s analysis after conversion to six times per week HD, BDI scores decreased 
from baseline values of 11.2±0.8 to 7.4±0.6 at four months, and this improvement 
was sustained at 12 months (7.8±0.7; P<0.001) However, the intention-to-treat 
analysis revealed less robust results, and BDI scores decreased from 12.8 to 10.7 
(P<0.001). One criticism of this study was that the percentage of prescribed 
antidepressant and anxiolytic medications also increased during the course of the 
study from 26% to 35% (P = 0.02). However, after adjustment for antidepressant use, 
the improvement in BDI scores remained statistically significant. Given the lack of a 
control group, the improvement in BDI scores may have occurred for reasons other 
than the intervention alone. 
The Frequent Haemodialysis Network (FHN) was a 12-month randomised trial 
comparing six-times-per-week in-centre HD with three-times-per-week conventional 
HD (250). Dialysis adequacy (Standardised Kt/V) was higher in the frequent HD 
group (3.54±0.56 v 2.49±0.27). Significant improvements in the physical health 
composite score of the Short Form-36 (SF-36) health-related quality-of-life 
questionnaire were observed. BDI scores were lower in the six-times-per-week HD 
patients, but the difference was not statistically significant.  
 
2.4.9.2.3 Exercise Training Programmes 
The impaired physical functioning of ESRD patients is well documented, the causes 
of which are multifactorial (252). An association between physical functioning 
impairments and various health-related quality-of-life measures has been well 
established (253). Thus, recent studies suggesting a beneficial effect of exercise 
programmes on depressive symptoms in ESRD are of interest (254, 255). 
A randomized 2 × 2 factorial trial of anabolic steroid administration and resistance 
exercise training was conducted in 79 maintenance HD patients (256). Interventions 
included double-blinded weekly nandrolone decanoate or placebo injections and 
lower extremity resistance exercise training for 12 weeks during HD using ankle 
weights. Exercise was associated with an improvement in self-reported physical 
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functioning on the physical functioning scale of the SF-36 (P = 0.03). In addition, 
there was a trend toward a reduction in fatigue in the groups that were assigned to 
exercise (P = 0.06). In another trial of HD patients with reduced aerobic capacity 
(measured as VO2 max (volume per time, oxygen, maximum), 35 patients were 
randomised to a 10-month intradialytic exercise training programme. There was a 
21% increase in VO2 max in the exercise group and a 39% reduction in BDI scores – 
significantly different than in the control group, in whom there was no change in 
either exercise capacity or BDI scores (254). Finally, BDI scores decreased by 34.5% 
(P<0.001) in 24 HD patients randomized to a one-year intradialytic exercise training 
programme versus 20 patients randomised to the control group (257).There was an 
inverse correlation between BDI scores and heart rate variability indices before and 
after exercise training, suggesting that decreased heart rate variability may play a 
mechanistic role in the association of depression with poor CV outcomes. 
 
2.4.9.2.4 Others 
Alternative interventions to treat depression in ESRD patients include addressing 
marital and family discord and barriers to social interactions. Marital and family 
tensions in ESRD patients are well documented, related at least in part to the stress of 
illness (258, 259). These tensions have been associated with the presence of a 
depressive affect (258). Problems with social interactions of ESRD patients are also 
well documented and have been associated with poor outcomes (259). Involvement 
of community and religious organisations could be explored (24, 55, 259). 
Addressing the concerns of caregivers of patients with disabilities may also be 
helpful in relieving stress in difficult relationships (260). 
Future directions could include exploring the possible association of depression with 
inflammation in ESRD patients. Data suggest that the reduction in cytokine 
activation associated with inflammatory conditions alone without the concomitant 
administration of antidepressant medications can result in amelioration of depressive 
symptoms. For example, in 618 patients with psoriatic arthritis treated with 
etanercept, there was marked improvement in depressive symptoms, independent of 
an improvement in associated skin or joint problems (261). 
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2.5 Summary 
Depression is common in general medical patients, approaching the prevalence of 
hypertension. It is often unrecognised and undertreated in patients with chronic 
medical illness, often leading to negative outcomes. It is particularly unlikely to be 
recognised in patients with ESRD because symptoms of depression overlap with 
those of uraemia. Consequently, prevalence estimates of depression in this 
population vary widely from 15% to 69% depending on the diagnostic instrument 
and the cut-off point used.  
Depression has now become a public health priority and it is important to consider 
instituting strategies to screen for and diagnose depression in CKD patients. What 
needs to be determined before this is whether or not treatments are efficacious and 
safe in this patient population. Importantly, the impact of treating depression on 
morbidity and mortality needs to be established though successful improvement of 
clinical depression and its symptoms. 
Overlapping symptoms of ESRD and depression may obscure the effects of 
treatment in this population. Fatigue is the major overlapping symptom. Data on 
fatigue in ESRD patients is sparse. The next chapter will give an overview on fatigue 
in ESRD. 
 
 
  
75 
 
Chapter 3 
Fatigue in End-stage Renal Disease 
 
3.1 Definitions of Fatigue 
The term ‘fatigue’ is Latin in origin. According to the Oxford Dictionary of English 
Etymology (262), the Latin word ‘fatigare’, from which the word fatigue is derived, 
means ‘to exhaust as with riding or working, to weary or to harass’. The definition of 
fatigue provided by Mosby’s (1990) Dictionary of Medical, Nursing and Allied 
Health is similar (263), which is a state of exhaustion or loss of strength and ability 
that follows an episode of physical activity or a period of emotional and mental 
pressure. 
Subjective fatigue is a sense of weakness, lack of energy, and tiredness. It can be 
conceptualised as located on a continuum of exhaustion and tiredness at one end, 
with energy and vitality at the opposite (43). This position has been supported by the 
National Institutes of Health Patient-Reported Outcomes Measurement Information 
System (PROMIS). It was also suggested that fatigue is ‘an unrelenting overall 
condition which interferes with individuals’ ability to function to their normal 
capacity’ (264).  
Objective fatigue is the inability to sustain a specified force output or work rate 
during exercise (265). Objective fatigue can also be experienced by patients with 
circulatory disorders, as in ischemic heart disease and left ventricular failure (266).  
Physical fatigue, or muscle fatigue, is the temporary physical inability of a muscle to 
perform optimally. The onset of muscle fatigue during physical activity is gradual, 
and depends upon an individual's level of physical fitness, and also upon other 
factors, such as sleep deprivation and overall health. It can be reversed by rest. It 
should not be confused with chronic fatigue syndrome (CFS), which is the complaint 
of fatigue, not relieved by rest, and lasting at least six months in the absence of 
chronic physical illness. Musculoskeletal structures may have co-evolved with their 
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corresponding brain structures in a way that allows them to adapt to environmental 
conditions (e.g. proprioception). 
Mental fatigue is a temporary inability to maintain optimal cognitive performance. 
The onset of mental fatigue during any cognitive activity is gradual, and depends 
upon an individual's cognitive ability, and also upon other factors, such as sleep 
deprivation and overall health. Mental fatigue has also been shown to decrease 
physical performance. It can manifest as somnolence, lethargy, or directed attention 
fatigue.  
Central fatigue may be defined as the failure to initiate and/or sustain attentional 
tasks (‘mental fatigue’) and physical activities (‘physical fatigue’) requiring self-
motivation (as opposed to external stimulation). This should exist in the absence of 
any clinically detectable motor weakness or dementia. Diseases that lead to the loss 
of endurance in both physical and mental tasks in the absence of serious weakness or 
dementia will therefore cause (‘central fatigue’). Central fatigue represents a failure 
of physical and mental tasks that require self-motivation and internal cues in the 
absence of demonstrable cognitive failure or motor weakness. Patients with central 
fatigue have less difficulty to perform when stimulated externally or cued in advance, 
though they have a much higher perceived effort for the executed tasks. These 
patients may also fail to complete the execution of incremental or serial tasks that 
require sustained motivation and attention. This failure of focused attention, which 
normally provides the unconscious (‘automatic’) link between the self-guided 
voluntary effort, performance of sequential motor or cognitive tasks and sensory 
input, is a characteristic feature of central fatigue.  
Peripheral or motor fatigue is due to fatigue in either the muscle itself or due to 
brain control over the muscle. Lee et al. (43) categorised the multi-dimensional 
fatigue experience of HD patients in Taiwan into three inextricably linked domains: 
physical, affective, and cognitive. These theoretical frameworks underscore the 
multi-dimensional aspects of fatigue and suggest that physiological, psychological, 
and socio-demographic factors contribute to fatigue. Figure 11 illustrates the most 
likely interaction between central and peripheral fatigue. 
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In clinical terms, fatigue is a non-specific symptom, with many possible causes. 
Fatigue is considered a symptom, rather than a sign, because it is a subjective feeling 
reported by the patient, rather than an objective one that can be observed by others.  
 
Figure 11 Schematic diagram illustrating the likely interactions between central 
and peripheral components of fatigue, (267) 
 
 
3.2 Aetiology of Fatigue 
The exact aetiology of fatigue is unknown; however, the factors contributing to 
fatigue can be categorised as physiological, psychological, and situational factors, as 
illustrated in Figure 12, all of which have multiple complex and reciprocal 
interactions with fatigue. There are a variety of interactions among the contributing 
factors and various symptoms, resulting in a synergistic impact on performance, 
which in turn reciprocally influence the symptoms and contributing factors. 
The criteria defining cancer-related fatigue (268) could be extrapolated to develop 
criteria specific for ESRD-related fatigue. The criteria include the presence of 
significant fatigue every day or nearly every day during the same two-week period in 
the past month. In addition, there should be the presence of five or more of following 
symptoms – generalised weakness or limb heaviness, diminished concentration, 
decreased interest in engaging in usual activities, insomnia or non-refreshing sleep, 
perceived need to struggle to overcome inactivity, marked emotional reactivity to 
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feeling fatigued, difficulty completing daily tasks, perceived problems with short-
term memory, and post-exertional malaise lasting several hours. The use of such 
criteria to define clinically important fatigue would help to better understand the 
prevalence and predictors of fatigue in the ESRD population.  
Figure 12: Theory of unpleasant symptoms, (269) 
 
3.3 Measurement of Fatigue 
There are a number of choices when selecting a brief assessment tool for fatigue in 
patients with ESRD. Measures of fatigue can be categorised in a number of ways. 
Some are generic, others disease-specific. Some measures are evaluative, designed to 
measure the severity of fatigue, while others have a discriminative purpose, designed 
to differentiate fatigued from non-fatigued individuals. The most widely used 
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instrument in the dialysis population is the vitality scale of the SF-36 (270). The SF-
36 vitality subscale, which consists of four items, is considered to be at one end of a 
spectrum of fatigue. The vitality construct captures a mild reduction in energy level 
but fails to capture the negative aspects of fatigue such as weakness, lack of 
motivation, and difficulty with concentration. In addition to the SF-36, a number of 
symptom indices use single items to measure the presence and severity of fatigue. 
Fatigue scales vary in brevity, reliability, and responsiveness to interventions and 
most of them have not been validated in the CKD population, although the Revised 
Piper Fatigue Scale (271), comprised of 22 items, has been shown to be reliable. The 
Multi-Functional Fatigue Inventory (MFI-20) (272) has also been used to capture 
overall fatigue. Multiple aspects of fatigue and its impact on daily life are measured 
by the Functional Assessment of Chronic Illness Therapy Fatigue (FACIT-F). In 
patients with cancer and rheumatoid arthritis, the FACIT-F scale has shown excellent 
reliability and strong association with the vitality scales of the SF-36. While most 
fatigue instruments measure the overall experience of fatigue over a period of time 
ranging from weeks to months, dialysis patients also experience day-to-day and 
diurnal variation in fatigue. Fatigue assessments using traditional instruments may 
fail to capture this variability due to recall bias.  
Ecological momentary assessment (EMA) (273) provides an important measurement 
tool to assess subjective fatigue repeatedly and reliably while avoiding recall bias. 
EMA incorporates repeated real-time measurement of phenomena such as symptoms, 
behaviours, or physiological processes as they occur in naturalistic settings. It may 
be that a real-time or experiential assessment of fatigue would provide additional 
information on the experience of dialysis patients, leading to improved treatment of 
severe fatigue. 
 Common instruments include: 
 Unidimensional: Self-report scales that focus on one dimension, typically 
severity (Table 16) 
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Table 16: Unidimensional fatigue measures 
 
Name Scale 
type 
Subscale/ 
Factor 
Time 
frame 
Target 
population 
Reliability Validity Robust 
psychometric 
properties 
Brief Fatigue 
Inventory (BFI) – 
nine items 
Eleven 
point 
Likert  
1: severity Mainly 
last 
24hrs, 
past 
week and  
present 
time 
Generic 
although not 
validated in a 
non-cancer 
population 
Internal 
consistency 
0.89-0.96 
Test-retest: 
r=0.70-0.91 
Construct: factor analysis 
verified 1 factor Convergent: 
Correlation with cancer 
fatigue scale  
(r=0.64-0.76), POMS fatigue 
(r=0.60-0.70)   
Moderate 
 
Fatigue Assess 
Scale (FAS) – 
10 items 
Five- 
point 
Likert 
1: severity How a 
person 
usually 
feels 
General 
population 
also used in 
sarcoidosis 
Internal 
consistency: 0.9 
Convergent: with CIS  
(r= 0.83, P < 0.001), with FS 
(r = 0.82, P < 0.001) 
Moderate 
 
Fatigue Severity 
Scale (FSS) - 
 
One item 
Seven-
point 
Likert 
1: impact Past 
week 
None 
specified 
Internal 
consistency: 
0.88e0.95 
Test-retest: 0.84 
Convergent: Pearson 
correlation with MAF  
(r = 0.74,P < 0.05),  
VAS-F (r = 0.37,P < 0.05),  
and Rhoten Fatigue Scale 
(RFS) (r=0.03, P> 0.05) 
Discriminative: 
Between patients with MS or 
SLE and healthy subjects and 
cut-off for severe fatigue 
Good 
 
Pearson-Byars 
Fatigue Feeling 
Checklist – 
13 items 
Two 
check 
list  
1: severity Present 
time 
General 
population, 
cancer, 
pregnancy 
related 
fatigue 
 Concurrent:  
Rating of nausea 105 
Discriminative: 
Nonclinical sample after 
fatigue-inducing task from 
control group 
Poor 
 
Rhoten 
Fatigue Scale –
One item 
10/11 
point 
self-
rating 
1: severity Present 
time 
General 
population 
although only 
validated in 
cancer  
Test-retest: not 
Reported 
Construct: did not show a 
difference between patient 
and control group 
Convergent: 
Correlated with POMS 
fatigue subscale (r=0.636); 
correlated with the Lee 
Fatigue Scale (r= 0.80) 
Poor 
 
Schedule of 
Fatigue 
and Anergia 
(SOFA)- 
10 items 
Five-
point 
Likert 
1: nature 
and 
severity 
Past few 
weeks 
General 
population 
 Discriminative: 
Between patients with CFS 
and primary care patients 
Moderate 
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 Multidimensional self-report scales gather information on more than one 
dimension of fatigue; for example, severity of fatigue and nature of fatigue, 
allowing for the calculation of a number of scores and a global score (in most 
cases) (Table 17) 
Table 17: Multidimensional fatigue measures 
Name Scale type Subscale/ 
Factor 
Time frame Target 
population 
Reliability Validity Robust 
psychometric 
properties 
Fatigue Impact 
Scale – 40 items 
Five-point 
Likert scale 
3: physical, 
cognitive, 
psychosocial 
Present 
some items 
related to 
last month 
General 
validated with 
MS and liver 
disease 
Internal consistency: 
0.93 
Concurrent: 
Sickness impact profile 
Discriminative: 
Significant difference 
between scores of MS 
and hypertensive patients 
on all scales 
Moderate 
Fatigue scale – 
11 items 
Yes/no 
response or 
four-point 
Likert scale 
2: physical 
fatigue and 
mental 
fatigue 
 General 
population 
Internal consistency: 
0.88-0.90 
Concurrent: Revised 
Clinical Interview 
Schedule (CIS-R) fatigue 
question 
Discriminative: between 
patients 
with and without fatigue 
assessed on the CIS 
Ceiling effect 
Noted 
Moderate 
Fatigue Symptom 
Inventory (FSI) – 
13 items 
Eleven 
point 
Likert scale 
3: intensity, 
duration, 
impact on 
quality of life 
Past week General pop Internal 
consistency: 
0.88-0.90 
Concurrent: Revised 
Clinical Interview 
Schedule (CIS-R) fatigue 
question 
Discriminative: 
Between patients with 
and without fatigue 
assessed on the CIS 
Ceiling effect 
Noted 
Moderate 
Multi-
dimensional 
Assessment of 
Fatigue (MAF) – 
14 items 
 4: degree, 
severity, 
distress, 
impact on 
activities 
Past week General Internal 
consistency: 
0.93 
Test-retest: 
R= 0.47-0.73 
and 0.87 
 
Construct: factor analysis 
did not support four 
factors 
Convergent: 
correlated with POMS 
fatigue 
(r= 0.78-0.84) and vigour 
(r=0.60-0.62) subscales 
Correlated with FSS  
(r= 0.74) 
Moderate 
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Discriminative: 
detects significant 
differences in fatigue 
between patients and 
controls 
The sensitivity of the 
scale has not been fully 
explored, but the scale 
did not appear to be able 
to detect small changes 
in fatigue 
Multi-
dimensional 
Fatigue 
Inventory 
(MFI-20) –  
20 items 
Five-point 
Likert scale 
5: general 
fatigue, 
physical 
fatigue, 
reduced 
activity, 
reduced 
motivation, 
and mental 
fatigue 
Previous 
days 
General: 
validated 
with a wide 
range of 
conditions 
Cancer, 
people with 
chronic 
fatigue 
syndrome, 
psychology 
students, 
medical 
students, 
army recruits, 
and 
junior 
physicians 
Internal consistency: 
range 0.53-0.93 
(mean 0.84), 
Test-retest: r= 0.76 
(total), 0.60-0.72 
(subscales) 
Factor analysis 
confirmed the 
five-factor model and 
74.2% variance 
Convergent: with a VAS 
measuring fatigue  
(r= 0.22-0.78)  
and the RFS 
(r= 0.44=0.59) 
Some limitations in the 
general fatigue scale that 
failed to discriminate 
between people with 
cancer and students. 
Mental fatigue was found 
to be less severe in 
patient group compared 
with the student sample 
Moderate 
Piper Fatigue 
Scale (PFS) – 
76 items 
Visual 
analog 
7: temporal, 
affective, and 
sensory 
dimensions of 
fatigue and 
fatigue 
severity 
Now General Internal consistency: 
0.85 
Concurrent:  
With POMS-I 
 
Poor 
Revised Piper 
Fatigue Scale 
(PFS-R) – 
22 items 
 
Eleven 
point 
numerical 
self-report 
and five 
open-ended 
4: sensory, 
affective 
meaning, 
cognitive/ 
mood, 
behavioural/ 
severity 
Now General: also 
validated with 
HIV 
 
Internal 
consistency: 
0.80-0.99 
Construct:  
factor analysis verified 
four factors. 
Convergent: 
correlated with Fatigue 
Symptoms Checklist 
(r=0.55) and Fatigue 
Subscale of POM 
(r=0.42) 
Moderate 
The Visual 
Analog 
Fatigue Scale 
(VAS-F) – 
18 items 
100mm 
VAS 
2: energy, 
fatigue 
Now General 
population 
Internal consistency: 
0.96 and 0.91, 
respectively, for 
fatigue measured in 
the morning and 
evening. Internal 
consistency: r=96 
for both mothers and 
fathers over five 
data collection times 
Concurrent validity was 
established using the 
Stanford Sleepiness 
Scale and the Profile of 
Moods States Fatigue 
subscale 
 
Moderate 
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I will focus below in the description of the two fatigue screening questionnaires that 
were used in the empirical studies. 
1. Description of the MFI-20 
The Multidimensional Fatigue Inventory (Appendix 6) is a self-report instrument. 
The current version contains 20 statements that cover different aspects of fatigue. 
These 20 items are organised into five scales. Each scale contains four items. The 
scales are balanced to reduce the influence of response tendencies as much as 
possible; each scale contains two items indicative for fatigue and two items contra-
indicative for fatigue. Indicative items (e.g. ‘I tire easily’) are formulated in such a 
way that a high score suggests a high degree of fatigue. In the case of contra-
indicative items (e.g. ‘I feel fit’), a high score indicates a low degree of fatigue. 
The respondent must compare each of the 20 statements with how he or she has felt 
lately. The choice for this timeframe was made on the basis of the considerations that 
a) the instrument has to measure persistent fatigue contrary to acute fatigue resulting 
from effort, and b) the instrument has to be sensitive to changes resulting, for 
example, from treatment. Because of the latter, the timeframe cannot be too long. 
The response scale consists of five boxes and runs from agreement with the 
accompanying statement ‘yes, that is true’ to disagreement, ‘no, that is not true’. The 
respondent must mark the box that intuitively corresponds most with his or her own 
condition. 
MFI-scales: General Fatigue (GF) (items: 1, 5, 12, 16), Physical Fatigue (PF) (items: 
2, 8, 14, 20), Reduced Activity (RA) (items: 3, 6, 10, 17), Reduced Motivation (RM) 
(items: 4, 9, 15, 18), and Mental Fatigue (MF) (items: 7, 11, 13, 19). 
The instrument can be presented as a written questionnaire, to be completed in the 
absence of a researcher or interviewer. The instructions for completing the 
questionnaire are printed on the instrument. The respondent must read these 
instructions carefully. If the instrument is used orally in an interview situation it may 
be recommended that the interviewer reads the instructions out loud. It must be 
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stressed that all questions need to be answered and that the statements refer to the 
situation of the last few days. 
The scores per item run from 1 to 5. A higher score indicates more fatigue. 
Therefore, the items indicative for fatigue need to be recoded (1=5, 2=4, 3=3, 4=2, 
5=1). This concerns items 2, 5, 9, 10, 13, 14, 16, 17, 18, 19. 
For each scale a total score is calculated by summation of the scores of the individual 
items. Scores can range from the minimum of 4 to the maximum of 20. After all, 
when a total score obtained by summation is interpreted as a global judgement 
concerning the degree of fatigue, the question remains as to whether the separate 
dimensions contribute by a similar degree to this global judgement. 
2. Description of the SF-36 energy/fatigue subscale 
The vitality (energy and fatigue) category is one of the eight health concepts (number 
7) of the SF-36. It is a 36-item short form (SF-36) constructed to survey health status 
in the Medical Outcomes Study. The SF-36 was designed for use in clinical practice 
and research, health policy evaluations, and general population surveys. The SF-36 
includes one multi-item scale that assesses eight health concepts: 1) limitations in 
physical activities because of health problems; 2) limitations in social activities 
because of physical or emotional problems; 3) limitations in usual role activities 
because of physical health problems; 4) bodily pain; 5) general mental health 
(psychological distress and well-being); 6) limitations in usual role activities because 
of emotional problems; 7) vitality (energy and fatigue); and 8) general health 
perceptions. The survey was constructed for self-administration by persons 14 years 
of age and older, and for administration by a trained interviewer in person or by 
telephone. 
The energy and fatigue subscale comprises four questions (Appendix 6). They are 
question numbers 23, 27, 29, and 31 in the SF-36. It is a six-point Likert scale, with 
each item scored on a 0-100 range so that the lowest and the highest possible scores 
are set at 0 and 100 (0, 20, 40, 60, 80, 100); extreme limitation is represented with a 
high score and absence of limitation with a low score. Scores represent the 
percentage of total possible score achieved; the reliability, central tendency, and 
variability (alpha is 0.86, mean is 52.15, and SD is 22.39).  
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3.4 Fatigue Associated with Chronic Medical Disorders 
Studies of fatigue associated with medical disorders have shown a high degree of 
correspondence between fatigue and depression. For example, ‘vital exhaustion’, 
defined as unusual fatigue, demoralisation, and increased irritability, and associated 
with the pathogenesis of cardiovascular disease, shares many features with 
depression and is highly correlated with this condition in patients with cardiovascular 
disorders (274, 275). Results of studies that have attempted to identify possible 
differences between depression and vital exhaustion have been conflicting, and 
questions remain about whether depression and vital exhaustion are independent risk 
factors for cardiovascular disorders and morbidity (275). Fatigue has also been 
highly correlated with depression in patients with rheumatological disorders (276, 
277) and other medical disorders, such as multiple sclerosis (278), cancer (279), 
heart failure (280), and HIV/AIDS (281).  
The symptomatic overlap between fatigue and depression might have confounded the 
findings of the high correspondence between fatigue and depression in medical 
disorders. This problem has been addressed in studies of cancer-related fatigue. 
Though the assessment of depression was limited to its mood components, there was 
still a high correlation between depression and fatigue. Furthermore, the association 
between fatigue and depression remained high even after items reflecting symptoms 
of fatigue were removed from measures of depression (282, 283). The strong 
association between fatigue and depression in cancer patients is not simply a function 
of overlap in their assessment. There is some evidence that depression is a secondary 
response to the experience of fatigue produced by cancer and indirect evidence to 
support the possibility that fatigue associated with cancer occurs as a consequence of 
depression (279) However, the most compelling data suggest that fatigue and 
depression share etiologic factors, e.g. pancreatic tumours may secrete neuropeptides 
and neuro-hormones that contribute to the development of both depression and 
fatigue (279). Having said this, the relationship between unexplained chronic fatigue 
and depression is still unclear (161). 
Numerous studies in a range of medical settings have shown a strong association of 
medically unexplained chronic fatigue and depression (284-287). Furthermore, a 
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lifetime history of major depressive disorder occurs in approximately 50-75% of 
individuals with CFS (288). Even after removing fatigue symptoms as criteria for 
depression, the majority of patients with CFS meet criteria for a lifetime history of 
major depressive disorder, suggesting that the comorbidity is not simply a 
consequence of diagnostic overlap between major depression and CFS (288, 289). 
The strong association of chronic fatigue and depression and the high rates of 
lifetime major depressive disorder in persons with CFS suggest that it may be a 
manifestation of major depressive disorder. One of the main arguments against this 
possibility is that about one-quarter to one-half of patients with chronic fatigue do 
not have a history of major depressive disorder (290). It is, however, important to 
consider that the presence of only one subtype of depression, melancholic major 
depressive disorder, excludes a patient from a diagnosis of chronic fatigue syndrome 
according to the Centres for Disease Control and Prevention (CDC) definition (291, 
292). It is possible that patients with CFS may have sub-threshold symptoms of 
depression, which, as discussed above, represents an important but understudied 
clinical problem. Furthermore, other subtypes of depression, such as atypical 
depression, are not excluded when making a diagnosis of CFS. As reviewed above, 
atypical depression is characterised by prominent fatigue and, like CFS, 
predominately affects women and is associated with a history of abuse (physical 
and/or psychological) (293). Unlike melancholic depression, both atypical depression 
and CFS are associated with reduced activation of the HPA axis (294).  
 
3.4.1 Prevalence of Fatigue in Community and Medical Setting 
Fatigue is a common symptom in the community, with up to half of the general 
population reporting fatigue in large surveys (295, 296) . It also is reported by at least 
20% of patients seeking medical care (39, 297-300).  
Typically, the fatigue is transient, self-limiting, and explained by prevailing 
circumstances. However, a minority of persons experience persistent and debilitating 
fatigue. When the fatigue cannot be explained by a medical condition such as 
anaemia or hypothyroidism, it may represent CFS (291). 
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Data from the Epidemiologic Catchment Area (ECA) study shed light upon the 
relationship between fatigue and psychiatric disorders, in terms of current and 
lifetime comorbidity (301). 
The prevalence of fatigue in general practice attenders, using an extensive fatigue 
questionnaire, was 10.2% of men and 10.6% of women, all of whom complained of 
feeling tired all or most of the time for more than a month (298).  
Prolonged and excessive fatigue had 13.2% prevalence in a study by Hickie et al. 
(302). In the majority of cases the symptom of fatigue was clinically significant and 
not caused by drugs, alcohol, physical illness, or injury. In addition, as a common 
symptom in the community, fatigue is also a highly prevalent complaint in primary-
care medicine (303).  
 
3.4.2 Prevalence of Frailty in Haemodialysis and its Relationship to 
Fatigue 
Ageing and demographic changes are worldwide. Although a large proportion of  
older  adults  consider  themselves  as  in  good health  and  lead  independent  lives,  
91% of this population has one or more chronic conditions, 40% live with a disability 
as reported by the National  Advisory  Council  on  Aging (304),  and  a  significant  
proportion  (10%–25%)  are  considered  frail (305).  
The prevalence of frailty for adults undergoing haemodialysis is 41.8%. Frailty is 
associated with a 2.6 times higher risk of mortality and a 40% increased risk of 
hospitalization (306). The prevalence  is 5-7 times higher than community estimates 
and compares with a frailty prevalence of 7% in adults with cardiovascular disease 
(307).   
There is a direct relationship between fatigue and frailty. The hypothesis is supported 
by the common biomedical determinants shared by frailty and fatigue, as well as by 
the established relationship of fatigue with the core elements of the cycle of frailty 
(227). 
Frailty  is increasingly  recognized  as a geriatric syndrome  that  is  distinct  from  
disability  and  comorbidity and shares common biomedical determinants with rapid 
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fatigue, aging, disease, inflammation, physical inactivity, malnutrition, hormone 
deficiencies, and changes in neuromuscular function and structure .This syndrome is 
a result of cumulative declines across multiple physiological  systems  and  
represents the  failure  of one’s functional reserve capacity  to sustain   homeostasis   
to meet the demands of everyday life (308). In addition, there is an established 
relationship between fatigue and core elements of the cycle of frailty including aging, 
disease, gender, nutrition, physical activity, inflammation, muscle strength, size, 
structure, metabolism, and blood flow, and neural and hormonal factors (309). The 
cycle of frailty in which the biological and physiological determinants of frailty were 
sarcopenia, neuroendocrine dysregulation and immunologic dysfunction, results from 
the interaction of these three systems (310). Frail   older   adults   are   vulnerable   to 
physiological and psychological stressors, and are at risk for a  range  of  adverse  
health  outcomes,  including  falls,  fractures,  disability,  death,  and  increased  
utilization  of  medical and social resources in the community, hospital, home, and  
long-term  care  institutions (136).  
 
3.5 Fatigue in ESRD 
Fatigue is one of the most frequently reported symptoms in renal patients (311, 312). 
As shown in Figure 13, a significant proportion of patients with renal disease report 
fatigue, rates that are comparable to other physical conditions. However, the exact 
prevalence remains contentious as most of the research has focused on the HD 
population and neglected patients receiving PD and transplant patients.  
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Figure 13: Prevalence estimates of fatigue in ESRD (%),  (313) 
 
Tx = Transplant patients; HD = Haemodialysis; PD = Peritoneal dialysis; PAL = Palliative care; VAS = Visual 
Analogue Scale – Fatigue; BFI = Brief Fatigue Inventory; FAS = Fatigue Assess Scale; MOS SF-36 = 
Medical Outcomes Study SF-36.  
 
3.5.1 Prevalence and Severity of Fatigue in ESRD 
Overall, there is variation regarding the estimated prevalence of fatigue, ranging 
between 42% and 89% according to treatment modality and the instruments used to 
measure the presence of fatigue. A recent large investigation using a VAS reported 
that 81.5% of HD patients experienced fatigue (226). A similarly high prevalence of 
fatigue in the HD population (77.9%) is reported elsewhere (314). Others, however, 
report lower rates when using the SF36 vitality subscale (41.9%) (Figure 13) (315).  
The severity and frequency of patients’ fatigue also varies according to the 
instrument used (Table 18). Studies using the FSS report total sum severity scores 
between 31 and 47 (44, 316-318) and mean severity item scores between 5.15 and 
6.14 (319, 320). The nine-item FSS total score ranges from a minimum of 9 to a 
maximum of 63, suggesting that the scores for renal patients indicate problematic 
levels of fatigue. Studies in the general population report significantly lower mean 
scores (M = 3.7 (321); M = 2.5 (322)). Similar findings have been reported using the 
MFI-20 (38, 323, 324). 
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Table 18: Severity of fatigue among renal patients, (313) 
Study Measure/cut-off Population  Mean Severity (SD) Scale 
Range  
n  
Akin et al. VAS HD Fatigue subscale 72.1 (20.3)  
Energy subscale 23.9 (7.8) 
13-130 
5-50  
325 
Bonner et al.  FSS CKD 47.7 (13.2) 9-63 28 
Bonner et al.  FSS Pre-Dx, HD, 
PD, Tx 
Females 43.7 (14.6) 
Males 38.7 (13.3)  
9-63 92 
Bonner et al.  FSS Pre-Dx, HD, 
PD 
39.9 (14.5)  9-63 112 
Chang et al.  Chalder Fatigue Scale  PD 5.8 (2.7)  0-14 64 
Joshwa et al.  FSS HD 31 (13.2) 9-63 47 
Karadag et al.  FSS HD Females 6.14 (1.1)  
Males 5.30 (1.9) 
1-7 73 
McCann & Boore  MFI-20  
VAS 
HD 15.3 (2.7)  
69.2 (25.3) 
4-20  
0-100 
39 
O’Sullivan & 
McCarthy  
MFI-20  HD 12.6 (4.3) 4-20  46 
Sajadi et al.  FSS HD 5.2 (1.5) 1-4 56 
Tsay et al.  PFS, VAS HD PFS = 6.0 (1.5) 
VAS = 57.7 (22.2) 
3-10 106 
Lobbedez et al.  MFI-20  HD, PD, 
controls                 
Dialysis: 14 (3)       
Controls 10.8 (4) 
4-20 54 
Tx = Transplant patients; HD = Haemodialysis; PD = Peritoneal dialysis; CKD = Chronic Kidney Disease; 
VAS = Visual Analogue Scale – Fatigue; FSS = Fatigue Severity Scale; MFI-20 = Multidimensional Fatigue 
Inventory, PFS = Piper Fatigue Scale. Mean severity data rounded to 1 d.p. 
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3.5.2 Fatigue in Haemodialysis 
The literature regarding the experience of fatigue in HD patients indicates that 
fatigue impacts the physical and mental domains. Physical fatigue was described by 
patients as a constant lack of energy, which seemed worse on dialysis days. Fatigue 
is negatively correlated with physical functioning (38, 323), role limitations (38), 
activity levels (40), and mental and physical quality of life (41). It interferes with 
patients’ abilities to manage their everyday activities (42, 43), which require more 
time to complete when patients are fatigued and cause patients to feel isolated from 
others and society. Some feel too fatigued to communicate with others and have 
difficulty maintaining close relationships (42).  
Fatigue also negatively affects patients’ abilities to remember and concentrate on 
conversations and on what is going on around them (43). Clearly, fatigue is 
frequently debilitating and hinders participation in even simple physical and mental 
activities for patients on dialysis. 
 
3.5.3 Post-dialysis Fatigue (Post-dialysis Recovery Time) 
Post-dialysis fatigue is a frequent complaint of haemodialysis patients. Patients who 
experience fatigue after dialysis require almost five hours of sleep to recover after 
their session and have more depression, insomnia, and body aches than those who do 
not experience post-dialysis fatigue (325).  
Furthermore, patients with post dialysis fatigue experience limitations in their 
functional independence and participation in social activities on the day of dialysis. 
The symptom is not predicted by clinical measures such as nutrition, laboratory 
results, or the adequacy of dialysis (326). Research suggests that it may be part of a 
symptom complex that includes nausea, muscle cramps, and headache, which may be 
the result of the fluid shifts that occur during haemodialysis (327). It is possible that 
post dialysis fatigue is conceptually similar to the persistent fatigue that patients 
experience, though it differs in severity and timing. It is a common, often 
incapacitating, and may be improved with more frequent treatment (43, 325, 327). In 
addition, the relationship between recovery time (time needed for the patient to 
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recover) and fatigue is strongest immediately after dialysis and weakens 
progressively during the time between sessions. The time to recover from HD also 
shows a significant positive association with the total dialysis stress score, which 
encompasses an array of physical signs and symptoms that can arise during HD 
procedure (328). 
 
3.5.4 Contributors to Fatigue in ESRD 
In the dialysis population, physiological, behavioural, treatment-related, and 
individual characteristics may be associated with fatigue. Physiological aetiologies 
include anaemia, malnutrition, uraemia, dialysis inadequacy, hyperparathyroidism, 
coexisting chronic illnesses, sleep disorders, depression, and side effects of 
medications. Dietary and fluid restriction may also play a role. Physical inactivity 
has been associated with higher levels of fatigue. Socio-demographic factors, 
including age, sex, race, education, marital, and vocational status, may also play a 
role in the experience of fatigue in dialysis patients. It is also important to note that 
pro-inflammatory cytokines have emerged as potential mediators of fatigue, 
providing a common biological pathway for physiologic, behavioural, and treatment-
related factors to cause fatigue in the dialysis population. 
 
3.5.4.1 Demographic Factors 
In general, patients who are older, female, and white/Caucasian may have higher 
levels of fatigue, but at times, the evidence is not clear (329). Some studies found no 
relation between fatigue and demographic variables such as age (323), gender (314), 
and education level (330). Others, though, found significant relationships between 
these and other demographic variables and fatigue. Most findings indicate that 
women report higher levels of fatigue than men (331). Others demonstrate that age is 
associated with higher fatigue levels among patients on dialysis (315). Patients 
receiving haemodialysis in their early sixties report significantly higher total fatigue 
levels than those in their thirties (330). In contrast, in other studies, age has been 
found to be negatively correlated with fatigue levels (315, 332). Some studies 
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suggest that being Caucasian and unemployed may be related to higher levels of 
fatigue (333). Others, though, found no significant differences in fatigue levels 
between the employed and unemployed (323, 334). It is possible that demographic 
variables such as these may help identify a group of patients who are more at risk for 
fatigue than others. 
 
3.5.4.2 Psychosocial Factors 
There are limited studies of the relationship between psychosocial variables and 
fatigue in the haemodialysis population, though depression, anxiety, and social 
support may all have a role. Three studies (314, 315, 335) found that fatigue was 
significantly correlated with depression in haemodialysis patients. Furthermore, not 
only depression but also a risk of suicide were correlated with fatigue (336). 
Depression has been shown to be related to fatigue severity, both physical and 
mental fatigue (38, 314). Fatigue scores are significantly higher for haemodialysis 
patients who are depressed rather than those who are not depressed. Depression is a 
significant predictor of fatigue in this population (38, 330, 337). Similarly, mood 
disorder, which includes depression and anxiety, significantly predicts fatigue in this 
population (338). Anxiety has been shown to be significantly correlated with fatigue 
(38, 315, 336, 338), though not all studies agree (332). Social support is not related 
to fatigue in haemodialysis patients (327, 338), but this relationship has not been 
studied extensively. 
 
3.5.4.3 Physiological Factors 
Physiological variables have been investigated in relation to fatigue in patients on 
dialysis. It is difficult to determine which specific facet of human physiology is most 
culpable in the occurrence of fatigue. Indeed, it may be a combination of 
physiological factors that contribute to fatigue. Interdialytic weight gain, weight gain 
that occurs between dialysis sessions as a result of fluid accumulation, has been 
significantly correlated with fatigue in dialysis patients. There is a weak but 
significant correlation between fatigue and interdialytic weight gain fatigue 
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(beta=0.43, p<0.001 and beta=0.25, p<0.05, respectively) (314). This association 
indicates that weight gain may be one of the many contributors to fatigue in 
haemodialysis patients.  
Serum chemistry and haematology measures for the most part do not seem to 
significantly contribute to fatigue in this population. There have been suggestions of 
a weak correlation between fatigue and anaemia (338), though, in cross-sectional 
analyses, most studies found that anaemia (38, 314, 331, 334, 335, 339), albumin 
levels (38, 330, 331, 334), blood urea nitrogen and creatinine levels (38, 314), 
calcium and phosphorus (38), potassium, and magnesium levels (335) were not 
related to fatigue. In contrast, fatigue increased with lower creatinine levels (due to 
lower muscle mass) and decreased significantly with higher albumin levels (315). 
The use of erythropoietin stimulating agents (ESA) to correct anaemia in dialysis 
patients has been shown to improve fatigue and HRQOL and I will expand on this in 
detail in section 3.7.3.  
There is conflicting evidence about the relationship between dialysis vintage 
(number of months or years on dialysis treatment) and fatigue (40, 332). Suboptimal 
dialysis adequacy has been suspected as the source of various uremic symptoms 
including fatigue in patients on haemodialysis (340). Studies investigating Kt/V, a 
measurement of dialysis adequacy, have failed to confirm a relation between 
adequacy and fatigue in haemodialysis patients (330, 331, 335). 
 
3.5.4.4 Inflammation  
ESRD is an inflammatory state characterised by elevated circulating levels of pro-
inflammatory cytokines (341-343).  
Cytokines might contribute to fatigue by directly activating the central nervous 
system, hypothalamic pituitary, and adrenal axis or indirectly triggering multi-system 
deregulation due to chronic inflammation (344). For example, Interferon (IFN) 
produces neurasthenia, a neurological fatigue suggestive of frontal lobe changes 
manifesting as lack of motivation (345). Cytokines such as IL-1, IL-6, and TNF-α 
suppress erythropoiesis and have been hypothesised as contributing to anaemia and 
fatigue in cancer patients (346). Cytokines (IL-6, TNF), trigger hyper-responsiveness 
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of muscular ergoreceptors, which sense fatigue or the work performed by the muscle, 
and thus contribute to fatigue (347). Cytokine-mediated malnutrition and hypo-
albuminemia may also contribute to fatigue (348). 
Although the causes of elevated cytokines in HD patients are not fully understood, it 
has been suggested that these patients have overproduction of cytokines by 
peripheral blood mononuclear cells secondary to chronic activation by interaction 
with dialysis membranes (349, 350). Moreover, in this complex pathological 
condition, the possibility of intrinsic alterations of signalling pathways and immune 
defects cannot be excluded (351). IL-6, CRP, and TNF-α have been associated with 
mortality, decreased muscle strength, and vital exhaustion in the elderly and post-
myocardial infarction patients (352-355). IL-6 also induces protein catabolism, 
lipolysis, and insulin resistance and has been shown to have a strong negative 
correlation with serum albumin in patients undergoing HD (349, 356). 
A number of human studies have linked inflammatory cytokines to fatigue in both 
aging and chronic health conditions such as cancer and CFS (346, 348, 357). 
Interestingly, elevated levels of pro-inflammatory cytokines have been linked to an 
increase in energy expenditure, mortality, and lower functional status in HD patients 
(358-360). Higher levels of IL-6 have been associated with significantly higher 
levels of resting energy expenditure (359), which has been previously associated 
with higher mortality in HD and PD (344, 358-360).  
 
3.5.4.5 Physical Activity 
Dialysis patients have severe exercise limitation, which has been attributed to muscle 
atrophy and weakness, the presence of abnormal mitochondria, and impaired 
oxidative capacity (361). Muscle fatigue, defined as the reduction in force with 
repeated or sustained contractions, can lead to manifestations of myopathy. 
Contributors to excessive muscle fatigue in dialysis patients include poor oxidative 
metabolism, greater accumulation of metabolic by-products, central activation 
failure, and impaired neuromuscular propagation (362). Endurance training has been 
shown to increase muscle strength, power, peak work rate, VO2 peak, and physical 
function (363). In addition, exercise rehabilitation programmes may have 
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morphological and metabolic benefits in the skeletal muscles and improve work 
capacity (364). 
Physical inactivity is associated with higher levels of fatigue in ESRD patients (40). 
In addition, obesity, which has been described as a chronic inflammatory state, may 
also mediate alterations in levels of certain cytokines leading to fatigue (365). Acute 
exercise results in an inflammatory response (e.g. increases in white blood cell 
counts, IL-1, and C-reactive protein (CRP), whereas regular exercise has an anti-
inflammatory effect and reduces the level of pro-inflammatory cytokines (366-368). 
However, the effect of physical activity on the immune system may be different in 
HD patients than in healthy adults (369). There is also evidence that muscle 
catabolism is increased in dialysis patients, which may be due to insulin resistance, 
acidosis. or inflammation. This may lead to muscular fatigue and further physical 
inactivity (43, 370). 
 
3.5.4.6 Sleep 
Sleep disorders have been hypothesised as associated with fatigue through two 
mechanisms: the disturbance of sleep resulting in daytime sleepiness and the separate 
underlying biological pathways associated with a variety of sleep disorders. Dialysis 
patients have high rates of sleep apnoea, insomnia, restless legs syndrome, and 
excessive daytime sleepiness (371, 372).  
Impaired sleep initiation, maintenance, and adequacy are associated with 
significantly lower vitality in both HD and PD patients (38, 53, 373). Sleep apnoea 
has been associated with lower HRQOL in patients on HD, and those without sleep 
apnoea experience significantly better vitality, social functioning, and emotional and 
mental health (48). Other symptoms, such as restless legs, which is common in 
dialysis patients, can affect sleep quality and may also impact vitality. Symptoms of 
restless legs are significantly associated with lower physical and mental well-being, 
lower vitality, higher bodily pain, and lower sleep quality (53). 
HD patients often suffer from nocturnal pruritus and difficulties finding a 
comfortable sleeping position, resulting in impaired sleep quality, which contributes 
to daytime sleepiness and fatigue (373).  
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The relationship of sleep disorders and increased levels of inflammatory cytokines 
may help explain the association of sleep disorders with fatigue in this population. 
Higher levels of Interleukin (IL)-18 were associated with poor sleep quality in HD 
patients (374). In healthy people, the administration of Tumour Necrosis Factor 
(TNF)-α and IL-1β increase the amount of non-rapid eye movement (NREM) sleep 
and decrease rapid eye movement (REM) sleep (375). IL-6 is associated with the 
amount and depth of sleep, and higher levels are associated with poor sleep (376, 
377). IL-1α and TNF-α have also been associated with sleep disordered breathing in 
dialysis patients (378). In healthy people, elevated levels of TNF-α and IL-6 have 
been associated with circadian rhythm disruption and obstructive sleep apnoea 
(OSA) independent of obesity (376, 379, 380). 
Poor sleep quality may be the result of a combination of physiological and 
psychological factors and presents a problem for many patients on dialysis (381). 
However, the extent to which poor sleep is related to fatigue in this population is 
unclear, though overall trouble with sleep is significantly correlated with general and 
mental fatigue (38). Intuitively, poor sleep is a likely cause of fatigue in the dialysis 
population, though research is lacking. 
 
3.6 Fatigue Overlapping in Depression and Uraemia 
Fatigue and depression are closely interrelated and depression may manifest as 
feelings of tiredness and lack of energy. Depression has also been shown to correlate 
strongly with overall symptom burden and severity, including fatigue in dialysis 
patients (382). 
There are conceptual similarities between depression and fatigue. Fatigue, like 
depression, can be assessed as a single symptom (a uni-dimensional approach), a 
cluster of symptoms (a multi-dimensional approach), or as a clinical syndrome with a 
set of criteria for the diagnosis of fatigue such as CFS or cancer-related fatigue (279). 
Symptoms of fatigue include physical (e.g. reduced activity, low energy, tiredness, 
decreased physical endurance, increased effort with physical tasks and with 
overcoming inactivity, general weakness, heaviness, slowness or sluggishness, non-
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restorative sleep, and sleepiness); cognitive (e.g. decreased concentration, decreased 
attention, decreased mental endurance, and slowed thinking); and emotional 
dimensions (e.g. decreased motivation or initiative, decreased interest, feeling 
overwhelmed, feeling bored, aversion to effort, and feeling low). 
Physical fatigue or loss of energy is included as a single item in the DSM-IV criteria 
for major depressive disorder. However, all of the dimensions of fatigue can be 
found in other criteria for MDD. For example, mental fatigue (e.g. difficulty 
concentrating) and emotional fatigue (e.g. anhedonia) are also associated with 
depression (383). The overlap in symptomatology makes it difficult to disentangle 
the complex relationship between depressive syndromes and fatigue syndromes in 
relation to chronic disease. Further complications in the assessment of fatigue are the 
presence of different subtypes of depression. 
Atypical depression is of particular interest when considering fatigue because 
patients with this subtype are significantly more likely than patients with other forms 
of depression to report fatigue (384). Both community-based studies and studies of 
psychiatric outpatients have shown that approximately one-fifth to one-fourth of 
depressed individuals exhibit the atypical subtype (385, 386). There is emerging 
evidence that atypical depression is associated with endocrine abnormalities that 
differ from the classic melancholic depression. In many studies of the HPA axis, 
melancholic depression is associated with hypercortisolism, which is thought to be a 
result of elevation in hypothalamic corticotropin-releasing hormone (CRH). In 
contrast to a centrally activated HPA axis in melancholic depression, atypical 
depression may be associated with a pathological reduction of stress-system 
mediators and a deficiency in hypothalamic CRH. Hypo-activity of the core stress 
system components that promote arousal could contribute to the fatigue that is 
characteristic of atypical depression (387). 
A twin study showed that fatigue during a severe major depressive episode is more 
likely to be reported by women than men (388). This evidence, along with the 
preponderance of women with the atypical subtype of depression, suggests that 
women are at greater risk of developing fatigue in depression. However, the reasons 
for the sex difference are unknown. 
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Fatigue is common in major depressive disorder (389), especially in the atypical 
subtype, and it is the depressive symptom that correlates most strongly with 
diminished functioning (390). It is also a common prodromal symptom in patients 
with their first major depressive episode (391), and it strongly predicts progression to 
a chronic course of depression (392).  
There are several competing hypotheses in the literature about the temporal 
relationship of chronic fatigue and major depression and what the differences could 
mean. Does chronic fatigue cause depression, or is it depression that causes the 
fatigue? Or perhaps fatigue and depression are conditions that arise concurrently as a 
result of a common underlying pathophysiological process.  
In a study of a national birth cohort, the causal relationship between psychiatric 
disorder and physical symptoms of fatigue seemed likely to operate in both 
directions. These findings further substantiate the idea that fatigue is neither purely 
predictive nor a consequence of psychiatric disturbance, but rather is aetiologically 
heterogeneous (393).  
In the DSM-IV diagnosis of MDD, fatigue or loss of energy nearly every day is the 
A6 criterion – and is not considered a core symptom. Furthermore, fatigue with a 
distinct quality is used as the B3 criterion for an atypical feature specifier: leaden 
paralysis (heavy, leaden feelings in arms and legs). However, in the definition of 
depressive episode according to ICD-10 (66), reduced energy is described as a core 
feature besides depressed mood and loss of interest and enjoyment. Reduced energy 
is specified as leading to increased fatigability and diminished activity, with marked 
tiredness after only slight effort being common.  
The different wordings of ‘fatigue’ in DSM-IV and ICD-10 reflect its complexity 
and heterogeneity. This is highlighted even more by the coverage of fatigue in 
different depression rating scales. The Hamilton Depression Rating Scale (HDRS) 
covers fatigue in two different items: item 7 (work and interests) and item 13 
(general somatic symptoms) (86, 394). In the BDI-II (181) fatigue is described by 
item 15 (loss of energy) and item 20 (tiredness or fatigue). Item 7 of the MADRS 
(88)] describes lassitude as representing a difficulty getting started or slowness 
initiating and performing everyday activities: a construct covering both fatigue and 
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retardation. The HDRS, BDI-II, and MADRS not only differ in their 
coverage/wording of fatigue but also in the perspective of the observer (HDRS and 
MADRS being observer-rating scales, BDI-II being a self-rating scale). Energy and 
worry are the most important symptoms differentiating depressed medical patients 
from depressed psychiatric patients, while suicidal ideation and loss of interest are 
the most important symptoms differentiating depressed psychiatric patients from 
depressed medical patients (395). 
The prevalence of fatigue and its relationship with major depression over a 13-year 
prospective follow-up study was 14.0% of individuals reporting unexplained fatigue 
for two weeks or more in their lifetimes, with an 11-fold greater risk of a lifetime 
diagnosis of major depression compared to non-fatigued participants. Baseline 
depression was predictive of both recurrent/chronic fatigue and incident fatigue. 
Participants with recurrent/chronic fatigue had a 28-fold greater risk of developing 
major depression than those without fatigue (301). 
 
3.7 Management of Fatigue 
3.7.1 Assessment and Treatment of the Cause 
Fatigue is viewed by health professionals as something that cannot be changed as it 
is part of the disease process (38). Thus, fatigue is rarely specifically treated 
medically.  
Patients with ESRD, who require maintenance haemodialysis often, reported 
symptoms of fatigue and a poor quality of life (325, 396). Yet, despite the high 
incidence of fatigue and its negative impact on life quality, few interventions have 
been developed, tested, and directed at managing this debilitating symptom in 
persons with ESRD. People with a chronic illness, especially ESRD, often feel 
helpless in dealing with their disease. This sense of helplessness or loss of control 
often occurs when medical science does not have a curative treatment to offer. 
Because there is no widely accepted tool for screening fatigue in the ESRD 
population, healthcare providers should consider screening for a sense of fatigue and 
tiredness that has a substantial impact on patients’ functional abilities. Given the high 
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rate of sleep disorders, practitioners should clarify if the patient is sleepy or drowsy 
rather than weak and lacking energy. If the patient reports that fatigue leads to 
functional impairment, providers should actively consider common causes such as 
worsening heart failure, CFS, hypothyroidism, liver disease, depression, sleep 
disorders, and autoimmune diseases as well as the kidney-disease-related factors 
outlined in this review.  
Due to the complexity of fatigue, a multi-disciplinary approach to treatment should 
be adopted by nephrologists. In order to address the level of fatigue, this symptom 
first needs to be recognised and accurately measured by healthcare providers. All 
renal providers should receive training on identifying and addressing the issue of 
fatigue, which will help to identify patterns in the severity of fatigue in patients with 
ESRD.  
A better understanding of the pathogenesis of fatigue, particularly the role of 
cytokines, may help in designing interventions aimed at reducing inflammation and 
fatigue. Management of factors such as anaemia and sleep disorders is fundamental.  
Treatment of depression, anxiety, stress, substance abuse, obesity, and malnutrition 
may be helpful, although studies substantiating the role of these interventions are 
lacking. 
Dialysis nurses may be able to assist patients understanding the importance of diet, 
exercise, sleep, and strategies to improve good practice. To provide holistic care, 
nurses should try first to understand their patients’ unique experience and try to assist 
them in developing strategies to address their problems. 
 
3.7.2 Non-pharmacological Approach 
Non-pharmacological interventions targeting nutrition, sleep hygiene, stress 
management, and treatment of depression may potentially decrease fatigue.  
An RCT of 106 HD patients who were randomly assigned into acupressure group, 
sham group, or control group showed that acupressure may help improve fatigue, 
depression, and sleep quality in dialysis patients (397).  
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Fatigue is an important outcome for daily dialysis trials since the frequency of 
dialysis may also affect fatigue in HD patients. Some studies demonstrate that, 
compared to conventional therapy, daily dialysis significantly improves perceived 
energy level, uremic symptoms, cognitive functioning, and overall HRQOL (339, 
398, 399). 
Exercise and yoga have also been studied as effective measures in improving fatigue 
(363, 400). Whether this is due to the direct effect of muscle strengthening or indirect 
effect on the cytokines (or both) is unknown.  
Energy conservation strategies, such as those used for multiple sclerosis patients, 
may similarly improve fatigue in ESRD patients (401). Overall, the bulk of evidence 
of non-pharmacologic interventions in the ESRD population in reducing fatigue 
consists of small trials assessing the impact of rehabilitation, exercise, and more 
frequent haemodialysis (402). 
‘Energy management’ is a promising method for fatigue management because it can 
be used to regulate energy and treat or prevent fatigue. There are two levels of 
energy management, including preserving energy and producing energy. For 
preserving energy, nurses must know how to teach patients to balance their rest and 
activities and use skills to save energy. Preserving energy is not enough for patients. 
Thus, nurses should provide strategies that can produce energy to help patients (403). 
The best way to create energy is regular aerobic exercise, which may actually 
improve energy levels. If the interventions can be provided, the participants’ energy 
can be saved or increased in appropriate ways, and fatigue and its effects may be 
minimised (403). 
Improving the social support for the patient with severe fatigue is crucial and helps 
the patient cope with the disabling symptoms. Fatigue and tiredness may extend to 
the caregiver, who may provide support for home dialysis or the care of a child with 
ESRD (172).Therefore, the care for patients with ESRD includes education for the 
family as well as addressing fatigue issues to the caregiver. 
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3.7.3 Pharmacological Approach 
Medical treatment for fatigue in ESRD patients may involve routine supplement of 
erythropoietin to correct anaemia that may be related to the symptom of fatigue 
(404). The use of ESA to correct anaemia in dialysis patients has been shown to 
improve HRQOL, fatigue, exercise tolerance, and work capacity (405, 406). ESA 
therapy in patients with renal insufficiency and cancer revealed a consistently 
positive relationship between HRQOL and haematocrit levels, with the strongest 
effect on the energy/fatigue domains (407). These findings were confirmed by a 
meta-analysis of the impact of epoetin alfa in patients with chronic kidney disease 
(408).  
In pre-dialysis CKD patients, the Correction of Haemoglobin Outcomes in Renal 
Insufficiency (CHOIR) and Cardiovascular Risk Reduction by Early Anaemia 
Treatment with Epoetin Beta (CREATE) studies compared the HRQOL in patients 
with higher versus lower target haemoglobin levels (409, 410). The CREATE study 
reported significantly improved fatigue symptoms in patients with higher 
haemoglobin, whereas the CHOIR study did not reveal any significant differences 
between the two groups (411).  
The lack of association between anaemia and fatigue in recent studies may relate to 
the relatively higher targeted haemoglobin levels for the control groups in the post-
erythropoietin era (412). Although anaemia, resulting from reduced erythropoietin 
production, has been cited as an important contributor to fatigue in both the dialysis 
population and other chronic conditions (413), the optimal haemoglobin target 
remains unclear and may vary among individuals depending on the severity of 
fatigue.  
The treatment of uraemia by dialysis may also influence fatigue, as the mode and 
frequency of dialysis are associated with fatigue. The potential impact of dialysis 
modality was shown in the CHOICE study (414), comparing the HRQOL in 
conventional HD and PD patients. There was no significant difference in the vitality 
scores among HD and PD patients at the initiation of dialysis therapy; however, 
patients on PD experienced significantly lower vitality at one year (415). The stimuli 
for inflammatory response in PD patients include fluid overload, decreased cytokine 
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clearance, presence of uraemia modified proteins, presence of chronic infections, and 
metabolic disturbances including hyperglycaemia (416, 417).  
Typically, fatigue and lack of energy improve with antidepressant treatment, 
although their improvement may be less rapid than other symptoms of MDD (418). 
Antidepressant-treated patients experience an improvement in energy symptoms as 
their overall depression improves. 
Besides being a common symptom of MDD or a prodromal symptom, fatigue can 
also be a side effect of antidepressant treatment, although this happens more typically 
with sedating antidepressants. On the other hand, even activating agents may be 
associated with fatigue as a side effect; this has been generally thought to be the 
result of disruption of sleep architecture, with sleepiness and fatigue being the 
consequence of poor sleep quality and sleep deprivation (419). Fatigue may also be a 
residual symptom of MDD. Studies in patients on maintenance antidepressant 
therapy showed that complaints of physical tiredness were related primarily to 
residual depression (420). One of the best known and most frequently utilised 
approaches to the treatment of residual symptoms in MDD is to augment a serotonin 
selective reuptake inhibitor (SSRI) or a serotonin norepinephrine reuptake inhibitor 
(SNRI) with bupropion, an norepinephrine (NE) and dopamine (DA) reuptake 
inhibitor (421, 422). Bupropion can increase both DA and NE in the frontal cortex, 
as well as in other areas of the brain (383, 423, 424). Bupropion may be effective in 
improving energy and fatigue, as well as executive function (425).  
There are little data suggesting that any particular antidepressant specifically 
addresses the effects on fatigue-related symptoms. Among the first-line 
antidepressant monotherapies, agents that increase NE, DA, or both, particularly in 
pathways associated with physical and mental fatigue, may be preferable for patients 
with prominent fatigue and lack of energy (426). Thus, the pharmacological profiles 
of venlafaxine, bupropion, fluoxetine, and sertraline suggest that, of the first-line 
antidepressants, these agents may be most likely to relieve symptoms of fatigue in 
depression, but this has never been adequately studied.  
A retrospective analysis of seven double-blind, placebo-controlled trials of fluoxetine 
in depression demonstrated that fluoxetine caused significant reductions in the  
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HDRS retardation factor (item 1 (depressed mood), item 7 (work and activities), item 
8 (retardation), item 14 (genital symptoms) compared to placebo (427). 
When first-line antidepressant monotherapies are not effective in the treatment of 
fatigue, a novel strategy is to target the neurotransmitters in the circuits that 
hypothetically underlie this residual symptom with a variety of augmenting strategies 
(428). Augmenting agents in the past have classically included buspirone, thyroid 
hormone, and lithium, based largely upon empirical observations (429, 430). 
However, a new set of augmenting agents can now be added to this armamentarium 
as atomoxetine or, perhaps more commonly, psycho-stimulants or modafinil (431).  
Pharmacological augmentation of antidepressant therapy has shown promise in the 
treatment of residual fatigue. Bupropion or atomoxetine, which enhance DA and NE 
in the cortical and subcortical areas of the brain, have been added to selective 
serotonergic antidepressants to improve residual fatigue (432, 433). Studies suggest 
that modafinil, which activates orexin-containing and histaminergic neurons in the 
hypothalamus and releases histamine in the hypothalamus, as well as dopamine, 
norepinephrine, and serotonin in the cortex, may relieve residual fatigue after 
treatment with antidepressants (434, 435). Modafinil, unlike central nervous 
stimulants, does not release dopamine and norepinephrine in the nucleus accumbens, 
which reduces its abuse potential. There is an advantage of modafinil over placebo in 
treating fatigue among partial responders to antidepressant treatment (436). There is 
no evidence of this pharmacological intervention in HD patients. 
A better understanding of the prevalence and pathogenesis of fatigue in HD patients, 
particularly the role of cytokines, may help in designing interventions aimed at 
reducing inflammation and fatigue. Management of factors such as anaemia and 
sleep disorders is fundamental. Treatment of depression, anxiety, stress, substance 
abuse, obesity, and malnutrition may be helpful, although studies substantiating the 
role of these interventions are lacking. In the empirical chapters to follow, we will 
focus on the interaction between depression and fatigue.  
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3.8 Summary 
Fatigue is a common complaint in the community and primary care as well as being 
associated with several medical and psychiatric illnesses and a key area of overlap in 
depression and ESRD. The literature regarding the prevalence of fatigue in 
haemodialysis patients is sparse. Physical fatigue was described by patients as a 
constant lack of energy, which seemed worse on dialysis days.  
Fatigue is negatively correlated with physical functioning, role limitations, activity 
levels, and mental and physical quality of life. It impacts patients’ abilities to manage 
their everyday activities, which leads them to feel isolated from others and society. 
Fatigue also negatively affects patients’ abilities to remember and concentrate on 
conversations and what is going on around them.  
The overlap in symptomatology makes it difficult to disentangle the complex 
comorbidities between depressive syndromes and fatigue syndromes both in 
depression and haemodialysis, hence, complicating the assessment and management 
of fatigue. 
It is, therefore, very important to establish the relationships of depression and fatigue 
and their relationships with clinical, biochemical, and haematological parameters, 
and to explore the extent to which somatic symptoms of depression such as fatigue 
contribute to the diagnosis of depression in this chronic disease state. Understanding 
these issues will enhance opportunities to improve clinical outcomes and quality of 
life in the HD population. 
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Chapter 4 
Methods 
4.1 Overview 
In this chapter, I will explain the design and methods for the two distinct phases of 
the ASSertID (A Study of Sertraline In Dialysis) study. The study comprised two 
phases, as shown in Figure 14. These were the prevalence of depression and fatigue 
in patients on HD (phase I) and the feasibility RCT of sertraline versus placebo in 
HD patients (phase II). 
 
Figure 14: Schematic diagram of overall design 
 
 
 
 
 
The study was funded by the National Institute for Health Research (NIHR) 
programme, Research for Patient Benefit (RfPB). The NIHR-RfPB is a Programme 
funding regionally derived applied research projects in health services and social 
care. The aim of the programme is to realise, through evidence, the huge potential for 
improving, expanding and strengthening the way that healthcare is delivered for 
patients, the public and the NHS.   
PHASE I PHASE II 
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The reference number was PB-PG-0110-21073, and Research Ethical Committee 
(REC) reference 12/LO/1554 and EudraCT reference 2012-000547-27. Copies of the 
approval letters are shown in the appendix 1.  
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4.1.1 My Role in the Studies  
A large part of the design was already finalised when I started as a clinical research 
fellow and subsequently a PhD student; however, I will emphasise throughout this 
chapter my contribution and input into the design and methods of these studies.  
During the initial months, I researched the literature on depression and its 
management in ESRD, as well as attending several renal 
outpatient/dialysis/transplant clinics to consolidate my knowledge in renal medicine. 
I became familiar with the protocol, contributed to final versions of the ASSertID 
protocol after the research ethics committee required a number of changes to be 
made before approval was granted. Once approvals and permissions were received, I 
worked with my colleagues on the set up of the paper CRF and the e-CRF, testing the 
e-CRF and making several amendments to the psychiatric assessment tools. I helped 
prepare information for training and educating non-psychiatric trained clinical staff 
on the recognition and management of depression for each site. I assisted with all the 
research site visits, prepared the sites for data collection, and familiarised myself 
with the different requirements, site policies, personnel, and operational procedures 
at each site.  
I was involved in data collection, which included screening, diagnosing, and 
recruiting patients on dialysis with MDD into the trial phase. This involved careful 
assessment of patients and ongoing management of, for example, psychiatric or 
somatic adverse events. Finally, I contributed to the analysis and interpretation of the 
data and the dissemination of the findings from the research in the form of papers to 
peer-reviewed journals as well as conference poster and presentations. The main 
statistical plan and analysis, including RCT analysis, were undertaken by Dr David 
Wellsted. Sertraline plasma levels were done by Dr Alun Hutchings, of Cardiff 
Toxicology Laboratories, the Academic Centre, University Hospital Llandough.  
In addition, I was keen to develop my own ideas stemming from the ASSertID study. 
From the literature review, it became clear that there is a vast range of overlapping 
symptoms of depression and ESRD, mainly the biological symptoms of depression, 
which could be due to psychological or physical factors, or both. The most common 
overlapping symptom was fatigue and tiredness. After discussion with my 
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supervisors, the decision was made to include a careful assessment of fatigue as a 
psychosomatic syndrome that spans depression and renal disease. I conducted a 
review of fatigue and fatigue rating scales and it became clear that there is minimal 
data on the prevalence of fatigue in ESRD. There was no data to help identify 
whether fatigue was due to the physical illness or secondary to depression, or both. 
This was an opportunity to contribute to the evidence base by collecting data on 
fatigue from newly recruited patients using validated fatigue assessment tools. An 
amendment was made to the study protocol, and IRAS and MHRA application forms 
were completed, submitted, and approved. 
 
4.2 Prevalence of Depression and Fatigue Study 
4.2.1 Aims 
1- To establish the prevalence of depression in patients on dialysis. 
2- To establish the relative effectiveness of screening tools for depression 
(PHQ-2, PHQ-9, and BDI-II) in this group of patients and compare the rating 
to a psychiatric diagnosis. 
3- To establish the proportion of ESRD patients who scored positive on fatigue 
scales MFI and SF-36, and the energy/fatigue subscale. 
4- To establish the relationship of depression and fatigue scores and their 
relationship to clinical, biochemical, and haematological parameters. 
5- To establish whether there was a difference between drug and placebo on the 
measures of fatigue over the period of the study.  
 
4.2.2 Design, Setting, and Sample 
The prevalence study was an observational questionnaire survey of HD patients. We 
recruited from five renal centres in England within the following NHS Trusts: 
1. East and North Herts NHS Trust  
2. Southend University Hospital NHS Foundation Trust  
3. University Hospitals Birmingham NHS Foundation Trust 
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4. Royal Free London NHS Foundation Trust 
5. Basildon and Thurrock University Hospital NHS Foundation Trust 
 
The chief investigator (CI) for the study was Prof. Ken Farrington, and principal 
investigators (PI) at each centre (see above), respectively, were Dr Enric Vilar, Dr 
Mike Almond, Dr Clara Day, Dr Andrew Davenport, and Dr Ian Barton.  
Research nurses approached all HD patients who met the eligibility criteria, asking 
each patient to complete several questionnaires. Eligibility included patients with 
ESRD, receiving HD for at least three months, over 18 years of age, and with the 
ability to read and speak English fluently. Figure 14 shows the number of patients 
who received RRT at each of the five centres during 2013 (2). 
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Figure 15 Numbers of RRT in the five centres (1, 2) 
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4.2.3 Measures and Data Collected 
The following data were collected directly from patients or their medical notes onto a 
study-specific designed case report form (CRF): 
 Demographics (date of birth, gender, ethnicity, marital status, and social 
class/education).  
 Information on the primary renal disease and date of starting renal 
replacement therapy. Previous transplants and dates, if there were any. 
 Past history of depression or anxiety diagnosed by a doctor. 
 Treatment for depression or anxiety by a GP or psychiatrist or any other 
involvement with psychology or psychiatry services. 
 Social support – who they lived with. 
 Questions on comorbid problems, including: heart disease, stroke, amputation 
of limbs, diabetes, cancer, liver disease, lung disease, and any other medical 
conditions such as rheumatoid arthritis. 
 Clinical parameters, including: haemoglobin, serum albumin, calcium and 
phosphate, and Kt/V (most recent values). 
 Estimated urine volume per day, dry weight, height, dialysis time, 
interdialytic weight gain, and number of missed and truncated treatment 
sessions in past month. 
 Midweek pre- and post-dialysis blood pressure. 
 Estimated recovery time from dialysis sessions. 
In addition to the above data, the research nurses administered the BDI-II (180) and 
PHQ-9 (79) to screen for depressive symptoms and the vitality scale of the SF-36 
energy/fatigue subscale (270) and MFI (272) for fatigue symptoms. These 
questionnaires were described in detail in Chapters 2 and 3, respectively.  
Following the ASSertID steering group meeting (13/04/2015) after the completion of 
the study, it was agreed to collect additional data on CRP and survival from the five 
centres. A substantial amendment to ethics was submitted and approval granted on 
24/04/2015 (Appendix 1; we obtained information about whether the patient was still 
receiving dialysis or had died, the date of death, and date of transplantation/transfer 
to a different centre). In two units (Royal Free and East and North Herts) information 
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about baseline CRP results was also collected. The data was collected by the local PI 
and supplied to us under the original patient identification (PID) number. The data 
allowed us to determine whether having a high depression score at screening has an 
impact on prognosis.  
 
4.2.4 Procedures 
The CI/PIs at each renal centre drew up a list of all the ESRD patients aged 18 or 
above who were on HD in their units. They asked the research nurse or clinical 
studies officer to approach each patient about the prevalence and screening phase 
(Figure 16).  
The research nurse: 
1- Allocated a unique study patient identification number (PID) to each patient 
on the list. This number remained with the patient throughout the different 
stages of this study and was the unique identifier of each patient. It was used 
on all CRFs. 
2- Excluded those patients who were unable to speak and read English, as well 
as receiving HD for less than three months, and recorded this on the paper 
CRF and database.  
3- Approached all remaining patients and explained the purpose of the 
prevalence and screening phase. The research nurse gave each patient the 
Patient Information Sheet about the prevalence and screening phase, which 
was recorded in the CRFs. They gave each patient at least 24 hours and up to 
one week to think about the study before they asked the patient for written 
consent on the Informed Consent Form (ICF) [1]. If consent was obtained, 
the research nurse asked the patient a number of questions and gave the 
patient four standardised questionnaires to complete. 
I played a role in the recruitment at the Royal Free units as well as screening patients. 
I recruited 70 patients from the four Royal Free satellite units and this included 
approaching the patients, providing the required information, answering any queries, 
and consenting the patients.  
115 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
CI/PI produced a list of all patients with current 
ESRD undergoing HD in their unit. 
CI/PI gave the list to the research nurse, who allocated a unique study PID 
to each patient. 
Research nurse explained the screening phase to eligible patient 
and gave them the PIS for the screening and prevalence phase. 
Research nurse excluded the patients who do 
not fit the screening eligibility criteria. 
After at least 24 hours later, the patient saw the research nurse who 
obtained a written consent to take part in the screening phase of the study 
(i.e. to complete the baseline questionnaires, including the BDI-II and 
PHQ-9). Patient entered screening phase. The research nurse asked 
patient to complete the baseline, BDI II, PHQ-9, MFI and SF 36 
questionnaires.  
Some patients refused to take part in this phase 
after explanation from the research nurse. 
Some patients changed their mind and 
refused to enter this phase of the study. 
Research nurse applied the eligibility criteria for the 
prevalence and screening phase.  
Figure 16 Phase I recruitment 
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4.3 The RCT 
4.3.1 Aims  
1- The main aim was to evaluate the feasibility of conducting a fully powered, 
double-blind, placebo-controlled RCT by measuring the number of ESRD 
patients who took part and completed the study as well as evaluating their 
outcomes. The safety and drug exposure of sertraline in ESRD patients was 
also assessed. 
2- To establish the potential effectiveness of sertraline as a treatment for 
depression in this patient group. Was the drug tolerated well? Did it have an 
acceptable adverse effect profile? Were there indications that it was more 
effective than placebo in reducing depressive symptoms? 
 
4.3.2 Design and Setting  
This was multi-centre double blind feasibility RCT of sertraline versus placebo in 
patients with end-stage kidney disease receiving haemodialysis treatment who have 
MDD. The RCT was conducted in the same five renal centres listed in section 4.2.2. 
Patients were invited to participate for six months.  
 
4.3.3 Intervention and Control  
Patients were randomised to take sertraline plus usual care and additional psychiatric 
monitoring or placebo plus usual care and additional psychiatric monitoring for six 
months. 
Sertraline is a licensed SSRI indicated for the treatment of major depressive 
episodes, prevention of recurrence of major depressive episodes, and other disorders 
including anxiety disorder. A recent meta-analysis recommended sertraline due to its 
favourable balance between efficacy and acceptability, and low acquisition cost 
(437). It has been found to be effective and to have fewer side effects (except for 
diarrhoea) than many other commonly prescribed antidepressants (438). Several 
studies found sertraline to be safe to administer to patients with cardiovascular 
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disease (246, 439) as it has the most robust safety profile for cardiac disease. It is 
hepatically cleared, and believed to require no dosage adjustment in ESRD (246). 
The study placebo was microcrystalline cellulose and magnesium stearate. The 
sertraline and placebo tablets were sourced and prepared from the Royal Free 
Hospital Pharmacy Manufacturing Unit, who identically over-encapsulated the 
tablets. 
Each medication bottle contained 37 capsules (50mg) of sertraline or placebo enough 
for one month supply at a dose of 50mg/day. This represents more than a month’s 
supply to allow a window for any possible delays in follow-up assessments and 
dispensing of the medication. The bottles were labelled as ASSertID Study 
Medication with a tear-off portion that indicated if the bottle was treatment A or B. 
Sufficient numbers of bottles were shipped out to the main pharmacies at each 
research site.  
Usual care consisted of standard care received from the multidisciplinary renal team, 
including doctors, nurses, dieticians, pharmacists, social workers, counsellors, and/or 
psychologists. Patients received centre-based haemodialysis three times weekly for 
around four hours each session. Dialysis and regular monitoring of physiological 
parameters before, during, and after each dialysis session was carried out by 
specialist nurses and support staff. These highly trained personnel were well placed 
to detect clinical as well as social and psychological problems and to initiate referral 
of patients for expert professional help from relevant members of the 
multidisciplinary team. Care also included management of renal-related problems, 
including hypertension, bone and metabolic problems, and anaemia, and 
management of extra-renal comorbidities, including diabetes, heart disease, and 
inter-current infections. In addition, there was social and psychological support with 
access to trained social workers, renal counsellors, and/or psychologists at some 
study centres. 
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4.3.4 Sample 
4.3.4.1 Inclusion Criteria 
The following patients were included in the study: 
 Patients with a BDI-II of 16 or above, a cut-off found and validated by 
Chilcot et al. (177).  
 Patients who, according to the CI/PIs, had a prognosis of more than one year. 
 Further inclusion criteria included assessment by the research psychiatrist: 
 Patients who were diagnosed with a mild to moderate MDD according to 
a DSM-IV interview.  
 Patients who scored 18 or above on the MADRS. 
 Patients who had the mental capacity to understand the trial and were able 
to give consent. 
 
4.3.4.2 Exclusion Criteria 
Patients were excluded who:  
 Were treated or had been treated for depression and/or anxiety with any 
antidepressant or formal psychological therapy or had been involved in a drug 
intervention study in the last three months. 
 Were waiting a planned living donor transplant within the period of the trial. 
 Had less than a year survival prognosis according to the CI/PIs 
 Had a contraindication to sertraline.  
 Had hepatic impairment (serum levels of alanine transaminase (ALT) more than 
twice the upper limit of normal), hepatitis B or C, HIV/AIDS, and/or Creutzfeldt-
Jakob disease or elevated INR greater than 1.3. 
 Were pregnant or of childbearing potential and not using adequate birth control. 
 Were taking any of the following medications: MAOIs or pimozide triptans, 
antipsychotics, dopamine antagonists, tramadol, linezolid, or warfarin. 
 Further exclusion criteria by the research psychiatrist assessment included: 
 A diagnosis of a severe MDD. 
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 Judged to be at any acute and moderate to severe risk of self-harm.  
 Scored above 4 on item 10 on the MADRS or answered yes to question 
A3G on the MINI. These are questions related to suicide risk. 
 
4.3.5 Recruitment into the Trial 
The research nurses drew up a list of eligible patients for the psychiatric assessment 
interview, as shown in Figure 17, as well as a list of non-eligible patients but who 
scored 16 or above on the BDI-II. Then, the CI/PI reviewed all these patients and 
applied the relevant eligibility criteria for the psychiatric assessment interview and 
gave the research nurse a revised list of eligible and non-eligible patients.  
The research nurse approached all the eligible and non-eligible patients. The research 
nurse told each patient that they had scored 16 or above on the BDI-II and that they 
could suffer from low mood. The research nurse gave the patient several options of 
further care. For the non-eligible, it included referral back to their nephrologist, or 
referral to their general practitioner. The nephrologist or GP would discuss with the 
patient whether or not they needed a further referral to a mental healthcare 
professional, for example, a counsellor working in the renal team. For the eligible 
patients, the options were the same, in addition to the option to join the trial outcome 
phase of this study.  
The research nurse explained the aims, methods, anticipated benefits, and potential 
hazards of the trial outcome phase. At least 24 hours and up to one week were given 
to each patient to decide which option they wished to take. If the patient decided to 
enter the trial, the research nurse repeated the information on the trial outcome phase 
and invited them to take part in the initial psychiatric interview and baseline 
assessment. The research nurse asked the patient to sign a study-specific ICF 2a to 
take part in the baseline assessment and psychiatric interview. If a patient decided 
not to enter the trial, the research nurse ensured that the alternative options of care 
were facilitated and the relevant healthcare professional was informed once verbal 
consent was given by the patient. Once the patient had signed the consent form to see 
the research psychiatrist and agreed to complete the baseline assessment, the research 
nurse arranged a mutually convenient time for the patient to see myself as the 
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research psychiatrist. At the same time, the research nurse asked the patient to 
complete the baseline questionnaires and collect relevant baseline information from 
the medical notes or computerised medical records. I completed this recruitment 
process instead of the research nurse for 12 patients at the Royal Free.  
On completion of the psychiatric interview, the research psychiatrist applied the 
additional eligibility criteria. The research psychiatrist told the patient if they were 
eligible for the trial outcome phase. Patients who did not fulfil the additional 
eligibility criteria were thanked for taking part so far. The research psychiatrist gave 
each non-eligible patient a set of options for further care, which included referral 
back to their nephrologist, a referral to their GP, or a referral to the local Community 
Mental Health Team (CMHT). For patients who were diagnosed by the research 
psychiatrist with severe mental illness and at risk of self-harm, the research 
psychiatrist referred the patient to the local CMHT. 
If the patient was eligible for the trial outcome phase, the research psychiatrist 
repeated the information on the aims, methods, anticipated benefits, and potential 
hazards of this phase. They referred to the PIS-2 that the research nurse gave them. 
As the patient had already received that information more than 24 hours prior to 
meeting the research psychiatrist, the research psychiatrist asked for written consent 
on the ICF 2b to take part in the trial outcome phase. The study-specific ICF 2b had 
to be signed by the patient and the research psychiatrist and dated. On receiving 
consent, the research psychiatrist performed the randomisation. Both the research 
psychiatrist and patient were blind to the allocation. The research psychiatrist was 
also responsible for preparing and sending a letter to the GP informing them that 
their patient had entered this study, and recorded this action on the CRF. 
  
121 
 
Figure 17: Phase II recruitment  
 
 
 
 
 
 
 
 
 
 
4.3.6 Randomisation and blinding 
 
 
 
 
 
 
 
 
 
 
 
 
Some patients’ choose different 
options of care. The research 
nurse ensured that these 
alternative options are facilitated 
and that the relevant health 
professional was informed.  
The research nurse compiled a list of all patients who scored 16 or 
above on the BDI-II and gave this list to the local CI/PI. The CI/PI 
assessed eligibility for the psychiatric assessment interview. 
Patients scoring below 16 on the BDI-II 
were not be eligible for further phases 
and were referred back to usual care. 
The research nurse returned. If patient agreed to see the research 
psychiatrist for the psychiatric diagnostic interview, the research nurse 
asked the patient to sign ICF 2a for the interview and baseline assessment. 
Once ICF 2a is signed the psychiatric interview was arranged.   
The research psychiatrist carried out the randomisation. GP 
was informed of patient entering the study. 
The research psychiatrist conducted the psychiatric interview and applied 
the additional eligibility criteria. If the patient was eligible for the trial 
outcome phase, the research psychiatrist repeated information about this 
phase, with reference to PIS 2, invited questions, and reinforced that the 
patient can withdraw at any time. If the patient wishes to enter the phase, 
the research psychiatrist asked to patient to complete ICF 2b.  
 
Patient who did not fit eligibility 
criteria were withdrawn from the 
study. Some patients changed their 
minds and did not consent to take part 
in this phase. The research 
psychiatrist discussed various 
alternative options of care with these 
patients.  
The research nurse gave eligible patients several options of care 
including entering the trial outcome phase. The research nurse gave 
each patient the PIS 2. The research nurse gave each patient at least 24 
hours to consider the options. 
The CI/PI applied the relevant eligibility criteria to these patients and 
gave the nurse a revised list of eligible and non-eligible patients. 
Research nurse gave non-eligible 
patients alternative options of care. 
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Patients were randomised to either treatment A or treatment B. The Norwich CTU 
prepared the randomisation list. A block randomisation was used at each of the five 
centres. There were 50 codes for each centre. These codes were incorporated into a 
protected web-based randomisation programme prepared by Norwich CTU. Only the 
research psychiatrist had authorised access to the online randomisation programme. 
They were provided with an identification code and a password to access the 
randomisation programme. All the clinical team and research team were blind to 
study medication and only the data manager held the code. 
The research psychiatrist entered the specific internet site, using their username and 
password, and entered the study PID, which included the centre code. The computer 
allocated the next consecutive randomised code. The computer sent an email to the 
relevant pharmacy to inform them that the patient (using the study PID) had been 
entered into the study and that they had been allocated to treatment A or treatment B. 
Only the pharmacist knew about the allocation of A or B. They tore off a small label 
that indicated that the bottle contained medication A or B, as described above in 
section 4.3.3. 
Upon randomisation, the research psychiatrist gave the patient a study-specific 
Patient Carrying Card, which included the study title, study PID, date of birth, 
information about taking the medication, medications to be avoided, and the contact 
details of the CI or PI and out-of-hours contact details in cases of emergency. 
The Norwich CTU held the data on the random allocation of each patient. They held 
the master file on their server and only the CI and PI had access to this file via a 
special login.  
After randomisation, the research psychiatrist informed the trial manager (TM) of 
patients entering the study. The research psychiatrist sent a standard letter to the 
patient’s GP informing them about the study and that their patient had entered this 
study.  
Once randomisation had occurred, the pharmacy staff received an email from 
Norwich CTU. The email detailed the PID and the treatment allocation (A or B). The 
research nurse from the renal unit was responsible for presenting the study 
prescription with the PID to the local hospital pharmacy. The pharmacy staff checked 
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the PID with the email detailing the allocation to treatment. The pharmacist recorded 
the PID on the label of the study medication bottles. They tore off the label saying 
treatment A or B on the bottle and dispensed the correct study drug to the research 
nurse. The research nurse did not know if the patient was receiving drug A or B. The 
pharmacist recorded the details of dispensing in the pharmacy dispensing log, part of 
the study pharmacy file. The research nurse was also responsible for recording in the 
CRF that they had received the medication bottles and given them to the patient.  
 
4.3.6.1 Emergency Unblinding 
The study randomisation codes were intended to be broken only for valid medical 
and safety reasons. Blinding could be broken in a medical emergency when the 
knowledge of the blinded treatment was necessary, such as: 
 Deterioration in mood involving suicidal thoughts or attempted suicide 
 Suspected serotonin syndrome or neuroleptic malignant syndrome 
 Cardiac arrhythmias or GI bleed 
 Where a child in a participant’s household accidentally took an 
investigational medicinal product (IMP) 
 In an event of a suspected unexpected serious adverse reaction (SUSAR) 
In addition, the randomisation code could be broken if: 
 Requested by the Data Monitoring and Ethics Committee 
 A patient in the study withdrew due to the offer of a transplant  
All emergency unblinding was recorded in the CRFs. In practice, in the trial there 
was no need to invoke emergency unblinding. 
 
4.3.7 Dispensing the Medication to the Patient 
At baseline, the patient was prescribed 50mg of sertraline hydrochloride or placebo 
capsules, to be taken orally once a day in the morning for one month. The patient had 
another prescription for 50mg per day of the study medication for the second month. 
The research psychiatrist assessed each patient at two weeks to check for mental state 
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and tolerability of the drug in both groups. The research psychiatrist again assessed 
each patient at the two-month follow-up for tolerability, and if clinically indicated, 
the dose was titrated to 100mg per day if required. The research psychiatrist issued 
two prescriptions for either 50mg or 100mg per day, each for one month. At the four-
month follow-up, the research psychiatrist repeated the assessment of mood and drug 
tolerability and issued two prescriptions of either 50mg or 100mg per day, each for 
one month. The dose was not further titrated. At the end of the six months, when the 
patient had their final assessment with the research psychiatrist and the research 
nurse, the patient was advised to taper their study drug (medicinal product or 
placebo). Patients on 100mg were advised to take 50mg for one week, then take 
50mg on alternate days for one week, and then stop taking the study medication. 
Patients on 50mg were advised to take 50mg on alternate days for one week and then 
stop taking the study medication. At the end of the tapering period, the CI/PIs were 
responsible for ensuring the appropriate future management of the patient. They 
acted on the advice of the research psychiatrist who carried out the final study 
assessment and the patient wishes. Management options included prescribing 
sertraline at an initial dose of 50mg daily or continuing on no antidepressant 
medication. In either case, the patient’s GP was informed and early review was 
arranged within 2-4 weeks within the multidisciplinary team. Patients were referred 
to the local CMHT if deemed appropriate on psychiatric advice.  
The research psychiatrist and research nurse provided the patient with information 
about possible withdrawal symptoms, reassuring them that they were usually mild 
and temporary. Patients were told to contact the CI/PIs if they experienced 
continuous and unpleasant symptoms while stopping the medication or placebo. Any 
adverse events (AE) were recorded in the medical notes or computerised records and 
Adverse Event form in the CRF.  
If a patient withdrew before the end of the intervention period, the same tapering 
plan was recommended as described above. The research nurse alerted the CI/PIs to 
assess the patient at the end of the tapering period to decide on alternative treatment 
options as outline above.  
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4.3.8 Assessment and Data Collection 
 Baseline assessment by the research nurse  
The research nurse collected the data on the patient’s medical history specified below 
on the study-specific CRFs. Data was collected via the medical notes, from self-
report questionnaires completed by the patient, as well as the research nurse who 
asked the patient directly or asked the nephrologist to provide the data.  
 List of all drug treatments 
 Description of the current dialysis treatment, including dialysis type 
(HD/HDF), dialysis session duration, and target Kt/V 
 Achieved dialysis adequacy assessed using the last Kt/V recorded 
within the last month 
 Dry weight 
 Current interdialytic weight gain 
 Mid-week pre- and post-dialysis blood pressure during the previous 
week 
 Haematology blood results – Hb, white blood cell count, platelets 
 Biochemistry blood results – urea/electrolytes and liver function 
tests, including bilirubin, alanine transaminase (ALT) and/or 
aspartate transaminase (AST), alkaline phosphate (ALP), 
bicarbonate, albumin, calcium, and phosphate 
 
 Psychiatric assessment 
The research psychiatrist formally assessed depression by interviewing patients with 
the: 
 MINI version 6.0 (74) and the Folstein Mini Mental Status Exam 
(MMSE) (440). These were used by the psychiatrist to make a formal 
DSM-IV diagnosis of MDD. 
In addition, the research psychiatrist administrated the following assessment: 
  MADRS (88)  
 Clinical Global Impression – Severity Scale (92) 
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The research psychiatrist assessed each patient clinically for suicidal risk. A score of 
greater than 4 on item 10 on the MADRS or yes to question A3G on the MINI 
excluded the patient from the study. The plan was for patients with a high suicide 
risk score to be referred by the research psychiatrist to the local acute services and 
they would inform the CI and/or PI who would contact the patient’s GP. This 
happened only once during the course of the study. 
The above questionnaires were described in detail in Chapter 2.  
 
 Subsequent assessments by the psychiatrist 
 
Two weeks after the first prescription had been given, the research psychiatrist saw 
each patient in person, administered the PHQ-9, and asked about the study 
medication. A mental state exam was performed and recorded in the clinical 
psychiatry study file. All actions taken were recorded in the CRF. With regard to 
medication, the psychiatrist asked the question, ‘How have you managed with your 
medication so far?’. Any adverse events or action taken were recorded in the CRF. If 
question 9 (suicidality) on the PHQ-9 was answered positively (either 2 or 3), the 
research psychiatrist would perform a full psychiatric assessment. The patients would 
be withdrawn and unblinded if they were found to be at high risk of suicide. No 
incidences of this occurred during the study. 
The research psychiatrist assessed each patient again after two, four, and six months 
in person to check their psychological status and, in particular, suicide risk. A mental 
state exam was performed by the research psychiatrist and recorded in the clinical 
psychiatry study file. Any action taken was recorded on the CRF. The research 
psychiatrist asked the patient to complete the self-reported measures MFI and SF-36 
energy/fatigue subscale and administered the following assessment: 
 MADRS (88) 
 Clinical Global Impression – Severity Scale and Clinical Global 
Impression - Improvement Scale (92) 
At the two- and four-month follow-ups, the research psychiatrist assessed the 
tolerability of the medication taken. Any adverse events or action taken were 
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recorded in the CRF. A decision was made on the basis of psychiatric state and 
tolerability of medication on whether or not to titrate the dose of the intervention 
from 50mg to 100mg at the two-month follow-up appointment. All data was 
recorded on study-specific CRFs. 
 
 Subsequent assessments by the research nurse 
The research nurse, together with the CI/PIs, recorded the following data on a 
monthly basis, including the final assessment at six months: 
 PHQ-9 score 
 Question, ‘How are you getting on with your medication?’ 
 Compliance data – how many tablets were missed and the reasons 
 Dry weight 
 Changes to medication at the end of each month 
 Change of the dialysis treatment over the last month, including 
dialysis type, time on dialysis, target Kt/V 
 Achieved dialysis adequacy assessed using the last recorded Kt/V 
(measured monthly) 
 Interdialytic weight gain 
 Mid-week pre- and post-dialysis blood pressure in the last week of 
each month 
 Last values of the month – haematology blood results: Hb, calcium, 
phosphate, and albumin  
 ECG – conducted by the research nurse and interpreted by the CI/PIs 
at the two-, four-, and six-month follow-up dates 
 
The research nurse recorded the above data on study-specific CRFs. They involved 
the CI/PIs to interpret the ECGs and other relevant tests. To minimise demand on the 
patients, all study assessments by the research nurse and CI/PIs were undertaken 
during routine clinic visits. The nurse formally assessed the patient’s mood by using 
the PHQ-9
 
and asked the patient how they had got on with the study medication. If 
question 9 on the PHQ-9 was answered positively (either 2 or 3), then the P4 
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suicidality screener (441) was administered. The P4 screener asks about the ‘4 Ps’: 
past suicide attempts, suicide plan, probability of completing suicide, and preventive 
factors. Patients were classified as minimal, lower, and higher risk based upon 
responses to these four items. If the patient was found to be at high risk of suicide 
according to the P4 screener, the research psychiatrist would be contacted. At the 
two-, four-, and six-month visits, the research psychiatrist would assess the patient in 
person that day. At the one-, three, and five-month visits, when a formal psychiatric 
assessment was not scheduled, the research psychiatrist would be contacted by the 
research nurse and they would both endeavour to see the patient on that day. If this 
was not possible, the research psychiatrist would review the patient with the research 
nurse on the phone and decide if the patient needed to be referred to the PI and 
referred urgently for assessment to the local mental health services. This happened 
with one patient during the course of the study. BDI-II was also completed at the 
final visits (month six). A summary of the collected data is shown in Table 19. 
 Adverse events 
All AEs were recorded in patient medical notes or computerised records and 
recorded on the CRFs. Deterioration of mood was monitored closely as a possible 
side effect from the study medication. SAEs were recorded on a study specific form. 
The sponsor was informed of each new SAE and a log of all SAEs was kept up to 
date. 
 Patient safety and drug exposure 
The research nurses took two blood samples (one pre- and one post-dialysis) during 
routine clinical sampling from each patient who had been on the study medication for 
three to five months to examine sertraline levels. Blood was taken into a plain or 
EDTA container and centrifuged on site. 
The plasma samples were couriered overnight to the CI main research site and were 
frozen until the end of the study when the unblinding of the participants had 
occurred. The frozen plasma samples for the placebo group were discarded and only 
the frozen samples of the sertraline group were sent to the toxicology laboratory for 
analysis. The CI/PIs and the research nurses were responsible for recording that the 
samples had been taken in the medical notes/computerised notes and the CRFs.
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Table 19: Summary of data collection 
  Screening  Psychiatric 
interview 
Entry 
to 
clinical 
trial  
1-2 
weeks 
1 
month 
2 
months 
3 
months 
4 
months 
5 
months 
6 
months 
Informed Consent  X X  X               
Inclusion/exclusion criteria 
fulfilled 
X X  X               
Demographics X   
 
              
Comorbid conditions (self-
report) 
X                   
Brief psychiatric history X     
   
  
   
BDI-II X                 X 
PHQ-9 X      X X  X  X  X   X X 
MFI X     X  X  X 
SF-36 energy/fatigue  X     X  X  X 
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P4 suicidality screener    X X  X  X  
Psychiatric assessment  X  X  X  X  X 
Montgomery- Åsberg 
Depression Rating Scale 
  X        X   X   X 
Mini International 
Neuropsychiatric Interview  
  X                  
List of medications     X   X X X X X X 
Description of dialysis 
treatment 
    X   X X X X X X 
Mid-week pre- and post-
dialysis blood pressure 
X   X   X X X X X X 
Dry weight X   X   X X X X X X 
Adherence to dialysis 
treatment 
X   X   X X X X X X 
Interdialytic weight gain X   X   X X X X X X 
Urine volume per 24 hours X          
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Dialysis adequacy Kt/V X   X   X X X X X X 
Dialysis time  X   X   X X X X X X 
Full blood count X   X   X X X X X X 
Electrocardiogram     X     X   X   X 
IMP review         X  X X  X X  X 
Drug compliance       X X X X X X X 
Sertraline plasma blood test        X   
Baseline assessment of signs 
and symptoms 
  X        
Adverse events       X X X X X X X 
Clinical Global Impression 
Severity Scale 
   X   
 
  X   X   X  
Clinical Global Impression 
Improvement Scale 
     X  X  X 
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4.4 Original Sample Size Calculation and Amendments to 
the Studies 
4.4.1 Sample Size 
As a feasibility study, sample size was determined by the need to estimate the 
population variance of the outcome measures, and pragmatic considerations about 
potential recruitment. A sample size of 30 per arm (N=60) was selected allowing the 
population variance to be estimated with reasonable precision (1.2 x variance) (442), 
allowing reliable estimates to be derived for the outcome measures, and design of the 
planned full-scale trial. Previous studies suggested that 30% of patients would screen 
positive on the BDI-II (177), 50% of patients scoring ≥16 on the BDI-II would be 
subsequently diagnosed with MDD, and 50% would agree to be randomised. Given a 
target of 60 patients representing 7.5% of the screen sample, the target for screening 
was 800 patients, to be screened from four renal units with a population of 2,000 
patients receiving dialysis (2).  
During the screening phase, it was challenging to recruit the numbers due to the high 
prevalence of patients already taking antidepressants, an exclusion criterion to the 
study. Based on this finding the numbers were recalculated and an additional centre 
was added. Current research suggested that 33% of patients would screen positive on 
the BDI-II, of whom approximately 34% would be eligible, and 20% to 30% of those 
eligible would be diagnosed as depressed and agree to take part. This would give a 
recruitment rate of 3-4%. To meet a sample size of 25 to 30 patients, we had to 
screen approximately 700 patients (giving 24 to 32 patients). Hence, our revised 
target recruitment numbers for the first phase was approximately 700 patients. A 
sample of this magnitude enabled the proportion of positive screened patients to be 
estimated with a 95% confidence interval width of less than 8%.   
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4.4.2 Prevalence and Screening 
The primary purpose of the prevalence and screening phase were to determine the 
proportion of patients who screened positive on the BDI-II. The secondary purpose 
was to assess the feasibility of using the PHQ-9 in clinical practice.  
The analysis initially documented the proportions of patients meeting the (wide) 
inclusion criteria, and characterised those patients excluded from the study. The 
analysis also recorded the proportions of patients who refused to be screened, and the 
given reasons for refusal. In all cases, proportions were estimated with 95% 
confidence intervals assuming a normal distribution unless otherwise indicated. 
The demographic and clinical characteristics of the patients identified for screening 
were described. Patients were subdivided into two groups, into a no depression group 
or a possible depression group, using the cut-off criteria for the BDI-II (a score ≥16). 
Comparisons between patients ≥16 or not were considered for each of the clinical 
and demographic parameters using appropriate paired comparisons (t-tests or2). 
Finally, the analysis considered agreement between the BDI-II and the PHQ-9 to 
evaluate the extent to which the PHQ-9 can be used in place of the BDI-II for 
patients with ESRD. We used ROC analysis to define the best cut-off for the PHQ-9 
in relation to the known performance of the BDI-II. Levels of agreement of these 
different cut-offs were examined.  
 
4.4.1 Fatigue 
The primary purpose of this element of the prevalence and screening phase was to 
determine the relationship of the fatigue scales (MFI and SF-36 energy/fatigue 
subscale) to depression and fatigue and their relationship to demographic, clinical, 
biochemical, and haematological parameters.   
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4.4.2 RCT 
The study aimed to recruit 30 patients from the five centres, giving 15 patients in 
each arm. A sample size of 30 would provide estimates of the population variance to 
a precision of 1.2 times the sample variance, allowing reliable estimates to be derived 
for the outcome measures, and inform design of the planned full-scale trial (442).  
Baseline characteristics for all patients randomised were evaluated (means, 
proportions, counts) for patients in the treatment and placebo arms. To meet the 
Consolidated Standards of Reporting Trials (CONSORT) reporting criteria, the flow 
of patients through recruitment to this phase of the study were recorded, and the 
numbers of patients falling into each group evaluated. 
The primary analysis was descriptive, seeking to characterise the acceptability of the 
study to patients by estimating the proportions of patients who agreed to take part in 
this phase, or not, those withdrew from randomised treatment, and those who agreed 
to continue with the trial measures despite withdrawing from randomised treatment. 
The degree of adherence to the randomised treatment was evaluated in general terms 
to inform future trial design. 
Lastly, the nature and number of the reported AEs were classified to examine the 
safety profile of the study drug. 
The aim of the secondary analysis was to characterise the variability of the outcome 
measures at six months, and estimate the effect size of treatment versus placebo for 
each outcome. Using an ‘as treated’ sample, the effect size (Cohen’s d) was 
estimated for all the outcome measures. Analysis considered the influence of 
covariates on the outcome measures to determine the need for stratification in the 
larger RCT to follow. Additional analysis sought to characterise the effect of 
treatment centre on the observed effect (e.g. the intraclass correlation), to estimate 
bias introduced by missing data and non-completion, the extent to which somatic 
symptoms of depression such as fatigue contributed to the diagnosis of depression in 
this chronic disease state, and whether there was a difference between drug and 
placebo on the measures of fatigue over the period of the study.  
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The statistical packages used were SPSS version 23 for all routine analysis and 
STATA version 13.1 (Stata Corp LP) for the trial outcome phase. The primary 
analysis of the trial outcome phase was carried out mainly by Dr David Wellsted.  
 
4.5 Protocol Amendments 
The main protocol amendments were: 
 Protocol 1.0, dated 17/4/12: Original Submission 
 Protocol 2.0, dated 2/9/12: New application to ethics committee 
 Protocol 3.0, dated 3/10/12: Further information to provisional opinion and 
changes had been requested by ethics  
 Protocol 4.0, dated 18/1/13: Changes in safety or integrity of trial subjects, 
changes in conduct/management of trial, clarification to protocol 
 Protocol 5.0, date 5/7/13: Added short patient information sheets, added two 
self-report questionnaires, clarification and version control of patient 
information sheets, consent forms, and GP letter 
 Protocol 6.0, date 9/1/14: Added an additional research site, changes to the 
eligibility criteria for phase 3, the qualitative study, and a reduction in the 
sample size estimation 
 Protocol 6.1, date 19/3/14: Version control of patient information sheets, 
consent forms, and GP letter and separate from protocol. Spelling mistake in 
SAE form 
 Protocol 6.2, date 11/4/14: Updating the whole research protocol to mention 
that we had five sites, not four, i.e. replacing the word ‘four’ with ‘five’ when 
relating to sites 
 Protocol 7.0, date 20/4/15: Collecting additional data on CRP and survival 
data, clarifying archiving, adding patient study card, and informing about end 
date 
Relevant regulatory documents are found in appendix 1.  
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Chapter 5 
Prevalence and Screening 
Details of the design, setting, and measures were explained in full in the method 
chapter previously but will be reiterated briefly here. Patients over the age of 18 
years who had receive treatment by HD for three months or more were approached. 
Patients who could not read and speak English were excluded. Consenting patients 
completed the BDI-II and PHQ-9 questionnaire during dialysis. Data relating to 
demographics, medical and psychiatric history, and dialysis treatment were also 
collected. Those with a BDI-II score ≥16, not on current treatment for depression 
(antidepressants or psychological therapies) in the past three months and without any 
pre-defined exclusion criteria, which included planned living-donor kidney transplant 
within the period of the trial, a prognosis of less than a year, several associated 
medical conditions and contraindicated medications, were approached to undergo a 
diagnostic interview by a psychiatrist using the MINI to confirm the presence of 
MDD. Following this, consenting patients diagnosed with mild to moderate MDD 
and with a score of 18 or above on the MADRS were randomised into the trial phase. 
Patients with severe depression or suicidal ideation were excluded and referred 
urgently to psychiatric services. Patients were also excluded who had evidence of 
cognitive impairment on the Folstein Mini mental status examination (MMSE). We 
sought written informed consent from patients at three separate points in the study, 
before screening, before interview by the study psychiatrist, and before 
randomisation to enter the trial. 
 
5.1 Data Collection 
Data were collected from electronic records and directly from patients. This 
included: age, gender, marital status, ethnicity, current living arrangements (alone, 
with partner, or family or friends), and educational attainment. The amount of time 
the patients had been receiving dialysis (vintage) was recorded to sessional adequacy 
(Kt/V), as well as routine clinical observations (blood pressure and dry weight) on 
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the day of completion of the questionnaire. The most recent biochemical and 
haematological data were collected from the electronic patient record including: 
blood haemoglobin and serum albumin, calcium, and phosphate. We collected 
information on history of depression and its management. Comorbidities were 
recorded as the presence or absence of: diabetes, heart disease, stroke, amputation, 
cancer, lung disease, and liver disease. Transplant history was recorded as never 
transplanted or transplanted and returned to dialysis. We also asked patients to self-
report urine output as being less than one cup per day or greater than one cup per day 
and post-dialysis recovery time categorised as <1hr, 1-4hrs, 4-8hrs, 8-12hrs, or 
>12hrs.  
 
5.2 Results 
In this chapter, I will discuss the baseline results.  
1,355 haemodialysis patients were approached at five renal centres, as shown in the 
CONSORT diagram in Figure 18.  
 
of an inability to read and understand English.  
 
 
 
 
 
 
 
 
 
 
63 patients were eligible for psychiatric 
evaluation and consented for interview 
709 eligible patients consented to take part in 
the screening 
 
231 patients had a score of ≥16 on the BDI-II 
1,110 eligible patients approached for the 
screening study 
401 were unwilling to consent 
1,353 patients eligible for screening phase 
were approached  
243 excluded predominantly because of 
inability to read and understand English 
168 excluded – (130) due to exclusion criteria for 
trial phase and (38) unwilling to consent 
Figure 18 Screening CONSORT 
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243 patients were excluded predominantly because of inability to read and 
understand English. 1,110 eligible patients were approached to enter the screening 
study, of which 401 were unwilling to consent. 709 eligible patients consented to 
take part in the screening. All were adults (>18 years) on haemodialysis for over 
three months. The mean age was 64 years (±16.4), and 449 were male (63.3%). 493 
(69%) were white, 76 (10.6%) Asian, 55 (7.7%) black, 67 (9.4%) mixed race and 
others totalled 17 (2.4%). 364 (51%) were married or in a civil partnership. 211 
(30%) were living alone. 291 (41%) patients had received formal educational 
qualifications beyond the age of 16. The mean dry weight was 75.5kg (±18.4), with a 
BMI of 26.9 (±7.9), and the median dialysis vintage was 4.4 years (IQR 5.2).  
The commonest comorbidities recorded were: diabetes (33.5%), followed by heart 
disease (32%). Other comorbidities were: cancer, stroke, lung disease, liver disease, 
and amputation, as shown in Table 20. 25% had a past history of depression, 16% 
were receiving treatment for depression, including 11% on antidepressants in the last 
three months, and 5% undergoing psychological therapy in the last three months. 699 
completed the BDI-II and the median score was 10 (IQR 14). 702 completed the 
PHQ-9 with a median score of 5 (IQR 8).  
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Table 20: Characteristics of screened cohort (n=709).  
Values are recorded as mean ± SD or median (interquartile range) 
Number 709 
Age (years) 64 ± 16.4 
Gender (% male) 63.3 
Ethnicity (% white) 73 
Weight (kg) 75.5 ± 18.4 
BMI 26.9 ± 7.9 
Pre-dialysis systolic BP (mmHg) 140 ± 27 
Pre-dialysis diastolic BP (mmHg) 75 ± 17 
Married/partner (%) 51 
Single/living alone (%) 30 
BDI-II 10 (14) 
PHQ-9 5 (8) 
Comorbidity (%)  
Diabetes 33 
Heart disease 32 
Cancer 11 
Stroke 8 
Dialysis parameters  
Vintage (years) 2.8 (4.9) 
Kt/V 1.45 ± 0.35 
Laboratory parameters  
Haemoglobin (mg/l) 112 ± 12.2 
Albumin (g/l) 37 ± 4.4 
Calcium (mmol/l) 2.26 ± 0.19 
Phosphate (mmol/l) 1.60 ± 0.49 
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Past history of depression (%) 25 
Treatment of depression in the last three months (%) 16 
Antidepressants in last three months (%) 11 
Psychological treatment last three months (%) 5 
 
231 of these had a BDI-II score of ≥16. The main differences between the high BDI-
II scorers and the 709 patients were that the high BDI-II scorers were of a younger 
age, at 59.5±16.5 vs 64.0 ±16.4 (p<0.001), and a higher prevalence of people lived 
alone, at 53.5% vs 30% (p<0.001). There was a higher prevalence of patients with a 
past history of depression, at 46% vs 25% (p<0.001), undergoing current treatment 
of antidepressants, at 20.4% vs 11% (p=0.001), and undergoing current 
psychological treatment, at 11% vs 3.8% (p<0.001). 
Of those 231 patients, 168 patients were excluded from consideration for the trial 
phase due to the exclusion criteria (Table 21) and/or unwillingness to consent. 39 
patients were not considered for the trial phase because of current antidepressant 
treatment, 12 because of current psychological therapy, and 17 were receiving both 
of these treatments. Other reasons for ineligibility were medical and other psychiatric 
problems (34), other contraindicated medications (17), and miscellaneous other 
reasons (11), including participation in other interventional studies and inadequate 
birth control. 38 patients declined to consent to take part in the psychiatric interview. 
63 patients were eligible for and consented to psychiatric interview. 
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Table 21: Exclusion criteria 
Medical reasons Hepatic impairment 
 Hepatitis B and C 
 HIV/AIDS 
 Creutzfeldt-Jakob disease 
 Pregnancy or childbearing potential and not using 
adequate birth control 
 Psychiatric conditions, including substance 
dependency, psychosis, personality disorder, and 
dementia or panic disorder, with the exception of 
other anxiety disorders  
Contraindicating medications Monoamine oxidase inhibitors (MAOIs)  
 Pimozide 
 Triptans 
 Antipsychotics 
 Dopamine antagonists 
 Tramadol 
 Linezolid 
 Warfarin 
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5.3 Characteristics of Screened Patients with Elevated BDI-
II (≥16) 
231 (32.5%) of patients scored ≥16 on the BDI-II and 467 patients scored below this 
cut-off. The characteristics of these two groups are compared in Table 22. There 
were major differences in the median BDI-II score (25 [IQR 13] vs 6 [IQR 15]: 
p<001) and the PHQ-9 score (13 [IQR 8] vs 3.5 [IQR 4]: p<001) between the 
groups. 
Other major differences were that the patients with high BDI-II scores were younger 
(59.5 ±16.5 vs 66.4±17.5: p<001), less likely to be married or have a stable partner 
(46.5% vs 54.3: p=0.053), more likely to have been on dialysis for longer – i.e. to 
have a higher dialysis vintage (3.6 [IQR 5] vs 2.5 [IQR 4.8] years: p=0.004), more 
likely to have a past history of depression (46% vs 15%: p<0.001), more likely to 
have had previous treatment with antidepressants (35% vs 12%: p<0.001), anti-
depressant treatment in the last three months (21% vs 6%: p<0.001), and 
psychological treatments in the last three months (11% vs 1%: p<001). 
There were no differences in comorbidity (diabetes, heart disease, cancer, and 
stroke), ethnicity, body weight, blood pressure, haemoglobin, albumin, calcium, 
phosphorus, Kt/V, or maximum educational attainment. However, anuria was more 
prevalent in patients with a BDI-II ≥16 than in those with lower scores (53% vs 41%: 
p=0.003). In addition, anuric patients had higher BDI-II scores than those passing 
urine (11 [IQR 16] vs 9 [IQR 14]): p=0.001). PHQ-9 scores were also higher (6 [IQR 
10] vs 4 [IQR 7]: p<0.001). Among patients who screened positive on BDI-II, those 
on antidepressants had higher BDI-II scores than those not receiving these agents (30 
[IQR 17] vs 24 [IQR 11]; p=0.008). In logistic regression analysis (controlled for 
ethnicity, living with partner or not, haemoglobin, serum albumin, sessional Kt/V, 
dialysis vintage, and comorbidities, including diabetes, heart disease, and stroke), 
significant predictors of high depressive symptom scores (BDI-II≥16) were age 
(odds ratio 0.973: p<0.001), anuria (odds ratio 1.712; p=0.002), past history of 
depression (odds ratio 4.686; <0.001), and having cancer (odds ratio 1.923; 
p=0.033). However, the model predicted only 20% of the variation (Nagelkerke R 
square 0.203).  
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The median BDI-II score was higher in those patients with high BDI-II who were 
taking antidepressants (or had taken them in the previous three months) than in those 
not taking these agents (30 [IQR 17] vs 24 [IQR 11]; p=0.008).  
 
Table 22: Characteristic differences of patients with high BDI-II (≥16: n=231) 
and low BDI-II (<16; n=467)  
Values are recorded as mean ± SD or median (interquartile range) 
 High BDI Low BDI P value 
Number                                231 467  
Age (years) 59.5 ± 16.5 66.4 ± 17.5 <001 
Gender (% male) 66 63                    NS 
Ethnicity (% white) 68 70 NS 
Weight (kg) 76 ± 19 75 ± 18.1 NS 
Pre-dialysis systolic BP (mmHg) 144 ± 27 142 ± 24 NS 
Pre-dialysis diastolic BP (mmHg) 74 ± 18 72 ± 15 NS 
Anuria (% <1 cupful of urine/day) 53 41 0.003 
Marital status (%)    
Married/partner 46.5 54.3 0.053 
Single/living alone 30 30 NS 
BDI-II 25 (13) 6 (15) <001 
PHQ-9 13 (8) 3.5 (4) <001 
Comorbidity (%)    
Diabetes 33 32 NS 
Heart disease 33 31 NS 
Cancer 11 11 NS 
Stroke 9.1 7.5 NS 
Dialysis parameters    
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Vintage (IQR) years 3.6 (5) 2.5 (4.8) 0.004 
Kt/V 1.45 ± 0.35 1.45 ± 0.31 NS 
Laboratory parameters    
Haemoglobin (mg/l) 111 ± 13 112 ± 12 NS 
Albumin (g/l) 38 ± 5 37 ± 4 NS 
Calcium (mmol/l) 2.26 ± 0.19 2.27 ± 0.19 NS 
Phosphate (mmol/l) 1.62 ± 0.55 1.60 ± 0.47 NS 
Past history of depression (%) 46 15 <001 
Treatment of depression (%) 35 12 <001 
Anti-depressants in last three months (%) 21 6 <001 
Psychological treatment last three months (%) 11 1 <001 
 
5.3.1 Relationship of BDI-II ≥16 with Previous Failed 
Transplantation  
The median BDI-II score was higher in those who had previously received a 
transplant compared to those who had not: (13.5 [IQR 20] vs 10 (IQR 13]: p=0.022). 
45.6% of those previously transplanted had a BDI-II of ≥16 compared to 30.8% of 
those never transplanted (p=0.002). There was a significant difference between the 
BDI-II score in relation to the number of previous transplants (0, 1, and 2). The 
median BDI-II scores were 10 (IQR 13), 13 (IQR 22), and 15 (IQR 20) (p=0.02), 
respectively. Fifty percent of those who had two previous transplants had a BDI-II 
score of ≥16, compared with 44.8% with one transplant and 30.8% of those never 
transplanted (p=0.002). However, adding the presence of transplantation to the 
logistic regression model, described above in 5.3, did not improve the model.  
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5.3.2 Relationship of BDI-II ≥16 with Post-dialysis Recovery Times  
Post-dialysis recovery is a frequent complaint of haemodialysis patients after dialysis 
sessions. Post-recovery duration was collected using patients’ self-reports and 
divided in to five groups, and is presented in Table 23 below. 
 
Table 23: Post-dialysis recovery time groups 
 Frequency % Median BDI-II (IQR) Median PHQ-9 (IQR) 
< 1 hour 169 23.8 6 (9) 2.25 (6) 
1-4 hours 190 26.8 10.25 (14) 5 (8) 
4-8 hours 107 15.1 11.5 (15) 6 (9) 
8-12 hours 76 10.7 12 (17) 6.75 (10) 
> 12 hours 159 22.4 12 (17) 6.88 (10) 
 
The median BDI-II and PHQ-9 scores were closely related to recovery time (p<0.001 
in both cases by the Kruskal Wallis test. The biggest difference was between those 
who recovered within one hour and the rest. In patients with prolonged recovery 
times (>1 hour), the median BDI-II score was significantly higher than in those with 
faster recoveries (12 [IQR 15] vs 6 [IQR 9]: p<001). The PHQ-9 was also higher     
(6 [IQR 9] vs 2.25 [IQR 6]; p<0.001). More had a history of depression in the 
prolonged recovery group (29.5% vs 10.7%; p< 0.001), more had taken 
antidepressants (22.7% vs 10.1%; p<0.001), and more had significant depressive 
symptoms – BDI-II ≥16 (38.7% vs 15.5%; p< 0.001). Women were more prevalent 
in those with prolonged recovery than in those who recovered more quickly (36.8% 
vs 27.2%; p =0.003). Patients with prolonged recovery times were more likely to be 
anuric (47.4% vs 36.9%; p=0.02) than those recovering more quickly, and less likely 
to be living with a partner (48.7% vs 61.5%; p=0.005). There was also a significant 
centre effect with the proportion of subjects reporting long recovery varying from 
71.3% to 93.8% among the five centres (p=0.047). There was no relation to age, 
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ethnicity, or comorbidity (diabetes, heart disease, cancer, stroke, and amputation), 
dialysis vintage, haemoglobin, serum albumin, Kt/V, pre- or post-dialysis systolic 
pressure, or weight.  
The best logistic regression model of recovery time >1 hour, in Table 24, showed 
that gender, past history of depression, and BDI-II score were significant 
independent predictors. Centre and Living with Partner approached significance 
though the model and explained only 15% of the variation (Nagelkerke R square = 
0.152). 
 
Table 24: Logistic regression model of predictors of prolonged post-dialysis 
recovery (>1 hour) 
 B SE p-value Exp (B) 
 Gender (Female) .450 .207 .030 1.569 
Centre .132 .075 .077 1.141 
Past history of depression .723 .285 .011 2.060 
BDI-II score .060 .012 .000 1.061 
Living with partner -.342 .194 .078 .711 
Constant -.058 .317 .856 .944 
 
5.4 Comparison of BDI-II, PHQ-9, and PHQ-2  
We compared screening cut-off values for the PHQ-9 and PHQ-2 with that of the 
BDI-II in the HD population. We compared the two measures against the validated 
cut-off point on the BDI-II of ≥16, using Receiver Operating Characteristics (ROC) 
analysis (Figure 19).  
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The median scores for BDI-II, PHQ-9, and PHQ-2 were 9 (IQR 13), 5 (IQR 7), and 1 
(IQR 2), respectively. Using the BDI-II cut-off ≥16, the area under the curve in the 
ROC analysis (Figure 19) for PHQ-9 was 0.946 and for PHQ-2 was 0.902 (both 
p>0.001). 
Figure 19: ROC curve relating PHQ-9 and PHQ-2 to BDI-II ≥16 
 
The optimal cut-off point for PHQ-9 in this context was ≥8 and for PHQ-2 was≥2 
(sensitivity 87%, 87%, specificity 89%, 83%, respectively). The PHQ-9 ≥10 was 
more specific but less sensitive and with a lower negative predictive value (Table 
25). 
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Table 25: Comparison between cut-off points of PHQ according to the BDI-II 
≥16 
 PHQ-9 ≥8 PHQ-9 ≥10 PHQ-2 ≥2 
% population identified 36% 28% 40% 
Sensitivity 87% 75% 87% 
Specificity 89% 95% 83% 
Positive predictive value 80% 89% 71% 
Negative predictive value  93% 88% 92% 
κ values 0.743 0.730 0.678 
p-value <0.001 <0.001 <0.001 
 
The proportion of patients with PHQ-9 ≥8 was 36%, with PHQ-9 ≥10 at 28%, and 
PHQ-2 ≥ 2 at 40%. Levels of agreement of PHQ-9 ≥8, PHQ-9 ≥10, and PHQ-2 ≥2 
with BDI-II ≥16 were substantial (κ = 0.743, 0.730, and 0.678, respectively) (Table 
25). 
 
5.5 Characteristics of Patients Eligible for Psychiatric 
Assessment 
63 patients were eligible for psychiatric assessment and consented to take part in the 
interview. One was found to have cognitive impairment at diagnostic interview and 
was not considered in the subsequent analysis. The demographic and clinical 
characteristics of the remaining 62 are shown in Table 26. 37 (58.7%) had a 
diagnosis of major depressive episode (MDE) according to the MINI. The 
differences between those diagnosed with MDE and those with no MDE are 
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presented in Table 26. Patients with no MDE tended to be older, but not 
significantly. A greater proportion of patients with MDE were divorced or separated 
(22% vs 0%; p=0.02). In addition, those with MDE had higher scores on the BDI-II 
and PHQ-9 questionnaires. There were no other significant differences between the 
groups. Both these parameters (BDI-II and PHQ-9) were significant independent 
predictors of a diagnosis of MDE in logistic regression analysis (controlled for age, 
gender, ethnicity, and past history of depression). An increase of one point on the 
BDI-II score increased the likelihood of a diagnosis of MDE by 20% (p=0.002). The 
odds ratio and significance of the predictive power of being divorced or separated 
was indeterminate. The model explained 47% of the variance. 
In the ROC analysis, there was a significant relationship between BDI-II scores and 
the MINI diagnosis of MDD (C-statistic 0.788; p< 0.001). The relationship of MDD 
with PHQ-9 was weaker (C-statistic 0.690; p=0.012). The best cut-off point for 
predicting MINI diagnosis for MDD in this population was PHQ-9 ≥10 (κ=0.444; 
p<0.001). In comparison, the level of agreement for PHQ-9 ≥8 was 0.252 (p= 0.013). 
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Table 26: Characteristic differences between patients with and without diagnosis of depression by MINI.  
P-value refers to significance of difference between those with and without MDE 
 All MDE No MDE P value 
Number 62 37 25  
Age (years) 61.4 ± 15.0 59.4 ± 13.9 64.1 ± 16.1 NS 
Gender (% male) 73 73 72 NS 
Ethnicity (% white) 60 57 64 NS 
Weight (kg) 76 ± 18 75 ± 16 77 ± 21 NS 
Pre-dialysis systolic BP (mmHg) 146 ± 25 148 ± 25 145 ± 26 NS 
Pre-dialysis diastolic BP (mmHg) 76 ± 18 75 ± 18 77 ± 18 NS 
Anuria 55 57 52 NS 
Marital status (%)     
Married/partner 52 49 58 NS 
Single 23 19 29 NS 
Divorced/Separated 13 22 0 0.02 
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Widowed 12 11 13 NS 
     
Depression screening     
BDI-II 25 (11) 30 (14) 21 (7) 0.001 
PHQ-9 13 (7) 13 (7) 11 (6) 0.011 
PHQ-2 3 (2) 3 (3) 3 (2) NS 
BDI-II ≥16 (%) 100 100 100 - 
PHQ-9 ≥8 (%) 86 92 72 0.013 
PHQ-9 ≥10 (%) 75 92 52 <0.001 
PHQ-2 ≥2 (%) 90 92 88 NS 
     
Dialysis parameters     
Vintage (IQR) 2.9 (4.7) 2.9 (3.3) 3.0 (5.5) NS 
Kt/V 1.50±0.35 1.46±0.25 1.57±0.45 NS 
Comorbidity (%)     
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Diabetes 37 43 28 NS 
Heart disease 60 46 32 NS 
Cancer 14 8 24 NS 
Stroke 6 11 0 NS 
Amputation 3 5 0 NS 
     
Laboratory parameters     
Haemoglobin (g/l) 114 ± 12 114 ± 12 114 ± 11 NS 
Albumin (g/l) 39 ± 5 39 ± 4 39 ± 5 NS 
Calcium (mmol/l) 2.26 ± 0.17 2.26 ± 0.16 2.27 ± 0.19 NS 
Phosphate (mmol/l) 1.56 ± 0.47 1.56 ± 0.54 1.57 ± 0.37 NS 
     
Past history of depression (%) 29 35 20 NS 
Previous antidepressants (%) 13 16 8 NS 
Current treatment of depression (%) 0 0 0 NS 
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5.6 Discussion 
Our results confirmed that many patients on HD suffer from depression. A high 
proportion (32.5%) screened positive on the BDI-II using the cut-off ≥16, which 
corresponds with previous literature (173), and 36% had a PHQ-9 of ≥8. Indeed, 
people with CKD identify improving psychosocial aspects of living with their illness 
among their most important research priorities (59, 172). Our study showed that 46% 
of those screening positive for depression had a past history of depression. This is 
considered to be the largest screening multi-centre study to date. It is noteworthy 
that, in the general population, the point prevalence of depression has been reported 
to be 5-9% in women and 2-3% in men, and the lifetime prevalence of depression in 
the general population is 21.3% among women and 12.7% among men (443). This 
study demonstrated that the prevalence of depression is much higher in the HD 
population, which may in part be due to the presence of overlapping somatic 
symptoms related to uraemia (444).  
One of the major findings was the high prevalence of HD patients receiving 
treatment for their depression either by antidepressants or psychological therapy, 
despite the lack of evidence for the efficacy of antidepressants in this setting. The 
only previous report in the literature citing the use of antidepressants in this setting is 
that of Lopes et al. (228). We demonstrated in our study that antidepressants are 
commonly prescribed in this population. It was notable that 24% of patients with a 
high BDI-II score were currently taking antidepressants and 12.5% were receiving 
psychological therapies (7% were receiving both). Positively screened BDI-II 
patients receiving antidepressants had higher BDI-II scores than their untreated 
counterparts, questioning the role of antidepressants in this population. These factors 
raised questions regarding the prescribing practices and efficacy of these agents in 
this population. As a result of these findings, it was decided to gain further ethical 
approval for a further study to explore the progression of depressive symptoms in 
this group of patients, that is, HD patients on antidepressants. This will be fully 
covered in a subsequent chapter.  
There were no differences in comorbidities: heart disease, stroke, amputation, lung 
disease, cancer, and liver disease (the latter two are not shown in the table due to 
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very small numbers) and this differed from previous literature (220, 228), which 
found that patients with depression identified by physicians were more likely to have 
comorbid conditions. However, in multivariable analysis, the presence of cancer was 
associated with a high BDI-II. Similarly, we found no relationship between high 
BDI-II scores and haemoglobin levels and this also differed from past literature 
(445). This may be due to extensive use of erythropoietin (EPO) in our population, 
which may have limited the variation in haemoglobin levels and reduced some of the 
somatic symptoms often associated with depression. 
We were unable to find an association between depression and body weight, 
albumin, calcium, and phosphorus, which was similar to previous studies (162, 224). 
However, a Korean group showed negative correlations between BDI scores and 
these parameters (446). Similar findings regarding albumin levels were obtained by 
Lacovides et al. (447) in a disparate group of 82 European ESRD patients treated 
with HD and PD. Friend et al. (448), in a study of HD patients, showed that 
depression preceded a decrease in serum albumin concentration. The reasons for 
these disparities remain unclear, but may be because of differences in ethnicity, 
gender, or age compositions of the study populations, and cultural and 
socioeconomic factors. Treatment conditions and nutritional differences may also 
play a role. 
There was no relationship between dialysis vintage and BDI-II scores in our study, 
which accords with previous studies (162). However, there are studies that showed 
differences between mean levels of BDI-II scores in incident and prevalent HD 
populations (449) and others that found a trend for greater prevalence of depression 
in patients treated for ESRD for more than one year (220). Chilcot et al. (450) found 
that higher levels of depression were associated with a poorer understanding of 
illness, coherence to treatment, perceptions that kidney failure has severe 
consequences, and a more recurring timeline. In addition, beliefs that treatment-
controlled kidney failure decreased over time in patients with increasing depression 
symptoms. 
The number of studies on the psychosocial condition of patients with renal graft 
failure and patients on the transplantation waiting list are limited, though there are 
indications that, upon returning to HD after graft rejection, patients are prone to 
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develop severe depression (451). Other studies have found that depression is a 
prevalent and problematic comorbidity and predicts poor outcomes, including graft 
survival in transplant patients in general (452). Patients with longer functional graft 
duration had lower levels of depression, whereas early transplant failure patients tend 
to be depressed due to unfulfilled high expectations. In addition, patients who had 
been on dialysis longer before their graft loss were less likely to be depressed, 
perhaps due to having a longer period of adaptation to dialysis 
challenges/restrictions. Patients awaiting a cadaveric donor have been reported to 
have a greater risk of anxiety and more severe depressive disorders than patients with 
an available living-related donor (453). We also found higher BDI-II scores in 
patients who had previous transplants – the higher the number of previous 
transplants, the higher the BDI-II score.  
Marital status and social support have been associated with depression in studies of 
patients in the presence and absence of renal disease (24, 162, 258, 454); we found 
that there was a trend towards a lower proportion of patients married or with a 
partner among those with high BDI-II scores.  
We also found that anuric patients (<1cup of urine/day) had higher BDI-II scores 
than those passing more urine, and were more likely to have a BDI ≥16, which was 
similar to previous literature. This may be due to patients’ perception of kidney loss 
and subsequent low mood being heightened by low urine volumes and loss of the 
social elements afforded by drinking. Both may increase depressive vulnerability 
(455). 
There is only a weak association of depressive symptoms with post-dialysis recovery 
time and this is likely to be mediated by the somatic element of the BDI-II score, to 
which the symptom of fatigue is a major contributing factor. This will be discussed 
in detail in Chapter 7. 
Our findings also suggest that PHQ-9 and PHQ-2 are acceptable screening tools 
compared to the BDI-II in dialysis patients, with cut-off points of ≥8 in PHQ-9 and 
≥2 in PHQ-2 approximating the BDI-II cut-off of ≥16. There is perhaps some 
conflict between this finding and previous literature (175), which validated the BDI-
II and PHQ-9 against the Structured Clinical Interview for Diagnostic and Statistical 
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Manual of Mental Disorders, fourth edition. The optimal BDI-II and PHQ-9 cut-off 
values for depressive disorders combined were ≥16 and ≥10, respectively. However, 
we did find that the strongest predictor of the MINI diagnosis in patients with high 
depressive symptoms (BDI-II ≥16) was a PHQ-9 of ≥10.  
It may be possible to reconcile these findings. The BDI-II score reflects both the 
somatic and cognitive aspects of depression. Hence, the BDI-II scores are inflated in 
HD patients due to an overlap of depressive symptoms and those of uraemia. This is 
partially compensated by use of a higher cut-off in the HD group (≥16) than in the 
general population. Nevertheless, a high proportion of those with BDI-II ≥16 do not 
have MDD on formal interview. Use of a lower cut-off in the PHQ-9 scale (≥8 vs 
≥10) in screening also inflates the number of screen-positive patients, to a level 
comparable to those identified by the BDI-II ≥16 cut-off. However, in the general 
HD population, the PHQ-9 ≥10 cut-off is superior at identifying those with 
diagnosed MDD (175), a group that excludes those patients whose depressive 
symptom scores showed inflated somatic symptom overlap. The same seems to hold 
true in the selected group of HD patients we studied, i.e. those already identified with 
high BDI-II scores (≥16).  
 
5.7 Effectiveness of Screening Methodology in Identifying 
Potential Trial Participants 
The main purpose of the screening phase was to identify HD patients with depression 
suitable to enter the RCT. In spite of approaching 1,353, only 37 were ultimately 
deemed suitable to be randomised, and only 30 agreed. The main reasons for 
dropping out were: 
 Inability to speak and understand English; this excluded 243 patients from 
being considered for screening 
 Refusal to consent for screening; this excluded 401 patients  
 Of the patients who screened positive with high depressive symptoms with 
the BDI-II, exclusions included: 
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o Current treatment for depression either by antidepressants, 
psychological therapy, or both [68]  
o Medical and other psychiatric problems [34]  
o Contraindicated medications [17]  
o Declined to consent for trial [38] 
The screening process was very robust. It might be questioned if it was too robust. 
Opportunities that may have increased the number of patients suitable for the RCT 
were:  
 Using validated-translated versions of the screening tools to enable inclusion 
of more non-English speaking patients; this would require translated versions 
with multiple languages, none of which are currently available. 
 Giving the opportunities for patients who were already on antidepressants to 
be considered for the RCT after a washout period; this approach has a number 
of risks, including worsening of depressive symptoms for some patients and 
increased complexity of the RCT. Using patients receiving psychological 
therapy might have similar complexities. It may also be possible to conduct 
an RCT of stopping antidepressants in a selected group of patients. Each of 
these possibilities is associated with difficult ethical issues, which may 
complicate regulatory approval.  
 Relaxed criteria concerning other medical/medications exclusions. It would 
be difficult to justify using patients with limited prognosis and other major 
conditions. It would be difficult to justify simultaneous treatment with agents 
cautioned or contraindicated with pharmacopeia. 
 Encouraging patients to consent to participate in the study may have been 
improved by a more consistent approach across the participating units. The 
consent rate for the screening phase was 709/1110 (64.5%) of those eligible. 
The consent rate for the psychiatric interview was 63/101 (62.4%) and the 
consent for the RCT was 30/34 (88.2%). The four who refused consent for 
the RCT preferred the offer of definitive antidepressant treatment rather than 
entering into the study and having a 50% chance of receiving the active drug.  
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 From a general perspective, therefore, these consent data seem very 
reasonable. There may be some scope to increase the consent rate, but it may 
be difficult to increase in reality. 
Considering all of these recruitment challenges, screening seems to be reasonably 
successful. 
  
5.8 Concluding Remarks 
The prevalence of depressive symptoms is high in HD patients. Antidepressant 
therapy is common, despite little evidence of efficacy in HD patients and a high 
potential for adverse effects. This was an important clinical finding, which also had 
ramifications for our feasibility RCT study – limiting identification of recruitable 
subjects. 
In addition to the planned feasibility study of the efficacy of sertraline in depressed 
HD patients, and as a result of these findings, a further study was designed and 
ethically approved to follow up a cohort of those HD patients on antidepressants to 
examine the natural history of this phenomenon. This will be described in Chapter 8.  
The predictors of high depressive symptoms (BDI-II ≥16) were younger age, anuria, 
past history of depression, and the presence of cancer. Previous failed transplantation 
was also associated with high depressive symptoms. 
BDI-II scores were also predictive of post-dialysis recovery time.  
PHQ-9 ≥8 is the best cut-off of the PHQ-9 test to detect patients with BDI-II ≥16.  
PHQ-9 ≥10 is the best cut-off to detect patients with MDD in a cohort with high 
depressive symptoms (BDI-II ≥16). 
Longitudinal studies and studies correlating depressive symptoms with psychiatric 
diagnoses are urgently needed in ESRD patients.  
Depressive affect rather than a pychiatric illness may be an important risk factor for 
ESRD patients, and may be amenable to treatment, with ramifications beyond mere 
changes in affect. 
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Chapter 6 
The RCT 
6.1 Introduction 
We conducted a multicentre, double-blind, placebo-controlled, feasibility 
randomised trial of sertraline in HD patients with mild to moderate MDD. The main 
purpose of the study was to evaluate the feasibility of conducting a fully powered 
double-blind, placebo-controlled RCT, by measuring the number of ESRD patients 
who took part and completed the study, as well as evaluating their outcomes.  
We wished to establish the potential effectiveness of sertraline as a treatment for 
depression in patients on HD. We also wished to establish whether the drug was well 
tolerated, whether it had an acceptable adverse effect profile, and whether there were 
indications that it was more effective than placebo in reducing depressive symptoms, 
in particular, fatigue. The safety and drug exposure of sertraline was also assessed. 
 
6.2 Brief Methodology 
Full details of the design, setting, outcomes, and statistical analysis are documented 
in Chapter 4. In brief, patients over the age of 18 who had been receiving treatment 
by HD for three months or more were approached. Those who could not read and 
speak English were excluded. Consenting patients completed the BDI-II 
questionnaire. Demographics, medical and psychiatric history, and dialysis treatment 
data were also collected. Those scoring ≥16 on the BDI-II, not on treatment for 
depression (antidepressants or psychological therapies) currently or in the past three 
months, and without any pre-defined exclusion criteria, including planned living-
donor kidney transplant within the period of the trial, a prognosis of less than a year, 
several associated medical conditions and contraindicated medications, were 
approached to undergo diagnostic interview by a psychiatrist using the MINI to 
confirm the presence of MDD. Following this, consenting patients diagnosed with 
mild-moderate MDD and with a score of 18 or above on the MADRS were 
randomised into the trial phase. We planned to exclude patients with severe 
160 
 
depression and active suicidal ideation from the study and refer them urgently to 
psychiatric services. We also planned to exclude patients who had evidence of 
cognitive impairment on MMSE (440). We required written informed consent from 
patients at three separate points during the study, before screening, before interview 
by the study psychiatrist, and before randomisation to enter the trial.  
 
6.3 Results 
Screening and recruitment into the study took place between 1 April 2013 and 30 
April 2015. The CONSORT flow diagram for the study is shown in Figure 20 . We 
approached 1,353 patients in five UK renal units, to enter the screening phase. 243 
were excluded mainly due to lack of proficiency in English. Of the remaining 1,110 
patients, 709 (64%) consented to screening. On screening, 231 patients (32.6%) had 
a BDI-II score of 16 or above. 168 of these were excluded from consideration for the 
trial phase – 39 were not considered because of current antidepressants treatment, 12 
because of current psychological therapy, and 17 were receiving both these 
treatments. Other reasons for exclusion were medical and other psychiatric problems 
(34), other contraindicated medications (17), and miscellaneous other reasons (11), 
including participation in other interventional studies and inadequate birth control. 38 
patients declined to consent to take part in the psychiatric interview (see Chapter 5).  
Sixty-three of those eligible for the trial phase consented to be seen by the study 
psychiatrist for diagnostic interview. Thirty-seven of these (58.7%) were diagnosed 
with MDD. However, three had recently started antidepressants, one had severe 
cardiac disease, one had severe cognitive impairment, one was diagnosed with 
substance misuse, and another preferred to be seen by their primary care physician. 
The remaining 30 consented to enter the RCT. On unblinding, it was apparent that 15 
had been randomised to the sertraline and 15 to the placebo group.  
The baseline characteristics of the patients randomised in these groups are shown in 
Table 27. All characteristics were similar in these groups, except that patients in the 
sertraline group were on average five years older (61.7 ± 13.2 vs 56.4 ± 14.4 years; 
p=0.15). The sample was predominately men (77%). For the whole study sample, the 
mean age was 59.0 ± 13.8; 60% were white, 20% Asian, and 20% other ethnicities. 
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Fifty percent were married or living in a civil partnership, and 33% lived alone. Over 
80% had at least one comorbidity, with diabetes and heart disease the most common. 
Thirty-three percent had a past history of depression and 17% had previously used 
antidepressants. 
 
Table 27: Baseline characteristics  
 
Sertraline 
n=15 
Placebo 
n=15 
Age (years) 61.7 (13.2) 56.4 (14.4) 
Male  11 (73%)  12 (80%) 
Ethnicity White 10 (67%) 
Asian 2 (13%) 
Black 2 (13%) 
Mixed 1 (7%) 
White 8 (53%) 
Asian 4 (27%) 
Mixed 3 (20%) 
Living conditions  Alone 5 (33%) 
With partner 5 (33%) 
With family 5 (33%) 
Alone 5 (33%) 
With partner 6 (40%) 
With family 4 (27%) 
Dialysis vintage (years) 3.1 (5.1) 3.3 (5.4) 
Diabetes  6 (40%) 7 (47%) 
History of depression 5 (33%) 5 (33%) 
Haemoglobin (g/L) 118 (19) 117 (14) 
Urea (mmol/L) 16.0 (6.3) 15.7 (7.6) 
Creatinine (umol/L) 707 (285) 664 (315) 
Kt/V (Last value at month 1) 1.43 (0.36) 1.47 (.21) 
Pre-dialysis BP (mmHg) 148/77 147/84 
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709 eligible patients consented to take part in the 
screening 
231 patients had a score of ≥16 on the BDI-II 
30 patients consented to take part in the trial 
Baseline 
15 Sertraline 
Baseline 
15 Placebo 
2- Month Follow-up 
9 Sertraline 
2- Month Follow-up 
14 Placebo 
4- Month Follow-up 
8 Sertraline 
4- Month Follow-up 
13 Placebo 
6- Month Follow-up 
8 Sertraline 
6- Month Follow-up 
13 Placebo 
63 patients were eligible for psychiatric evaluation 
and consented for interview 
168 excluded – due to application of 
inclusion/exclusion criteria for trial phase and 
unwillingness to consent 
37 patients were diagnosed with Major 
Depressive Disorder 
7 patients excluded  
3 started on anti-depressants 
2 had severe medical problems 
1 had a drug dependency problem 
1 preferred referral to primary care 
6 discontinued 
1 death 
3 adverse events 
1 serious adverse event 
1 withdrew consent 
1 withdrew consent 
1 discontinued due to adverse 
event 
 1 withdrew consent 
  
1,110 eligible patients approached for the screening 
study 
401 were unwilling to consent 
1,353 patients eligible for screening phase were 
approached  
243 excluded predominantly because of 
inability to read and understand English 
Figure 20 Study CONSORT diagram 
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6.4 Comparison between Sertraline and Placebo Groups 
Twenty-one patients completed the trial (70%) at the six-month follow-up. There 
were eight (53%) in the sertraline group and 13 (87%) in the placebo group (χ2=3.97: 
p=0.046). In the sertraline group, six withdrew within the first two months. One of 
them took no tablets as they were concerned about side effects. Three patients 
experienced adverse effects (one withdrew after three days because of nausea, 
another after 12 days with headaches and dizziness, and a third due to insomnia after 
23 days). One patient died following cardiac arrest having taken one tablet. The sixth 
was admitted for a prolonged hospital stay with leg ulcers shortly after randomisation 
and was subsequently withdrawn without having taken any study medication. A 
further patient withdrew after three months because of sweating and palpitations. In 
the placebo group, one withdrew after baseline assessment because of concern about 
taking extra medication, and another decided against continuing after three months 
with no reported reason. There were no significant differences in safety data, 
including ECG, haemoglobin, and liver function tests between groups during the 
course of the study. 
The number of drop-outs due to adverse or severe adverse events was greater in the 
sertraline group (33% vs 0%; p =0.042). Patients who withdrew were older (70 vs 54 
years: p=0.001) and had lower baseline haemoglobin levels (109 vs 121 g/L: 
p=0.04). There were no other differences between those who withdrew and those 
who remained in the study.  
 
6.5 Comparison between BDI-II and MADRS scores in 
sertraline and placebo groups 
There was a significant fall in the BDI-II from baseline to month 6 (29.1 ± 8.4 to 
17.3 ± 12.4: p<0.001) and in the MADRS scores (24.9 ± 4.3 to 10.7 ± 5.2: p<0.001), 
with similar significant falls in both sertraline and placebo groups (Figure 21 and 
Table 28). The mean change in the MADRS score over the six months of the study 
was -14.5 (CI -20.2 to -8.8) in the sertraline group and -14.9 (CI -18.4 to -11.5) in the 
placebo group. Changes in BDI-II were similar at -15.7 (CI -24.3 to -7.1) in the 
164 
 
sertraline group and -13.0 (CI -19.6 to -6.4) in those on placebo. There were no 
statistically reliable differences between the groups. For the MADRS score there 
were no differences between the groups at any other time point with respect to 
change from baseline values. The maximum difference occurred at two months, at 
which stage, nine patients remained on sertraline and 14 on placebo (MADRS scores 
13.9 ± 5.7 and 15.8 ± 4.8 respectively, difference 1.89 [CI -2.7 to 6.5]: p=0.20) 
(Table 28 and Figure 21). The effect size at this time point was estimated at 0.37 
using Cocks et al.’s approach (442).  
Eighteen patients experienced adverse events and/or serious adverse events (SAEs), 
nine in each randomised group. Infections (8) and nausea (4) were the most 
commonly reported adverse events. With regard to the SAEs, there was one death 
that was possibly related to the study medication, as mentioned above, six SAEs that 
were unlikely to be related, and six SAEs that were not related to the study 
medication. In none of these events was emergency unblinding needed. For neither 
was urgent referral to psychiatric services necessary during the course of the study. 
There was one patient who was retrospectievely was found to be on Tramadol 
(started by GP), which was a relative contraindication with sertraline; in view of the 
fact that she had experienced satisfactory pain relief on this agent without developing 
side effects, we decided to continue this medication and continue her in the trial.  
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Figure 21: MADRS score over six months  
 
Table 28: Comparison between the MADRS score in sertraline and placebo 
groups 
 
 Sertraline Placebo Treatment effect 
MADRS Baseline 
 
24.5 (4.5) 
n=15 
25.3 (4.2) 
n=15 
 
 2 months 13.9 (5.8) 
n=9 
15.8 (4.8) 
n=14 
-1.9 (-6.5, 2.7) 
 4 months 10.6 (6.6) 
n=8 
11.1 (5.5)  
n=13 
-0.45 (-6.0, 5.1) 
 6 months 10.3 (5.8)  
n=8 
10.9 (5.1)  
n=13 
-0.67 (-5.7, 4.4) 
 Change from baseline   
 To 2 months -10.4 (-16.4, -4.4) -8.9 (-13.3, -6.4)  
 To 4 months -14.1 (-19.6, -8.6) -14.8 (-18.1, -11.4)  
 To 6 months -14.5 (-20.2, -8.8) -14.9 (-18.4, -11.5)  
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6.6 Medication Adherence and Safety 
Mean medication adherence among those who completed the study, estimated by a 
count of returned tablets, was 88% (range 46 – 100%). In only one patient was 
adherence to the study medication less than 75% (it was 46%). Pre- and post-dialysis 
sertraline levels were analysed after unblinding at the end of the study and the 
process was previously explained in Chapter 4. Five of the eight patients, all taking 
100mg daily, had similar pre- and post-dialysis levels (32 ± 12 ug/l vs 34 ± 18 ug/l). 
In two others, both taking 50mg daily, levels were <10 ug/l. One had been 46% and 
the other 94% adherent on tablet counts. Levels were unmeasurable in one patient 
due to an interfering compound, possibly verapamil. 
 
6.7 Discussion 
This feasibility study is the largest trial of an antidepressant in HD patients to date. 
We recruited 30 patients and 21 (70%) patients completed the six-month study.  
Recruitment to the trial, however, was constrained. The final number of 30 patients 
was well below the original planned sample size, which was 60. Just over 70% of the 
screend patients with BDI-II ≥16 were non-eligible or were unwilling to consent to 
psychiatric interview. 29% were already taking anti-depressants or receiving 
psychological therapies, which were exclusion criteria. Some patients seemed 
reluctant to take additional medication because of already high pill burdens.  
Our results confirmed that a high proportion of patients on HD (32.3%) screened 
positive on the BDI-II and suffered from significant depression. 46% had a past 
history of depression, and 25% were currently taking antidepressants or receiving 
psychological therapies. We also confirmed that sertraline is not removed 
substantially in the haemodialysis procedure and adherence to the medication also 
seemed to have been adequate.  
Mean (and standard deviation) values for the MADRS score at two, four, and six months for the sertraline and 
placebo groups. The treatment effect is estimated as the difference between the observed outcome scores (with 95% 
confidence intervals) for the sertraline and placebo groups. As the difference between the groups was effectively 0 at 
six months, no adjusted differences have been estimated.  The change in the MADRS score from baseline to two, 
four, and six months (with 95% confidence intervals) is provided in the 2nd half of the table. 
167 
 
Eighteen patients, nine in each randomised group, experienced adverse events, with 
infections and nausea the most commonly reported. With regard to the SAEs, there 
was one death that was possibly related to the study medication, six SAEs that were 
unlikely to be related, and six SAEs that were not related to the study medication. 
Depression scores for both BDI-II and MADRS improved significantly in the 
sertraline and placebo groups over six months. There was no significant difference 
between the groups. There was a suggestion that the rate of decrease in the MADRS 
scores over two months tended to be greater in those on sertraline, though this may 
relate to the higher drop-out rate in this group. 
The significant improvement in depression over six months could be due to a strong 
placebo effect, to the effect of study participation (Hawthorne effect) (456), or 
perhaps related to the natural history of MDD in this context. There is also a 
possibility that sertraline may cause harm, related to adverse effects. The only death 
occurred was in this group.  
Our main study limitation was the small sample size. RCT recruitment was difficult 
and constrained by exclusion of an unexpectedly high number of patients already 
receiving treatment for depression. These exclusions not only limited recruitment but 
also may have inadvertently introduced a selection bias in our sample. The clinical 
outcomes we have described need to be interpreted with great caution due to the 
study design and the small sample size. 
 
6.8 Concluding Remarks 
Our study raises concerns about the benefits and risks of antidepressant treatment in 
patients on HD, a highly comorbid group with a huge pill burden and with high 
prevalence of depression. Identifying effective treatments is a major clinical need, 
hence the need for a definitive study. 
We recommend that the design of such a study should enable inclusion, rather than 
exclusion, of patients currently taking antidepressants. This would require a washout 
period, in cases that have been judged to be appropriate on clinical grounds.  
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To evaluate the potential advantage for sertraline over placebo at two months, 
assuming alpha=0.05 and 1-beta=0.90 with a one-sided test, the required sample size 
would be 135 patients per study arm. If such a study included patients already on 
depression treatment, 3,600 HD patients would need to be screened to achieve this 
recruitment target. A shorter follow-up period of two to three months could be 
sufficient as recovery may be more rapid on the active drug and most drop-outs 
appear to occur in this timescale. The definitive trial could be powered based on our 
effect size at two months, with a required sample size of 270 patients randomised to 
two study arms. Given the high degree of symptom overlap between depression and 
advanced kidney disease, depression should be diagnosed by psychiatric interview, 
rather than questionnaires. It must be recognised that the basis of this power 
calculation is speculative given the small differences found between the sertraline 
and placebo effects.  
Current UK guidelines for treating depression in patients with chronic physical 
illness, issued by NICE, advocate pharmacological therapy for patients with MDD 
(457). We strongly agree with the European Renal Best Practice Group 
recommendations that ‘The evidence on the effectiveness of antidepressants versus 
placebo in patients with CKD stages 3-5, and with DSM-IV-defined depression is 
insufficient, and in view of the high prevalence, a well-designed RCT is greatly 
needed’ (230), and with the recent Cochrane review (458): ‘Despite the high 
prevalence of depression in dialysis patients and the relative priority that patients 
place on effective treatments, evidence for antidepressant medication in the dialysis 
setting is sparse and data are generally inconclusive. The relative benefits and harms 
of antidepressant therapy in dialysis patients are poorly known and large randomised 
studies of antidepressants versus placebo are required’.  
We believe it is highly recommended to conduct a large randomised placebo-
controlled trial of antidepressants in this group of patients due to uncertainty about 
the efficacy and safety of antidepressants, and in consideration of the large numbers 
of haemodialysis patients currently taking these agents. We also recognise the 
potential difficulties of undertaking such a study. 
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Chapter 7 
Fatigue 
7.1 Aims 
1- Establish the proportion of ESRD patients who scored positive on fatigue 
scales MFI and SF-36 energy/fatigue subscale. 
2- Establish the relationship between depression and fatigue scores and their 
relationship to clinical, biochemical, and haematological parameters.  
3- Explore the extent to which somatic symptoms of depression such as fatigue 
contribute to the diagnosis of depression in this chronic disease state. 
4- Establish whether there is a difference between drug and placebo on the 
measures of fatigue over the period of the study.  
 
7.2 Brief Overview of Methodology 
As part of the screening phase of the ASSertID study, patients over the age of 18 
years who had been receiving treatment by HD for three months or more were 
approached. Patients who could not read and speak English were excluded. 
Consenting patients completed the MFI and SF-36 energy/fatigue subscale 
questionnaires at bedside during dialysis. These questionnaires are described in detail 
in the introductory fatigue chapter 3, section 3.3. Data relating to demographics, 
medical and psychiatric history, and dialysis treatment were also collected.  
 
7.3 Data Collection 
Data was collected from electronic records and directly from patients on age, gender, 
marital status, ethnicity, current living arrangements (alone, with partner or family, 
or friends), and educational attainment. The duration (vintage) of dialysis time was 
recorded, in addition to dialysis adequacy (Kt/V) and routine clinical observations on 
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 the day of completion of the questionnaire (blood pressure and dry weight). The 
most recent biochemical and haematological data were collected from the electronic 
patient record – haemoglobin, albumin, calcium, and phosphate. Details of patients’ 
transplant history were recorded as never transplanted or transplanted and returned to 
dialysis. We also asked to self-report urine output as being less than one cup per day 
or greater than one cup per day and post-dialysis recovery was categorised as <1hr, 
1-4hrs, 4-8hrs, 8-12hrs, or >12hrs. C reactive protein (CRP) was measured in a 
smaller subgroup.  
 
7.4 Results 
Ethical approval for the fatigue study was granted after the start of recruitment to the 
ASSertID screening study. An amendment to the ASSertID study to include the 
fatigue questionnaire was approved (Appendix 1). Hence, of the 709 eligible patients 
who entered the screening phase of the ASSertID study, 464 candidates completed 
both fatigue questionnaires. 
  
7.4.1 Characteristics of the Whole Cohort 
The characteristics of this cohort (464) were as follows: the mean age was 64 years 
(± 16.6); 306 were male (65%); 291 (62%) were white and all others, including 
Asian, black, and mixed race, totalled 176 (38%); 235 (51%) were married or in a 
civil partnership; 231 (49%) were living alone; 186 (40%) patients had received 
formal educational qualifications beyond age 16; dry weight was 76.5kg (± 19); and 
dialysis vintage was 4.1 years (IQR 5.2). Comorbidities were recorded and were 
highly prevalent in diabetes (35.5%), followed by heart disease (30%), cancer, 
stroke, lung disease, liver disease, and amputation. Blood pressure and the most 
recent biochemical and haematological data are shown in Table 29. 
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Table 29: Cohort characteristics (n=464) 
Age (years) 64 ± 16 
Gender (% male) 65 
Ethnicity (% white) 62 
Weight (kg) 76.5 ± 19 
Pre-dialysis systolic BP (mmHg) 140 ± 25 
Pre-dialysis diastolic BP (mmHg) 71 ± 16 
Marital status (%)  
Married/partner 51 
Single 49 
Depression (%)  
Past history 24 
Antidepressants 18 
Psychological therapy 4 
BDI-II 10 (11.4) 
PHQ-9  5(6.2) 
Comorbidity (%)  
Diabetes 35.5 
Heart disease 30 
Cancer 10 
Stroke 8 
Lung disease 6 
Amputation 6 
Dialysis parameters  
Vintage (IQR) years 4.1 (5.2) 
Kt/V 1.5 ± 0.32 
Laboratory parameters  
Haemoglobin (g/l) 112 ± 12.6 
Albumin (g/l) 37.4 ± 4.7 
Calcium (mmol/l) 2.23 ± 0.18 
Phosphate (mmol/l) 1.60 ± 0.5 
 
Median MFI score for general fatigue (GF), physical fatigue (PF), mental fatigue 
(MF), reduced activity (RA), and reduced motivation (RM) were: 13 (IQR 6), 15 
(IQR 6), 9 (IQR 6), 13 (IQR 6), and 13 (IQR 6), respectively. The mean SF-36 
energy/fatigue subscale score was 48.1 ± 23.9.  
 
7.4.2 Predictors of Fatigue 
7.4.2.1 Clinical Factors  
There was an inverse correlation between GF and age (rho=-0.132; p=0.004) and a 
positive correlation with weight (rho=0.121: p=0.009). PF did not correlate with age 
but did correlate positively with weight (rho=0.169: p<0.001). MF did not correlate 
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with age or weight. There were no differences in relation to gender or ethnicity with 
respect to any of the fatigue subdomains.  
There were no correlations with haemoglobin, albumin, calcium, phosphate, Kt/V, 
and systolic or diastolic blood pressure with any of the fatigue domains.  
GF and PF were higher in patients with heart disease (14 (IQR 6) vs 13 (IQR 6): 
p=0.014 and 16 (IQR 6) vs 15 (IQR 7): p=0.002, respectively). Likewise, GF and PF 
were higher in patients with diabetes (14 (IQR 5) vs 13 (IQR 6); p=0.013 and 16 
(IQR 6) vs 15 (IQR 6); p<0.001, respectively). There were no differences with 
respect to stroke, amputation, and cancer. There were no differences in MF scores 
with respect to any of these conditions. In a smaller group of patients (n=114), the PF 
score was higher in those with a CRP>5mg/l (15 (IQR 6) vs 14 (IQR 7): p=0.010). 
There were no differences with respect to either GF or MF.  
Overall, GF was weakly related to age (but negatively), weight, heart disease, and 
diabetes. PF was similarly related to weight, heart disease, and diabetes, but also to 
high CRP. There were no associations of MF. 
   
7.4.2.2 Depression Screening Scores 
There were very strong correlations between the BDI-II, PHQ-9, and PHQ-2 scores 
and all MFI subdomains (GF, PF, and MF) (Table 30). The best correlations were 
between GF with BDI-II and PHQ-9 (rho=0.607 and rho=0.606: p< 0.001 in both 
cases). 
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Table 30: Correlation between BDI-II, PHQ-9, PHQ-2, and MFI 
 BDI-II PHQ-9 PHQ-2 
 General fatigue Rho .607
**
 .606
**
 .484
**
 
p-value .000 .000 .000 
    
Physical fatigue Rho .524
**
 .529
**
 .467
**
 
p-value .000 .000 .000 
    
Mental fatigue Rho .588
**
 .584
**
 .508
**
 
p-value .000 .000 .000 
 
7.4.3 Distribution of MFI in Patients with High BDI (≥16) 
We compared the distribution of fatigue subdomains in the whole cohort and in 
patients with BDI-II ≥16 (high) and those with lower scores (normal), focusing on 
the general, physical, and mental fatigue subdomains, as shown in the graphs below. 
There were no differences in the median values of reduced motivation and reduced 
activities between those with high and normal BDI-II scores. These domains have 
been omitted from the remainder of the analysis. 
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Figure 22 Distribution of MFI subdomain scores 
 
Figure 22 shows the distribution of MFI subdomains (GF, PF, and MF) in the whole 
cohort. The GF score was approximately normally distributed, and PF and MF scores 
were not. There was a negative skew in the PF score and a positive skew in the MF 
score.  
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Figure 23: Mental fatigue distribution in patients with high and normal BDI-II 
(1 = high) 
 
With MF, there was a positive skew distribution in patients with a normal BDI-II 
compared to a relatively normal distribution in those with high BDI-II scores, as 
shown in Figure 23 above. This contrasts with the situation for PF. In this setting, 
patients with high BDI-II scores have a marked negatively skewed distribution of PF 
scores, as shown in Figure 24. The distribution in patients with normal BDI-II scores 
was more normal. There was a similar distribution in GF scores, as shown in Figure 
25.  
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Figure 24: Physical fatigue distribution in patients with high and normal BDI- 
II scores (1 = high) 
 
 
 
Figure 25: General fatigue distribution in patients with high and normal BDI-II 
scores (1 = high) 
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7.4.4 Relationship between BDI-II, PHQ, and MFI (GF, PF, MF) SF-
36 
GF, PF, and MF scores were all higher in patients with a BDI-II ≥ 16 compared to 
those with lower BDI-II scores. The same was true for patients with PHQ-9 ≥ 8 
compared to those with lower scores (Table 31).  
 
Table 31: Comparison between BDI-II, PHQ-9, and fatigue  
 BDI-II <16 BDI-II ≥ 16 p-value PHQ-9 <8 PHQ-9 ≥ 8 p-value 
MFI       
GF 12 (IQR5) 16 (IQR4) <0.001 12 (IQR5) 16 (IQR5) <0.001 
PF 14 (IQR6) 17 (IQR4) <0.001 14 (IQR6) 17 (IQR5) <0.001 
MF 7 (IQR6) 13 (IQR5) <0.001 7 (IQR6) 12 (IQR6) <0.001 
SF-36 57.2 ± 20.5 30.5 ± 20.5 <0.001 57.4 ± 20.1 32.1 ± 22.7 <0.001 
 
7.4.5 Fatigue Scores as Predictors of High Depressive Symptoms  
7.4.5.1 BDI-II ≥16 
We first explored general factors predicting high BDI-II scores (≥16) in this group of 
patients, including factors likely on clinical grounds to have an influence. Factors 
considered were: age, gender, ethnicity, marital status, comorbidities, including heart 
disease, stroke, amputation, diabetes, and cancer, dialysis vintage, anuria, and past 
history of depression (Table 32).  
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Table 32: Baseline predictors of BDI-II ≥16 in logistic regression model  
 
n=464 B SE P value Odds ratio 
S
t
e
p
 
1
a 
Age (years) -.026 .006 .000 .975 
Gender (male) .332 .201 .098 1.394 
Ethnicity (non-white) -.086 .216 .691 .918 
Married/partner .091 .193 .636 1.096 
Heart disease .210 .208 .313 1.234 
Stroke .316 .343 .357 1.372 
Amputation -.229 .544 .674 .796 
Diabetes .002 .215 .993 1.002 
Cancer .673 .302 .026 1.960 
Dialysis vintage (years) -.001 .002 .644 .999 
Anuria .568 .199 .004 1.764 
Past history of depression 1.579 .207 .000 4.848 
Constant -.104 .457 .820 .901 
 
The best logistic regression model of BDI-II ≥16, including the factors above, was 
highly significant (p<0.001) but explained only 19.9% of variation. Age, cancer, 
anuria, and past history of depression were significant predictors, and gender 
approached significance (Table 32). We then in turn added the fatigue subdomain 
scores to a model containing these significant predictors. Because of the high 
correlation between fatigue subdomains, we built individual models for each 
subdomain. The best model included MF. The model explained 48% of the variation 
in BDI-II ≥16. Significant predictors in this model were age and past history of 
179 
 
depression (Table 33). Cancer, gender, and anuria were not significant in this model, 
suggesting their effects in the previous model (Table 33) may have been mediated by 
fatigue. The models including GF and PF explained 41.5% and 34.7% of the 
variation, respectively.  
 
Table 33: Logistic regression of predictors of BDI-II ≥16 including baseline 
factors and mental fatigue score  
n=464 B SE P value Odds ratio 
S
t
e
p
 
1
a 
Age (years) -.025 .008 .002 .975 
Gender (male) .399 .281 .156 1.491 
Cancer .230 .461 .617 1.259 
Anuria .345 .259 .184 1.412 
Past history of depression 1.168 .292 .000 3.216 
Mental fatigue score .337 .036 .000 1.400 
Constant -3.332 .665 .000 .036 
 
In a smaller group of patients with available CRP measurements we built an 
additional model using the same factors and including CRP >5mg/l. The best model 
included in this factor explained 50% of variation in BDI-II ≥16 (Table 34). 
Significant predictors in this model were: age, past history of depression, MF, and 
CRP >5mg/l. Similarly to the previous model, cancer, gender, and anuria were not 
significant in this model, suggesting their effects in the original model (Table 33) 
may have been mediated by fatigue. Models including GF and PF explained 42.2% 
and 35.2% of the variation, respectively.  
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Table 34: Logistic regression of predictors of BDI-II ≥16 including baseline 
factors and mental fatigue score and high CRP 
n=114 B SE P value Odds ratio 
S
t
e
p
 
1
a 
Age (years) -.025 .008 .001 .975 
Gender (male) .405 .284 .153 1.500 
Cancer .220 .459 .632 1.246 
Anuria .280 .263 .287 1.324 
Past history of depression 1.226 .298 .000 3.408 
Mental fatigue score .342 .037 .000 1.408 
CPR >5mg/l -.784 .296 .008 .457 
Constant -2.768 .691 .000 .063 
 
7.4.5.2 PHQ-9 ≥8 
We first explored general factors predicting high PHQ-9 (≥8) in this group of 
patients, including factors likely on clinical grounds to have an influence. Factors 
considered were: age, gender, ethnicity, marital status, vintage, comorbidities, 
including heart disease, stroke, amputation, diabetes, and cancer, anuria, and past 
history of depression (Table 35). 
Patients with PHQ-9 ≥8 were younger (60 ± 16 vs 66 ± 16.4), with greater anuria 
(53%), and with a past history of depression (44%). There were no differences in 
gender, ethnicity, dialysis vintage, comorbidities (heart disease, stroke, amputation of 
limb, and diabetes), and marital status.  
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Table 35: Predictors of fatigue scores with PHQ-9 ≥8 
n=464 B SE P value Odds ratio 
S
t
e
p
 
1
a 
Age (years) -.021 .006 .000 .979 
Gender (male) -.025 .189 .893 .975 
Ethnicity (non-white) -.423 .206 .040 .655 
Married/partner .056 .185 .762 1.058 
Dialysis vintage .000 .002 .838 1.000 
Heart disease .284 .199 .153 1.328 
Stroke .082 .338 .808 1.086 
Amputation of limbs .558 .507 .271 1.747 
Diabetes .238 .203 .240 1.269 
Cancer .735 .292 .012 2.086 
Anuria .682 .190 .000 1.978 
Past history of depression 1.310 .202 .000 3.706 
Constant .100 .443 .822 1.105 
 
The best logistic regression model of PHQ-9 ≥8 including these factors was highly 
significant (p<0.001) but explained only 19% of variation. Age, ethnicity, cancer, 
anuria, and past history of depression were significant predictors. 
We then in turn added the fatigue subdomain scores to a model containing these 
significant predictors. Because of the high correlation between fatigue subdomains 
we built individual models for each subdomain. The best model included MF. The 
model explained 42.3% of the variation in PHQ-9 ≥8. Significant predictors in this 
model were: age, past history of depression, and MF (Table 36). Cancer was not 
significant in this model and ethnicity and anuria were less significant than in the 
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previous model (Table 35). This suggests the effects of these parameters on PHQ-9 
≥8 were mediated by fatigue. The models including GF and PF explained 38.7% and 
34.2%, respectively.  
 
Table 36: Logistic regression for predictors of PHQ-9 ≥8 including MF score  
n=464 B SE P value Odds ratio 
S
t
e
p
 
1
a 
Age (years) -.020 .007 .007 .980 
Ethnicity (non-white) -.426 .255 .095 .653 
Cancer .081 .428 .849 1.085 
Anuria .414 .241 .085 1.512 
Past history of depression .814 .283 .004 2.257 
 Mental fatigue score .298 .033 .000 1.347 
Constant -2.427 .575 .000 .088 
 
In a smaller group of patients with available CRP measurements we built an 
additional model using the same factors and including CRP >5mg/l. The best model 
included in this factor explained 43% of variation in PHQ-9 ≥8 (Table 37). 
Significant predictors in this model were: age, past history of depression, and MF. 
CRP >5mg/l tended towards significance. The difference between its predictive 
power for BDI-II ≥16 is likely to be due to there being more somatic domains in the 
BDI-II score. 
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Table 37: Logistic regression of predictors of PHQ-9 ≥8 including MF score and 
high CRP (>5 mg/l) 
n=114 B SE P value Odds ratio 
S
t
e
p
 
1
a 
Age (years) -.021 .008 .006 .980 
Ethnicity (non-white) -.394 .257 .125 .674 
Cancer .072 .426 .867 1.074 
Anuria .375 .242 .122 1.455 
Past history of depression .832 .285 .004 2.298 
 Mental fatigue score .302 .033 .000 1.352 
CPR > 5mg/l .513 .275 .063 1.670 
Constant -2.567 .583 .000 .077 
 
7.4.6 Comparison between MINI diagnosis and MFI  
Out of the cohort of 464, 45 patients had a psychiatric interview. 28 had a diagnosis 
of MDD with the MINI. The only MFI subdomain that approached being 
significantly higher in patients with a diagnosis of MDD than in patients without was 
MF (Table 38).  
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Table 38: Relationship between MINI diagnosis and MFI subdomain scores 
 MINI  N Median IQR P value 
General fatigue  No MDD 17 15 5 NS 
MDD 28 16 6  
Physical fatigue No MDD 17 16 5 NS 
MDD 28 18 4  
 Mental fatigue No MDD 17 12 7 0.085 
MDD 28 13 4  
 
  
7.4.7 Relationship between MFI and Post dialysis recovery time 
In this group of 464 patients, post-dialysis recovery time was distributed into five 
groups as follows: <1hr (24%), 1-4hrs (27%), 4-8hrs (15%), 8-12hrs (11%), and 
>12hrs (23%). 
MFI subdomain scores differed in relation to dialysis recovery time. The biggest 
difference was between patients who recovered quickly (<1hr) and patients with all 
other categories of recovery time. This is represented in Table 39. 
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Table 39: Median values of GF, PF, and MF by post-dialysis recovery time.  
P values represent differences in median values by the Kruskal Wallis test 
 <1hr 1-4 hrs 4-8 hrs 8-12 hrs >12 hrs p value  
GF 10 (IQR6) 13 (IQR5) 14 (IQR6) 15 (IQR5) 14 (IQR5) <0.001 
PF 13 (IQR6) 15 (IQR6) 14 (IQR7) 16 (IQR5) 17 (IQR5) <0.001 
MF 8 (IQR7) 10 (IQR7) 8 (IQR7) 8 (IQR7) 10 (IQR5) <0.002 
  
We have previously found (Chapter 5) that centre, gender, past history of depression, 
living with partner, and BDI-II score were significant independent predictors of 
prolonged recovery time (>1 hrs).  
We built logistic regression models to predict prolonged recovery time (>1hr) 
including the above factors and in turn adding MFI subdomains (GF, PF, and MF). 
The best model (model 1), controlled for centre, gender, and living with partner, was 
that including GF, which was highly predictive of prolonged recovery time. Past 
history of depression was also significant in this model. The BDI-II score was not 
significant. The model explained 25.2% of the variation (Table 40).  
In the model of the same baseline factors including PF (model 2), both past history of 
depression and BDI-II score were predictive of prolonged recovery time. The PF 
score was highly predictive. However, the model explained only 17.8% of the 
variation (Table 40).  
In the model using the same baseline factors and MF (model 3), past history of 
depression and BDI-II score were also predictive of prolonged recovery time, while 
MF was not. However, the model explained only 15.5% of the variation (Table 40).  
This implies that post-dialysis recovery has both physical and mental components in 
relation to fatigue and that the physical component plays the greater role. 
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Table 40: Logistic regression models of predictors of prolonged recovery time 
 B SE P value Odds ratio 
 All models controlled for centre, gender, living with partner 
 Model 1. Nagelkerke R-square 0.252     
 Past history of depression .820 .401 .041 2.270 
S
t
e
p
 
1
a 
BDI-II score .014 .0167 .401 1.014 
General fatigue score .224 .041 .000 1.251 
Model 2. Nagelkerke R-square 0.178     
Past history of depression .876 .390 .025 2.402 
BDI-II score .045 .017 .007 1.406 
Physical fatigue score .087 .032 .006 1.091 
Model 3. Nagelkerke R-square 0.155     
Past history of depression .939 .387 .015 2.558 
BDI-II score .062 .018 .001 1.064 
Mental fatigue score .015 .037 .680 1.020 
 
 
7.4.8 Fatigue and Survival Prediction 
A number of Cox models were built to model survival in this cohort of 464 patients. 
The baseline model (Table 41) included those parameters pragmatically chosen as 
being likely to influence survival. In subsequent models, we added in turn each MFI 
subdomain. GF and MF were not significant in the model; however, PF was a highly 
significant predictor of mortality (HR 1.097: p=0.008). This implies that for every 
additional point increase on the PF subdomain scale, there is a 10% increase in 
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mortality risk. A further set of models were produced adding depression screening 
parameters to the baseline model, including MFI subdomains. None of these 
parameters (BDI-II score, BDI-II ≥16, PHQ-9 score, PHQ-9 ≥8, and PHQ-9 ≥10) 
predicted mortality in these models. 
 
Table 41: Baseline Cox regression model predicting survival (n=464) 
 B SE P value Hazard ratio 
Age (years) .032 .010 .001 1.032 
Gender (male) .075 .251 .764 1.078 
Ethnicity (white) .608 .301 .043 1.837 
Heart disease .463 .230 .044 1.588 
Stroke -.095 .429 .825 .909 
Amputation .841 .472 .075 2.318 
Diabetes .645 .255 .011 1.907 
Cancer -.432 .436 .322 .649 
Anuria .442 .248 .074 1.556 
Kt/V -.641 .392 .103 .527 
Albumin (g/l) -.110 .027 .000 .896 
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7.5 Effect of Treatment with Sertraline and Placebo on the 
Measures of Fatigue during the Trial Phase 
The collection of the fatigue data only commenced some way into the screening 
study, so the numbers of patients in the trial phase of the study with baseline fatigue 
scores was 23 compared with 30 for the depression scores (see Chapters 5 and 6). 
The numbers in each treatment group were: sertraline: 11 at baseline, eight at two 
months, seven at four months, and seven at six months; and placebo: 12 at baseline, 
11 at two months, 11 at three months, and 10 at six months.  
The changes in fatigue scores during the trial phase are shown in Figure 26. There 
were no significant changes in any of the MFI subdomains – general, physical, and 
mental (panels A-C in Figure 26). However, in the energy/fatigue subdomain of the 
SF-36 there was a significant increase in the score – representing improvement – 
between baseline and four months in the sertraline group, but no change in the 
placebo group. This is represented in panel D in Figure 26 and also in Table 42, 
which compares mean differences in this score between baseline and two, four, and 
six months in the sertraline and placebo groups. 
 
Table 42: SF-36 score difference at two, four, and six months (sertraline vs 
placebo) 
 Sertraline Placebo p-value 
2 months -15.6 ± 29.8 
n=8 
-4.6 ± 24.5 
n=11 
NS 
4 months -24.3 ± 32.3 
n=7 
-3.3 ± 15.7 
n=11 
0.04 
6 months -20.7 ± 27.3 
n=7 
-6.5 ± 20.4 
n=10 
NS 
189 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Significant change between baseline and months 4: P=0.04 
Figure 26 MFI (GF, PF, and MF) SF-36 over six months 
B 
D C 
A 
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7.6 Discussion 
Fatigue is a psychosomatic syndrome that is also common in chronic disease, and a key area of 
overlap with depression in patients receiving HD. Previous studies suggested that the point 
prevalence of fatigue in end-stage renal disease ranges from 42% to 89% according to the 
treatment modality and assessment instruments (226). It was not possible in our study to establish 
the proportion/prevalence of fatigue in HD by using the MFI because there is no validated cut-off 
point. 
Fatigue levels in this HD population are strikingly high in all domains – general, mental, and 
physical – are similar to those found in oncology patients. Hagelin et al. (459) looked at fatigue 
using the MFI scale in different groups of oncology patients (outpatient, radio therapy, and 
palliative care). We compared fatigue levels in these oncology patients with those in our HD 
patients. Mean fatigue levels in the general and physical domains were similar in HD and those 
receiving radiotherapy, though scores in the mental domain were slightly lower (Table 43 and 
Figure 27). 
 
Table 43: Comparison between GF, PF, and MF in oncology and HD patients (mean, SD) 
MFI Outpatients 
 
m              sd 
HD 
 
m               sd 
Radiotherapy 
 
m              sd 
Palliative care 
 
m            sd 
GF 11.0          4.7 13.1           4.0 13.5          5.1 16.8        3.7 
PF 11.1          5.1 14.5           4.1 12.6          5.0 17.8        3.2 
MF 8.7 3.8 9.6  4.4 10.2          4.5 11.7        4.3 
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Figure 27 Comparison between GF, PF, and MF in oncology and HD patients 
 
 
Females tended to have higher scores on the GF subdomain than males. This corresponds with 
previous literature (331), although the previous study reports related to total fatigue score rather 
than different fatigue domains. There were no gender differences in the PF and MF subdomains 
and no ethnicity differences in any subdomain corresponding with previous literature (314). 
Previous studies have demonstrated that increasing age and weight were associated with higher 
fatigue levels among patients on dialysis (315, 330). Contrary to this, though levels of GF and PF 
were higher with increasing weight, we found a weak inverse correlation between GF and age. The 
reasons for this are unclear. MF did not correlate with either age or weight. Similar to previous 
studies, we found no relationship between any fatigue subdomain and routine biochemical, 
haematological, and haemodynamic parameters, nor with dialysis adequacy (38, 314, 331, 334). 
However, the presence of comorbidity was associated with fatigue. GF and PF were higher in 
patients with heart disease (334) and diabetes, but not in those with stroke, amputation, and cancer. 
The PF score also was higher in those with inflammation (CRP >5mg/l). None of these conditions 
affected MF scores.  
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Previous studies found that fatigue was significantly correlated with depression in haemodialysis 
patients (314, 335, 460). Our studies confirm this. There were very strong correlations between 
BDI-II and PHQ-9 scores and all MFI subdomains (GF, PF, and MF). The best correlation was 
between GF with BDI-II and PHQ-9. These correlations are unlikely to solely represent artefacts 
from overlapping item content between the MFI and BDI-II as only two or perhaps three out of a 
total 21 BDI-II items measure fatigue symptoms and only one item in the PHQ-9. This suggests 
that the symptom of fatigue may be a true consequence of low mood. 
Fatigue scores in all subdomains (GF, PF, and MF) were also greater in patients with BDI-II ≥16 
than those with lower scores. The best predictor of high depression symptoms (BDI-II ≥16) was 
MF compared to GF and PF. There were similar findings in relation to PHQ-9 ≥8. There was also 
a trend to higher MF, but not GF and PF, scores in patients with a MINI diagnosis of MDD 
compared with those with no MDD. Taken together, these findings imply that high depressive 
symptoms, and indeed the diagnosis of MDD, relate more strongly to cognitive rather than somatic 
factors.  
However, the relationship between fatigue and depression is undoubtedly very complex. 
Depression may manifest as feelings of fatigue, tiredness, and lack of energy. Depression has also 
been shown to correlate strongly with overall symptom burden and severity, including fatigue, in 
dialysis patients (382). In keeping with this was the difference in distributions of MF and both GF 
and PF in patients with BDI-II ≥16. MF is normally distributed in these patients, while both GF 
and PF show a highly skewed distribution with many patients having very high GF and PF scores. 
These differences in distribution suggest that both PF and MF are major contributants to high 
depressive symptom scores.  
Throughout the RCT study we found very little difference between fatigue scores in those 
sertraline and placebo groups. In fact, there was little change in scores in either group throughout 
the study. The only significant change was an improvement in the energy/fatigue subdomain 
scores of the SF-36 between basline and three months. Whether this represents a genuine treatment 
effect, a chance finding, or perhaps an effect of the higher drop-out rate in the sertraline group, is 
not known. The dissociation between the changes in depression scores (BDI-II and MADRS – see 
Chapter 6) and fatigue scores during the trial phase is striking and suggests that the change in 
depression scores during the study was more related to changes in cognitive than somatic 
components. There are a number of caveats. Sertraline might not be the drug of chocice in 
improving fatigue symtoms, especially in HD patients. Previous research has suggested that 
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monotherapeutic antidepressant agents that increase NE, DA, or both, particularly in pathways 
associated with physical and mental fatigue, may be preferable for patients in whom symptoms of 
fatigue and lack of energy are prominent (426). Fatigue can also be a side effect of antidepressant 
treatment, although this happens more typically with sedating antidepressants, and sertraline does 
not belong to this group. However, even activating agents may be associated with fatigue as a side 
effect resulting from disruption of sleep architecture, with sleepiness and fatigue being the 
consequence of poor sleep quality and sleep deprivation (419).  
Fatigue may also be a residual symptom of MDD. Pharmacological augmentation of 
antidepressant therapy has shown promise in the treatment of residual fatigue (432, 435). Studies 
in patients on maintenance antidepressant therapy showed that complaints of physical tiredness 
were related primarily to residual depression (420). The approch to target this is to augment a 
SSRI with bupropion, an NE and DA reuptake inhibitor (421, 422). Bupropion can increase both 
DA and NE in the frontal cortex, as well as in other areas of the brain (423, 424). Bupropion may 
be effective in improving energy and fatigue, as well as executive function (425).  
Our study showed that there was a significant difference between all MFI subdomain scores and 
dialysis recovery time. The biggest differences were between patients who recovered promptly 
(<1hr) and those who took longer. It seems that both physical and mental components of post-
dialysis fatigue with the physical component play the greatest role. These factors seem to take 
precedence in predicting post-dialysis recovery time over others, including demographic factors, 
comorbidity, laboratory parameters, and dialysis adequacy, as has been previously described (326). 
We also found that PF was highly predictive of mortality. There was no impact of any parameters 
related to depressive symptomatology on the prediction of mortality in these models. This suggests 
that the previously reported effects of depression on mortality (461) may be mediated by PF.  
We have thus addressed all the aims of the study, except that we have not defined the prevalence 
of fatigue in our haemodialysis cohort. This is because there is no validated cut-off point for the 
MFI. Neither was it possible to establish whether there was a difference between sertraline and 
placebo on the measures of fatigue over the period of the study due to the small numbers recruited.  
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7.7 Concluding Remarks 
Fatigue is a common and burdensome consequence of advanced kidney disease and is associated 
with depression symptoms, past history of depression, longer dialysis recovery, and higher 
mortality. Inflammation also appears to be associated with greater fatigue. 
Depression scores are strongly associated with all fatigue subscales – general, mental, and 
physical. This emphasises the strong overlap of depressive symptoms and fatigue in this 
population, which complicates the diagnosis of depression, its management, as well as the 
management of fatigue. Though the relationship is complex, the mental component of fatigue 
seems to have a closer relationship to depression than the physical component, while the physical 
component seems to be a stronger predictor of post-dialysis recovery and mortality.  
There was a slight improvement in the energy/fatigue subscale of the SF-36 on sertraline but little 
or no effect in relation to any of the MFI subscales. The dissociation between changes in 
depression scores and changes in fatigue scores during the RCT adds to the complexity of the 
relationship between fatigue and depression. This suggests that the improvements in depression 
scores during the RCT were mediated by elements not related to fatigue. Other interpretations 
include the possibility that sertraline is not the drug of choice for alleviating the symptom of 
fatigue in the context of depression in haemodialysis patients. Fatigue may even feature as a side 
effect of sertraline. 
Further work in this area should focus on better defining physical and mental components of 
fatigue. Since fatigue is the major overlapping symptom of uraemia and depression, this might 
facilitate the diagnosis of depression in this condition. It might also guide the search for 
interventions aimed at managing fatigue in its own right. 
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Chapter 8 
Progression of Depressive Symptoms in HD Patients on 
Antidepressants 
8.1 Introduction 
During screening in the ASSertID study, one of the major findings was that a large proportion 
(about 30%) of the HD cohort was already on antidepressant medication. Most of these patients 
appeared to have ongoing depressive symptoms but had been excluded from the interventional 
phase of the study because current antidepressant therapy was one of the exclusion criteria. It was 
felt to be important to follow up this cohort of patients taking antidepressants to ascertain the 
natural history of this phenomenon. Hence, a further study was devised to follow up these patients 
6-15 months following their initial screening. We planned to repeat baseline screening tests, and to 
carry out a full clinical and psychiatric history, including a formal diagnostic interview to 
determine whether patients had major depressive disorder. Beliefs about antidepressant medication 
and adherence to this therapy would be ascertained using validated questionnaires.  
The study was sponsored by East and North Herts NHS Trust, REC reference number 14/EE/0143. 
Copies of the approval letters are shown in the appendix 1.  
 
8.2 Aims and Objectives 
8.2.1 Primary Aim  
To determine the prevalence of diagnosed MDD according to the MINI in this cohort of HD 
patients who had been taking antidepressant therapy at the ASSertID screening interview. 
          
8.2.2 Secondary Aims  
1) To describe the changes in depressive symptoms in these patients 6-15 months following 
initial screening, according to the BDI-II and PHQ-9 screening instruments.  
2) To describe the relationship between scores in the MFI and diagnosed depression by the 
MINI. 
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3) To describe the use of antidepressant therapy (type, dosage) during the 6-15 months 
following the ASSertID screening interview. 
4) To examine patient beliefs and attitudes about and adherence to antidepressant treatment 
according to the MARS (462), the Beliefs about Medicines Questionnaire – specific to 
antidepressants (BMQ) (463) (please see the questionnaires for details).  
5) To describe the setting in which antidepressant medication was initiated (primary care, 
nephrology, psychiatry), and estimate the degree to which subsequent management was 
consonant with relevant NICE guidelines (150). 
 
8.3 Questionnaires  
8.3.1 Medication Adherence Rating Scale (MARS) 
The Medication Adherence Rating Scale (MARS) was developed from Morisky et al.’s (464) 
Medication Adherence Questionnaire (MAQ). The MARS is a quick, non-intrusive measure of 
medication adherence. It is a ten-item self-report measure of medication adherence in psychosis. It 
evaluates both attitudes about medications and actual medication-taking behaviour. Compliance is 
considered if there is a No response for questions 1-6 and 9-10, and a Yes response for questions 7 
and 8. Scoring requires some interpretation: a Yes response does not necessarily indicate a positive 
attitude or behaviour. Items in the MARS about attitude to medication may be informative to 
clinicians identifying barriers to adherence in individual cases, but do not appear to be valuable in 
predicting adherence behaviour over a large sample. The MARS total score reproduced the 
expected relationships of higher adherence with more insight into the need for medication, and 
higher adherence with less psychopathology. Its reliability is adequate, but validity appears only 
moderate/weak. The internal consistency of the MARS was moderate (alpha=0.60), but lower than 
the value produced by Thompson et al. (465) during the original development of the scale 
(alpha=0.75). This may not represent a weakness of the scale, however, as there are reasons to 
expect a reduced alpha value for scales with the format of the MARS, notably the binary response 
choice, a small number of items, and scale multidimensionality.  
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8.3.2 Beliefs about Medicines Questionnaire (BMQ) 
The BMQ was validated for use in the chronic illness groups studied (466). The BMQ comprises 
two sections: BMQ-Specific, which assesses representations of medication prescribed for personal 
use, and the BMQ-General, which assesses beliefs about medicines in general. The test items were 
derived from themes identified in published studies and from interviews with chronically ill 
patients. The Principal Component Analysis (PCA) of the test items resulted in a logically 
coherent, 18-item, four-factor structure that was stable across various illness groups. The BMQ-
Specific comprises two five-item factors assessing beliefs about the necessity of prescribed 
medication (Specific-Necessity) and concerns about prescribed medication based on beliefs about 
the danger of dependence and long-term toxicity and the disruptive effects of medication 
(Specific-Concerns). The BMQ-General comprises two four-item factors assessing beliefs that 
medicines are harmful, addictive poisons that should not be taken continuously (General-Horn) 
and that medicine are overused by doctors (General-Overuse). The two sections of the BMQ can 
be used in combination or separately.  
The BMQ-Specific comprises two five-item scales assessing patients’ beliefs about the necessity 
of prescribed medication for controlling their illness and their concerns about the potential adverse 
consequences of taking it. Examples of items from the necessity scale include: 'My health, at 
present, depends on my medicines' and 'My medicines protect me from becoming worse'. 
Examples of items from the concerns scale include: 'I sometimes worry about the long-term effects 
of my medicines' and 'I sometimes worry about becoming too dependent on my medicines'. 
In assigning the scores to medication beliefs, participants indicate their degree of agreement with 
each individual statement about medicines on a five-point Likert scale, ranging from 1 (strongly 
disagree) to 5 (strongly agree). Scores obtained for the individual items within each scale are 
summed to give a scale score. The total scores for the necessity and concerns scales range from 5 
to 25. Therefore, it is possible to differentiate between patients on the basis of their beliefs about 
the necessity of their medication and their concerns about taking it. Scores can be interpreted in 
two ways: as a continuous scale in which higher scores indicate stronger beliefs in the concepts 
represented by the scale, or by dichotomising at the scale midpoint. The latter method is a 
convenient way of categorising respondents according to the strength of their views about 
medication. However, the continuous scale is used in statistical analyses as this provides richer 
information that is lost when the scale is dichotomised (467). Beliefs about medicines were related 
to reported adherence: higher necessity scores correlated with higher reported adherence (r=50.21, 
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n=5324, p<0.01) and higher concerns correlated with lower reported adherence (r=50.33, n=5324, 
p<0.01).  
  
8.4 Design and Setting 
The study combined prospective and retrospective observations of a cohort of ESRD patients who 
were initially screened for the ASSertID study. It was carried out at the renal centres at the 
following NHS Trusts: Lister Hospital Stevenage, University Hospitals Birmingham, Royal Free 
Hospital London, Southend University Hospital, and Basildon and Thurrock University Hospitals. 
 
8.4.1 Sample 
We aimed to study those patients who were taking antidepressant medication at the ASSertID 
screening interview. At approximately 6-15 months following that initial screening, we re-
approached members of this group and invited them to take part in this further study; anticipated 
numbers were as shown in Figure 28. The numbers were anticipated from the primary analysis of 
the data and the decision about the study, and ethical approval was granted before the end of the 
ASSertID study. 
 
 
 
 
 
 
 
 
 
 
 
ASSERTID 
Screened 
700 patients 
On 
Antidepressants 
100 
Interviewed 
Active HD 50 
Deceased 
15 
Transplanted 
10 
Refused to 
consent 25 
Figure 28 Study diagram (anticipated numbers) 
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8.4.2 Inclusion Criteria 
 Patients who were screened by BDI-II, PHQ-9, and/or MFI in the ASSertID study and were 
taking an antidepressant at the time of the screening interview. 
 
8.4.3 Exclusion Criteria 
 Patients who had other known psychiatric comorbidity, including substance dependency, 
psychosis, personality disorder, dementia, or panic disorder, with the exception of other 
anxiety disorders (e.g. Generalised Anxiety Disorder or Obsessive Compulsive Disorder).  
 Patients who lacked the mental capacity to consent to participate. 
 Patients who refused to consent to their GP being informed of the outcome of psychiatric 
assessment.   
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8.5 Procedures 
8.5.1 Identification of the Participant 
Patients were identified from the ASSertID database, the eligibility criteria were applied, and a 
suitability list was compiled. We used the same Patient Identification Number as the ASSertID 
study to enable us to isolate this data. 
 
8.5.2 Approach to Participants 
Patients were approached by the research psychiatrist during one of their routine dialysis sessions 
and asked if they were interested in taking part in a follow-up study to the ASSertID study. They 
were provided with a participant information sheet. The study psychiatrist explained the study to 
the patient and went through the participant information leaflet. He emphasised the intention to use 
some of the data from the previous ASSertID project in the new study. In addition, he explained 
that new data was collected as outlined above, which entailed seeing the research psychiatrist 
again and possibly a qualitative researcher. The research psychiatrist gave each patient an 
opportunity to ask questions and explained that they were under no obligation to enter the study. 
The research psychiatrist reinforced that the patient could withdraw at any time during the study, 
without having to give a reason. If the patient expressed an interest in participating, a follow-up 
appointment with the study psychiatrist was arranged at a mutually convenient time. The research 
psychiatrist gave the patient his contact details and it was made clear to the patient that they were 
perfectly free to change their mind about attending the appointment at any time. 
 
8.5.3 Informed Consent and Interview with the Study Psychiatrist 
At the follow-up appointment, the research psychiatrist repeated the information in the participant 
information leaflet and gave further opportunity for questions. He asked for written consent. Once 
written consent was received, the research psychiatrist carried out the medical and psychiatric 
assessment as well as administering the BDI-II, PHQ-9, MFI, MARS, and BMQ. 
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8.5.4 Data from the ASSERTID Study 
We retrieved data from the ASSertID screening phase onto a study-specific case report form. 
Additional data was collected, including a diagnostic interview.  
The following information was retrieved from the ASSertID database: 
 BDI-II, MFI, and PHQ-9 
 Demographics (date of birth, gender, ethnicity, marital status, and social class/education) 
 Information on the primary renal disease, date of starting renal replacement therapy, and 
previous transplants and dates 
 Past history and treatment of depression or anxiety diagnosed by GP or psychiatrist, or any 
other involvement with psychology or psychiatry services 
 Social support – who they lived with 
 Questions on comorbid problems, including: heart disease, stroke, amputation of limbs, 
diabetes, cancer, liver disease, lung disease, and any other medical conditions such as 
rheumatoid arthritis 
 Haemoglobin, urea and electrolytes, serum albumin, calcium and phosphate, and Kt/V 
(most recent values) 
 Estimated urine volume per day, dry weight, and height 
 
 8.5.5 New Data Collection 
The research psychiatrist used hospital medical records (paper and computerised) to collect the 
following new data, repeating all the ASSertID screening data collection, including the 
administration of the BDI-II, PHQ-9, and MFI. That was in addition to: 
 Full medical and psychiatric history 
 Assessment including the MINI to identify the diagnosis of MDD  
 Data on hospital admissions, change in comorbidities, medication, and blood results 
 History of any psychotropic medications and primary prescriber 
 Changes in clinical and social events, medication, and any additional psychological or 
psychiatric treatment that had taken place since screening 
 Antidepressant adherence and beliefs using MARS and BMQ 
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8.5.6 Study Power 
A pragmatic approach had to be taken for sampling in this study, since recruitment was planned to 
be opportunistic. It was planned to approach the whole cohort of patients who were taking 
antidepressants in the screening phase of the ASSertID study for consent to take part in this study. 
Anticipated numbers are showed in Figure 28.  
 
8.5.7 Analysis 
The following analysis was carried out: 
 The cohort was characterised in terms of the screening data and the additional data 
collected on the patients' history, using descriptive statistics. 
 Change in the measured outcomes (BDI-II, PHQ9, and MFI) during follow-up assessed by 
paired t test or Wilcoxon signed rank test as appropriate. 
 The relationship between the outcome of the psychiatric interview (i.e. currently 
depressed, recurrently depressed, past depression, and no depression) with: 
o Baseline and follow-up BDI, PHQ9, and MFI scores  
o Changes in these scores from baseline to follow-up  
o Findings in relation to beliefs about (BMQ) and adherence to antidepressant 
medication (MARS) 
Assessment was carried out using ANOVA, t-tests, or the Mann-Witney test, as appropriate. 
Logistic regression analysis was carried out to determine predictors of current depression. 
 We also examined whether patient beliefs (and other factors such as age, gender, length of 
time on antidepressants) predicted adherence, and whether adherence levels were related to 
changes in depression symptom scores  
 The setting in which the antidepressant therapy was commenced (primary care, 
nephrology, psychiatry), and the degree to which subsequent management was consonant 
with relevant NICE guidelines was analysed descriptively. 
Analyses were carried out using SPSS version 23. 
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8.6 Results 
41 patients were followed up a mean of 14±5 months following screening (Figure 29). 76 patients 
out of 709 screened were taking antidepressants at the time of screening. At the time of follow-up, 
six had been transplanted, one had been transferred to a renal unit in another trust, 12 had died, and 
two refused consent. We could not follow-up any of the patients at one non-participating centre 
[14] for logistics reasons. The demographic and clinical characteristics of these 41 patients are 
shown in Tables 44 and 45. Ten different antidepressant agents were being taken (Table 46), the 
most common being Citalopram (39%). The primary prescribers were as follows: GP 68%, 
nephrologist 22%, and psychiatrics 10%. There had been no review of antidepressant medication 
during follow-up in 16 patients (39%). Fourteen (34%) patients had their doses reviewed. A 
change in medications had occurred in 11 patients (27%). Most of these changes were instigated 
by the GPs. A significant proportion of patients (24%) were taking doses that might be considered 
sub-therapeutic or agents contraindicated or cautioned against in HD patients, e.g. dothiepin and 
Citalopram. 
ASSERTID 
Screened patients 
709 
On 
Antidepressants 
76 
Interview 
41 
Deceased 
12 
Non participating centre 
14 
Transferred to 
another unit 
1 
Refused to consent 
2 
Transplanted 
6 
Figure 29 Study design actual numbers 
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Table 44 Baseline parameters 
Age (years) 62 ± 16 
Gender (% male) 63 
Ethnicity (% white) 73 
Weight (kg) 81 ± 23 
Pre-dialysis systolic BP (mmHg) 140 ± 27 
Pre-dialysis diastolic BP (mmHg) 75 ± 17 
Marital status (%)  
Married/partner 49 
Single 27 
Divorced/separated 12 
Widowed 12 
Depression (%)  
Antidepressants  100 
Psychological therapy  32 
Previous ECT 2 
BDI-II 26 (IQR 19)  
PHQ-9 12 (IQR 9)  
Comorbidity (%)  
Diabetes 42 
Heart disease 37 
Cancer 22 
Amputation 5 
Dialysis parameters  
Vintage (IQR) years 3.5 (4.7) 
Kt/V 1.33 ± 0.31 
Laboratory parameters  
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Table 45 Follow-up parameters (n=41) 
Mean follow-up (month) 14 ± 5 
Events  
Life/social event (%) 20 (49%) 
Clinical event (%) 19 (46%) 
Depression screening  
BDI-II 21 (IQR 17) 
PHQ-9 10.5 (IQR 10) 
MFI scale  
General fatigue 9 (8.5) 
Physical fatigue 10 (7) 
Mental fatigue 8 (9) 
Reduced activity 8 (9.5) 
Reduced motivation 10 (7.5) 
MINI diagnosis  
Current MDE 8 (20%) 
Recurrent MDE 7 (17%) 
Past MDE 20 (48%) 
No MDE 6 (15%) 
Primary prescriber  
GP 28 (68%) 
Nephrologist 9 (22%) 
Haemoglobin (g/l) 110 ± 13 
Albumin (g/l) 39 ± 4.2 
Calcium (mmol/l) 2.26 ± 0.26 
Phosphate (mmol/l) 1.50 ± 0.48 
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Psychiatrist 4 (10%) 
Medication review  
Antidepressant agents used 10 
Dose change 14 (34%) 
Medication change 11 (27%) 
None 16 (39%) 
 
Table 46 Name, frequency of prescription, and dose of used antidepressant 
Antidepressant Number of patients Dose range 
Citalopram 16 (39%) 10mg (2), 20mg (10), 30mg (3), 40mg (1) 
Fluoxetine  9 (22%) 20mg (8), 40mg (1) 
Sertraline 6 (15%) 50mg 
Mirtazapine  2 (5%) 30mg 
Venlafaxine  2 (5%) 225mg (1), 75mg (1) 
Escitalopram  2 (5%) 10mg (1), 15mg (2) 
Paroxetine  1 (2%) 10mg 
Dothiepin  1 (2%) 100mg 
Nortriptyline  1 (2%) 40mg 
Duloxetine  1 (2%) 60mg 
 
8.6.1 Comparison of Baseline and Follow-up Values 
There were no significant differences between baseline and follow-up with respect to weight, pre-
dialysis blood pressure, Kt/V, haemoglobin, albumin, and calcium and phosphate. Twenty patients 
had life events and 19 had clinical events during follow-up (Table 47). Fourteen of these patients 
had both life and clinical events. 
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Table 47 Descriptions of life and clinical events 
Life event/patient Clinical event/patient 
Death of wife Knee replacement 
Father died 2 x hospital admissions – cardiac events 
Wife diagnosed with brain tumour Failure of kidney transplant 
Dog died, 
daughter hysterectomy 
Hip replacement 
Divorce Failure of kidney transplant 
Wife diagnosed with dementia Nephrectomy 
Lost job – financial constrains Angioplasty 
Mother died Prolonged admission in isolation ward 
Wife had affair Failure of fistula  
Death of two dialysis friends Multiple hospital admissions (11) with 
epilepsy 
Neighbour died, sister relocated Melanoma becoming worse 
Family breakdown Urology operation in hospital over 
Christmas 
Stressful family event HD changed to PD 
Reduced family support Cardiac event – Boxing Day 
Death of wife Psoriasis deteriorating 
Death of grandchildren Removal of transplanted kidney 
Daughter developed breast cancer Memory clinic?? Dementia 
Husband died Amputation 
Son migrated Fracture R arm (operation) 
Hip replacement 
Divorce  
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There was a significant reduction in BDII-II score over the course of the study (26 (IQR 19) to 21 
(IQR 17): p=0.015). The change in the PHQ-9 score was not significant (12 (IQR 9) to 10.5 (IQR 
10): p=0.091). 
At screening, 30 patients had a BDI-II score ≥16, indicating high depressive symptoms. Of these, 
22 remained with high depressive symptoms at follow-up while eight improved (BDI-II <16 at 
follow-up). Those who improved had lower BDI-II scores (23 (IQR 13) vs 32 (IQR 15): p= 0.006) 
at baseline, lower dialysis vintage (3.7 (IQR 3.10) vs 5.9 (IQR 4.2) years: p=0.035), and fewer 
were anuric (13% vs 55%: p=0.04). Age, gender, ethnicity, marital status, comorbidity, 
haematological and biochemical profile, and clinical events during follow-up did not differ.  
Of the 11 with BDI-II <16 at baseline, five had increased their BDI-II score to ≥16 at follow-up. 
These tended to be younger, 61 ± 12 vs 68 ± 21 years, to have higher dialysis vintage (3.9 (14.6) 
vs 2.4 (IQR 1.4)) and higher baseline BDI-II score (10 (IQR 8) vs 7.5 (IQR 7)), though none of 
these changes was statistically significant. No differences in comorbid load were apparent. 
However, baseline serum albumin tended to be lower in those who deteriorated (32.6 ± 5.1 v 38.8 
± 1.6: p=0.051) and more patients in this group had experienced clinical events, including below-
knee amputation and stroke during follow-up (80% vs 17%: p=0.036). There was also a tendency 
for patients who were married/partnered to be less likely to have depressive symptoms in relation 
to BDI-II (17% vs 80%: p= 0.036).  
Although 27 of 41 patients (66%) either deteriorated or failed to improve during follow-up, only 
11 changes in antidepressant prescription (27%) were made during that time.  
 
8.6.2 Comparison of Patients with High and Low Depressive Symptoms at 
Follow-up 
At follow-up, 27 patients had a BDI-II score ≥16. These patients were younger, but not 
significantly, than those with lower BDI-II scores. There were no other differences with respect to 
demographic, clinical, or biochemical parameters, except that those with high BDI-II scores tended 
to have experienced more clinical events during follow-up (Table 48). There were, however, 
significant differences between the median values of the all MFI domains in patients with high 
BDI-II scores than those with lower scores (Table 48). Patients with a high follow-up BDI-II score 
also had a significantly lower necessity score on the BMQ questionnaire. The best logistic 
regression model (Table 49) showed that general fatigue (p=0.038: odds ratio 1.25) was an 
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independent predictor of high BDI-II, as were clinical events during follow-up (p=0.028: odds 
ratio = 11.33), and log of dialysis vintage (p=0.026: odds ratio=48.72). Necessity score (p=0.110: 
odds ratio = 0.76) approached significance, while age and gender were not significant in this 
model. The model predicted 58% of the variation (Nagelkerke R square 0.579). 
 
Table 48 Comparison of depressed (BDI-II ≥16) and non-depressed (BDI-II <16) at follow-up 
 Depressed Non-depressed p-value 
Numbers 27 14  
Age (years) 60 ± 15 67 ± 18 NS 
% Male 56 79 NS 
% Married/partner 41 64 NS 
% Clinical events 58 29 0.079 
% Life events 54 43 NS 
% Heart disease 37 36 NS 
% Diabetes  44 36 NS 
% Cancer 26 14 NS 
Dialysis vintage (years) 5.7 (4.7) 2.9 (2.3) 0.005 
General fatigue 10 (8) 6 (5) 0.013 
Physical fatigue 10 (7) 9 (5) 0.008 
Mental fatigue 9 (8) 3 (6) 0.017 
BDI-II (baseline) 28 (17) 17 (18) 0.002 
PHQ-9 (baseline) 14.5 (7) 7.5 (8) 0.005 
BMQ necessity score 12.2 ± 3 14.5 ± 2.8 0.022 
BMQ concerns score 12.7 ± 2.8 13.3 ± 2.5 NS 
MARS score 7.9 ± 1.5 8.6 ± 1.1 NS 
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Table 49 Logistic regression model of predictors of high BDI-II ≥16 at follow-up 
 B SE p-value Odds ratio 
 Clinical events 2.427 1.105 .028 11.33 
BMQ necessity score -.281 .175 .110 .76 
Log dialysis vintage 3.886 1.751 .026 48.72 
General fatigue score .222 .107 .038 1.25 
Constant -5.196 4.001 .194 .006 
 
8.6.3 Comparisons between BDI-II, PHQ-9, and PHQ-2 Scores in MINI 
Diagnostic Groups 
There were no differences between patients subsequently diagnosed on the MINI with current, 
recurrent, past, and no depression with respect to any baseline parameter (Table 50). However, 
there were significant differences with respect to follow-up BDI-II, PHQ-9, and PHQ-2 scores, 
which tended to be higher in those with current or recurrent depression, though there were no 
overall differences on Kruskal-Wallis analysis (Table 50). There were no differences between 
these groups with respect to age, gender, marital status, the presence of comorbidities, clinical or 
life event, any measured biochemical parameter, MFI scores, beliefs about antidepressant 
medications (BMQ) scores, or adherence to (MARS) antidepressant medication scores (Table 50). 
A change of prescription during follow-up occurred in only four patients (27%) with current or 
recurrent MDD. 
 
8.6.4 Comparison of Depressed and Non-depressed Groups at Follow-up 
Fifteen patients had MDD (eight current and seven recurrent). Table 51 compares these patients 
with those 26 who were not depressed at follow-up (20 past depressed plus six never depressed). 
All 15 patients with current or recurrent MDE at follow-up were among the 27 whose BDI-II 
scores deteriorated or did not improve (56%). BDI-II, PHQ-9, and PHQ-2 scores were 
significantly higher in patients with MDD compared to those without. The only other differences 
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between these groups was a tendency for depressed patients to have a higher likelihood of having 
diabetes, and to have experienced one or more clinical events during follow-up (Table 51), though 
neither of these reached statistical significance. There were no differences with respect to MFI 
fatigue scores, BMQ scores, or MARS scores (Table 51). 
Depression symptom scores were the only significant predictors of MDD in logistic regression 
analysis; for example, a model of BDI-II scores explained 35% of the variation (Nagelkerke R 
square = 0.350). PHQ-9 and PHQ-2 scores were also predictive, explaining 24% and 25%, 
respectively, of the variation. 
 
Table 50 Differences between MINI diagnosis categories at baseline and follow-up 
 MDD (MINI Diagnosis)  
 Current Recurrent Past Never  
Number 8 7 20 6  
Baseline      
Age (years) 63 ± 11 58 ± 20 60 ± 17 73 ± 12 NS 
% Male 75 43 65 67 NS 
% Married/partner 63 29 45 67 NS 
% Heart disease 63 29 30 33 NS 
% Diabetes  63 57 25 50 NS 
% Cancer 38 14 15 33 NS 
Dialysis vintage (months) 5.2 (6.2) 5.7 (5.7) 4.3 (4.9) 3.1 (2.2) NS 
BDI-II baseline 32 (17) 18 (16) 26.5 (14) 14.5 (27) NS 
PHQ-9 baseline 12 (6) 9 (10) 12 (9) 7.5 (16) NS 
PHQ-2 baseline 3 (1) 2 (4) 3 (2) 1.5 (3.5) NS 
Follow-up      
% Clinical events 63 71 40 20 NS 
% Life events 50 71 40 60 NS 
General fatigue 9 (9) 9 (10) 11 (10) 6.5 (5) NS 
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Physical fatigue 10 (10) 10 (7) 11 (8) 9 (4) NS 
Mental fatigue 9 (3) 8 (8) 8.5 (13) 3.5 (5) NS 
BDI-II – follow-up 28 (13) 27 (12) 16.5 (15) 11 (23) 0.006 
PHQ-9 – follow-up 13 (7) 14 (5) 7.5 (6) 6.5 (13) 0.023 
PHQ-2 – follow-up 3 (1) 2 (2) 2 (1.75) 0 (1.75) 0.019 
BMQ (necessity) 11.4 ± 2.9 13.1 ± 3.1 13.2 ± 2.9 14.2 ± 3.8 NS 
BMQ (concerns) 12.1 ± 2.5 12.7 ± 3.6 13.5 ± 2.6 12.3 ± 3.3 NS 
MARS (adherence) 8.1 ± 1.5 7.4 ± 1.7 8.5 ± 1.4 8.2 ± 1.0 NS 
 
Fifteen patients had current or recurrent depression. Table 51 compares these patients with those 
non-depressed. The only significant differences were in the depression symptom scores as might 
be predicted. More depressed patients had diabetes and more had experienced clinical events 
during follow-up, but these differences did not reach statistical significance. There were no 
differences in either the BMQ or MARS scores.  
 
Table 51 Comparison of depressed and non-depressed (MINI diagnosis) at follow-up 
 Depressed Non-depressed p-value 
Number 15 26  
Age (years) 60 ± 16 63 ± 17 NS 
% Male 60 65 NS 
% Married/partner 47 50 NS 
% Clinical events 67 36 0.06 
% Life events 60 44 NS 
% Heart disease 47 31 NS 
% Diabetes  60 31 0.067 
% Cancer 27 19 NS 
Dialysis vintage (years) 5.8 (12.5) 4.2 (3.3) NS 
213 
 
General fatigue 9 (9) 8.5 (9) NS 
Physical fatigue 10 (7) 10 (7) NS 
Mental fatigue 9 (7) 6 (11) NS 
BDI-II 28 (10) 14.5 (16) 0.001 
PHQ-9 14 (6) 7.5 (8) 0.003 
PHQ-2 3 (2) 2 (2) 0.003 
BMQ (necessity) 12.2 ± 3.1 13.4 ± 3.1 NS 
BMQ (concerns) 12.4 ± 2.8 13.2 ± 3.6 NS 
MARS (adherence) 7.8 ± 1.6 8.4 ± 1.3 NS 
 
Six patients were found to never have been depressed on the MINI. These six were significantly 
older than the others (current, recurrent, and past MDD). Their median age was 76.6 years (IQR 
10) vs 64.6 (IQR 24). There were no differences with respect to gender, marital status, clinical and 
life events, dialysis vintage, comorbidities, haematological and biochemical parameters, or BMQ 
or MARS scores. Depressive symptoms scores were generally lower, though the difference was 
only significant for PHQ-2 (Table 52). Although there were no differences in MFI domain scores 
across the whole cohort of MINI diagnoses (see Table 51), MFI domain scores were lower in the 
six patients who had never been depressed than in all other patients. Differences were not 
significant for general fatigue (Table 52).  
Table 52 Demographic, depressive symptom scores, and MFI domain scores in never-
depressed vs other (current, recurrent, and past depression).  
Values quoted as median (IQR) 
 
 
Depressed  
(n=35) 
Never depressed  
(n-6) 
p-value 
Age (years) 64.9 (24) 76.6 (12) 0.030 
BDI-II 22 (15) 11 (23) NS 
PHQ-9 11 (9) 6.5 (13) NS 
PHQ-2 2 (6) 0 (1.75) 0.021 
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General fatigue 9 (8) 6.5 (5) NS 
Physical fatigue 10 (8) 9 (5) 0.032 
Mental fatigue 9 (8) 3.5 (5) 0.049 
 
8.6.5 Beliefs and Attitudes Towards Antidepressants 
There were no differences in adherence to antidepressant treatment according to the MARS score 
between patients with high depression scores (as judged by the follow-up BDI-II score) nor 
between patients with diagnosed depression and those without (as judged by the MINI). It was 
apparent, however, that patients with high depression scores at follow-up (BDI-II ≥16) had a 
significantly lower necessity score on the BMQ (Table 52). Concerns scores were not different 
between these groups. In addition, neither necessity nor concerns scores were different in patients 
with MDD diagnosed by the MINI and those without MDD (Tables 51 and 52). 
 
8.6.6 ROC analysis  
ROC analysis showed significant relationships between the diagnosis of current or recurrent MDD 
by MINI (n=15) and BDI-II scores (Area under Curve (AUC) = 0.813: p=0.001; PHQ-9 (AUC = 
0.773: p=0.004) and PHQ-2 (AUC = 0.774: p=0.004) (Figure 30 and Table 53). The best cut-off 
point for the BDI-II was ≥16. This identified 27 patients (66% of sample). Sensitivity at this cut-
off point was 100% and specificity was 54%. The best cut-off for PHQ-9 was ≥8. This identified 
28 patients (68% of sample). Sensitivity at this cut-off was 100% and specificity was 50%. The 
PHQ-9 cut-off ≥10 identified 24 patients (59% of sample). Sensitivity at this cut-off point was 
80% and specificity was 54%. The best cut-off point for PHQ-2 was ≥2. This identified 28 patients 
(68% of sample). Sensitivity at this cut-off was 93%. Specificity was 46%. Levels of agreement 
were κ 0.46, 0.42, and 0.30, respectively) (Table 54). 
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Figure 30 ROC curve relating BDI-II, PHQ-9, and PHQ-2 to DSM-IV diagnosis of MDD 
 
 
Table 53 Relationship between BDI-II, PHQ-9, and PHQ-2 and the diagnosis of MDD by 
MINI.  
*AUC = Area under Curve 
  AUC* Std. Error p-value 
BDI-II .813 .067 .001 
PHQ-9 .773 .073 .004 
PHQ-2 .774 .073 .004 
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Table 54 Comparison between cut-off points of BDI-II and PHQ for the diagnosis of MDD 
 BDI-II ≥16 PHQ-9 ≥8 PHQ-9 ≥10 PHQ-2 ≥2 
% Population identified 66% 68% 59% 68% 
Sensitivity 100% 100% 80% 93% 
Specificity 54% 50% 54% 46% 
Positive predictive value 56% 54% 54% 50% 
Negative predictive value 100% 100% 82% 92% 
κ values 0.46 0.42 0.30 0.33 
p-value 0.000 0.001 0.034 0.010 
 
8.7 Discussion 
Two-thirds of HD patients who were taking antidepressants had persistently high or deteriorating 
depressive symptom scores after around the 12-month follow-up. A high proportion of these 
(56%) had clinical depression as diagnosed by the MINI. 15% of the cohort had no evidence MDD 
according to the MINI over their lifetime; however, they were already on antidepressants. Current 
NICE policy recommends that chronically ill patients with comorbid depression be treated with 
CBT and/or SSRIs as the first choice. When antidepressants are chosen, the patient should be 
reviewed after two weeks from the date of commencement, to review side effects, response, and 
suicidality. If a response is absent or minimal after three to four weeks of treatment with a 
therapeutic dose of an antidepressant, an increase in the level of support is recommended, along 
with consideration of either increasing the dose in line with the SPC if there are no significant side 
effects or switching to another antidepressant. If the person's depression shows some improvement 
by four weeks, the recommendation is to continue treatment for another two to four weeks, or 
consider switching to another antidepressant if the response is still not effective, side effects 
develop, or the patient chooses to change.  
In our study, a high proportion had no review of or amendment to their antidepressant prescription 
during follow-up and NICE guidelines did not appear to be being applied in the many of these 
patients. This is compatible with previous literature, which suggests that depression is often 
undertreated in patients with chronic medical illness (468), and that this can lead to negative 
outcomes (469). Although all patients in this cohort were on antidepressants at baseline, many had 
inadequate follow-up, were receiving sub-therapeutic doses, or both. This, again, raises the same 
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question discussed in Chapter 6, about the safe and effective use of antidepressants in this setting, 
and, indeed, whether they were indicated for some of these patients.  
There were 10 different antidepressants used, the commonest being Citalopram, which is not 
considered to be the drug of choice in this setting due to the high potential for side effects, 
including prolonged QT interval and bleeding. A few patients (5%) were taking tricyclic 
antidepressants, despite these being contraindicated for patients with heart disease. This may be 
especially risky in HD patients as heart disease is very common in this population, accounting for 
more than 50% of the deaths in uraemic patients (6, 7).  
Antidepressant medication was prescribed by GPs in most cases. Nephrologists were not the 
primary prescribers. There might be a number of reasons. Nephrologists may be more likely to 
think that depression is 'part of the illness and/or its treatment'. They may also be much more 
aware of the complexity of this cohort in terms of comorbidity and polypharmacy with its hugely 
increased potential for adverse drug effects and interactions. They may be reluctant to add to the 
tablet burden. 
The average depressive episode lasts about nine to 12 months without treatment, although about 
20% run a chronic course of two years or longer. Once established, chronic episodes last an 
average of five to eight years (93) and this might have been the reason in our study for many 
patients' antidepressant status remaining essentially unchanged during follow-up. More often, 
major depressive episodes recur with increasing frequency. In fact, after a second lifetime episode, 
the risk of a third is at least 70% within three years (without prophylactic treatment (100)). Early 
withdrawal of antidepressant medication before three months results in the return of the symptoms, 
and as the course of the disorder progresses, patients tend to have more frequent episodes that last 
longer. Over 30 years, the mean number of episodes is five to six (101).  
Previous literature explored the impact of fatigue on mood and the overlap with the patient's 
mental state (41). We found that there was a substantial difference between fatigue scores in 
patients with high and low BDI-II scores but not, in general, between patients with depression 
diagnosed by MINI and those without. This testifies to fatigue having a greater influence on 
depressive symptoms than on the diagnosis of depression. Interestingly, it was only when 
comparing the never depressed versus the rest that a difference in fatigue was noted compared to 
those with current, recurrent, or past depression in diagnosed depression. The lower fatigue scores 
in the never depressed group is remarkable considering the much higher age of this patient group. 
Fatigue and depression are closely interrelated and depression may manifest as feelings of 
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tiredness and lack of energy. Depression has also been shown to correlate strongly with overall 
symptom burden and severity, including fatigue, in HD patients (382). 
There were also differences in the necessity score between those with high and low BDI-II, 
suggesting that people who think the medication is necessary may respond better or actually take 
the treatment – though this did not persist in multivariate analysis nor reflect in the MARS scores. 
The best screening tool for MDD in this high-risk group was the BDI-II. A cut-off point of ≥16 
was highly sensitive and adequately specific, which agrees with previous literature (177). Use of 
the PHQ-9 with a cut-off ≥8 is a suitable, though slightly less specific alternative. Either of these 
options are suitable screening measures in this high-risk group. Psychiatric evaluation should be 
considered in patients with scores above these cut-offs. MDD can be confidently excluded in 
patients with lower BDI-II and PHQ-9 values. The PHQ-9 with a cut-off of ≥10 was less sensitive 
than a ≥8 cut-off. The PHQ-2 cut-off of ≥2 was less sensitive and also less specific in this high-
risk group (Table 54). 
 
8.8 Concluding Remarks 
The main differences between depressed and non-depressed diagnosed patients at follow-up were: 
1- The severity of the depressive symptoms as judged by the score of the BDI-II, PHQ-9, and 
PHQ-2. 
2- There were small effects of comorbidity (diabetes) and clinical events during follow-up. 
3- Fatigue scores relate more to depression symptoms as assessed by the BDI-II scores than to 
diagnosed depression by the MINI. 
BDI-II ≥16 was the best screening tool for the detection of possible depression in this selected 
cohort. Patients with BDI-II ≥16 require a diagnostic interview. Depression can be safely excluded 
in those with BDI-II <16. PHQ-9≥ 8 may be a useful alternative.  
We found multiple problems with the use of antidepressants in the HD setting: 
1- Multiple types of antidepressants were being used, some of which are contraindicated in 
this setting. 
2- There was over-prescription – 15% had never had depression.  
3- There was inadequate follow-up. 
4- There was sub-optimal adherence to NICE guidelines. 
5- There was little evidence of nephrological awareness and supervision.  
There is a real need for improvements in depression management in HD patients. 
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Chapter 9 
Final Discussion 
Depression is known to be common in HD patients (444, 470), though the diagnosis is challenging 
due to symptom overlap between depression and uraemia (444). Estimates of the prevalence of 
depression in this population have varied from as high as 40%, based on screening questionnaires, 
to around 20%, based on psychiatric interviews (173). This large multicentre study has confirmed 
that many patients on HD suffer from high depression symptoms. A high proportion (32.5%) 
screened positive by BDI-II using the cut-off ≥16, which accords with previous literature (173). A 
similar number (36%) screened positive on the PHQ-9, using a cut-off point of ≥8, which in this 
study was the cut-off point corresponding to ≥16 on the BDI-II. 
One of the major findings was the high prevalence of HD patients receiving treatment for their 
depression either by antidepressants or psychological therapy, in spite of the dearth of evidence for 
the efficacy of antidepressants in this setting. There is very little data in the literature on this topic, 
the only previous report being that of Lopes et al. (228). It was notable that 17% of patients with a 
high BDI-II score were currently taking antidepressants or receiving psychological therapies (5%), 
or both (7%) – a total of 29% on one or both of these therapies. It was noticeable that BDI-II 
screen positive patients receiving antidepressants had higher BDI-II scores than their untreated 
counterparts. There are number of potential explanations for this. These include the possibility that 
the treated patients have more severe symptoms of depression. It also raises questions about 
prescribing practices, patients' adherence, and therapeutic efficacy in this setting.  
PHQ-9 and PHQ-2 were found to be acceptable screening tools compared to the BDI-II in dialysis 
patients, with cut-off points of ≥8 in PHQ-9 and ≥2 in PHQ-2, approximating the BDI-II cut-off of 
≥16. Previous literature (175) has suggested that the optimal BDI-II and PHQ-9 cut-off values for 
the diagnosis of MDD in the HD population were ≥16 and ≥10, respectively. Similarly, we found 
that the strongest predictor of MDD in patients with a BDI ≥16 was a PHQ-9 ≥10. Hence, there 
seem to be different PHQ-9 cut-offs for predicting depressive symptoms and diagnosed 
depression. These differences probably relate to the sensitivity of the BDI-II instrument to somatic 
symptoms and the overlap of these symptoms in depression and uraemia. These findings may be 
helpful in interpreting the results of these screening tools in the HD population.  
220 
 
The purpose of the screening phase was to identify HD patients with depression suitable to enter 
the RCT. In spite of approaching 1,353 potential participants, only 37 were ultimately deemed 
suitable to be randomised, and only 30 agreed to take part. There were multiple challenges, 
including language barriers, robust exclusion criteria, most notably patients already receiving 
antidepressants, and refusal to consent. The refusal rate was in fact very acceptable – 30% at 
screening, 16% for psychiatric interview, and 3% for the RCT. Considering all of these 
recruitment challenges, screening seems to have been reasonably successful.  
An important finding was that use of antidepressant therapy is common in HD patients, despite 
little evidence of efficacy in this population and its high potential for adverse effects. This finding 
has implications for extending this feasibility RCT study into a definitive RCT. This will be 
discussed later in this section. 
Fatigue is very common in HD patients, the prevalence ranging from 42% to 89% according to the 
treatment modality and assessment instruments (226). It was not possible in our study to establish 
prevalence since the MFI lacks validated cut-off points. However, fatigue levels in our HD 
population were strikingly high in all domains, general, physical, and mental, and similar to those 
found in oncology patients (459). There were weak relationships with age, gender, weight, and 
comorbidity, particularly diabetes and heart disease, but no relationship with dialysis vintage, 
haemoglobin, albumin, or dialysis adequacy. In general, these findings align with previous studies 
(38, 314, 315, 330, 331, 334). Fatigue scores (all subdomains) were closely related to dialysis 
recovery time, the closest relationship being the physical component. Physical fatigue was also 
highly predictive of mortality. There was no impact from any parameters related to depressive 
symptomatology on the prediction of mortality in the models, including the fatigue domains.  
Previous literature has demonstrated strong correlations between depression in HD patients and 
overall symptom burden (382). The association between fatigue and depression is particularly 
strong (41, 314, 335, 460). These findings have been confirmed in the present study, which 
showed strong correlations between BDI-II, PHQ-9, and PHQ-2 scores and the MFI subdomains 
general, physical, and mental. Fatigue scores were higher in patients with high BDI-II scores 
(≥16). There were, however, differences in the distributions of the general, physical, and mental 
fatigue scores in patients with high and low BDI-II scores. Of the MFI domains, mental fatigue 
was the strongest independent predictor of high depressive symptoms (BDI-II ≥16, PHQ-9 ≥8). 
Mental fatigue, but not general or physical fatigue, also tended to be higher in patients with MDD 
compared to those with high depressive symptoms but without MDD. In addition, the dissociation 
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between the changes in BDI-II and MADRS scores and fatigue scores during the RCT suggests 
that the change in depression scores during the study was more related to changes in cognitive than 
somatic components. 
Taken together, these findings suggest that, though the relationships are complex, some principles 
can be established with respect to the role of fatigue in the HD setting. Firstly, post-dialysis 
recovery time and survival seem to relate more strongly to physical (somatic factors) rather than 
mental fatigue (cognitive factors). The failure of depression scores to improve models of survival 
that include physical fatigue suggests that the previously reported effects of depression on 
mortality (461) may be mediated by physical fatigue. Secondly, high depressive symptoms, and 
indeed the diagnosis of MDD, relate more strongly to mental fatigue (cognitive factors) rather than 
physical fatigue (somatic factors). The capacity to distinguish somatic and cognitive factors by 
such means may be useful in directing further research in these areas with a view to designing 
specific management strategies. 
The progression study was carried out to examine the natural history of antidepressant therapy in 
patients on HD. The impetus for this came from the finding in the screening study that a 
significant proportion of the dialysis population were taking antidepressant medication, sometimes 
without the knowledge of the treating nephrologist, and in spite of the dearth of evidence of 
efficacy in this setting. Two-thirds of HD patients who were taking antidepressants at baseline had 
persistently high or deteriorating depressive symptom scores after around the 12-month follow-up. 
A high proportion of these (56%) had clinical depression. It transpired that, on psychiatric 
examination, in 15% of this cohort there was no evidence that the patient had ever had MDD over 
their lifetime. Many had never had the treatment reviewed or amended during follow-up in spite of 
NICE recommendations. Ten different antidepressants were being used, the commonest being 
Citalopram, not considered to be the drug of choice in this setting due to the high potential for side 
effects, including prolonged QT interval and bleeding. A few patients (5%) were taking tricyclic 
antidepressants despite these being contraindicated for patients with heart disease, which is 
common in this setting (6, 7). Antidepressants were prescribed by GPs in most cases. There may 
be a number of reasons for this. Nephrologists may be more likely to think that depression is 'part 
of the illness and its treatment', may also be much more aware of the complexity of this cohort in 
terms of comorbidity and polypharmacy with its hugely increased potential for adverse drug 
effects and interactions, as well as adding to the tablet burden. Previous literature suggests that 
depression is often unrecognised and undertreated in patients with chronic medical illness (468), 
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and that this can lead to negative outcomes (469). It might be added to this that, in HD patients, 
even when depression is recognised it is usually sub-optimally treated. Our findings also suggest 
that antidepressants are often prescribed inappropriately for patients who are not depressed.  
Perhaps one of the most important points is that the GP practice on prescribing antidepressants 
should be addressed either by teaching and raising the awareness of prescriptions guidelines or 
encouraged through Commissioning for Quality and Innovation driven by NHS England. This is 
scheme intended to deliver clinical quality improvements and drive transformational change eg; 
improving the outcomes and experience of patients with mental health needs, or The Quality, 
Innovation, Productivity and Prevention programme which is a large-scale programme developed 
by the Department of Health to drive forward quality improvements in NHS care. These range 
from improving commissioning or purchasing of care for patients with long-term conditions, to 
improving how organisations are run, staffed and supplied.  
There is also a strong argument for more involvement for nephrologists in the assessment, 
diagnosis and management of depression in their patients. This would involve a drive to increase 
the awareness of nephrologists about the condition and a lowered threshold for direct involvement 
of psychiatrist in the care of these patients.    
In summary, we found multiple problems with the use of antidepressants in the HD setting: 
1- Multiple types of antidepressants were being used, some of which are contraindicated in 
this setting. 
2- There was over-prescription – 15% had never had depression.  
3- There was inadequate follow-up. 
4- There was little evidence of adherence to NICE guidelines. 
5- There was little evidence of nephrological awareness and supervision.  
These raise major issues of safety and efficacy, which need to be addressed by education and 
further empirical study. 
This brings us to the final element of these studies. The feasibility RCT reported here is the largest 
randomised trial of antidepressant use in HD patients to date. We recruited 30 patients and 21 
(70%) patients completed the six-month study. Recruitment to the RCT was difficult. Over 70% of 
the 231 positively BDI-II screened patients were ineligible or unwilling to consent to psychiatric 
interview. The commonest reason for non-eligibility was current antidepressant medication and/or 
psychological therapy. Patients also seemed to have concerns about adding to already considerable 
pill burdens and about becoming dependent on antidepressant drugs. Adverse events were 
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common and, though they occurred with similar frequency in treatment and placebo groups, more 
patients withdrew in the treatment group because of them. The only death that occurred was in the 
treatment group. Depression scores (BDI-II and MADRS) improved significantly in both sertraline 
and placebo groups over six months. There was no significant difference between the groups, 
similar to previous findings in other chronic illnesses (471, 472). 
This study raises concerns about the benefits and risks of antidepressants in patients on HD, a 
highly comorbid group with a huge pill burden confounding their high prevalence of depression. 
The study suggests that current practice patterns may be subjecting patients to substantial risk for 
little or no benefit. Identifying whether antidepressant medication is effective in this context is a 
major clinical need.  
The European Renal Best Practice Group recommends that 'The evidence on the effectiveness of 
antidepressants versus placebo in patients with CKD stages 3-5, and with DSM-IV-defined 
depression is insufficient, and in view of the high prevalence, a well-designed RCT is greatly 
needed' (230). This sentiment is echoed by a recent Cochrane review (458): 'Despite the high 
prevalence of depression in dialysis patients and the relative priority that patients place on 
effective treatments, evidence for antidepressant medication in the dialysis setting is sparse and 
data are generally inconclusive. The relative benefits and harms of antidepressant therapy in 
dialysis patients are poorly known and large randomised studies of antidepressants versus placebo 
are required'. 
This feasibility RCT suggests that a definitive trial would require significant amendments to study 
design to enhance its chances of success. These have been outlined in the RCT chapter. We believe 
that, though it would be difficult to conduct such a large randomised placebo-controlled trial of 
antidepressants in this group of patients, it is important to carry this out, given the prevalence of 
depression in the HD population, uncertainty about the efficacy and safety of antidepressants, the 
widespread use of these agents, and current sub-optimal practice patterns, all of which have been 
highlighted by the series of studies reported here. 
 
 
 
 
224 
 
References  
1. Fogarty D, Cullen R. UK Renal Registry 16th Annual Report. Renal Association. 2014. 
2. Gilg J, Rao A, Fogarty D. UK renal registry 16th annual report: chapter 1 UK renal replacement 
therapy incidence in 2012: national and centre-specific analyses. Nephron Clinical Practice. 2014;125(1-
4):1-28. 
3. Vanholder R, De Smet R, Glorieux G, Argilés A, Baurmeister U, Brunet P, et al. Review on uremic 
toxins: classification, concentration, and interindividual variability. Kidney international. 2003;63(5):1934-
43. 
4. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D. A more accurate method to estimate 
glomerular filtration rate from serum creatinine: a new prediction equation. Annals of internal medicine. 
1999;130(6):461-70. 
5. Eknoyan G, Levin NW. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, 
classification, and stratification. Am J Kidney Dis. 2002;39(2 Suppl 1):S1-266. 
6. Vanholder R, Baurmeister U, Brunet P, Cohen G, Glorieux G, Jankowski J. A bench to bedside view 
of uremic toxins. Journal of the American Society of Nephrology. 2008;19(5):863-70. 
7. Vanholder R, Van Laecke S, Glorieux G. What is new in uremic toxicity? Pediatric Nephrology. 
2008;23(8):1211-21. 
8. Go AS, Chertow GM, Fan D, McCulloch CE, Hsu C-y. Chronic kidney disease and the risks of death, 
cardiovascular events, and hospitalization. New England Journal of Medicine. 2004;351(13):1296-305. 
9. McCullough PA, Verrill TA. Cardiorenal interaction: appropriate treatment of cardiovascular risk 
factors to improve outcomes in chronic kidney disease. Postgraduate medicine. 2010;122(2):25-34. 
10. Berger I, Wu S, Masson P, Kelly PJ, Duthie FA, Whiteley W, et al. Cognition in chronic kidney 
disease: a systematic review and meta-analysis. BMC medicine. 2016;14(1):206. 
11. Rock P, Roiser J, Riedel W, Blackwell A. Cognitive impairment in depression: a systematic review 
and meta-analysis. Psychological medicine. 2014;44(10):2029-40. 
12. Cooper BA, Branley P, Bulfone L, Collins JF, Craig JC, Fraenkel MB, et al. A randomized, controlled 
trial of early versus late initiation of dialysis. New England Journal of Medicine. 2010;363(7):609-19. 
13. Arora P, Obrador GT, Ruthazer R, KAUSZ AT, Meyer KB, Jenuleson CS, et al. Prevalence, predictors, 
and consequences of late nephrology referral at a tertiary care center. Journal of the American Society of 
Nephrology. 1999;10(6):1281-6. 
14. Innes A, Rowe P, Burden R, Morgan A. Early deaths on renal replacement therapy: the need for 
early nephrological referral. Nephrology Dialysis Transplantation. 1992;7(6):467-71. 
15. NKF K. DOQI Guidelines: clinical practice guidelines and clinical practice recommendations. 2006 
updates. Hemodialysis adequacy, peritoneal dialysis adequacy and vascular access The National Kidney 
Foundation. 2006;48:S1-322. 
16. Warwick G MA, Russon L, Hardy R. Renal Association Clinical Practice Guidelines- Planning, 
Initiating and Withdrawal of Renal Replacement Therapy  
http://www.renal.org/guidelines/modules/planning-initiating-and-withdrawal-of-renal-replacement-
therapy#sthash.4Hq3TccD.dpuf: Renal Association; 2014 [cited 2014]. 
17. Korevaar JC, Jansen MA, Dekker FW, Jager KJ, Boeschoten EW, Krediet RT, et al. When to initiate 
dialysis: effect of proposed US guidelines on survival. The Lancet. 2001;358(9287):1046-50. 
225 
 
18. O'Connor NR, Kumar P. Conservative management of end-stage renal disease without dialysis: a 
systematic review. Journal of palliative medicine. 2012;15(2):228-35. 
19. National Heart L, Institute B. National Institute of Diabetes and Digestive and Kidney Diseases. 
Clinical guidelines on the identification, evaluation and treatment of overweight and obesity in adults: the 
evidence report Bethesda: National Institutes of Health. 1998:1-228. 
20. Baune BT, Stuart M, Gilmour A, Wersching H, Heindel W, Arolt V, et al. The relationship between 
subtypes of depression and cardiovascular disease: a systematic review of biological models. Translational 
psychiatry. 2012;2(3):e92. 
21. Sarnak MJ, Levey AS, Schoolwerth AC, Coresh J, Culleton B, Hamm LL, et al. Kidney disease as a risk 
factor for development of cardiovascular disease a statement from the American Heart Association 
Councils on kidney in cardiovascular disease, high blood pressure research, clinical cardiology, and 
epidemiology and prevention. Circulation. 2003;108(17):2154-69. 
22. Soni RK, Weisbord SD, Unruh ML. Health-related quality of life outcomes in chronic kidney 
disease. Current opinion in nephrology and hypertension. 2010;19(2):153. 
23. Lindsay RM, Henderson LW. Adequacy of dialysis. Kidney international Supplement. 1988;24:S92-
9. 
24. Kimmel PL. Psychosocial factors in dialysis patients. Kidney international. 2001;59(4):1599-613. 
25. Kimmel PL, Weihs K, Peterson RA. Survival in hemodialysis patients: the role of depression. Journal 
of the American Society of Nephrology. 1993;4(1):12-27. 
26. group W. The World Health Organization quality of life assessment (WHOQOL): position paper 
from the World Health Organization. Social science & medicine. 1995;41(10):1403-9. 
27. Kalender B, Ozdemir A, Dervisoglu E, Ozdemir O. Quality of life in chronic kidney disease: effects of 
treatment modality, depression, malnutrition and inflammation. International Journal of Clinical Practice. 
2007;61(4):569-76. 
28. Vázquez I, Valderrábano F, Fort J, Jofré R, López-Gómez JM, Moreno F, et al. Psychosocial factors 
and health-related quality of life in hemodialysis patients. Quality of Life Research. 2005;14(1):179-90. 
29. Drayer RA, Piraino B, Reynolds CF, Houck PR, Mazumdar S, Bernardini J, et al. Characteristics of 
depression in hemodialysis patients: symptoms, quality of life and mortality risk. General hospital 
psychiatry. 2006;28(4):306-12. 
30. Sayin A, Mutluay R, Sindel S, editors. Quality of life in hemodialysis, peritoneal dialysis, and 
transplantation patients. Transplantation proceedings; 2007: Elsevier. 
31. Akman B, Uyar M, Afsar B, Sezer S, Nurhan Ozdemir F, Haberal M. Adherence, depression and 
quality of life in patients on a renal transplantation waiting list. Transplant International. 2007;20(8):682-
7. 
32. Kovacs AZ, Molnar MZ, Szeifert L, Ambrus C, Molnar-Varga M, Szentkiralyi A, et al. Sleep disorders, 
depressive symptoms and health-related quality of life—a cross-sectional comparison between kidney 
transplant recipients and waitlisted patients on maintenance dialysis. Nephrology Dialysis Transplantation. 
2010:gfq476. 
33. Dickinson D, Bodfish L, Pisoni R, Akizawa T, Locatelli F, Akiba T. International variation in the 
employment status of hemodialysis (HD) patients: results from the DOPPS. J Am Soc Nephrol. 
2000;11:229A. 
34. Rasgon S, James-Rogers A, Chemleski B, Ledezma M, Mercado L, Besario M, et al. Maintenance of 
employment on dialysis. Advances in renal replacement therapy. 1997;4:152-9. 
226 
 
35. Theorell T, KONARSKI‐SVENSSON J, Ahlmen J, Perski A. The role of paid work in Swedish chronic 
dialysis patients—a nation‐wide survey: paid work and dialysis. Journal of internal medicine. 
1991;230(6):501-9. 
36. Binik YM, Baker AG, Kalogeropoulos D, Devins GM, Guttmann RD, Hollomby DJ, et al. Pain, control 
over treatment, and compliance in dialysis and transplant patients. Kidney Int. 1982;21(6):840-8. 
37. Unruh M, Yan G, Radeva M, Hays RD, Benz R, Athienites NV, et al. Bias in assessment of health-
related quality of life in a hemodialysis population: a comparison of self-administered and interviewer-
administered surveys in the HEMO study. Journal of the American Society of Nephrology. 
2003;14(8):2132-41. 
38. McCann K, Boore JR. Fatigue in persons with renal failure who require maintenance 
haemodialysis. Journal of Advanced Nursing. 2000;32(5):1132-42. 
39. Cathébras PJ, Robbins JM, Kirmayer LJ, Hayton BC. Fatigue in primary care. Journal of General 
Internal Medicine. 1992;7(3):276-86. 
40. Brunier G, Graydon J. The influence of physical activity on fatigue in patients with ESRD on 
hemodialysis. ANNA journal/American Nephrology Nurses' Association. 1993;20(4):457-61; discussion 62, 
521. 
41. Davison SN, Jhangri GS. Impact of pain and symptom burden on the health-related quality of life 
of hemodialysis patients. Journal of pain and symptom management. 2010;39(3):477-85. 
42. Kazemi M, Nasrabadi AN, Hasanpour M, Hassankhani H, Mills J. Experience of Iranian persons 
receiving hemodialysis: A descriptive, exploratory study. Nursing & health sciences. 2011;13(1):88-93. 
43. Lee BO, Lin CC, Chaboyer W, Chiang CL, Hung CC. The fatigue experience of haemodialysis patients 
in Taiwan. Journal of clinical nursing. 2007;16(2):407-13. 
44. Bonner A, Wellard S, Caltabiano M. The impact of fatigue on daily activity in people with chronic 
kidney disease. Journal of clinical nursing. 2010;19(21‐22):3006-15. 
45. Kimmel PL, editor Sleep apnea in end‐stage renal disease. Seminars in Dialysis; 1991: Wiley Online 
Library. 
46. Zoccali C, Mallamaci F, Tripepi G. Sleep apnea in renal patients. Journal of the American Society of 
Nephrology. 2001;12(12):2854-9. 
47. Iliescu EA, Coo H, McMurray MH, Meers CL, Quinn MM, Singer MA, et al. Quality of sleep and 
health‐related quality of life in haemodialysis patients. Nephrology Dialysis Transplantation. 
2003;18(1):126-32. 
48. Sanner BM, Tepel M, Esser M, Klewer J, Hoehmann‐Riese B, Zidek W, et al. Sleep‐related 
breathing disorders impair quality of life in haemodialysis recipients. Nephrology Dialysis Transplantation. 
2002;17(7):1260-5. 
49. Williams SW, Tell GS, Zheng B, Shumaker S, Rocco MV, Sevick MA. Correlates of sleep behavior 
among hemodialysis patients. The kidney outcomes prediction and evaluation (KOPE) study. American 
journal of nephrology. 2001;22(1):18-28. 
50. Montplaisir J, Boucher S, Poirier G, Lavigne G, Lapierre O, Lespérance P. Clinical, 
polysomnographic, and genetic characteristics of restless legs syndrome: a study of 133 patients 
diagnosed with new standard criteria. Movement Disorders. 1997;12(1):61-5. 
51. Sevim S, Dogu O, Kaleagasi H, Aral M, Metin O, Camdeviren H. Correlation of anxiety and 
depression symptoms in patients with restless legs syndrome: a population based survey. Journal of 
Neurology, Neurosurgery & Psychiatry. 2004;75(2):226-30. 
227 
 
52. Takaki J, Nishi T, Nangaku M, Shimoyama H, Inada T, Matsuyama N, et al. Clinical and 
psychological aspects of restless legs syndrome in uremic patients on hemodialysis. American journal of 
kidney diseases. 2003;41(4):833-9. 
53. Unruh ML, Levey AS, D'Ambrosio C, Fink NE, Powe NR, Meyer KB. Restless legs symptoms among 
incident dialysis patients: association with lower quality of life and shorter survival. American journal of 
kidney diseases. 2004;43(5):900-9. 
54. Szentkiralyi A, Molnar MZ, Czira ME, Deak G, Lindner AV, Szeifert L, et al. Association between 
restless legs syndrome and depression in patients with chronic kidney disease. Journal of psychosomatic 
research. 2009;67(2):173-80. 
55. Patel SS, Peterson RA, Kimmel PL, editors. Psychosocial factors in patients with chronic kidney 
disease: The Impact of Social Support on End‐Stage Renal Disease. Seminars in dialysis; 2005: Wiley Online 
Library. 
56. Patel SS, Shah VS, Peterson RA, Kimmel PL. Psychosocial variables, quality of life, and religious 
beliefs in ESRD patients treated with hemodialysis. American Journal of Kidney Diseases. 2002;40(5):1013-
22. 
57. Devins GM, Beanlands H, Mandin H, Paul LC. Psychosocial impact of illness intrusiveness 
moderated by self-concept and age in end-stage renal disease. Health Psychology. 1997;16(6):529. 
58. Devins GM, Edworthy SM, Paul LC, Mandin H, Seland TP, Klein G, et al. Restless sleep, illness 
intrusiveness, and depressive symptoms in three chronic illness conditions: rheumatoid arthritis, end-
stage renal disease, and multiple sclerosis. Journal of psychosomatic research. 1993;37(2):163-70. 
59. Tong A, Sainsbury P, Chadban S, Walker RG, Harris DC, Carter SM, et al. Patients' experiences and 
perspectives of living with CKD. American Journal of Kidney Diseases. 2009;53(4):689-700. 
60. Devins GM. Illness intrusiveness and the psychosocial impact of lifestyle disruptions in chronic life-
threatening disease. Adv Ren Replace Ther. 1994;1(3):251-63. 
61. Cohen G, Rudnicki M, HÖORL WH. Uremic toxins modulate the spontaneous apoptotic cell death 
and essential functions of neutrophils. Kidney International. 2001;59:S48-S52. 
62. Organization WH. The World health report: 2001: Mental health: new understanding, new hope. 
2001. 
63. Murray CJ, Lopez AD. Evidence-Based Health Policy---Lessons from the Global Burden of Disease 
Study. Science. 1996;274(5288):740-3. 
64. Wells KB, Stewart A, Hays RD, Burnam MA, Rogers W, Daniels M, et al. The functioning and well-
being of depressed patients: results from the Medical Outcomes Study. Jama. 1989;262(7):914-9. 
65. Fineberg NA, Haddad PM, Carpenter L, Gannon B, Sharpe R, Young AH, et al. The size, burden and 
cost of disorders of the brain in the UK. Journal of Psychopharmacology. 2013:0269881113495118. 
66. Organization WH. The ICD-10 classification of mental and behavioural disorders: clinical 
descriptions and diagnostic guidelines: Geneva: World Health Organization; 1992. 
67. Association AP. Diagnostic and statistical manual of mental disorders, text revision (DSM-IV-TR): 
American Psychiatric Association; 2000. 
68. Association AP. Diagnostic and Statistical Manual of Mental Disorders (DSM-5®): American 
Psychiatric Pub; 2013. 
69. Wittchen H-U, Höfler M, Meister W. Prevalence and recognition of depressive syndromes in 
German primary care settings: poorly recognized and treated? International clinical psychopharmacology. 
2001;16(3):121-35. 
228 
 
70. Andrews G, Anderson T, Slade T, Sunderland M. Classification of anxiety and depressive disorders: 
problems and solutions. Depression and anxiety. 2008;25(4):274-81. 
71. Wells KB, Burnam MA, Rogers W, Hays R, Camp P. The course of depression in adult outpatients: 
results from the Medical Outcomes Study. Archives of general psychiatry. 1992;49(10):788-94. 
72. Kessler RC, Zhao S, Blazer DG, Swartz M. Prevalence, correlates, and course of minor depression 
and major depression in the National Comorbidity Survey. Journal of affective disorders. 1997;45(1):19-30. 
73. Sheehan DV, Lecrubier Y, Sheehan KH, Amorim P, Janavs J, Weiller E, et al. The Mini-International 
Neuropsychiatric Interview (MINI): the development and validation of a structured diagnostic psychiatric 
interview for DSM-IV and ICD-10. Journal of clinical psychiatry. 1998;59:22-33. 
74. Lecrubier Y, Sheehan D, Weiller E, Amorim P, Bonora I, Sheehan KH, et al. The Mini International 
Neuropsychiatric Interview (MINI). A short diagnostic structured interview: reliability and validity 
according to the CIDI. European psychiatry. 1997;12(5):224-31. 
75. Williams JB, Gibbon M, First MB, Spitzer RL, Davies M, Borus J, et al. The structured clinical 
interview for DSM-III-R (SCID): II. Multisite test-retest reliability. Archives of general psychiatry. 
1992;49(8):630-6. 
76. Beck A, Steer R, Brown G. Manual for the BDI—Fast Screen for Medical Patients. Psychological 
Corporation, San Antonio, TX, USA. 2000. 
77. Steer RA, Ball R, Ranieri WF. Dimensions of the Beck Depression Inventory-II in clinically depressed 
outpatients. Journal of clinical psychology. 1999;55(1):117-28. 
78. Storch EA, Roberti JW, Roth DA. Factor structure, concurrent validity, and internal consistency of 
the beck depression inventory—second edition in a sample of college students. Depression and anxiety. 
2004;19(3):187-9. 
79. Kroenke K, Spitzer RL, Williams JB. The Phq‐9. Journal of general internal medicine. 
2001;16(9):606-13. 
80. Diez-Quevedo C, Rangil T, Sanchez-Planell L, Kroenke K, Spitzer RL. Validation and utility of the 
patient health questionnaire in diagnosing mental disorders in 1003 general hospital Spanish inpatients. 
Psychosomatic Medicine. 2001;63(4):679-86. 
81. Radloff LS. The CES-D scale a self-report depression scale for research in the general population. 
Applied psychological measurement. 1977;1(3):385-401. 
82. Zung W. Zung self-rating depression scale and depression status inventory.  Assessment of 
depression: Springer; 1986. p. 221-31. 
83. Zigmond AS, Snaith RP. The hospital anxiety and depression scale. Acta psychiatrica scandinavica. 
1983;67(6):361-70. 
84. Bjelland I, Dahl AA, Haug TT, Neckelmann D. The validity of the Hospital Anxiety and Depression 
Scale: an updated literature review. Journal of psychosomatic research. 2002;52(2):69-77. 
85. Rush AJ, Carmody T, Reimitz PE. The Inventory of Depressive Symptomatology (IDS): Clinician (IDS‐
C) and Self‐Report (IDS‐SR) ratings of depressive symptoms. International Journal of Methods in 
Psychiatric Research. 2000;9(2):45-59. 
86. Hamilton M. Development of a rating scale for primary depressive illness. British journal of social 
and clinical psychology. 1967;6(4):278-96. 
87. Williams JB, Kobak KA. Development and reliability of a structured interview guide for the 
Montgomery–Åsberg Depression Rating Scale (SIGMA). The British Journal of Psychiatry. 2008;192(1):52-
8. 
229 
 
88. Montgomery SA, Asberg M. A new depression scale designed to be sensitive to change. The British 
journal of psychiatry. 1979;134(4):382-9. 
89. Müller-Thomsen T, Arlt S, Mann U, Maß R, Ganzer S. Detecting depression in Alzheimer’s disease: 
evaluation of four different scales. Archives of Clinical Neuropsychology. 2005;20(2):271-6. 
90. Herrmann N, Black S, Lawrence J, Szekely C, Szalai J. The Sunnybrook stroke study a prospective 
study of depressive symptoms and functional outcome. Stroke. 1998;29(3):618-24. 
91. McDowell I. Measuring health: a guide to rating scales and questionnaires: Oxford university 
press; 2006. 
92. Guy W. ECDEU Assessment Manual for Psychopharmacology: Revised (DHEW publication no. ADM 
76–338). Rockville, MD: US Department of Health, Education and Welfare. Public Health Service.534-7. 
93. Wittchen H-U, Jacobi F. Size and burden of mental disorders in Europe—a critical review and 
appraisal of 27 studies. European neuropsychopharmacology. 2005;15(4):357-76. 
94. Ayuso-Mateos JL, Vázquez-Barquero JL, Dowrick C, Lehtinen V, Dalgard OS, Casey P, et al. 
Depressive disorders in Europe: prevalence figures from the ODIN study. The British Journal of Psychiatry. 
2001;179(4):308-16. 
95. Kessler RC, Berglund P, Demler O, Jin R, Merikangas KR, Walters EE. Lifetime prevalence and age-
of-onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication. Archives of 
general psychiatry. 2005;62(6):593-602. 
96. Bromet E, Andrade LH, Hwang I, Sampson NA, Alonso J, De Girolamo G, et al. Cross-national 
epidemiology of DSM-IV major depressive episode. BMC medicine. 2011;9(1):90. 
97. Kessler RC, McGonagle KA, Zhao S, Nelson CB, Hughes M, Eshleman S, et al. Lifetime and 12-
month prevalence of DSM-III-R psychiatric disorders in the United States: results from the National 
Comorbidity Survey. Archives of general psychiatry. 1994;51(1):8-19. 
98. Kessler RC, Berglund P, Demler O, Jin R, Koretz D, Merikangas KR, et al. The epidemiology of major 
depressive disorder: results from the National Comorbidity Survey Replication (NCS-R). Jama. 
2003;289(23):3095-105. 
99. Kessler RC, Chiu WT, Demler O, Walters EE. Prevalence, severity, and comorbidity of 12-month 
DSM-IV disorders in the National Comorbidity Survey Replication. Archives of general psychiatry. 
2005;62(6):617-27. 
100. Frank E, Kupfer DJ, Perel JM, Cornes C, Jarrett DB, Mallinger AG, et al. Three-year outcomes for 
maintenance therapies in recurrent depression. Archives of General Psychiatry. 1990;47(12):1093-9. 
101. Sadock BJ, Sadock VA. Synopsis of psychiatry. 2003. 
102. Hays RD, Wells KB, Sherbourne CD, Rogers W, Spritzer K. Functioning and well-being outcomes of 
patients with depression compared with chronic general medical illnesses. Archives of general psychiatry. 
1995;52(1):11-9. 
103. Akiskal HS, Maser JD, Zeller PJ, Endicott J, Coryell W, Keller M, et al. Switching from'unipolar'to 
bipolar II: an 11-year prospective study of clinical and temperamental predictors in 559 patients. Archives 
of General Psychiatry. 1995;52(2):114-23. 
104. Schildkraut JJ. The catecholamine hypothesis of affective disorders: a review of supporting 
evidence. American Journal of Psychiatry. 1965;122(5):509-22. 
105. Janowsky DS, El-Yousef KM, Davis JM. Acetylcholine and Depression*. Psychosomatic Medicine. 
1974;36(3):248-57. 
230 
 
106. Petty F. GABA and mood disorders: a brief review and hypothesis. Journal of affective disorders. 
1995;34(4):275-81. 
107. Tsapakis EM, Travis MJ. Glutamate and psychiatric disorders. Advances in Psychiatric treatment. 
2002;8(3):189-97. 
108. Delgado PL. Depression: the case for a monoamine deficiency. Journal of Clinical Psychiatry. 2000. 
109. Stetler C, Miller GE. Depression and hypothalamic-pituitary-adrenal activation: a quantitative 
summary of four decades of research. Psychosomatic medicine. 2011;73(2):114-26. 
110. Hennings JM, Owashi T, Binder EB, Horstmann S, Menke A, Kloiber S, et al. Clinical characteristics 
and treatment outcome in a representative sample of depressed inpatients–findings from the Munich 
Antidepressant Response Signature (MARS) project. Journal of psychiatric research. 2009;43(3):215-29. 
111. Kaser M, Zaman R, Sahakian B. Cognition as a treatment target in depression. Psychological 
medicine. 2017;47(6):987-9. 
112. Jaeger J, Berns S, Uzelac S, Davis-Conway S. Neurocognitive deficits and disability in major 
depressive disorder. Psychiatry research. 2006;145(1):39-48. 
113. Landrø NI, Stiles TC, Sletvold H. Neuropsychological function in nonpsychotic unipolar major 
depression. Cognitive and Behavioral Neurology. 2001;14(4):233-40. 
114. Porter RJ, Gallagher P, Thompson JM, Young AH. Neurocognitive impairment in drug-free patients 
with major depressive disorder. The British Journal of Psychiatry. 2003;182(3):214-20. 
115. Dunkin JJ, Leuchter AF, Cook IA, Kasl-Godley JE, Abrams M, Rosenberg-Thompson S. Executive 
dysfunction predicts nonresponse to fluoxetine in major depression. Journal of affective disorders. 
2000;60(1):13-23. 
116. Basso MR, Bornstein RA. Relative memory deficits in recurrent versus first-episode major 
depression on a word-list learning task. Neuropsychology. 1999;13(4):557. 
117. Kluger A, Goldberg E. IQ patterns in affective disorder, lateralized and diffuse brain damage. 
Journal of Clinical and Experimental Neuropsychology. 1990;12(2):182-94. 
118. Snyder HR. Major depressive disorder is associated with broad impairments on 
neuropsychological measures of executive function: A meta-analysis and review. American Psychological 
Association; 2013. 
119. Belmaker R, Agam G. Major depressive disorder. New England Journal of Medicine. 
2008;358(1):55-68. 
120. Hankin BL, Abramson LY, Moffitt TE, Silva PA, McGee R, Angell KE. Development of depression 
from preadolescence to young adulthood: emerging gender differences in a 10-year longitudinal study. 
Journal of abnormal psychology. 1998;107(1):128. 
121. Wakefield JC, Schmitz MF, First MB, Horwitz AV. Extending the bereavement exclusion for major 
depression to other losses: evidence from the National Comorbidity Survey. Archives of General 
Psychiatry. 2007;64(4):433-40. 
122. Afridi MI, Hina M, Qureshi IS, Hussain M. Cognitive disturbance comparison among drug-naive 
depressed cases and healthy controls. Journal of the College of Physicians and Surgeons–Pakistan. 
2011;21:351-5. 
123. Reppermund S, Ising M, Lucae S, Zihl J. Cognitive impairment in unipolar depression is persistent 
and non-specific: further evidence for the final common pathway disorder hypothesis. Psychological 
medicine. 2009;39(4):603-14. 
231 
 
124. Kotov R, Gamez W, Schmidt F, Watson D. Linking “big” personality traits to anxiety, depressive, 
and substance use disorders: a meta-analysis. Psychological bulletin. 2010;136(5):768. 
125. Beck AT, Rush A. Shaw, BF, & Emery, G.(1979). Cognitive therapy of depression. 1979:171-86. 
126. Westen D. The scientific legacy of Sigmund Freud: Toward a psychodynamically informed 
psychological science. Psychological Bulletin. 1998;124(3):333. 
127. Sullivan PF, Neale MC, Kendler KS. Genetic epidemiology of major depression: review and meta-
analysis. American Journal of Psychiatry. 2014. 
128. Kendler KS, Gatz M, Gardner CO, Pedersen NL. A Swedish national twin study of lifetime major 
depression. American Journal of Psychiatry. 2006;163(1):109-14. 
129. Kendler KS, Gardner CO, Prescott CA. Clinical characteristics of major depression that predict risk 
of depression in relatives. Archives of General Psychiatry. 1999;56(4):322-7. 
130. Holmans P, Weissman MM, Zubenko GS, Scheftner WA, Crowe RR, DePaulo Jr JR, et al. Genetics of 
recurrent early-onset major depression (GenRED): final genome scan report. The American journal of 
psychiatry. 2007;164(2):248-58. 
131. Lesch K-P, Bengel D, Heils A, Sabol SZ, Greenberg BD, Petri S, et al. Association of anxiety-related 
traits with a polymorphism in the serotonin transporter gene regulatory region. Science. 
1996;274(5292):1527-31. 
132. Lesch K, Greenberg B, Higley J, Bennett A, Murphy D. Serotonin transporter, personality, and 
behavior: toward dissection of gene–gene and gene–environment interaction. Molecular genetics and the 
human personality. 2002:109-35. 
133. Pezawas L, Meyer-Lindenberg A, Drabant EM, Verchinski BA, Munoz KE, Kolachana BS, et al. 5-
HTTLPR polymorphism impacts human cingulate-amygdala interactions: a genetic susceptibility 
mechanism for depression. Nature neuroscience. 2005;8(6):828-34. 
134. Caspi A, Sugden K, Moffitt TE, Taylor A, Craig IW, Harrington H, et al. Influence of life stress on 
depression: moderation by a polymorphism in the 5-HTT gene. Focus. 2005. 
135. Weaver IC, Cervoni N, Champagne FA, D'Alessio AC, Sharma S, Seckl JR, et al. Epigenetic 
programming by maternal behavior. Nature neuroscience. 2004;7(8):847-54. 
136. Fugate Woods N, LaCroix AZ, Gray SL, Aragaki A, Cochrane BB, Brunner RL, et al. Frailty: 
emergence and consequences in women aged 65 and older in the Women's Health Initiative 
Observational Study. Journal of the American Geriatrics Society. 2005;53(8):1321-30. 
137. Soysal P, Veronese N, Thompson T, Kahl KG, Fernandes BS, Prina AM, et al. Relationship between 
depression and frailty in older adults: A systematic review and meta-analysis. Ageing Research Reviews. 
2017. 
138. Vaughan L, Corbin AL, Goveas JS. Depression and frailty in later life: a systematic review. Clinical 
interventions in aging. 2015;10:1947. 
139. Veronese N, Stubbs B, Fontana L, Trevisan C, Bolzetta F, Rui MD, et al. A comparison of objective 
physical performance tests and future mortality in the elderly people. Journals of Gerontology Series A: 
Biomedical Sciences and Medical Sciences. 2016;72(3):362-8. 
140. Hajek A, Brettschneider C, Posselt T, Lange C, Mamone S, Wiese B, et al. Predictors of frailty in old 
age–results of a longitudinal study. The journal of nutrition, health & aging. 2016;20(9):952-7. 
141. Bortolato B, Miskowiak KW, Köhler CA, Maes M, Fernandes BS, Berk M, et al. Cognitive remission: 
a novel objective for the treatment of major depression? BMC medicine. 2016;14(1):9. 
232 
 
142. Newberg AR, Davydow DS, Lee HB. Cerebrovascular disease basis of depression: post-stroke 
depression and vascular depression. International Review of Psychiatry. 2006;18(5):433-41. 
143. Brown PJ, Rutherford BR, Yaffe K, Tandler JM, Ray JL, Pott E, et al. The depressed frail phenotype: 
the clinical manifestation of increased biological aging. The American Journal of Geriatric Psychiatry. 
2016;24(11):1084-94. 
144. Murri MB, Pariante C, Mondelli V, Masotti M, Atti AR, Mellacqua Z, et al. HPA axis and aging in 
depression: systematic review and meta-analysis. Psychoneuroendocrinology. 2014;41:46-62. 
145. Benraad CE, Kamerman‐Celie F, Munster BC, Oude Voshaar RC, Spijker J, Rikkert O, et al. Geriatric 
characteristics in randomised controlled trials on antidepressant drugs for older adults: a systematic 
review. International journal of geriatric psychiatry. 2016;31(9):990-1003. 
146. Lakey SL, LaCroix AZ, Gray SL, Borson S, Williams CD, Calhoun D, et al. Antidepressant use, 
depressive symptoms, and incident frailty in women aged 65 and older from the Women's Health 
Initiative Observational Study. Journal of the American Geriatrics Society. 2012;60(5):854-61. 
147. Schuch FB, Deslandes AC, Stubbs B, Gosmann NP, da Silva CTB, de Almeida Fleck MP. 
Neurobiological effects of exercise on major depressive disorder: a systematic review. Neuroscience & 
Biobehavioral Reviews. 2016;61:1-11. 
148. Schuch FB, Vancampfort D, Rosenbaum S, Richards J, Ward PB, Veronese N, et al. Exercise for 
depression in older adults: a meta-analysis of randomized controlled trials adjusting for publication bias. 
Revista Brasileira de Psiquiatria. 2016(AHEAD):0-. 
149. Regier DA, Farmer ME, Rae DS, Locke BZ, Keith SJ, Judd LL, et al. Comorbidity of mental disorders 
with alcohol and other drug abuse: Results from the Epidemiologic Catchment Area (ECA) study. Jama. 
1990;264(19):2511-8. 
150. Depression N. Treatment and management of depression in adults, including adults with a chronic 
physical health problem. Clinical Guideline 09 and. 2009;91. 
151. Klerman G, Weissman M, Rounsaville B, Chevron E. Interpersonal psychotherapy of 
depressionBasic Books. New York. 1984. 
152. Bolwig TG. How does electroconvulsive therapy work? Theories on its mechanism. Canadian 
Journal of Psychiatry/Revue Canadienne de Psychiatrie. 2011;56(1):13. 
153. Groves DA, Brown VJ. Vagal nerve stimulation: a review of its applications and potential 
mechanisms that mediate its clinical effects. Neuroscience & Biobehavioral Reviews. 2005;29(3):493-500. 
154. Kringelbach ML, Jenkinson N, Owen SL, Aziz TZ. Translational principles of deep brain stimulation. 
Nature Reviews Neuroscience. 2007;8(8):623-35. 
155. Berlim M, Van den Eynde F, Tovar-Perdomo S, Daskalakis Z. Response, remission and drop-out 
rates following high-frequency repetitive transcranial magnetic stimulation (rTMS) for treating major 
depression: a systematic review and meta-analysis of randomized, double-blind and sham-controlled 
trials. Psychological medicine. 2014;44(02):225-39. 
156. Wulsin LR, Vaillant GE, Wells VE. A systematic review of the mortality of depression. 
Psychosomatic medicine. 1999;61(1):6-17. 
157. Pinquart M, Duberstein P. Depression and cancer mortality: a meta-analysis. Psychological 
medicine. 2010;40(11):1797-810. 
158. Rutledge T, Reis VA, Linke SE, Greenberg BH, Mills PJ. Depression in heart failure: a meta-analytic 
review of prevalence, intervention effects, and associations with clinical outcomes. Journal of the 
American College of Cardiology. 2006;48(8):1527-37. 
233 
 
159. Keitner GI, Ryan CE, Miller IW, Kohn R, Epstein NB. 12-month outcome of patients with major 
depression and comorbid psychiatric or medical illness (compound depression). Am J Psychiatry. 
1991;148:345-50. 
160. Moussavi S, Chatterji S, Verdes E, Tandon A, Patel V, Ustun B. Depression, chronic diseases, and 
decrements in health: results from the World Health Surveys. The Lancet. 2007;370(9590):851-8. 
161. Katon WJ. Clinical and health services relationships between major depression, depressive 
symptoms, and general medical illness. Biological psychiatry. 2003;54(3):216-26. 
162. Kimmel PL, Peterson RA, editors. Depression in end-stage renal disease patients treated with 
hemodialysis: tools, correlates, outcomes, and needs. Seminars in dialysis; 2004. 
163. Ruttley A, Reid S. Depression in physical illness. Clinical medicine. 2006;6(6):533-5. 
164. Creed FH, Davies I, Jackson J, Littlewood A, Chew-Graham C, Tomenson B, et al. The epidemiology 
of multiple somatic symptoms. Journal of psychosomatic research. 2012;72(4):311-7. 
165. Kaplan MS, McFarland BH, Huguet N, Newsom JT. Physical Illness, Functional Limitations, and 
Suicide Risk: A Population‐Based Study. American Journal of Orthopsychiatry. 2007;77(1):56-60. 
166. Audrey M. Psychiatric disorder in a sample of the general population with and without chronic 
medical conditions. Am J Psychiatry. 1988;145:976-98. 
167. Rodin G, Lloyd N, Katz M, Green E, Mackay JA, Wong RK, et al. The treatment of depression in 
cancer patients: a systematic review. Supportive Care in Cancer. 2007;15(2):123-36. 
168. Patten SB, Beck CA, Kassam A, Williams JV, Barbui C, Metz LM. Long-term medical conditions and 
major depression: strength of association for specific conditions in the general population. Can J 
Psychiatry. 2005;50(4):195-202. 
169. Patten SB, Williams JV, Lavorato DH, Modgill G, Jetté N, Eliasziw M. Major depression as a risk 
factor for chronic disease incidence: longitudinal analyses in a general population cohort. General hospital 
psychiatry. 2008;30(5):407-13. 
170. Nylev Stenager E, Stenager E. Physical illness and suicidal behaviour. The international handbook 
of suicide and attempted suicide. 2000:405-20. 
171. Quan H, Arboleda-Flórez J, Fick GH, Stuart HL, Love EJ. Association between physical illness and 
suicide among the elderly. Social psychiatry and psychiatric epidemiology. 2002;37(4):190-7. 
172. Tong A, Sainsbury P, Carter SM, Hall B, Harris DC, Walker RG, et al. Patients’ priorities for health 
research: focus group study of patients with chronic kidney disease. Nephrology Dialysis Transplantation. 
2008;23(10):3206-14. 
173. Palmer S, Vecchio M, Craig JC, Tonelli M, Johnson DW, Nicolucci A, et al. Prevalence of depression 
in chronic kidney disease: systematic review and meta-analysis of observational studies. Kidney 
international. 2013;84(1):179-91. 
174. Craven JL, Rodin G, Littlefield C. The Beck Depression Inventory as a screening device for major 
depression in renal dialysis patients. The International Journal of Psychiatry in Medicine. 1988;18(4):365-
74. 
175. Watnick S, Wang P-L, Demadura T, Ganzini L. Validation of 2 depression screening tools in dialysis 
patients. American journal of kidney diseases. 2005;46(5):919-24. 
176. Hedayati S, Bosworth H, Kuchibhatla M, Kimmel P, Szczech L. The predictive value of self-report 
scales compared with physician diagnosis of depression in hemodialysis patients. Kidney international. 
2006;69(9):1662-8. 
234 
 
177. Chilcot J, Norton S, Wellsted D, Almond M, Davenport A, Farrington K. A confirmatory factor 
analysis of the Beck Depression Inventory-II in end-stage renal disease patients. Journal of psychosomatic 
research. 2011;71(3):148-53. 
178. Hedayati SS, Minhajuddin AT, Toto RD, Morris DW, Rush AJ. Validation of depression screening 
scales in patients with CKD. American Journal of Kidney Diseases. 2009;54(3):433-9. 
179. Loosman W, Siegert C, Korzec A, Honig A. Validity of the Hospital Anxiety and Depression Scale 
and the Beck Depression Inventory for use in end‐stage renal disease patients. British Journal of Clinical 
Psychology. 2010;49(4):507-16. 
180. Beck AT, Steer RA, Ball R, Ranieri WF. Comparison of Beck Depression Inventories-IA and-II in 
psychiatric outpatients. Journal of personality assessment. 1996;67(3):588-97. 
181. Beck AT, Steer RA, Brown GK. Beck depression inventory-II. San Antonio. 1996. 
182. Grant D, Almond MK, Newnham A, Roberts P, Hutchings A. The Beck Depression Inventory 
requires modification in scoring before use in a haemodialysis population in the UK. Nephron Clinical 
practice. 2007;110(1):c33-8. 
183. Scalera A, Shear N. Use and citation of Beck Depression Inventory to assess depression in HIV 
infection. Psychosomatics. 2002;43(1):88. 
184. Watnick S, Kirwin P, Mahnensmith R, Concato J. The prevalence and treatment of depression 
among patients starting dialysis. American journal of kidney diseases. 2003;41(1):105-10. 
185. Spitzer RL, Williams JB, Kroenke K, Hornyak R, McMurray J, Group PHQO-GS. Validity and utility of 
the PRIME-MD patient health questionnaire in assessment of 3000 obstetric-gynecologic patients: the 
PRIME-MD Patient Health Questionnaire Obstetrics-Gynecology Study. American journal of obstetrics and 
gynecology. 2000;183(3):759-69. 
186. Spitzer RL, Kroenke K, Williams JB, Group PHQPCS. Validation and utility of a self-report version of 
PRIME-MD: the PHQ primary care study. Jama. 1999;282(18):1737-44. 
187. Pinto‐Meza A, Serrano‐Blanco A, Peñarrubia MT, Blanco E, Haro JM. Assessing Depression in 
Primary Care with the PHQ‐9: Can It Be Carried Out over the Telephone? Journal of General Internal 
Medicine. 2005;20(8):738-42. 
188. Löwe B, Unützer J, Callahan CM, Perkins AJ, Kroenke K. Monitoring depression treatment 
outcomes with the patient health questionnaire-9. Medical care. 2004;42(12):1194-201. 
189. Whooley MA, Avins AL, Miranda J, Browner WS. Case-finding instruments for depression. Journal 
of general internal medicine. 1997;12(7):439-45. 
190. Cukor D, Peterson RA, Cohen SD, Kimmel PL. Depression in end-stage renal disease hemodialysis 
patients. Nature clinical practice Nephrology. 2006;2(12):678-87. 
191. Kimmel PL. Psychosocial factors in adult end-stage renal disease patients treated with 
hemodialysis: correlates and outcomes. American Journal of Kidney Diseases. 2000;35(4):S132-S40. 
192. Hedayati SS, Jiang W, O'Connor CM, Kuchibhatla M, Krishnan KR, Cuffe MS, et al. The association 
between depression and chronic kidney disease and mortality among patients hospitalized with 
congestive heart failure. American journal of kidney diseases. 2004;44(2):207-15. 
193. Peterson RA, Kimmel PL, Sacks CR, Mesquita ML, Simmens SJ, Reiss D. Depression, perception of 
illness and mortality in patients with end-stage renal disease. The International Journal of Psychiatry in 
Medicine. 1991;21(4):343-54. 
235 
 
194. Bhalla RK, Butters MA, Mulsant BH, Begley AE, Zmuda MD, Schoderbek B, et al. Persistence of 
neuropsychologic deficits in the remitted state of late-life depression. The American journal of geriatric 
psychiatry. 2006;14(5):419-27. 
195. Son YJ, Choi K-S, Park Y-R, Bae J-S, Lee J-B. Depression, symptoms and the quality of life in patients 
on hemodialysis for end-stage renal disease. American journal of nephrology. 2008;29(1):36-42. 
196. Mucsi I, Kovacs AZ, Molnar MZ, Novak M. Co-morbidity and quality of life in chronic kidney disease 
patients. Journal of nephrology. 2008;21(2):S84. 
197. Cukor D, Rosenthal DS, Jindal RM, Brown CD, Kimmel PL. Depression is an important contributor 
to low medication adherence in hemodialyzed patients and transplant recipients. Kidney international. 
2009;75(11):1223-9. 
198. Manley M, Sweeney J. Assessment of compliance in hemodialysis adaptation. Journal of 
psychosomatic research. 1986;30(2):153-61. 
199. Wolcott DL, Maida C, Diamond R, Nissenson A. Treatment compliance in end-stage renal disease 
patients on dialysis. American journal of nephrology. 1986;6(5):329-38. 
200. Davenport A. Intradialytic complications during hemodialysis. Hemodialysis international. 
2006;10(2):162-7. 
201. Bame SI, Petersen N, Wray NP. Variation in hemodialysis patient compliance according to 
demographic characteristics. Social science & medicine. 1993;37(8):1035-43. 
202. Christensen AJ, Smith TW, Turner CW, Holman Jr JM, Gregory MC, Rich MA. Family support, 
physical impairment, and adherence in hemodialysis: an investigation of main and buffering effects. 
Journal of behavioral medicine. 1992;15(4):313-25. 
203. Schneider MS, Friend R, Whitaker P, Wadhwa NK. Fluid noncompliance and symptomatology in 
end-stage renal disease: cognitive and emotional variables. Health Psychology. 1991;10(3):209. 
204. Weed-Collins M, Hogan R. Knowledge and health beliefs regarding phosphate-binding medication 
in predicting compliance. ANNA journal/American Nephrology Nurses' Association. 1989;16(4):278-82, 85, 
discussion 86. 
205. Schulz R, Drayer RA, Rollman BL. Depression as a risk factor for non-suicide mortality in the 
elderly. Biological psychiatry. 2002;52(3):205-25. 
206. Gallo JJ, Bogner HR, Morales KH, Post EP, Ten Have T, Bruce ML. Depression, cardiovascular 
disease, diabetes, and two-year mortality among older, primary-care patients. The American journal of 
geriatric psychiatry. 2005;13(9):748-55. 
207. Bruce ML, Leaf PJ. Psychiatric disorders and 15-month mortality in a community sample of older 
adults. American Journal of Public Health. 1989;79(6):727-30. 
208. Bruce M, Leaf P, Rozal G. M., Florio, L., & Hoff, R. A.(1994). Psychiatric status and 9-year mortality 
data in the New Haven Epidemiologic Catchment Area Study. American lournu1 ofPsychiat ry.151,716-21. 
209. Penninx BW, Geerlings SW, Deeg DJ, van Eijk JT, van Tilburg W, Beekman AT. Minor and major 
depression and the risk of death in older persons. Archives of general psychiatry. 1999;56(10):889-95. 
210. Gallo JJ, Bogner HR, Morales KH, Post EP, Lin JY, Bruce ML. The effect of a primary care practice–
based depression intervention on mortality in older adults: a randomized trial. Annals of internal 
medicine. 2007;146(10):689-98. 
211. Kimmel PL, Peterson RA, Weihs KL, Simmens SJ, Alleyne S, Cruz I, et al. Multiple measurements of 
depression predict mortality in a longitudinal study of chronic hemodialysis outpatients. Kidney 
international. 2000;57(5):2093-8. 
236 
 
212. Kimmel PL, Peterson RA, Weihs KL, Simmens SJ, Alleyne S, Cruz I, et al. Psychosocial factors, 
behavioral compliance and survival in urban hemodialysis patients1. Kidney international. 1998;54(1):245-
54. 
213. Devins GM, Mann J, Mandin H, Paul LC, Hons RB, Burgess ED, et al. Psychosocial predictors of 
survival in end-stage renal disease. Journal of Nervous and Mental Disease. 1990. 
214. Christensen AJ, Wiebe JS, Smith TW, Turner CW. Predictors of survival among hemodialysis 
patients: effect of perceived family support. Health Psychology. 1994;13(6):521. 
215. Zimmermann PR, Camey SA, De Jesus Mari J. A cohort study to assess the impact of depression on 
patients with kidney disease. The International Journal of Psychiatry in Medicine. 2006;36(4):457-68. 
216. Ziarnik JP, Freeman CW, Sherrard DJ, Calsyn DA. Psychological correlates of survival on renal 
dialysis. The Journal of nervous and mental disease. 1977;164(3):210-3. 
217. Wai L, Burton H, Richmond J, Lindsay R. Influence of psychosocial factors on survival of home-
dialysis patients. The Lancet. 1981;318(8256):1155-6. 
218. Burton HJ, Kline SA, Lindsay RM, Heidenheim AP. The relationship of depression to survival in 
chronic renal failure. Psychosomatic Medicine. 1986;48(3):261-9. 
219. Shulman R, Price JD, Spinelli J. Biopsychosocial aspects of long-term survival on end-stage renal 
failure therapy. Psychological medicine. 1989;19(04):945-54. 
220. Lopes AA, Bragg J, Young E, Goodkin D, Mapes D, Combe C, et al. Depression as a predictor of 
mortality and hospitalization among hemodialysis patients in the United States and Europe. Kidney 
international. 2002;62(1):199-207. 
221. Hedayati SS, Bosworth HB, Briley LP, Sloane RJ, Pieper CF, Kimmel PL, et al. Death or 
hospitalization of patients on chronic hemodialysis is associated with a physician-based diagnosis of 
depression. Kidney international. 2008;74(7):930-6. 
222. Bouleware L, Liu Y, Fink N. The temporal relation be-tween depression symptoms, cardiovascular 
disease events and mortality in ESRD: Contribution of reverse causality. Clin J Am Soc Nephrol. 
2006;1:496-504. 
223. Palmer SC, Vecchio M, Craig JC, Tonelli M, Johnson DW, Nicolucci A, et al. Association between 
depression and death in people with CKD: a meta-analysis of cohort studies. American Journal of Kidney 
Diseases. 2013;62(3):493-505. 
224. Hedayati SS, Grambow SC, Szczech LA, Stechuchak KM, Allen AS, Bosworth HB. Physician-
diagnosed depression as a correlate of hospitalizations in patients receiving long-term hemodialysis. 
American journal of kidney diseases. 2005;46(4):642-9. 
225. Hedayati SS, Minhajuddin AT, Afshar M, Toto RD, Trivedi MH, Rush AJ. Association between major 
depressive episodes in patients with chronic kidney disease and initiation of dialysis, hospitalization, or 
death. Jama. 2010;303(19):1946-53. 
226. Caplin B, Kumar S, Davenport A. Patients' perspective of haemodialysis-associated symptoms. 
Nephrology Dialysis Transplantation. 2011;26(8):2656-63. 
227. Theou O, Jones GR, Overend TJ, Kloseck M, Vandervoort AA. An exploration of the association 
between frailty and muscle fatigue. Applied Physiology, Nutrition, and Metabolism. 2008;33(4):651-65. 
228. Lopes AA, Albert JM, Young EW, Satayathum S, Pisoni RL, Andreucci VE, et al. Screening for 
depression in hemodialysis patients: associations with diagnosis, treatment, and outcomes in the DOPPS. 
Kidney international. 2004;66(5):2047-53. 
237 
 
229. Fischer MJ, Kimmel PL, Greene T, Gassman JJ, Wang X, Brooks DH, et al. Sociodemographic factors 
contribute to the depressive affect among African Americans with chronic kidney disease. Kidney 
international. 2010;77(11):1010-9. 
230. Nagler EV, Webster AC, Vanholder R, Zoccali C. Antidepressants for depression in stage 3–5 
chronic kidney disease: a systematic review of pharmacokinetics, efficacy and safety with 
recommendations by European Renal Best Practice (ERBP). Nephrology Dialysis Transplantation. 
2012:gfs295. 
231. Cohen SD, Norris L, Acquaviva K, Peterson RA, Kimmel PL. Screening, diagnosis, and treatment of 
depression in patients with end-stage renal disease. Clinical Journal of the American Society of 
Nephrology. 2007;2(6):1332-42. 
232. Healthcare T. Micromedex â Healthcare Series [Intranet database]. Version 5.1. Greenwood 
Village, Colorado: Thomson Healthcare. Accessed January; 2012. 
233. Whooley MA, Simon GE. Managing depression in medical outpatients. New England Journal of 
Medicine. 2000;343(26):1942-50. 
234. Lapid MI, Rummans TA, editors. Evaluation and management of geriatric depression in primary 
care. Mayo clinic proceedings; 2003: Elsevier. 
235. Hedayati SS, Finkelstein FO. Epidemiology, diagnosis, and management of depression in patients 
with CKD. American Journal of Kidney Diseases. 2009;54(4):741-52. 
236. Wuerth D, Finkelstein SH, Finkelstein FO, editors. Psychosocial factors in patients with chronic 
kidney disease: the identification and treatment of depression in patients maintained on dialysis. Seminars 
in dialysis; 2005: Wiley Online Library. 
237. Wuerth D, Finkelstein SH, Ciarcia J, Peterson R, Kliger AS, Finkelstein FO. Identification and 
treatment of depression in a cohort of patients maintained on chronic peritoneal dialysis. American 
journal of kidney diseases. 2001;37(5):1011-7. 
238. Kennedy SH, Craven JL, Roin GM. Major depression in renal dialysis patients: an open trial of 
antidepressant therapy. Journal of Clinical Psychiatry. 1989. 
239. Levy NB, Blumenfield M, Beasley CM, Dubey AK, Solomon RJ, Todd R, et al. Fluoxetine in 
depressed patients with renal failure and in depressed patients with normal kidney function. General 
hospital psychiatry. 1996;18(1):8-13. 
240. Blumenfield M, Levy NB, Spinowitz B, Charytan C, Beasley CM, Dubey AK, et al. Fluoxetine in 
depressed patients on dialysis. The International Journal of Psychiatry in Medicine. 1997;27(1):71-80. 
241. Koo J-R, Yoon J-Y, Joo M-H, Lee H-S, Oh J-E, Kim S-G, et al. Treatment of depression and effect of 
antidepression treatment on nutritional status in chronic hemodialysis patients. The American journal of 
the medical sciences. 2005;329(1):1-5. 
242. Turk S, Atalay H, Altintepe L, Güney I, Okudan N, Tonbul H, et al. Treatment with antidepressive 
drugs improved quality of life in chronic hemodialysis patients. Clinical nephrology. 2006;65(2):113-8. 
243. Finkelstein FO, Finkelstein SH. Depression in chronic dialysis patients: assessment and treatment. 
Nephrology Dialysis Transplantation. 2000;15(12):1911-3. 
244. Streltzer J. Diagnostic and treatment considerations in depressed dialysis patients. Renal Failure. 
1983;7(4):257-74. 
245. Atalay H, Solak Y, Biyik M, Biyik Z, Yeksan M, Uguz F, et al. Sertraline treatment is associated with 
an improvement in depression and health-related quality of life in chronic peritoneal dialysis patients. 
International urology and nephrology. 2010;42(2):527-36. 
238 
 
246. Glassman AH, O'Connor CM, Califf RM, Swedberg K, Schwartz P, Bigger Jr JT, et al. Sertraline 
treatment of major depression in patients with acute MI or unstable angina. Jama. 2002;288(6):701-9. 
247. Cukor D, Ver Halen N, Asher DR, Coplan JD, Weedon J, Wyka KE, et al. Psychosocial intervention 
improves depression, quality of life, and fluid adherence in hemodialysis. Journal of the American Society 
of Nephrology. 2013:ASN. 2012111134. 
248. Duarte PS, Miyazaki MC, Blay SL, Sesso R. Cognitive–behavioral group therapy is an effective 
treatment for major depression in hemodialysis patients. Kidney international. 2009;76(4):414-21. 
249. Jaber BL, Lee Y, Collins AJ, Hull AR, Kraus MA, McCarthy J, et al. Effect of daily hemodialysis on 
depressive symptoms and postdialysis recovery time: interim report from the FREEDOM (Following 
Rehabilitation, Economics and Everyday-Dialysis Outcome Measurements) Study. American Journal of 
Kidney Diseases. 2010;56(3):531-9. 
250. Group FT. In-center hemodialysis six times per week versus three times per week. The New 
England journal of medicine. 2010;363(24):2287. 
251. Jaber BL, Finkelstein FO, Glickman JD, Hull AR, Kraus MA, Leypoldt JK, et al. Scope and design of 
the following rehabilitation, economics and everyday-dialysis outcome measurements (FREEDOM) study. 
American Journal of Kidney Diseases. 2009;53(2):310-20. 
252. Painter P. Determinants of exercise capacity in CKD patients treated with hemodialysis. Advances 
in chronic kidney disease. 2009;16(6):437-48. 
253. Kutner NG. Promoting functioning and well-being in older CKD patients: review of recent 
evidence. International urology and nephrology. 2008;40(4):1151-8. 
254. Ouzouni S, Kouidi E, Sioulis A, Grekas D, Deligiannis A. Effects of intradialytic exercise training on 
health-related quality of life indices in haemodialysis patients. Clinical rehabilitation. 2009;23(1):53-63. 
255. Levendoğlu F, Altintepe L, Okudan N, Uğurlu H, Gökbel H, Tonbul Z, et al. A twelve week exercise 
program improves the psychological status, quality of life and work capacity in hemodialysis patients. 
Journal of nephrology. 2003;17(6):826-32. 
256. Johansen KL, Painter PL, Sakkas GK, Gordon P, Doyle J, Shubert T. Effects of resistance exercise 
training and nandrolone decanoate on body composition and muscle function among patients who 
receive hemodialysis: a randomized, controlled trial. Journal of the American Society of Nephrology. 
2006;17(8):2307-14. 
257. Kouidi E, Karagiannis V, Grekas D, Iakovides A, Kaprinis G, Tourkantonis A, et al. Depression, heart 
rate variability, and exercise training in dialysis patients. European Journal of Cardiovascular Prevention & 
Rehabilitation. 2010;17(2):160-7. 
258. Daneker B, Kimmel PL, Ranich T, Peterson RA. Depression and marital dissatisfaction in patients 
with end-stage renal disease and in their spouses. American journal of kidney diseases. 2001;38(4):839-46. 
259. Cohen SD, Sharma T, Acquaviva K, Peterson RA, Patel SS, Kimmel PL. Social support and chronic 
kidney disease: an update. Advances in chronic kidney disease. 2007;14(4):335-44. 
260. Gayomali C, Sutherland S, Finkelstein FO. The challenge for the caregiver of the patient with 
chronic kidney disease. Nephrology Dialysis Transplantation. 2008;23(12):3749-51. 
261. Tyring S, Gottlieb A, Papp K, Gordon K, Leonardi C, Wang A, et al. Etanercept and clinical 
outcomes, fatigue, and depression in psoriasis: double-blind placebo-controlled randomised phase III trial. 
The Lancet. 2006;367(9504):29-35. 
262. Hoad TF. The concise Oxford dictionary of English etymology: Oxford University Press Oxford; 
1993. 
239 
 
263. Glanze WD, Anderson K, Anderson LE. Mosby's medical, nursing, and allied health dictionary: 
Mosby; 1990. 
264. Cella D, Yount S, Rothrock N, Gershon R, Cook K, Reeve B, et al. The Patient-Reported Outcomes 
Measurement Information System (PROMIS): progress of an NIH Roadmap cooperative group during its 
first two years. Medical care. 2007;45(5 Suppl 1):S3. 
265. Layzer RB. Asthenia and the chronic fatigue syndrome. Muscle & nerve. 1998;21(12):1609-11. 
266. Swartz MN. The chronic fatigue syndrome—one entity or many? New England Journal of 
Medicine. 1988;319(26):1726-8. 
267. Council NR. Opportunities in neuroscience for future army applications: National Academies Press; 
2009. 
268. Cella D, Peterman A, Passik S, Jacobsen P, Breitbart W. Progress toward guidelines for the 
management of fatigue. Oncology (Williston Park, NY). 1998;12(11A):369-77. 
269. Lenz ER, Pugh LC, Milligan RA, Gift A, Suppe F. The middle-range theory of unpleasant symptoms: 
an update. Advances in Nursing Science. 1997;19(3):14-27. 
270. Ware Jr JE, Sherbourne CD. The MOS 36-item short-form health survey (SF-36): I. Conceptual 
framework and item selection. Medical care. 1992:473-83. 
271. Piper BF, Dibble SL, Dodd MJ, Weiss MC, Slaughter RE, Paul SM, editors. The revised Piper Fatigue 
Scale: psychometric evaluation in women with breast cancer. Oncology nursing forum; 1998. 
272. Smets E, Garssen B, Bonke Bd, De Haes J. The Multidimensional Fatigue Inventory (MFI) 
psychometric qualities of an instrument to assess fatigue. Journal of psychosomatic research. 
1995;39(3):315-25. 
273. Shiffman S, Stone AA, Hufford MR. Ecological momentary assessment. Annu Rev Clin Psychol. 
2008;4:1-32. 
274. Kopp MS, Falger PR, Appels A, Szedmak S. Depressive symptomatology and vital exhaustion are 
differentially related to behavioral risk factors for coronary artery disease. Psychosomatic Medicine. 
1998;60(6):752-8. 
275. Pedersen SS, Daemen J, van de Sande M, Sonnenschein K, Serruys PW, Erdman RA, et al. Type-D 
personality exerts a stable, adverse effect on vital exhaustion in PCI patients treated with paclitaxel-
eluting stents. Journal of psychosomatic research. 2007;62(4):447-53. 
276. Wolfe F, Hawley DJ, Wilson K. The prevalence and meaning of fatigue in rheumatic disease. The 
Journal of rheumatology. 1996;23(8):1407-17. 
277. Tench C, McCurdie I, White P, D'Cruz D. The prevalence and associations of fatigue in systemic 
lupus erythematosus. Rheumatology. 2000;39(11):1249-54. 
278. Mohr DC, Hart SL, Goldberg A. Effects of treatment for depression on fatigue in multiple sclerosis. 
Psychosomatic medicine. 2003;65(4):542-7. 
279. Jacobsen P, Donovan K, Weitzner M, editors. Distinguishing fatigue and depression in patients 
with cancer. Seminars in clinical neuropsychiatry; 2003. 
280. Sullivan MD, Newton K, Hecht J, Russo JE, Spertus JA. Depression and Health Status in Elderly 
Patients With Heart Failure: A 6‐Month Prospective Study in Primary Care. The American journal of 
geriatric cardiology. 2004;13(5):252-60. 
240 
 
281. Millikin CP, Rourke SB, Halman MH, Power C. Fatigue in HIV/AIDS is associated with depression 
and subjective neurocognitive complaints but not neuropsychological functioning. Journal of Clinical and 
Experimental Neuropsychology. 2003;25(2):201-15. 
282. Kvale E, Azuero CB, Walker E. Depression and fatigue. Nutrition and the Cancer Patient. 2010:215. 
283. Fleishman SB. Treatment of symptom clusters: pain, depression, and fatigue. Journal of the 
National Cancer Institute Monographs. 2003(32):119-23. 
284. Henningsen P, Zimmermann T, Sattel H. Medically Unexplained Physical Symptoms, Anxiety, and 
Depression: A Meta‐Analytic Review. Psychosomatic medicine. 2003;65(4):528-33. 
285. Skapinakis P, Lewis G, Meltzer H. Clarifying the relationship between unexplained chronic fatigue 
and psychiatric morbidity: results from a community survey in Great Britain. International Review of 
Psychiatry. 2003;15(1-2):57-64. 
286. Kirmayer LJ, Groleau D, Looper KJ, Dao MD. Explaining medically unexplained symptoms. Canadian 
Journal of Psychiatry. 2004;49(10):663. 
287. Arnold LM. Understanding fatigue in major depressive disorder and other medical disorders. 
Psychosomatics. 2008;49(3):185-90. 
288. Afari N, Buchwald D. Chronic fatigue syndrome: a review. American Journal of Psychiatry. 2014. 
289. Wessely S. Chronic Fatigue Syndrome.  Somatoform Disorders: Springer; 1999. p. 80-110. 
290. Reuter K, Härter M. The concepts of fatigue and depression in cancer. European Journal of Cancer 
Care. 2004;13(2):127-34. 
291. Fukuda K, Straus SE, Hickie I, Sharpe MC, Dobbins JG, Komaroff A. The chronic fatigue syndrome: a 
comprehensive approach to its definition and study. Annals of internal medicine. 1994;121(12):953-9. 
292. Wessely S, Hotopf M, Sharpe M. Chronic fatigue and its syndromes: Oxford Univ Press; 1998. 
293. Taylor RR, Jason LA. Chronic fatigue, abuse-related traumatization, and psychiatric disorders in a 
community-based sample. Social science & medicine. 2002;55(2):247-56. 
294. Parker A, Wessely S, Cleare A. The neuroendocrinology of chronic fatigue syndrome and 
fibromyalgia. Psychological medicine. 2001;31(08):1331-45. 
295. Chen MK. The epidemiology of self-perceived fatigue among adults. Preventive medicine. 
1986;15(1):74-81. 
296. Pawlikowska T, Chalder T, Hirsch S, Wallace P, Wright D, Wessely S. Population based study of 
fatigue and psychological distress. Bmj. 1994;308(6931):763-6. 
297. Bates DW, Schmitt W, Buchwald D, Ware NC, Lee J, Thoyer E, et al. Prevalence of fatigue and 
chronic fatigue syndrome in a primary care practice. Archives of internal medicine. 1993;153(24):2759-65. 
298. David A, Pelosi A, McDonald E, Stephens D, Ledger D, Rathbone R, et al. Tired, weak, or in need of 
rest: fatigue among general practice attenders. Bmj. 1990;301(6762):1199-202. 
299. Kroenke K, Wood DR, Mangelsdorff AD, Meier NJ, Powell JB. Chronic fatigue in primary care: 
prevalence, patient characteristics, and outcome. Jama. 1988;260(7):929-34. 
300. McDonald E, David AS, Pelosi AJ, Mann AH. Chronic fatigue in primary care attenders. 
Psychological medicine. 1993;23(04):987-98. 
301. Addington A, Gallo J, Ford D, Eaton W. Epidemiology of unexplained fatigue and major depression 
in the community: the Baltimore ECA follow-up, 1981–1994. Psychological medicine. 2001;31(06):1037-
44. 
241 
 
302. HICKIE I, DAVENPORT T, ISSAKIDIS C, ANDREWS G. Neurasthenia: prevalence, disability and health 
care characteristics in the Australian community. The British Journal of Psychiatry. 2002;181(1):56-61. 
303. MANN AH. Chronic fatigue in primary care attenders. Psychological medicine. 1993;23:987-98. 
304. LaPierre TA, Hughes ME. Population aging in Canada and the United States.  International 
handbook of population aging: Springer; 2009. p. 191-230. 
305. Hébert R, Brayne C, Spiegelhalter D. Incidence of functional decline and improvement in a 
community-dwelling, very elderly population. American Journal of Epidemiology. 1997;145(10):935-44. 
306. McAdams‐DeMarco MA, Law A, Salter ML, Boyarsky B, Gimenez L, Jaar BG, et al. Frailty as a novel 
predictor of mortality and hospitalization in individuals of all ages undergoing hemodialysis. Journal of the 
American Geriatrics Society. 2013;61(6):896-901. 
307. Fried LP, Tangen CM, Walston J, Newman AB, Hirsch C, Gottdiener J, et al. Frailty in older adults: 
evidence for a phenotype. The Journals of Gerontology Series A: Biological Sciences and Medical Sciences. 
2001;56(3):M146-M57. 
308. Hamerman D. Toward an understanding of frailty. Annals of internal medicine. 1999;130(11):945-
50. 
309. Abbiss CR, Laursen PB. Models to explain fatigue during prolonged endurance cycling. Sports 
Medicine-ADIS International. 2005;35(10):865-98. 
310. Levers MJ, Estabrooks CA, Ross Kerr JC. Factors contributing to frailty: literature review. Journal of 
advanced nursing. 2006;56(3):282-91. 
311. Afshar M, Rebollo-Mesa I, Murphy E, Murtagh FE, Mamode N. Symptom burden and associated 
factors in renal transplant patients in the UK. Journal of pain and symptom management. 2012;44(2):229-
38. 
312. Curtin RB, Bultman DC, Thomas-Hawkins C, Walters BA, Schatell D. Hemodialysis patients' 
symptom experiences: Effects on physical and mental functioning. Nephrology Nursing Journal. 
2002;29(6):562-74. 
313. Artom M, Moss-Morris R, Caskey F, Chilcot J. Fatigue in advanced kidney disease. Kidney 
international. 2014. 
314. Kim HR, Son GR. Fatigue and its related factors in Korean patients on hemodialysis. Taehan Kanho 
Hakhoe Chi. 2005;35(4):701-8. 
315. Bossola M, Luciani G, Tazza L. Fatigue and its correlates in chronic hemodialysis patients. Blood 
purification. 2009;28(3):245-52. 
316. Bonner A, Caltabiano M, Berlund L. Quality of life, fatigue, and activity in Australians with chronic 
kidney disease: a longitudinal study. Nursing & health sciences. 2013;15(3):360-7. 
317. Bonner A, Wellard S, Caltabiano M. Levels of fatigue in people with ESRD living in far North 
Queensland. J Clin Nurs. 2008;17(1):90-8. 
318. Joshwa B, Khakha D, Mahajan S. Fatigue and depression and sleep problems among hemodialysis 
patients in a tertiary care center. Saudi Journal of Kidney Diseases and Transplantation. 2012;23(4):729. 
319. Karadag E, Kilic SP, Metin O. Relationship between fatigue and social support in hemodialysis 
patients. Nursing & health sciences. 2013;15(2):164-71. 
320. Sajadi A, Farahani, F., Zanjani, E., Durnanesh, B. & Zare, M. . Factors affecting fatigue in chronic 
renal failure patients treated with hemodialysis Iranian Journal of Critical Care Nursing 2010;3(1):33-8. 
242 
 
321. Lerdal A, Wahl AK, Rustoen T, Hanestad BR, Moum T. Fatigue in the general population: a 
translation and test of the psychometric properties of the Norwegian version of the fatigue severity scale. 
Scandinavian Journal of Public Health. 2005;33(2):123-30. 
322. Cauch-Dudek K, Abbey S, Stewart D, Heathcote E. Fatigue in primary biliary cirrhosis. Gut. 
1998;43(5):705-10. 
323. O'Sullivan D, McCarthy G. An exploration of the relationship between fatigue and physical 
functioning in patients with end stage renal disease receiving haemodialysis. Journal of clinical nursing. 
2007;16(11c):276-84. 
324. Lobbedez T, Desbordes E, Joly F, Ficheux M, Henri P, Ryckelynck J-P. [Fatigue in elderly patients on 
dialysis]. Néphrologie & thérapeutique. 2008;4(7):584-9. 
325. Sklar AH, Riesenberg LA, Silber AK, Ahmed W, Ali A. Postdialysis fatigue. American journal of 
kidney diseases. 1996;28(5):732-6. 
326. Guerini RD, Mercieri A, Yavuzer G. Multidimensional health-status assessment of chronic 
hemodialysis patients: the impact on quality of life. Europa medicophysica. 2006;42(2):113-9. 
327. Sklar A, Newman N, Scott R, Semenyuk L, Schultz J, Fiacco V. Identification of factors responsible 
for postdialysis fatigue. American journal of kidney diseases. 1999;34(3):464-70. 
328. Lindsay RM, Heidenheim PA, Nesrallah G, Garg AX, Suri R, Centre DHSGLHS. Minutes to recovery 
after a hemodialysis session: a simple health-related quality of life question that is reliable, valid, and 
sensitive to change. Clinical Journal of the American Society of Nephrology. 2006;1(5):952-9. 
329. Horigan AE. Fatigue in hemodialysis patients: a review of current knowledge. Journal of pain and 
symptom management. 2012;44(5):715-24. 
330. Liu H. Fatigue and associated factors in hemodialysis patients in Taiwan. Research in nursing & 
health. 2006;29(1):40-50. 
331. Morsch CM, Gonçalves LF, Barros E. Health‐related quality of life among haemodialysis patients–
relationship with clinical indicators, morbidity and mortality. Journal of clinical nursing. 2006;15(4):498-
504. 
332. Letchmi S, Das S, Halim H, Zakariah FA, Hassan H, Mat S, et al. Fatigue experienced by patients 
receiving maintenance dialysis in hemodialysis units. Nursing & health sciences. 2011;13(1):60-4. 
333. Jhamb M, Pike F, Ramer S, Argyropoulos C, Steel J, Dew MA, et al. Impact of fatigue on outcomes 
in the hemodialysis (HEMO) study. American journal of nephrology. 2011;33(6):515-23. 
334. Koyama H, Fukuda S, Shoji T, Inaba M, Tsujimoto Y, Tabata T, et al. Fatigue is a predictor for 
cardiovascular outcomes in patients undergoing hemodialysis. Clinical Journal of the American Society of 
Nephrology. 2010;5(4):659-66. 
335. Leinau L, Murphy TE, Bradley E, Fried T. Relationship between conditions addressed by 
hemodialysis guidelines and non-ESRD-specific conditions affecting quality of life. Clinical Journal of the 
American Society of Nephrology. 2009;4(3):572-8. 
336. Chen C-K, Tsai Y-C, Hsu H-J, Wu I-W, Sun C-Y, Chou C-C, et al. Depression and suicide risk in 
hemodialysis patients with chronic renal failure. Psychosomatics. 2010;51(6):528-. e6. 
337. Garcia TW, Veiga JPR, Motta LDCd, Moura FJDd, Casulari LA. Depressed mood and poor quality of 
life in male patients with chronic renal failure undergoing hemodialysis. Revista Brasileira de Psiquiatria. 
2010;32(4):369-74. 
338. Williams AG, Crane PB, Kring D. Fatigue in African American women on hemodialysis. Nephrology 
Nursing Journal. 2007;34(6):610. 
243 
 
339. Kutner NG, editor DAILY HEMODIALYSIS—SELECTED TOPICS: Quality of Life and Daily 
Hemodialysis. Seminars in dialysis; 2004: Wiley Online Library. 
340. Cambi V, David S, Tagliavini D, Ota K, Olbricht C, Lonnemann G, et al. The patient on dialysis. 
Oxford Textbook of Clinical Nephrology Volume 3. 2005;3:1897. 
341. Ganz PA, Bower JE. Cancer related fatigue: a focus on breast cancer and Hodgkin's disease 
survivors. Acta Oncologica. 2007;46(4):474-9. 
342. Rao M, Wong C, Kanetsky P, Girndt M, Stenvinkel P, Reilly M, et al. Cytokine gene polymorphism 
and progression of renal and cardiovascular diseases. Kidney international. 2007;72(5):549-56. 
343. Bergström J, Lindholm B, editors. What are the causes and consequences of the chronic 
inflammatory state in chronic dialysis patients? Seminars in dialysis; 2000: Wiley Online Library. 
344. Hopkins SJ. Central nervous system recognition of peripheral inflammation: a neural, hormonal 
collaboration. Acta Biomed. 2007;78(Suppl 1):231-47. 
345. Adams F, Quesada JR, Gutterman JU. Neuropsychiatric manifestations of human leukocyte 
interferon therapy in patients with cancer. Jama. 1984;252(7):938-41. 
346. Kurzrock R. The role of cytokines in cancer‐related fatigue. Cancer. 2001;92(S6):1684-8. 
347. Piepoli M, Clark AL, Volterrani M, Adamopoulos S, Sleight P, Coats AJ. Contribution of muscle 
afferents to the hemodynamic, autonomic, and ventilatory responses to exercise in patients with chronic 
heart failure effects of physical training. Circulation. 1996;93(5):940-52. 
348. Seymour JF, Talpaz M, Cabanillas F, Wetzler M, Kurzrock R. Serum interleukin-6 levels correlate 
with prognosis in diffuse large-cell lymphoma. Journal of Clinical Oncology. 1995;13(3):575-82. 
349. Memoli B, Minutolo R, Bisesti V, Postiglione L, Conti A, Marzano L, et al. Changes of serum 
albumin and C-reactive protein are related to changes of interleukin-6 release by peripheral blood 
mononuclear cells in hemodialysis patients treated with different membranes. American journal of kidney 
diseases. 2002;39(2):266-73. 
350. Girndt M, Sester U, Kaul H, Köhler H. Production of proinflammatory and regulatory monokines in 
hemodialysis patients shown at a single-cell level. Journal of the American Society of Nephrology. 
1998;9(9):1689-96. 
351. Le Meur Y, Lorgeot V, Aldigier J-C, Wijdenes J, Leroux-Robert C, Praloran V. Whole blood 
production of monocytic cytokines (IL-1β, IL-6, TNF-α, sIL-6R, IL-1Ra) in haemodialysed patients. 
Nephrology Dialysis Transplantation. 1999;14(10):2420-6. 
352. Cesari M, Penninx BW, Pahor M, Lauretani F, Corsi AM, Williams GR, et al. Inflammatory markers 
and physical performance in older persons: the InCHIANTI study. The Journals of Gerontology Series A: 
Biological Sciences and Medical Sciences. 2004;59(3):M242-M8. 
353. Harris TB, Ferrucci L, Tracy RP, Corti MC, Wacholder S, Ettinger WH, et al. Associations of elevated 
interleukin-6 and C-reactive protein levels with mortality in the elderly. The American journal of medicine. 
1999;106(5):506-12. 
354. Janszky I, Lekander M, Blom M, Georgiades A, Ahnve S. Self-rated health and vital exhaustion, but 
not depression, is related to inflammation in women with coronary heart disease. Brain, behavior, and 
immunity. 2005;19(6):555-63. 
355. Visser M, Pahor M, Taaffe DR, Goodpaster BH, Simonsick EM, Newman AB, et al. Relationship of 
interleukin-6 and tumor necrosis factor-α with muscle mass and muscle strength in elderly men and 
women The Health ABC Study. The Journals of Gerontology Series A: Biological Sciences and Medical 
Sciences. 2002;57(5):M326-M32. 
244 
 
356. Bologa RM, Levine DM, Parker TS, Cheigh JS, Serur D, Stenzel KH, et al. Interleukin-6 predicts 
hypoalbuminemia, hypocholesterolemia, and mortality in hemodialysis patients. American journal of 
kidney diseases. 1998;32(1):107-14. 
357. Buchwald D, Wener M, Pearlman T, Kith P. Markers of inflammation and immune activation in 
chronic fatigue and chronic fatigue syndrome. The Journal of Rheumatology. 1997;24(2):372-6. 
358. Balakrishnan VS, Guo D, Rao M, Jaber BL, Tighiouart H, Freeman RL, et al. Cytokine gene 
polymorphisms in hemodialysis patients: association with comorbidity, functionality, and serum albumin. 
Kidney international. 2004;65(4):1449-60. 
359. Kamimura MA, Draibe SA, Dalboni MA, Cendoroglo M, Avesani CM, Manfredi SR, et al. Serum and 
cellular interleukin-6 in haemodialysis patients: relationship with energy expenditure. Nephrology Dialysis 
Transplantation. 2007;22(3):839-44. 
360. Kimmel PL, Phillips TM, Simmens SJ, Peterson RA, Weihs KL, Alleyne S, et al. Immunologic function 
and survival in hemodialysis patients. Kidney international. 1998;54(1):236-44. 
361. Fitts R. Cellular mechanisms of muscle fatigue. Physiological reviews. 1994;74(1):49-94. 
362. Johansen KL, Doyle J, Sakkas GK, Kent-Braun JA. Neural and metabolic mechanisms of excessive 
muscle fatigue in maintenance hemodialysis patients. American Journal of Physiology-Regulatory, 
Integrative and Comparative Physiology. 2005;289(3):R805-R13. 
363. Storer TW, Casaburi R, Sawelson S, Kopple JD. Endurance exercise training during haemodialysis 
improves strength, power, fatigability and physical performance in maintenance haemodialysis patients. 
Nephrology Dialysis Transplantation. 2005;20(7):1429-37. 
364. Deligiannis A. Exercise rehabilitation and skeletal muscle benefits in hemodialysis patients. Clinical 
nephrology. 2004;61:S46-50. 
365. Vgontzas AN, Bixler EO, Chrousos GP. Obesity‐related sleepiness and fatigue. Annals of the New 
York Academy of Sciences. 2006;1083(1):329-44. 
366. Kasapis C, Thompson PD. The effects of physical activity on serum C-reactive protein and 
inflammatory markers: a systematic review. Journal of the American College of Cardiology. 
2005;45(10):1563-9. 
367. Nicklas BJ, Mychaleckyj J, Kritchevsky S, Palla S, Lange LA, Lange EM, et al. Physical function and its 
response to exercise: associations with cytokine gene variation in older adults with knee osteoarthritis. 
The Journals of Gerontology Series A: Biological Sciences and Medical Sciences. 2005;60(10):1292-8. 
368. Wilund K. Is the anti-inflammatory effect of regular exercise responsible for reduced 
cardiovascular disease? Clinical Science. 2007;112:543-55. 
369. Hung AM, Chertow GM, Young BS, Carey S, Johansen KL. Inflammatory markers are unrelated to 
physical activity, performance, and functioning in hemodialysis. Advances in renal replacement therapy. 
2003;10(3):232-40. 
370. Rajan VR, Mitch WE. Muscle wasting in chronic kidney disease: the role of the ubiquitin 
proteasome system and its clinical impact. Pediatric Nephrology. 2008;23(4):527-35. 
371. Merlino G, Piani A, Dolso P, Adorati M, Cancelli I, Valente M, et al. Sleep disorders in patients with 
end-stage renal disease undergoing dialysis therapy. Nephrology Dialysis Transplantation. 2006;21(1):184-
90. 
372. Unruh M, Levey A, D’Ambrosio C, Fink N, Powe N, Meyer K. Choices for Healthy Outcomes in 
caring for End-Stage Renal Disease (CHOICE) study: restless legs symptoms among incident dialysis 
patients: association with lower quality of life and shorter survival. Am J Kidney Dis. 2004;43(5):900-9. 
245 
 
373. Yngman‐Uhlin P, Edéll‐Gustafsson U. Self‐reported subjective sleep quality and fatigue in patients 
with peritoneal dialysis treatment at home. International journal of nursing practice. 2006;12(3):143-52. 
374. Yang J-Y, Huang J-W, Chiang C-K, Pan C-C, Wu K-D, Tsai T-J, et al. Higher plasma interleukin-18 
levels associated with poor quality of sleep in peritoneal dialysis patients. Nephrology Dialysis 
Transplantation. 2007;22(12):3606-9. 
375. Krueger JM, Fang J, Taishi P, Chen Z, Kushikata T, Gardi J. Sleep: A Physiologic Role for IL‐1β and 
TNF‐αa. Annals of the New York Academy of Sciences. 1998;856(1):148-59. 
376. Mills PJ, Dimsdale JE. Sleep apnea: a model for studying cytokines, sleep, and sleep disruption. 
Brain, behavior, and immunity. 2004;18(4):298-303. 
377. Vgontzas AN, Zoumakis M, Bixler EO, Lin H-M, Prolo P, Vela-Bueno A, et al. Impaired nighttime 
sleep in healthy old versus young adults is associated with elevated plasma interleukin-6 and cortisol 
levels: physiologic and therapeutic implications. The Journal of Clinical Endocrinology & Metabolism. 
2003;88(5):2087-95. 
378. Gul A, Aoun N, Trayner EM, editors. UNRESOLVED ISSUES IN DIALYSIS: Why Do Patients Sleep on 
Dialysis? Seminars in dialysis; 2006: Wiley Online Library. 
379. Entzian P, Linnemann K, Schlaak M, Zabel P. Obstructive sleep apnea syndrome and circadian 
rhythms of hormones and cytokines. American journal of respiratory and critical care medicine. 
1996;153(3):1080-6. 
380. Vgontzas AN, Papanicolaou DA, Bixler EO, Kales A, Tyson K, Chrousos GP. Elevation of plasma 
cytokines in disorders of excessive daytime sleepiness: role of sleep disturbance and obesity. The Journal 
of Clinical Endocrinology & Metabolism. 1997;82(5):1313-6. 
381. Murtagh FE, Addington-Hall J, Higginson IJ. The prevalence of symptoms in end-stage renal 
disease: a systematic review. Advances in chronic kidney disease. 2007;14(1):82-99. 
382. Weisbord SD, Fried LF, Arnold RM, Fine MJ, Levenson DJ, Peterson RA, et al. Prevalence, severity, 
and importance of physical and emotional symptoms in chronic hemodialysis patients. Journal of the 
American Society of Nephrology. 2005;16(8):2487-94. 
383. Stahl SM, Zhang L, Damatarca C, Grady M. Brain circuits determine destiny in depression: a novel 
approach to the psychopharmacology of wakefulness, fatigue, and executive dysfunction in major 
depressive disorder. The Journal of clinical psychiatry. 2002;64:6-17. 
384. Matza LS, Revicki DA, Davidson JR, Stewart JW. Depression with atypical features in the National 
Comorbidity Survey: classification, description, and consequences. Archives of general psychiatry. 
2003;60(8):817-26. 
385. Angst J, Gamma A, Sellaro R, Zhang H, Merikangas K. Toward validation of atypical depression in 
the community: results of the Zurich cohort study. Journal of affective disorders. 2002;72(2):125-38. 
386. Posternak MA, Zimmerman M. Partial validation of the atypical features subtype of major 
depressive disorder. Archives of General Psychiatry. 2002;59(1):70-6. 
387. Gold PW, Gabry KE, Yasuda MR, Chrousos GP. Divergent endocrine abnormalities in melancholic 
and atypical depression: clinical and pathophysiologic implications. Endocrinology and metabolism clinics 
of North America. 2002;31(1):37-62. 
388. Khan AA, Gardner CO, Prescott CA, Kendler KS. Gender differences in the symptoms of major 
depression in opposite-sex dizygotic twin pairs. American Journal of Psychiatry. 2002. 
246 
 
389. Tylee A, Gastpar M, Lépine J-P, Mendlewicz J. DEPRES II (Depression Research in European Society 
II): a patient survey of the symptoms, disability and current management of depression in the community. 
International clinical psychopharmacology. 1999;14(3):139-51. 
390. Swindle R, Kroenke K, Braun L. Energy and improved workplace productivity in depression. 
Research in Human Capital and Development. 2001:323-42. 
391. Fava GA, Grandi S, Canestrari R, Molnar G. Prodromal symptoms in primary major depressive 
disorder. Journal of affective disorders. 1990;19(2):149-52. 
392. Moos RH, Cronkite RC. Symptom-based predictors of a 10-year chronic course of treated 
depression. The Journal of nervous and mental disease. 1999;187(6):360-8. 
393. Hotopf M, Mayou R, Wadsworth M, Wessely S. Temporal relationships between physical 
symptoms and psychiatric disorder. Results from a national birth cohort. The British journal of psychiatry. 
1998;173(3):255-61. 
394. Hamilton M. A rating scale for depression. Journal of neurology, neurosurgery, and psychiatry. 
1960;23(1):56. 
395. Koenig HG, Cohen HJ, Blazer DG, Krishnan K, Sibert TE. Profile of depressive symptoms in younger 
and older medical inpatients with major depression. Journal of the American Geriatrics Society. 
1993;41(11):1169-76. 
396. Tsay S-L, Healstead M. Self-care self-efficacy, depression, and quality of life among patients 
receiving hemodialysis in Taiwan. International Journal of Nursing Studies. 2002;39(3):245-51. 
397. Tsay S-L. Acupressure and fatigue in patients with end-stage renal disease–a randomized 
controlled trial. International journal of nursing studies. 2004;41(1):99-106. 
398. Suri RS, Nesrallah GE, Mainra R, Garg AX, Lindsay RM, Greene T, et al. Daily hemodialysis: a 
systematic review. Clinical Journal of the American Society of Nephrology. 2006;1(1):33-42. 
399. Suri R, Garg A, Chertow G, Levin N, Rocco M, Greene T, et al. Frequent Hemodialysis Network 
(FHN) randomized trials: study design. Kidney international. 2007;71(4):349-59. 
400. Yurtkuran M, Alp A, Dilek K. A modified yoga-based exercise program in hemodialysis patients: a 
randomized controlled study. Complementary therapies in medicine. 2007;15(3):164-71. 
401. Mathiowetz VG, Matuska KM, Finlayson ML, Luo P, Chen HY. One-year follow-up to a randomized 
controlled trial of an energy conservation course for persons with multiple sclerosis. International Journal 
of Rehabilitation Research. 2007;30(4):305-13. 
402. Astroth KS, Russell CL, Welch JL. Non-Pharmaceutical Fatigue Interventions in Adults Receiving 
Hemodialysis: A Systematic Review. Nephrology Nursing Journal. 2013;40(5):407. 
403. Bulechek GM, Butcher HK, Dochterman JM. Nursing interventions classification (NIC): Mosby; 
2008. 
404. Movilli E, Pertica N, Camerini C, Cancarini GC, Brunori G, Scolari F, et al. Predialysis versus 
postdialysis hematocrit evaluation during erythropoietin therapy. American journal of kidney diseases. 
2002;39(4):850-3. 
405. Moreno F, Sanz-Guajardo D, Lopez-Gomez JM, Jofre R, Valderrabano F. Increasing the hematocrit 
has a beneficial effect on quality of life and is safe in selected hemodialysis patients. Journal of the 
American Society of Nephrology. 2000;11(2):335-42. 
406. Mann J. What are the short-term and long-term consequences of anaemia in CRF patients? 
Nephrology Dialysis Transplantation. 1999;14(suppl 2):29-36. 
247 
 
407. Ross SD, Fahrbach K, Frame D, Scheye R, Connelly JE, Glaspy J. The effect of anemia treatment on 
selected health-related quality-of-life domains: a systematic review. Clinical therapeutics. 
2003;25(6):1786-805. 
408. Jones M, Ibels L, Schenkel B, Zagari M. Impact of epoetin alfa on clinical end points in patients with 
chronic renal failure: a meta-analysis. Kidney international. 2004;65(3):757-67. 
409. Drüeke TB, Locatelli F, Clyne N, Eckardt K-U, Macdougall IC, Tsakiris D, et al. Normalization of 
hemoglobin level in patients with chronic kidney disease and anemia. New England Journal of Medicine. 
2006;355(20):2071-84. 
410. Singh AK, Szczech L, Tang KL, Barnhart H, Sapp S, Wolfson M, et al. Correction of anemia with 
epoetin alfa in chronic kidney disease. New England Journal of Medicine. 2006;355(20):2085-98. 
411. Levin A. Understanding recent haemoglobin trials in CKD: methods and lesson learned from 
CREATE and CHOIR. Nephrology dialysis transplantation. 2007;22(2):309-12. 
412. Chandran V, Bhella S, Schentag C, Gladman DD. Functional assessment of chronic illness therapy-
fatigue scale is valid in patients with psoriatic arthritis. Annals of the rheumatic diseases. 2007;66(7):936-
9. 
413. Ossareh S, Roozbeh J, Krishnan M, Bargman JM, Oreopoulos DG. Fatigue in chronic peritoneal 
dialysis patients. International urology and nephrology. 2003;35(4):535-41. 
414. Shafi T, Jaar BG, Plantinga LC, Fink NE, Sadler JH, Parekh RS, et al. Association of residual urine 
output with mortality, quality of life, and inflammation in incident hemodialysis patients: the Choices for 
Healthy Outcomes in Caring for End-Stage Renal Disease (CHOICE) Study. American Journal of Kidney 
Diseases. 2010;56(2):348-58. 
415. Wu AW, Fink NE, Marsh-Manzi JV, Meyer KB, Finkelstein FO, Chapman MM, et al. Changes in 
quality of life during hemodialysis and peritoneal dialysis treatment: generic and disease specific 
measures. Journal of the American Society of Nephrology. 2004;15(3):743-53. 
416. Cueto-Manzano AM, González-Espinoza L, del Campo FM, Fortes PC, Pecoits-Filho R. Inflammation 
in peritoneal dialysis: a Latin-American perspective. Peritoneal dialysis international. 2007;27(3):347-52. 
417. Pecoits-Filho R, Stenvinkel P, Wang A, Heimburger O, Lindholm B. Chronic inflammation in 
peritoneal dialysis: the search for the holy grail? Peritoneal Dialysis International. 2004;24(4):327-39. 
418. Worthington J, Fava M, Davidson K, Alpert J, Nierenberg AA, Rosenbaum JF. Patterns of 
improvement in depressive symptoms with fluoxetine treatment. Psychopharmacology bulletin. 1995. 
419. Beasley CM, Koke SC, Nilsson ME, Gonzales JS. Adverse events and treatment discontinuations in 
clinical trials of fluoxetine in major depressive disorder: an updated meta-analysis. Clinical therapeutics. 
2000;22(11):1319-30. 
420. Marraccini RL, Reynolds CF, Houck PR, Miller MD, Frank E, Perel JM, et al. A double‐blind, placebo‐
controlled assessment of nortriptyline's side‐effects during 3‐year maintenance treatment in elderly 
patients with recurrent major depression. International journal of geriatric psychiatry. 1999;14(12):1014-
8. 
421. Stahl SM, Grady MM, Moret C, Briley M. SNRIs: the pharmacology, clinical efficacy, and tolerability 
in comparison with other classes of antidepressants. CNS spectrums. 2005;10(09):732-47. 
422. Stahl SM. Essential psychopharmacology of depression and bipolar disorder: Cambridge university 
press; 2000. 
423. Bymaster FP, Katner JS, Nelson DL, Hemrick-Luecke SK, Threlkeld PG, Heiligenstein JH, et al. 
Atomoxetine increases extracellular levels of norepinephrine and dopamine in prefrontal cortex of rat: a 
248 
 
potential mechanism for efficacy in attention deficit/hyperactivity disorder. Neuropsychopharmacology. 
2002;27(5):699-711. 
424. de Saint Hilaire Z, Orosco M, Rouch C, Blanc G, Nicolaidis S. Variations in extracellular monoamines 
in the prefrontal cortex and medial hypothalamus after modafinil administration: a microdialysis study in 
rats. Neuroreport. 2001;12(16):3533-7. 
425. Bodkin JA, Lasser RA, Wines Jr JD, Gardner DM, Baldessarini RJ. Combining serotonin reuptake 
inhibitors and bupropion in partial responders to antidepressant monotherapy. The Journal of clinical 
psychiatry. 1997;58(4):137-45. 
426. Stahl SM, Zhang L, Damatarca C, Grady M. Brain circuits determine destiny in depression: a novel 
approach to the psychopharmacology of wakefulness, fatigue, and executive dysfunction in major 
depressive disorder. Journal of Clinical Psychiatry. 2003;64:6-17. 
427. Judge R, Plewes JM, Kumar V, Koke SC, Kopp JB. Changes in energy during treatment of 
depression: an analysis of fluoxetine in double-blind, placebo-controlled trials. Journal of clinical 
psychopharmacology. 2000;20(6):666-72. 
428. Stahl SM, Pradko JF, Haight BR, Modell JG, Rockett CB, Learned-Coughlin S. A review of the 
neuropharmacology of bupropion, a dual norepinephrine and dopamine reuptake inhibitor. Primary care 
companion to the Journal of clinical psychiatry. 2004;6(4):159. 
429. Fava M. Diagnosis and definition of treatment-resistant depression. Biological psychiatry. 
2003;53(8):649-59. 
430. Menza M, Marin H, Opper RS. Residual symptoms in depression: can treatment be symptom-
specific? Journal of Clinical Psychiatry. 2003;64(5):516-23. 
431. DeBattista C, Doghramji K, Menza MA, Rosenthal MH, Fieve RR. Adjunct modafinil for the short-
term treatment of fatigue and sleepiness in patients with major depressive disorder: a preliminary double-
blind, placebo-controlled study. The Journal of clinical psychiatry. 2003;64(9):1057-64. 
432. Pae C-U, Lim H-K, Han C, Patkar AA, Steffens DC, Masand PS, et al. Fatigue as a core symptom in 
major depressive disorder: overview and the role of bupropion. 2007. 
433. Baldwin DS, Papakostas GI. Symptoms of fatigue and sleepiness in major depressive disorder. The 
Journal of clinical psychiatry. 2005;67:9-15. 
434. Fava M, Thase ME, DeBattista C, Doghramji K, Arora S, Hughes RJ. Modafinil augmentation of 
selective serotonin reuptake inhibitor therapy in MDD partial responders with persistent fatigue and 
sleepiness. Annals of Clinical Psychiatry. 2007;19(3):153-9. 
435. Fava M, Thase ME, DeBattista C. A multicenter, placebo-controlled study of modafinil 
augmentation in partial responders to selective serotonin reuptake inhibitors with persistent fatigue and 
sleepiness. Journal of Clinical Psychiatry. 2005. 
436. Doghramji K, Menza M, Rosenthal M, Fieve R, editors. Adjunct modafinil for fatigue and 
wakefulness in MDD. 155th annual meeting of the American Psychiatric Association; 2002. 
437. Cipriani A, Furukawa TA, Salanti G, Geddes JR, Higgins JP, Churchill R, et al. Comparative efficacy 
and acceptability of 12 new-generation antidepressants: a multiple-treatments meta-analysis. The Lancet. 
2009;373(9665):746-58. 
438. Cipriani A, La Ferla T, Furukawa TA, Signoretti A, Nakagawa A, Churchill R, et al. Sertraline versus 
other antidepressive agents for depression. The Cochrane Library. 2010. 
439. O'Connor CM, Jiang W, Kuchibhatla M, Silva SG, Cuffe MS, Callwood DD, et al. Safety and efficacy 
of sertraline for depression in patients with heart failure: results of the SADHART-CHF (Sertraline Against 
249 
 
Depression and Heart Disease in Chronic Heart Failure) trial. Journal of the American College of 
Cardiology. 2010;56(9):692-9. 
440. Folstein MF, Folstein SE, McHugh PR. “Mini-mental state”: a practical method for grading the 
cognitive state of patients for the clinician. Journal of psychiatric research. 1975;12(3):189-98. 
441. Dube P, Kurt K, Bair MJ, Theobald D, Williams LS. The p4 screener: evaluation of a brief measure 
for assessing potential suicide risk in 2 randomized effectiveness trials of primary care and oncology 
patients. Prim Care Companion J Clin Psychiatry. 2010;12(6):12. 
442. Cocks K, Torgerson DJ. Sample size calculations for pilot randomized trials: a confidence interval 
approach. Journal of clinical epidemiology. 2013;66(2):197-201. 
443. Blazer DG, Kessler RC, McGonagle KA. The prevalence and distribution of major depression in a 
national community sample: the National Comorbidity Survey. Age (years). 1994;15(24):24-7. 
444. Chilcot J, Wellsted D, Farrington K, editors. Depression in end‐stage renal disease: current 
advances and research. Seminars in dialysis; 2010: Wiley Online Library. 
445. Kalender B, Corapcioglu Ozdemir A, Koroglu G. Association of depression with markers of nutrition 
and inflammation in chronic kidney disease and end-stage renal disease. Nephron Clinical Practice. 
2005;102(3-4):c115-c21. 
446. Koo J-R, Yoon J-W, Kim S-G, Lee Y-K, Oh K-H, Kim G-H, et al. Association of depression with 
malnutrition in chronic hemodialysis patients. American journal of kidney diseases. 2003;41(5):1037-42. 
447. Iacovides A, Fountoulakis KN, Balaskas E, Manika A, Markopoulou M, Kaprinis G, et al. Relationship 
of age and psychosocial factors with biological ratings in patients with end-stage renal disease undergoing 
dialysis. Aging clinical and experimental research. 2002;14(5):354-60. 
448. Friend R, Hatchett L, Wadhwa NK, Suh H. Serum albumin and depression in end-stage renal 
disease. Advances in peritoneal dialysis. 1997;13:155-7. 
449. Kimmel PL, Peterson RA, Weihs KL, Simmens SJ, Boyle DH, Umana WO, et al. Psychologic 
functioning, quality of life, and behavioral compliance in patients beginning hemodialysis. Journal of the 
American Society of Nephrology. 1996;7(10):2152-9. 
450. Chilcot J, Norton S, Wellsted D, Davenport A, Firth J, Farrington K. Distinct depression symptom 
trajectories over the first year of dialysis: associations with illness perceptions. Annals of Behavioral 
Medicine. 2013;45(1):78-88. 
451. Akman B, Özdemir F, Sezer S, Miçozkadioǧlu H, Haberal M, editors. Depression levels before and 
after renal transplantation. Transplantation proceedings; 2004: Elsevier. 
452. Chilcot J, Spencer BWJ, Maple H, Mamode N. Depression and kidney transplantation. 
Transplantation. 2014;97(7):717-21. 
453. Teran-Escandon D, Ruiz-Ornelas J, Estrada-Castillo J, Barajas-Juárez L, Díaz-Martínez A. [Anxiety 
and depression among renal transplantation candidates: impact of donor availability]. Actas españolas de 
psiquiatría. 2000;29(2):91-4. 
454. Gee CB, Howe GW, Kimmel PL, editors. PSYCHOSOCIAL FACTORS IN PATIENTS WITH CHRONIC 
KIDNEY DISEASE: Couples Coping in Response to Kidney Disease: A Developmental Perspective. Seminars 
in dialysis; 2005: Wiley Online Library. 
455. Chilcot J, Wellsted D, Vilar E, Farrington K. An association between residual renal function and 
depression symptoms in haemodialysis patients. Nephron Clinical Practice. 2009;113(2):c117-c24. 
456. Borg W, Gall M. Educational research 3rd edition. New York: Longman Inc; 1979. 
250 
 
457. Depression : treatment and management of depression in adults, including adults with a chronic 
physical health problem. London: National Institute for Health and Clinical Excellence; 2009. 
458. Palmer SC, Natale P, Ruospo M, Saglimbene VM, Rabindranath KS, Craig JC, et al. Antidepressants 
for treating depression in adults with end‐stage kidney disease treated with dialysis. The Cochrane Library. 
2016. 
459. Lundh Hagelin C, Wengström Y, Runesdotter S, Johan Fürst C. The psychometric properties of the 
Swedish Multidimensional Fatigue Inventory MFI-20 in four different populations. Acta Oncologica. 
2007;46(1):97-104. 
460. Bossola M, Di Stasio E, Antocicco M, Tazza L. Qualities of fatigue in patients on chronic 
hemodialysis. Hemodialysis International. 2013;17(1):32-40. 
461. Farrokhi F, Abedi N, Beyene J, Kurdyak P, Jassal SV. Association between depression and mortality 
in patients receiving long-term dialysis: a systematic review and meta-analysis. American journal of kidney 
diseases. 2014;63(4):623-35. 
462. Thompson K, Kulkarni J, Sergejew AA. Reliability and validity of a new Medication Adherence 
Rating Scale (MARS) for the psychoses. Schizophrenia Research. 2000;42(3):241-7. 
463. Horne R, Weinman J. Patients' beliefs about prescribed medicines and their role in adherence to 
treatment in chronic physical illness. Journal of Psychosomatic Research. 1999;47(6):555-67. 
464. Morisky DE, Green LW, Levine DM. Concurrent and predictive validity of a self-reported measure 
of medication adherence. Medical care. 1986;24(1):67-74. 
465. Thompson K, Kulkarni J, Sergejew A. Reliability and validity of a new Medication Adherence Rating 
Scale (MARS) for the psychoses. Schizophrenia research. 2000;42(3):241-7. 
466. Horne R, Weinman J, Hankins M. The beliefs about medicines questionnaire: the development and 
evaluation of a new method for assessing the cognitive representation of medication. Psychology and 
health. 1999;14(1):1-24. 
467. Oppenheim AN. Questionnaire design. Interviewing and Attitude measurement. 1992;2. 
468. Hirschfeld RM, Keller MB, Panico S, Arons BS, Barlow D, Davidoff F, et al. The National Depressive 
and Manic-Depressive Association consensus statement on the undertreatment of depression. Jama. 
1997;277(4):333-40. 
469. Zung WW, Magill M, Moore JT, George DT. Recognition and treatment of depression in a family 
medicine practice. Journal of Clinical Psychiatry. 1983. 
470. Wang PL, Watnick S, editors. Depression. Seminars in dialysis; 2004. 
471. Markowitz SM, Gonzalez JS, Wilkinson JL, Safren SA. A review of treating depression in diabetes: 
emerging findings. Psychosomatics. 2011;52(1):1-18. 
472. Üçeyler N, Häuser W, Sommer C. A systematic review on the effectiveness of treatment with 
antidepressants in fibromyalgia syndrome. Arthritis care & research. 2008;59(9):1279-98. 
 
 
 
  
251 
 
List of Appendices  
Appendix 1 – Ethical Approval 
 
 
 
NRES Committee London - Bentham 
Research Ethics Committee 
Offices Health 
Research Authority 
NRES Committee London 
Bentham Ground Floor, 
Skipton House 
80 London Road 
London SE1 6LH 
 
 
Telephone: 020 797 22551 
Facsimile: 020 797 22592 
 
 
01 November 2012  
Professor Ken Farrington 
East and North Hertfordshire NHS Trust  
Coreys Mill Lane 
Stevenage  
SG1 4AB 
 
Dear Professor Farrington 
 
 
Study title: A Pilot Randomised Controlled Trial of Drug Treatment 
for Depression in Patients undergoing Haemodialysis 
REC reference: 12/LO/1554 
Protocol number: CTIMPMCRENAL12 
EudraCT number: 2012-000547-27 
 
 
Thank you for your letter of 03 October 2012, responding to the Committee’s request for 
further information on the above research and submitting revised documentation. 
 
252 
 
The further information was considered in correspondence by a sub-committee of the REC. 
 
Confirmation of ethical opinion 
 
On behalf of the Committee, I am pleased to confirm a favourable ethical opinion for the above 
research on the basis described in the application form, protocol and supporting documentation 
as revised, subject to the conditions specified below. 
 
 
Ethical review of research sites 
 
NHS sites 
 
The favourable opinion applies to all NHS sites listed in the application, subject to 
management permission being obtained from the NHS/HSC R&D office prior to the start of 
the study (see "Conditions of the favourable opinion" below). 
 
Conditions of the favourable opinion 
 
The favourable opinion is subject to the following conditions being met prior to the start of 
the study. 
 
Management permission or approval must be obtained from each host organisation prior to the 
start of the study at the site concerned. 
Management permission ("R&D approval") should be sought from all NHS organisations 
involved in the study in accordance with NHS research governance arrangements. 
 
Guidance on applying for NHS permission for research is available in the Integrated 
Research Application System or at http://www.rdforum.nhs.uk. 
 
Where a NHS organisation’s role in the study is limited to identifying and referring potential 
participants to research sites ("participant identification centre"), guidance should be sought from 
the R&D office on the information it requires to give permission for this activity. 
 
For non-NHS sites, site management permission should be obtained in accordance with the 
procedures of the relevant host organisation. 
 
Sponsors are not required to notify the Committee of approvals from host organisations 
 
Clinical trial authorisation must be obtained from the Medicines and Healthcare products  
Regulatory Agency (MHRA). 
 
The sponsor is asked to provide the Committee with a copy of the notice from the MHRA, either 
confirming clinical trial authorisation or giving grounds for non-acceptance, as soon as this is 
available. 
 
It is the responsibility of the sponsor to ensure that all the conditions are complied with 
before the start of the study or its initiation at a particular site (as applicable). 
 
Approved documents 
253 
 
 
The final list of documents reviewed and approved by the Committee is as follows: 
 
 
Document Version Date 
Covering Letter  02 September 2012 
Investigator CV Dr Ayman 
Guirguis 
 
Investigator CV Naomi 
Fineberg 
 
Other: NRES Unfavourable opinion letter  04 July 2012 
Other: Response to unfavourable opinion letter  16 July 2012 
Other: Committee response to letter dated 16th July 2012  01 August 2012 
Other: Letter to researchers after meeting with Professor Katz and 
Professor Farrington 
 29 August 2012 
Other: Renal Association Guidelines   
Other: Summary of product characteristics- Sertralin 1A Pharma 50mg 
and 100mg coated tablets 
  
Other: RfPB Programme- Reviewer reference 1   
Other: RfPB Programme- Reviewer reference 2   
Other: RfPB Programme- Reviewer reference 3   
Other: RfPB Programme- Reviewer reference 4   
Other: RfPB Programme- Reviewer reference 5   
Protocol 3.0 03 October 2012 
REC application  03 September 2012 
Response to Request for Further Information  03 October 2012 
 
Statement of compliance 
 
This Committee is recognised by the United Kingdom Ethics Committee Authority under the 
Medicines for Human Use (Clinical Trials) Regulations 2004, and is authorised to carry out the 
ethical review of clinical trials of investigational medicinal products. 
 
The Committee is fully compliant with the Regulations as they relate to ethics committees and the 
conditions and principles of good clinical practice. 
 
The Committee is constituted in accordance with the Governance Arrangements for Research Ethics 
Committees and complies fully with the Standard Operating Procedures for Research Ethics 
Committees in the UK. 
 
After ethical review 
 
Reporting requirements 
 
The attached document “After ethical review – guidance for researchers” gives detailed 
guidance on reporting requirements for studies with a favourable opinion, including: 
 
Notifying substantial amendments 
254 
 
Adding new sites and investigators 
Notification of serious breaches of the protocol 
Progress and safety reports 
Notifying the end of the study 
 
The NRES website also provides guidance on these topics, which is updated in the light of changes 
in reporting requirements or procedures. 
 
Feedback 
 
You are invited to give your view of the service that you have received from the National 
Research Ethics Service and the application procedure. If you wish to make your views known 
please use the feedback form available on the website. 
 
Further information is available at National Research Ethics Service website > After Review 
 
12/LO/1554 Please quote this number on all correspondence 
 
With the Committee’s best wishes for the success of this project 
Yours sincerely 
 
 
Professor David Katz 
Chair 
 
Email: NRESCommittee.London-Bentham@nhs.net 
 
Enclosures: “After ethical review – guidance for researchers” 
 
Copy to: Dr   Karin Friedli, University of Hertfordshire 
 
Mrs Fiona Smith, East and North Hertfordshire NHS Trust 
255 
 
 
 
256 
 
 
 
 
 
NRES Committee London – Harrow 
Bristol REC Centre Level 3, Block B 
Whitefriars 
Lewins Mead 
Bristol BS1 2NT 
Tel: 01173 421383 
Fax: 01173 420455 
 
24 January 2013 
 
Professor Ken Farrington 
East and North Hertfordshire NHS Trust  
Coreys Mill Lane 
Stevenage SG1 4AB 
 
Dear Professor Farrington 
 
Study title: A Pilot Randomised Controlled Trial of Drug Treatment 
for Depression in Patients undergoing Haemodialysis 
REC reference: 12/LO/1554 
Protocol number: CTIMPMCRENAL12 
EudraCT number: 2012-000547-27 
Amendment number: Substantial Amendment 1 
Amendment date: 21 January 2013 
IRAS project ID: 100774 
 
The above amendment was reviewed by the Sub-Committee in correspondence. 
 
Ethical opinion 
 
The members of the Committee taking part in the review gave a favourable ethical 
opinion of the amendment on the basis described in the notice of amendment form and 
supporting documentation. 
 
Approved documents 
 
The documents reviewed and approved at the meeting were: 
Document Version Date 
Revised Label 2 21 January 2013 
Protocol 4 18 January 2013 
European Commission Notification of Substantial Amendment Form Substantial 
Amendment 
1 
21 January 2013 
Covering Letter  21 January 2013 
 
257 
 
Membership of the Committee 
The members of the Committee who took part in the review are listed on the attached sheet. 
R&D approval 
 
All investigators and research collaborators in the NHS should notify the R&D office for the relevant 
NHS care organisation of this amendment and check whether it affects R&D approval of the research. 
 
Statement of compliance 
 
This Committee is recognised by the United Kingdom Ethics Committee Authority under the Medicines 
for Human Use (Clinical Trials) Regulations 2004, and is authorised to carry out the ethical review of 
clinical trials of investigational medicinal products. 
 
The Committee is fully compliant with the Regulations as they relate to ethics committees and the 
conditions and principles of good clinical practice. 
 
The Committee is constituted in accordance with the Governance Arrangements for Research Ethics 
Committees and complies fully with the Standard Operating Procedures for Research Ethics Committees 
in the UK. 
 
We are pleased to welcome researchers and R & D staff at our NRES committee members’ training days 
– see details at http://www.hra.nhs.uk/hra-training/ 
 
 
Yours sincerely 
 
 
Miss Stephanie Ellis 
Chair 
 
E-mail: nrescommittee.london-harrow@nhs.net 
 
 
Enclosures: List of names and professions of members who took part in the 
Review 
 
Copy to: Mrs Fiona Smith, East and North Hertfordshire NHS Trust 
Dr Karin Friedli 
12/LO/1554: Please quote this number on all correspondence 
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NRES Committee London - Bentham 
 
Attendance at Sub-Committee of the REC meeting on 25 January 2013 
 
 
Name Profession Capacity 
Miss Stephanie Ellis Former Civil Servant Lay 
Dr John Keen General Practitioner Expert 
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NRES Committee London – Harrow 
Bristol REC Centre Level 3, Block B 
Whitefriars 
Lewins Mead 
Bristol BS1 2NT 
Tel: 01173 421383 
Fax: 01173 420455 
18 July 2013 
 
Professor Ken Farrington 
East and North Hertfordshire NHS Trust  
Coreys Mill Lane 
Stevenage  
SG1 4AB 
Dear Professor Farrington 
 
Study title: A Pilot Randomised Controlled Trial of Drug Treatment 
for Depression in Patients undergoing Haemodialysis 
REC reference: 12/LO/1554 
Protocol number: CTIMPMCRENAL12 
EudraCT number: 2012-000547-27 
Amendment number: Substantial Amendment 2 
Amendment date: 16
th  
July 2013 
IRAS project ID: 100774 
 
The above amendment was reviewed by the Sub-Committee in correspondence. 
 
Ethical opinion 
 
The members of the Committee taking part in the review gave a favourable ethical opinion of the 
amendment on the basis described in the notice of amendment form and supporting documentation. 
 
Approved documents 
 
The documents reviewed and approved at the meeting were: 
 
 
 
 
 
260 
 
Document Version Date 
Revised Label 5 11 April 2013 
Substantial Amendment Form Signature  16 July 2013 
Protocol 5.0 05 July 2013 
European Commission Notification of Substantial Amendment Form Substantial 
Amendment 
2 
 
Covering Letter  16 July 2013 
Questionnaire: SF-36 Scoring   
Questionnaire: SF-36 Questionnaire   
Questionnaire: MFI- English   
 
 
Membership of the Committee 
 
The members of the Committee who took part in the review are listed on the attached sheet. 
 
R&D approval 
 
All investigators and research collaborators in the NHS should notify the R&D office for the relevant NHS care 
organisation of this amendment and check whether it affects R&D approval of the research. 
 
Statement of compliance 
 
This Committee is recognised by the United Kingdom Ethics Committee Authority under the Medicines for Human 
Use (Clinical Trials) Regulations 2004, and is authorised to carry out the ethical review of clinical trials of 
investigational medicinal products. 
 
The Committee is fully compliant with the Regulations as they relate to ethics committees and the conditions and 
principles of good clinical practice. 
 
The Committee is constituted in accordance with the Governance Arrangements for Research Ethics Committees and 
complies fully with the Standard Operating Procedures for Research Ethics Committees in the UK. 
 
We are pleased to welcome researchers and R & D staff at our NRES committee members’ training days – see details 
at http://www.hra.nhs.uk/hra-training/ 
 
 
 
Yours sincerely 
 
 
Dr John Keen 
Chair 
 
12/LO/1554: Please quote this number on all correspondence 
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E-mail: nrescommittee.london-harrow@nhs.net 
 
 
Enclosures: List of names and professions of members who took part in the 
Review 
 
Copy to: Mrs Fiona Smith, East and North Hertfordshire NHS Trust 
Dr Karin Friedli 
 
 
 
 
NRES Committee London - Harrow 
 
Attendance at Sub-Committee of the REC meeting in correspondence 
  
Name Profession Capacity 
Miss Stephanie Ellis Former Civil Servant Lay Plus 
Dr John Keen GP Expert 
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NRES Committee London – Harrow 
Bristol REC Centre Level 3, Block B 
Whitefriars 
Lewins Mead 
Bristol BS1 2NT 
Tel: 01173 421383 
Fax: 01173 420455 
22 August 2013 
Professor Ken Farrington 
East and North Hertfordshire NHS Trust  
Coreys Mill Lane 
Stevenage  
SG1 4AB 
 
Dear Professor Farrington 
 
Study title: A Pilot Randomised Controlled Trial of Drug Treatment 
for Depression in Patients undergoing Haemodialysis 
REC reference: 12/LO/1554 
Protocol number: CTIMPMCRENAL12 
EudraCT number: 2012-000547-27 
Amendment number: Minor Amendment 1 
Amendment date: 20 August 2013 
IRAS  project ID: 100774 
 
Thank you for your letter of 20 August 2013, notifying the Committee of the above amendment. 
 
It is noted that you do not consider this to be a substantial amendment to the clinical trial authorisation, as 
defined in the Medicines for Human Use (Clinical Trials) Regulations 2004, and that ethical review by the 
Committee is therefore not required. 
 
Documents received 
 
The documents received were as follows: 
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Document Version Date 
Participant Consent Form: Consent Form 3 - Patient Experience Interview 
Phase 
5 05 July 2013 
Participant Information Sheet: PIS 1 - Screening and Prevalence Phase 5 05 July 2013 
GP/Consultant Information Sheets 5 05 July 2013 
Participant Information Sheet: PIS 2 - Psychiatric Assessment and Clinical Trial 
Phase 
5 05 July 2013 
Participant Consent Form: Consent Form 2b - Trial Outcome Phase 5 05 July 2013 
Notification of a Minor Amendment  20 August 2013 
Serious Adverse Event Reporting Form 5 05 July 2013 
Participant Consent Form: Consent Form 1 - Screening and Prevalence Phase 5 05 July 2013 
Participant Information Sheet: Short PIS 1 5 05 July 2013 
Interview Schedules/Topic Guides 5 05 July 2013 
Participant Information Sheet: PIS 3 - Patient Experience Interview Phase 5 05 July 2013 
Participant Consent Form: Consent Form 2a - Consent to Assessment with 
psychiatrists 
 
 
with Psychiatrist 
5 05 July 2013 
Participant Information Sheet: Short PIS 2 5 05 July 2013 
 
Statement of compliance 
 
This Committee is recognised by the United Kingdom Ethics Committee Authority under 
the Medicines for Human Use (Clinical Trials) Regulations 2004, and is authorised to 
carry out the ethical review of clinical trials of investigational medicinal products. 
 
The Committee is fully compliant with the Regulations as they relate to ethics 
committees and the conditions and principles of good clinical practice . 
The Committee is constituted in accordance with the Governance Arrangements for 
Research Ethics Committees and complies fully with the Standard Operating Procedures 
for Research Ethics Committees in the UK. 
 
Yours sincerely 
 
Libby Watson 
Committee Co-ordinator 
 
E-mail: nrescommittee.london-harrow@nhs.net 
 
Copy to: Mrs Fiona Smith, East and North Hertfordshire NHS Trust 
Dr Karin Friedli 
 
 
12/LO/1554: Please quote this number on all correspondence 
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NRES Committee London – Harrow 
Bristol REC Centre Level 3, Block B 
Whitefriars 
Lewins Mead 
Bristol BS1 2NT 
Tel: 01173 421383 
Fax: 01173 420455 
 
20 January 2014 
Professor Ken Farrington 
East and North Hertfordshire NHS Trust  
Coreys Mill Lane 
Stevenage  
SG1 4AB 
 
Dear Professor Farrington 
 
Study title: A Pilot Randomised Controlled Trial of Drug Treatment 
for Depression in Patients undergoing Haemodialysis 
REC reference: 12/LO/1554 
Protocol number: CTIMPMCRENAL12 
EudraCT number: 2012-000547-27 
Amendment number: Updates to Protocol including text and methodology. 
Amendment date: 09 January 2014 
IRAS project ID: 100774 
 
The above amendment was reviewed by the Sub-Committee in correspondence. 
 
Ethical opinion 
 
The Committee Members approved the changes to update the Protocol including 
text and methodology. 
 
The members of the Committee taking part in the review gave a favourable ethical 
opinion of the amendment on the basis described in the notice of amendment form 
and supporting documentation. 
 
Approved document 
 
The documents reviewed and approved at the meeting were: 
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Document Version Date 
Covering Letter  09 January 2014 
Protocol 6.0 09 January 2014 
 
European Commission Notification of Substantial Amendment Form Updates to 
Protocol 
including text 
and 
methodology 
. 
09 January 2014 
 
Membership of the Committee 
 
The members of the Committee who took part in the review are listed on the 
attached sheet. 
 
R&D approval 
 
All investigators and research collaborators in the NHS should notify the R&D office 
for the relevant NHS care organisation of this amendment and check whether it affects 
R&D approval of the research. 
 
Statement of compliance 
 
This Committee is recognised by the United Kingdom Ethics Committee Authority 
under the Medicines for Human Use (Clinical Trials) Regulations 2004, and is 
authorised to carry out the ethical review of clinical trials of investigational medicinal 
products. 
 
The Committee is fully compliant with the Regulations as they relate to ethics 
committees and the conditions and principles of good clinical practice. 
 
The Committee is constituted in accordance with the Governance Arrangements for 
Research Ethics Committees and complies fully with the Standard Operating Procedures 
for Research Ethics Committees in the UK. 
 
We are pleased to welcome researchers and R & D staff at our NRES committee 
members’ training days – see details at http://www.hra.nhs.uk/hra-training/ 
 
Yours sincerely 
 
 
 
Pp Miss Shelly Glaister-Young 
Alternate Vice- Chair 
12/LO/1554: Please quote this number on all correspondence 
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E-mail: nrescommittee.London-Harrow@nhs.net 
 
 
Enclosures: List of names and professions of members who took part in the 
Review 
 
Copy to: Mrs Fiona Smith, East and North Hertfordshire NHS Trust 
Fiona.smith@whht.nhs.uk 
                       Dr Karin Friedli                                   
k.friedli@herts.ac.uk 
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                                                       NRES Committee London– Harrow 
Bristol REC Centre Level 3, Block B 
Whitefriars 
Lewins Mead 
Bristol BS1 2NT 
Tel: 01173 421383 
Fax: 01173 420455 
23 April 2014 
Dr Karin Friedli 
Clicir, University of Hertfordshire  
Health Research Building  
College Lane, Hatfield 
AL10 9AB 
 
Dear Dr Friedli 
 
Study title: A Pilot Randomised Controlled Trial of Drug Treatment 
for Depression in Patients undergoing Haemodialysis 
REC reference: 12/LO/1554 
Protocol number: CTIMPMCRENAL12 
EudraCT number: 2012-000547-27 
Amendment number: Minor Amendment 2 Version Control 
Amendment date: 19 March 2014 
IRAS project ID: 100774 
 
Thank you for your letter of 19 March 2014, notifying the Committee of the above 
amendment. 
It is noted that you do not consider this to be a substantial amendment to the clinical trial 
authorisation, as defined in the Medicines for Human Use (Clinical Trials) Regulations 2004, 
and that ethical review by the Committee is therefore not required. 
Documents received 
The documents received were as follows: 
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Document Version Date 
Assertid CRF SAE Form 6.1 (Clean & Tracked) 19 March 2014 
Protocol 6.0 09 January 2014 
Notification of a Minor Amendment Minor Amendment 2 Version Control 19 March 2014 
Participant Information Sheet: PIS 1 6 09 January 2014 
Participant Information Sheet: PIS 2 6 09 January 2014 
Participant Information Sheet: PIS 3 6 09 January 2014 
Protocol 6.1 19 March 2014 
 
Statement of compliance 
This Committee is recognised by the United Kingdom Ethics Committee Authority 
under the Medicines for Human Use (Clinical Trials) Regulations 2004, and is 
authorised to carry out the ethical review of clinical trials of investigational 
medicinal products. 
The Committee is fully compliant with the Regulations as they relate to ethics 
committees and the conditions and principles of good clinical practice. 
The Committee is constituted in accordance with the Governance Arrangements for 
Research Ethics Committees and complies fully with the Standard Operating 
Procedures for Research Ethics Committees in the UK. 
 
Yours sincerely 
Miss Natasha Bridgeman REC Assistant 
E-mail: nrescommittee.london-harrow@nhs.net 
Copy to: Mrs Fiona Smith, East and North Hertfordshire NHS Trust 
Ken Farrington, East and North Hertfordshire NHS Trust 
 
 
 
12/LO/1554: Please quote this number on all correspondence 
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NRES Committee London – Harrow 
Bristol REC Centre Level 3, Block B 
Whitefriars 
Lewins Mead 
Bristol BS1 2NT 
Tel: 01173 421383 
Fax: 01173 420455 
25 April 2014 
Dr Karin Friedli 
Clicir, University of Hertfordshire  
Health Research Building  
College Lane, Hatfield 
AL10 9AB 
 
Dear Dr Friedli 
 
Study title: A Pilot Randomised Controlled Trial of Drug Treatment 
for Depression in Patients undergoing Haemodialysis 
REC reference: 12/LO/1554 
Protocol number: CTIMPMCRENAL12 
EudraCT number: 2012-000547-27 
Amendment number: Minor Amendment 3 
Amendment date: 11 April 2014 
IRAS project ID: 100774 
 
Thank you for your letter of 11 April 2014, notifying the Committee of the above 
amendment. 
 
It is noted that you do not consider this to be a substantial amendment to the 
clinical trial authorisation, as defined in the Medicines for Human Use (Clinical 
Trials) Regulations 2004, and that ethical review by the Committee is therefore 
not required. 
 
Documents received 
 
The documents received were as follows: 
 
Document Version Date 
Protocol 6.2 (Clean&Tracked) 11 April 2014 
Notification of a Minor Amendment  11 April 2014 
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Statement of compliance 
 
This Committee is recognised by the United Kingdom Ethics Committee 
Authority under the Medicines for Human Use (Clinical Trials) Regulations 
2004, and is authorised to carry out the ethical review of clinical trials of 
investigational medicinal products. 
 
The Committee is fully compliant with the Regulations as they relate to 
ethics committees and the conditions and principles of good clinical practice. 
The Committee is constituted in accordance with the Governance Arrangements 
for Research Ethics Committees and complies fully with the Standard Operating 
Procedures for Research Ethics Committees in the UK. 
 
Yours sincerely 
Miss Natasha Bridgeman REC Assistant 
 
E-mail: nrescommittee.london-harrow@nhs.net 
Copy to: Mrs Fiona Smith, East and North Hertfordshire NHS Trust 
Ken Farrington, East and North Hertfordshire NHS Trust 
 
 
 
 
 
 
 
 
 
 
 
12/LO/1554: Please quote this number on all correspondence 
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NRES Committee East of England - Cambridge South 
The Old Chapel Royal Standard Place 
Nottingham NG1 6FS 
Telephone: 0115 883 9525 
 
04 June 2014 
 
Dr Ayman Guirguis  
University Of Hertfordshire 
Centre for Lifespan and Chronic Illness Research Room 1F424  
Health Research Building 
College Lane AL10 9AB 
 
Dear Dr Guirguis 
Study title: Progression Of Depressive Symptoms In Haemodialysis 
Patients On Antidepressants 
REC reference: 14/EE/0143 
Protocol number: RD2014-30 
IRAS project ID: 151298 
 
Thank you for your letter of 19 May 2014, responding to the Committee’s request for 
further information on the above research and submitting revised documentation. 
The further information has been considered on behalf of the Committee by the 
Chair. 
We plan to publish your research summary wording for the above study on the HRA 
website, together with your contact details. Publication will be no earlier than three 
months from the date of this opinion letter. Should you wish to provide a substitute 
contact point, require further information, or wish to make a request to postpone 
publication, please contact the REC Manager, Ms Trish Wheat, 
nrescommittee.eastofengland-cambridgesouth@nhs.net 
 
Confirmation of ethical opinion 
272 
 
On behalf of the Committee, I am pleased to confirm a favourable ethical opinion for 
the above research on the basis described in the application form, protocol and 
supporting documentation as revised, subject to the conditions specified below. 
Conditions of the favourable opinion 
The favourable opinion is subject to the following conditions being met prior to the 
start of the study. 
Management permission or approval must be obtained from each host organisation 
prior to the start of the study at the site concerned. 
 
Management permission ("R&D approval") should be sought from all NHS 
organisations involved in the study in accordance with NHS research governance 
arrangements. 
 
Guidance on applying for NHS permission for research is available in the Integrated 
Research Application System or at http://www.rdforum.nhs.uk. 
 
Where a NHS organisation’s role in the study is limited to identifying and referring 
potential participants to research sites ("participant identification centre"), guidance 
should be sought from the R&D office on the information it requires to give 
permission for this activity. 
 
For non-NHS sites, site management permission should be obtained in accordance 
with the procedures of the relevant host organisation. 
 
Sponsors are not required to notify the Committee of approvals from host 
organisations 
 
Registration of Clinical Trials 
 
All clinical trials (defined as the first four categories on the IRAS filter page) must be 
registered on a publically accessible database within 6 weeks of recruitment of the first 
participant (for medical device studies, within the timeline determined by the current 
registration and publication trees). 
 
There is no requirement to separately notify the REC but you should do so at the earliest 
opportunity e.g when submitting an amendment. We will audit the registration details as 
part of the annual progress reporting process. 
 
To ensure transparency in research, we strongly recommend that all research is 
registered but for non clinical trials this is not currently mandatory. 
 
If a sponsor wishes to contest the need for registration they should contact Catherine 
Blewett (catherineblewett@nhs.net), the HRA does not, however, expect exceptions to 
be made. 
Guidance on where to register is provided within IRAS. 
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It is the responsibility of the sponsor to ensure that all the conditions are complied 
with before the start of the study or its initiation at a particular site (as applicable). 
 
Ethical review of research sites 
 
NHS sites 
 
The favourable opinion applies to all NHS sites taking part in the study, subject to 
management permission being obtained from the NHS/HSC R&D office prior to the start 
of the study (see "Conditions of the favourable opinion" below). 
 
Non-NHS sites 
 
Approved documents 
 
The final list of documents reviewed and approved by the Committee is as follows 
Document Version Date 
Covering letter on headed paper  31 March 2014 
Interview schedules or topic guides for participants 1.0 09 April 2014 
Other [Case Report Form] 1 28 February 2014 
Other [GP Letter] 1.0 28 February 2014 
Participant consent form 1 28 February 2014 
Participant information sheet (PIS) [including tracked 
(lay) changes] 
2.0 13 May 2014 
REC Application Form 151298/586431/1/541 27 March 2014 
Research protocol or project proposal 1.0 28 February 2014 
Response to Request for Further Information  19 May 2014 
Summary CV for Chief Investigator (CI) Dr Ayman Guirguis  
Summary CV for Chief Investigator (CI) Dr Karin Friedli  
Summary CV for Chief Investigator (CI) Ken Farrington  
Summary CV for Chief Investigator (CI) Naomi Fineberg  
 
Statement of compliance 
The Committee is constituted in accordance with the Governance Arrangements for 
Research Ethics Committees and complies fully with the Standard Operating 
Procedures for Research Ethics Committees in the UK. 
After ethical review 
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Reporting requirements 
The attached document “After ethical review – guidance for researchers” gives 
detailed guidance on reporting requirements for studies with a favourable opinion, 
including: 
 Notifying substantial amendments 
 Adding new sites and investigators 
 Notification of serious breaches of the protocol 
 Progress and safety reports 
 Notifying the end of the study 
The HRA website also provides guidance on these topics, which is updated in the 
light of changes in reporting requirements or procedures. 
Feedback 
You are invited to give your view of the service that you have received from the 
National Research Ethics Service and the application procedure. If you wish to make 
your views known please use the feedback form available on the HRA website: 
http://www.hra.nhs.uk/about-the-hra/governance/quality-assurance/ 
 
We are pleased to welcome researchers and R & D staff at our NRES committee 
members’ training days – see details at http://www.hra.nhs.uk/hra-training/ 
 
With the Committee’s best wishes for the success of this project. 
 
Yours sincerely 
pp 
 
Dr Leslie Gelling Chair 
14/EE/0143 Please quote this number on all correspondence 
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Email:nrescommittee.eastofengland-cambridgesouth@nhs.net 
 
Enclosures: “After ethical review – guidance for researchers” 
Copy to: Dr Shan Gowrie-Mohan 
Mrs Fiona Smith, East and North Hertfordshire NHS Trust 
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NRES Committee London – Harrow 
Bristol REC Centre Level 3, Block B 
Whitefriars 
Lewins Mead 
Bristol BS1 2NT 
Tel: 01173 421383 
Fax: 01173 420455 
01 June 2015 
Ken Farrington 
East and North Hertfordshire NHS Trust  
Coreys Mill Lane 
Stevenage  
SG1 4AB 
 
Dear Mr Farrington 
 
Study title:              A Pilot Randomised Controlled Trial of Drug Treatment for 
                                  Depression in Patients undergoing Haemodialysis 
REC reference: 12/LO/1554 
Protocol number: CTIMPMCRENAL12 
EudraCT number: 2012-000547-27 
Amendment number: 2 
Amendment date: 23 April 2015 
IRAS project ID: 100774 
 
The above amendment was reviewed by the Sub-Committee in correspondence. 
Ethical opinion 
The members of the Committee taking part in the review gave a favourable ethical 
opinion of the amendment on the basis described in the notice of amendment form 
and supporting documentation. 
Approved documents 
The documents reviewed and approved at the meeting were: 
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Document Version Date 
Covering letter on headed paper  22 April 2015 
Notice of Substantial Amendment (CTIMP) 2 23 April 2015 
Other [Archiving for the Assertid Study] 1 09 March 2015 
Participant information sheet (PIS) 7 01 June 2015 
Research protocol or project proposal 7.0 20 April 2015 
Sample diary card/patient card 1 13 May 2013 
 
Membership of the Committee 
 
The members of the Committee who took part in the review are listed on the attached sheet. 
 
R&D approval 
All investigators and research collaborators in the NHS should notify the R&D office for the 
relevant NHS care organisation of this amendment and check whether it affects R&D 
approval of the research. 
 
Statement of compliance 
This Committee is recognised by the United Kingdom Ethics Committee 
Authority under the Medicines for Human Use (Clinical Trials) Regulations 
2004, and is authorised to carry out the ethical review of clinical trials of 
investigational medicinal products. 
 
The Committee is fully compliant with the Regulations as they relate to 
ethics committees and the conditions and principles of good clinical practice. 
 
The Committee is constituted in accordance with the Governance 
Arrangements for Research Ethics Committees and complies fully with the 
Standard Operating Procedures for Research Ethics Committees in the UK. 
 
We are pleased to welcome researchers and R & D staff at our NRES 
committee members’ training days – see details at 
http://www.hra.nhs.uk/hra-training/ 
 
 
 
Yours sincerely 
12/LO/1554: Please quote this number on all correspondence 
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Dr Jan Downer  
Chair 
E-mail: nrescommittee.london-harrow@nhs.net 
Enclosures: List of names and professions of members who took part in the review 
Copy to:  Mrs Fiona Smith, East and North Hertfordshire NHS Trust              
Dr  Karin Fried 
 
NRES Committee London - Harrow 
     Attendance at Sub-Committee of the REC meeting on 01 May 2015 
Committee Members: 
Name Profession Present Notes 
Dr Jan Downer Consultant Anaesthetist 
(Chair) 
Yes  
Reverend Catherine McBride Vicar Yes  
 
Also in attendance: 
 
Name Position (or reason for attending) 
Miss Natasha Bridgeman REC Assistant 
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ASSERTID Amendment Log - Version 1.8 dated 20/1/2016 
 
 
Submission 
type and 
version 
Substantial 
or non-
substantial 
Reason 
for 
amendme
nt 
Submitted to 
ethics 
Approved 
by ethics 
Submitted to 
MHRA 
Approved by 
MHRA 
CTA issued Submitted 
to Sponsor 
and NHS 
R&D 
Approved 
by 
Sponsor 
and NHS 
R&D 
Status 
Protocol 1.0, 
dated 
17/4/12 
N/A Original 
Submissio
n 
24/04/2012 Not 
approved, 
Letter dated 
4/7/12 
22/06/2012 Grounds of 
non-
acceptance, 
letter dated 
26/7/12 
 N/A  Planning 
Protocol 1.0, 
dated 
17/4/12 
Right to 
amend 
request to 
MHRA 
   07/08/2012 08/08/2012 08/08/2012   Planning 
 
Protocol 
2.0, dated 
2/9/12 
 New 
applicatio
n to ethics 
committe
e 
02/09/2012 Provisional 
opinion, 
Letter dated 
1/10/12 
     Planning 
Protocol 3.0, 
dated 
3/10/12 
Further 
information to 
provisional 
opinion 
 03/10/2012 Approval, 
Letter 
dated 
1/11/12 
     Planning 
Protocol 3.0, 
dated 
3/10/12 
Substantial 
amendment to 
CTA 
application 
Changes had 
been requested 
by ethics 
  18/10/2012 22/11/2012    Planning 
Protocol 
4.0, dated 
18/1/3 
Substantial 
amendment to 
ethics and CTA 
application 
Changes in 
safety or 
integrity of trial 
subjects, 
changes in 
conduct/manag
ement of trial, 
clarification to 
protocol 
21/01/2013 Approval, 
Letter 
dated 
24/1/13 
21/01/2013 26/02/2013  25/03/2013 02/04/2013 R&D approval 
at ENHT 
2/4/13 
Protocol 4.0, 
dated 
18/1/13 
         R&D 
approval at 
Southend 
20/5/13 
Protocol 
5.0, date 
5/7/13 
Substantial 
amendment to 
ethics 
Added short 
patient 
information 
sheets, added 
two self-report 
questionnaires, 
clarification 
16/07/2013 Approval, 
Letter 
dated 
18/07/201
3 
Informed 
MHRA 
Acknowledge 
ment letter 
dated 2/8/2013 
   R&D 
approval in 
Birmingham 
20/8/13 
 
 
 
 
 
 
 
280 
 
Appendix 2 – List of Abstracts 
AMERICAN SOCIETY OF NEPHROLOGY- Philadelphia, PA- Nov 11-16 2014 
 
 
COMPARISON OF COMMON SCREENING TOOLS FOR DEPRESSION IN 
HAEMODIALYSIS PATIENTS 
 
Guirguis, A.
1, 2, 3
, Friedli, K.
2
, Fineberg, N.A.,
 2, 3
, Day, C.
4
, Almond. M.
5
, 
Davenport, A.
5
, Da Silva- Gane, M
1
., Chilcot, J.
7
, Wellsted, D.
 2
, Farrington, K.
1, 2 
 
1
E&N Herts NHS Trust,
 2
 University of Herts, 
3
Herts Partnership University NHS 
Foundation Trust,
 4
University Hospitals Birmingham NHS Foundation Trust, 
5
Southend University Hospital NHS Foundation Trust, 
6
Royal Free London NHS 
Foundation Trust and 
7King’s College London 
 
BACKGROUND: Depression is common in haemodialysis (HD) but diagnosis is 
difficult because of overlapping somatic symptoms of uraemia and depression. The 
Beck Depression Inventory -II (BDI-II) is a useful screening tool with good 
psychometric properties. A cut-off score ≥ 16 indicates probable depression in this 
setting. There are few data on other commonly used screening tools. We determined 
cut-off values for the Patient Health Questionnaire 9 (PHQ-9) and Patient Health 
Questionnaire 2 (PHQ-2), corresponding to BDI-II ≥ 16 in the HD setting. 
 
METHODS: We studied HD patients at 3 UK renal centres. Inclusion criteria were 
dialysis vintage >3 months, aged >18 years and ability to read and speak English. 
Patients were screened for depression with the BDI-II and PHQ-9.  We used ROC 
analysis to determine the cut-off points for the PHQ-9 and PHQ-2 corresponding to a 
BDI-II cut-off ≥ 16. We also determined levels of agreement.  
 
RESULTS: In 494 patients (61% males) median interquartile range for the BDI-II, 
PHQ-9 and PHQ-2 were 10(5-19), 5(2-11), and 1(0-2) respectively. Using the BDI-II 
cut-off, the area under the curve in the ROC analysis for the PHQ-9 and PHQ-2 were 
0.94 (CI 0.92-0.96) and 0.89 (CI 0.86-0.93) respectively with optimal cut-off points 
of ≥ 8 for PHQ-9 and ≥2 for PHQ2 (sensitivity 87% and 84%, and specificity 88% 
and 86% respectively). The proportion of patients with BDI ≥16 was 34%, with 
PHQ-9 ≥8 was 38% and PHQ-2 ≥ 2 was 38%. Levels of agreement of PHQ-9 > 8 
and PHQ-2 ≥2 with BDI-II ≥ 16 were substantial (κ = 0.724 and 0.678 respectively). 
 
CONCLUSION: The PHQ-9 and PHQ-2 are acceptable screening tools compared to 
the BDI-II in dialysis patients. Cut-off scores PHQ-9 ≥ 8 and PHQ-2 ≥2 compare 
well to a BDI-II cut-off ≥ 16. Use of simple screening tools may help detect 
depression in HD patients.  
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AMERICAN SOCIETY OF NEPHROLOGY- San Diego, CA- Nov 3-8 2015 
 
The ASSertID Study: Feasibility RCT of Drug Treatment for Depression in 
Patients on Haemodialysis 
Guirguis, A.
1, 2, 3
, Friedli, K.
2
, Fineberg, N.A.,
 2, 3
, Day, C.
4
, Almond. M.
5
, 
Davenport, A.
5
, Da Silva- Gane, M
1
., Chilcot, J.
7
, Wellsted, D.
 2
, Farrington, K.
1, 2 
 
1
E&N Herts NHS Trust,
 2
 University of Herts, 
3
Herts Partnership University NHS 
Foundation Trust,
 4
University Hospitals Birmingham NHS Foundation Trust, 
5
Southend University Hospital NHS Foundation Trust, 
6
Royal Free London NHS 
Foundation Trust and 
7King’s College London 
 
INTRODUCTION: Major Depressive Disorder (MDD) is common in patients on 
Haemodialysis (HD). Management is difficult. There are few studies of 
antidepressants, little evidence of a benefit and significant risks of adverse events. 
Hence we undertook feasibility RCT of sertraline versus placebo. 
  
METHODS: A screening phase identified patients with Beck Depression Inventory 
score (BDI-II) ≥16.  Those screen + ve patients, who met the eligibility criteria, 
underwent psychiatric assessment (Mini International Neuropsychiatric Interview). 
Treatment for depression in the previous 3 months was an exclusion criterion. Those 
with mild to moderate MDD and MADRS score ≥18 were invited to enter the Trial 
phase in which patients were randomised to sertraline or placebo. Review by study 
psychiatrist and nurses took place at 2 weeks then monthly for 6 months. Initial dose 
was 50 mg with titration to 100 mg if required. 
 
RESULTS: 1355 patients were approached and 715 consented for screening. BDI-II 
≥16 was present in 231 (32.3%). Forty-two (18.2%) were receiving anti-depressants, 
psychological therapy or 16 both, so were excluded.  Sixty-three underwent 
psychiatric assessment. MDD was diagnosed in 37 and 30 of these (mean age 61 
±15; 71% male; 60% white) agreed to be randomised. Nine had a past history of 
depression.  Twenty-one (70%) completed the trial, 8 (of 15) on sertraline and 13 (of 
15) on placebo. Over 6 months, there was a reduction in BDI-II and MADRS scores 
(t(17)=6.3, p<0.001 and t(20)=11.3, p<0.001 respectively). The reductions were not 
statistically different in sertraline and placebo groups.  Fewer on sertraline completed 
the trial (6 withdrawals and one death versus 2 withdrawals on placebo [Χ2=3.97, 
p=0.046]). There was a trend towards a more rapid fall in MADRS scores over the 
first 2 months in the sertraline group (effect size 0.37: lower bound >0). 
 
CONCLUSION:  This small study is nevertheless the largest RCT of an anti-
depressant in HD patients. There was a similar significant improvement in 
depression over 6 months in both groups. Recovery may have been quicker on the 
active drug.   
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AIMS: To recognise the degree to which depressive symptoms in End Stage Renal 
Disease (ESRD) patients undergoing haemodialysis (HD) are recognised and treated 
or not. 
 
BACKGROUND: Depression is often said to be unrecognized and undertreated in 
patients with chronic medical illness leading to negative outcomes. Part of the 
problem may be symptom overlap between depression and uraemia. Prevalence 
estimates of depression in this population vary widely from 15% to 69%. Depressive 
symptoms in ESRD may negatively affect general health awareness mortality rate, 
treatment adherence and inpatient hospitalisation. It is therefore an important health 
issue in this population. 
 
METHODS: We studied all haemodialysis patients at 3 renal centres across 
England. Inclusion criteria were; having been on dialysis >3 months, >18years of age 
and being able to read and speak English. All eligible patients were screened for 
depression using Beck Depressive Inventory Version II (BDI-II). Medication status 
was obtained by patients self-reports and medical records. 
 
RESULTS: In 480 HD patients (Male 310 (64.6%) mean age was 64.2 ±16.1 years. 
The mean BDI-II was 13.6, ±11.3. Of these, 168 patients (35%) scored ≥ 16 on the 
BDI-II representing moderate depressive symptomatology. They were younger than 
the non-depressed sub-group (mean age 60.6 v 66.1 years: p = 0.004). 89 patients 
(18.5% of the whole HD group) were already taking antidepressants-25 of 312 
patients with low BDI (8.1%) and 64 of 168 with high BDI (38%).  In those with 
high BDI-patients taking antidepressants had a higher mean BDI score (30.6 ± 10.4 v 
25.0 ± 7.2: p< 0.001) than untreated patients. They tend to be younger (55.9 SD 16.6 
v 62.2 SD 16.5 years: p = 0.081) but appeared to be similar with respect to gender, 
ethnicity, marital status, educational background, dialysis vintage or comorbidity. 
They had higher median scores in the BDI domains of worthlessness, past failure, 
and suicidal thoughts (p < 0.01 in all cases).  
 
CONCLUSION:  >1/3 HD patients had BDI-II ≥ 16 concordant with moderate 
depressive symptomatology. Antidepressants were commonly prescribed in this 
group and those taking antidepressants had high depressive symptomatology 
compared to their untreated counterpart, questioning the value of antidepressants in 
this cohort. This is contrary to many previous findings which suggest that depression 
is under-diagnosed and undertreated in this population. Prospective studies are 
required to investigate the diagnosis and management of depression in HD patients.  
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BACKGROUND: The length of time taken for a subject to recover following a 
haemodialysis session can be prolonged. This self-report parameter has been 
advocated as a marker of the quality of haemodialysis delivery but the factors 
associated with the phenomenon have received little attention. This is important 
since there is little point accumulating data on an indicator of quality if it cannot be 
modified. Depression is a potential contributant to prolonged self-report recovery 
times. This study investigates this relationship in a large cohort of centre-based 
haemodialysis patients. 
 
METHODS: We measured depressive symptoms using the Beck depression 
Inventory (BDI-II) in subjects on centre-based haemodialysis for more than 3 months 
in 5 UK centres. Subjects were also asked to provide an estimate of the time it 
normally took them to recover fully following a haemodialysis session.  
Demographic and clinical information was also collected including self-report 
comorbidity. In a smaller cohort of patients we screened for fatigue using the 
Multifactorial Fatigue Inventory (MFI). 
 
RESULTS: A total of 689 subjects were studied. In these subjects recovery time was 
reported as less than one hour in 23.7%, 1 to 4 hours in 26.3%, 4 to 8 hours in 14.9% 
, 8 to 12 hours in 10.9%, and over 12 hours in 22.4%. The median BDI-II score was 
closely related to recovery time being respectively 6 (range 35), 11 (range 45), 12 
(range 52), 14 (range 47), 12 (range 57) in these time periods (p < 0.001). In patients 
with prolonged recovery times (>8 hours), median BDI-II score was significantly 
higher than in those with faster recoveries [12(range 57) v 8(range 52): p<001]. More 
had a history of depression in the prolonged recovery group (34.2% v 20.4%: p < 
0.001), more were taking antidepressants (27.1% v 15.9%: p < 0.001) and more had 
significant depressive symptoms - BDI-II >15 (47% v 33%: p < 0.001). Median age 
was slightly but not significantly less in those prolonged recovery (64 v 69 years), 
and women were more prevalent in this group (45% v 32%:p =.0.001). There was no 
relation to ethnicity or co-morbidity (diabetes, heart disease, cancer, lung and liver 
disease), though there was a significant centre effect with the proportion of subjects 
reporting long recovery varying from 26.4% to 44.7% among the 5 centres (p = 
0.002). The best logistic regression model of prolonged recovery time included 
centre, gender, past history of depression, and BDI-II score but explained only 10% 
of the variation. In a smaller cohort (N = 445) of the same population the mean 
General Fatigue Score (component of the MFI) was also found to be significantly 
higher in those with prolonged recovery (14.6 ± 3.4 v 12.3 ±3.9: p <0.001). Adding 
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this to the previous logistic regression model improved its predictive power to 17% 
but rendered BDI-II score non-significant in the model. 
 
CONCLUSIONS: There is only a weak association of depressive symptoms with 
post-dialysis recovery time and this is likely to be mediated by the somatic element 
of the BDI-II score to which the symptom of fatigue is a major contributant. 
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BACKGROUND: Depression is common in haemodialysis (HD) patients but 
diagnosis is difficult because of the considerable overlap between symptoms with 
those of uraemia. Use of simple screening tools such as the Beck Depression 
Inventory Version II (BDI-II) may be helpful in identifying patients likely to be 
depressed but screening cut-off points – indicative of a high likelihood of diagnosed 
depression – are higher than those for the general population. For the BDI-II the 
widely accepted cut-off is ≥ 16 but there is little data on the corresponding cut-off 
values for other commonly used screening tools. We aimed to compare screening 
cut-off values for the Patient Health Questionnaire 9 (PHQ-9) with that of the BDI-II 
in the HD population.  
METHOD: We surveyed HD patients at 3 renal centres across England as part of a 
larger study. Inclusion criteria were dialysis vintage > 3 months, aged >18 years and 
ability to read and speak English. Eligible patients were screened for depression 
using the BDI-II and PHQ-9.  We compared the two measures and using the 
recognised cut-off point on the BDI-II of ≥ 16 we used Receiver Operating 
Characteristics (ROC) analysis to determine the cut-off point on the PHQ-9 scale. 
We then determined levels of agreement between these cut-off points using Cohen’s 
κ statistic. 
RESULTS: 337 patients (62% males) completed the screening questionnaires. 
Median (interquartile range) for the BDI-II and PHQ-9 were 10(5-20) and 5(2-11) 
respectively.  There was a significant correlation between the PHQ-9 and the BDI-II 
(rho 0.89: P <0.001). Using the BDI-II cut-off, the area under the curve in the ROC 
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analysis for the PHQ-9 was 0.96 (CI 0.94-0.98) and the optimal cut-off point for 
PHQ-9 was ≥8 (sensitivity 88%, specificity 89%). There was substantial agreement 
between PHQ-9 ≥ 8 and BDI-II ≥ 16 (κ = 0.758: p <0.001), exceeding the levels of 
agreement for all other possible PHQ-9 cut-off points. However 6.8% of patients 
with PHQ-9 < 8 had a BDI-II score ≥ 16, whilst 18.5% of those with a PHQ-9 ≥8 had 
a BDI-II score <16. 
CONCLUSION: Our results suggest that the PHQ-9 is an acceptable screening tool 
compared to the BDI-II in dialysis patients, with a cut-off point of ≥ 8 approximating 
a BDI-II cut-off ≥ 16. The availability of simple screening tools in clinical practice 
may assist the detection of depression in the HD population and lead to better clinical 
outcomes.  
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BACKGROUND: Delayed recovery post dialysis is a frequent complaint in 
haemodialysis patients. Its duration is not predicted by clinical measures such as; 
nutrition, laboratory results, or the adequacy of dialysis. Furthermore, patients with 
this problem experience significant limitations in their day to day activities, 
including participation in social activities, on the day of dialysis.  
METHOD: We conducted a survey of haemodialysis patients at 3 renal centres 
across England as part of a larger study. Inclusion criteria were dialysis vintage > 3 
months, age over 18 years and ability to read and speak English. Eligible patients 
were screened for depression using The Beck Depressive Inventory Version II (BDI-
II) and Patient Health Questionnaire 9(PHQ-9). Post-dialysis recovery duration was 
collected using patients self-reports, categorised as (<1hr, 1-4hrs, 4-8hrs, 8-12hrs, 
>12hrs).   
RESULTS: In 332 HD patients (male 62.7%:  mean age 64.2 ±16.1 years), mean 
BDI-II and PHQ-9 was 13.6± 11.3, 6.9 ± 6.2 respectively. 111 (35%) scored ≥ 16 on 
BDI-II, representing moderate depressive symptomatology. Recovery time was < 1hr 
in 25.7%, 1-2hrs in 20.4%, 4-8hrs in 26.3%, 8-12hrs in 10.9% and >12hrs in 14.8%. 
In groups with recovery time >8 hrs, the mean BDI-II was significantly higher than 
those with shorter recovery times (17.0 ± 12.3 versus 11.6 ± 10.0, p<0.001). 
Corresponding values for PHQ-9 were 8.7 ± 6.9 versus 6.0 ± 5.6 (p< 0.001). A 
higher recovery time was more common in females (46.3% versus 29.7%, p=0.002) 
and in those with a past history of depression (p=0.004). There were marginal 
differences in age (65.5 ± 15.9 versus 61.9 ± 16.1, p<0.054). There were no 
differences in comorbidity (heart disease, cancer, amputation, lung disease and liver 
disease), ethnicity, body weight, blood pressure, haemoglobin, albumin, Kt/V, 
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dialysis vintage, number of previous transplants, marital status, or maximum 
educational attainment. In logistic regression, depression screening score (BDI or 
PHQ9) and gender were the only significant predictors of recovery time > 8 hours. 
CONCLUSION: Prolonged recovery time following dialysis is more common in 
women and associated with high depression screening scores.  
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INTRODUCTION: Under-recognition of depression in patients with end-stage 
renal disease (ESRD) contributed to by symptom overlap with those of the uraemic 
syndrome, results in wide variation in prevalence estimates ranging from 15% to 
69%. Depressive symptoms in ESRD may negatively affect quality of life, mortality 
rate, treatment adherence and hospitalisation. We aimed to determine the frequency 
of depressive symptoms and antidepressant medications in ESRD patients 
undergoing haemodialysis (HD). 
METHODS: We studied HD patients at 3 UK renal centres. Inclusion criteria: being 
on dialysis for over 3 months, age over 18 years and proficiency in English. All 
eligible patients were screened using Beck Depressive Inventory Version II (BDI-II). 
Medication status was obtained by patient self-report and from medical records. 
RESULTS: In 317 HD patients (male 62.7%:  mean age 64.2 ±16.1 years) mean 
BDI-II was 13.6 ± 11.3. 111 (35%) scored ≥ 16 on BDI-II, representing moderate 
depressive symptomatology. These were younger than those with lower BDI (mean 
age 60.6 v 66.1 years: p = 0.004), and more had a past-history of depression (53% vs 
16%: p <0.001). 45 (14% of the whole HD group) were already taking 
antidepressants - 16 of 206 patients with low BDI (7.8%) and 29 of 111 with high 
BDI (26%).  In those with high BDI-patients taking antidepressants had a higher 
mean BDI score (30.6 ± 10.4 vs 25.0 ± 7.2: p< 0.001) than untreated patients. They 
were younger (55.9 ±16.6 vs 62.2 ± 16.5 years: p = 0.081) but appear to be similar 
with respect to gender, ethnicity, marital status, educational background, dialysis 
vintage or comorbidity. They had higher median scores in the BDI domains of 
worthlessness, past failure, and suicidal thoughts (p < 0.01 in all cases).  
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CONCLUSIONS: Over 1/3 of HD patients had moderate depressive 
symptomatology, concurring with existing literature. BDI scores were high despite 
antidepressant treatment in many, often higher than in untreated patients with high 
BDI, questioning the effectiveness of antidepressant pharmacotherapy in this 
population. Prospective studies of antidepressant efficacy in ESRD are required. 
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INTRODUCTION: Fatigue is a psychosomatic syndrome that is common in 
chronic disease. It is the major overlapping symptom linking depression and 
advanced kidney disease. The literature regarding the prevalence and determinants of 
fatigue in haemodialysis patients is sparse. We undertook this study in order to 
investigate the associations between fatigue and demographic, clinical and 
psychological factors in patients on Haemodialysis (HD). 
METHOD: We studied 104 unselected HD patients across 3 UK renal centres 
.Patients were screened for fatigue using Multidimensional Fatigue Inventory (MFI), 
and for depression using Beck Depressive Inventory Version II (BDI-II) and Patient 
Health Questionnaire 9 (PHQ-9). Demographic and clinical data were also collected. 
RESULTS: Mean age was (61.1±16.7). 71% were male. 72.1% were white. Median 
dialysis vintage was 31.5 (IQR 70.8) months. 31.7% were diabetics, 30.8% had heart 
disease, 7.7% had a previous stroke, 7.7% had previous history of cancer and 30.7% 
had a past history of depression. 34% had a high BDI score (>16). There was a weak 
negative correlation between age and Mental Fatigue score (rho = -0.227: p=0.02) 
but no relation between gender or ethnicity and any fatigue subscale. Dialysis vintage 
correlated with Mental Fatigue score (rho 0.290: p=0.005) but with no other fatigue 
subscale score. Patients with diabetes had higher scores for General Fatigue 
(14.2±3.0 v 12.6±3.6: p=0.026) and Physical Fatigue (15.9±3.0 v14.0±4.0: p=0.013), 
but Mental Fatigue scores was not different to that in non-diabetic. Patients with a 
high BDI score had higher scores in all 3 fatigue subscales than those below this 
threshold (General 15.1±2.5v12.2±3.5, Mental 11.8±4.3v8.2±3.7, Physical 
16.4±2.9v13.7±4.0: p<0.001 in all cases). There were strong correlations between 
292 
 
BDI score and General Fatigue (rho=0.542: p<0.001), Mental Fatigue score 
(rho=0.429: p<0.001) and Physical Fatigue score (rho= 0.419: p<0.001). 
Corresponding values for PHQ-9 were (rho=0.492, 0.470, 0.400: p<0.001) in all 
cases. In a series of multivariate models controlled for age, gender, ethnicity, dialysis 
vintage, marital status, diabetes, multi-morbidity, past history of depression, pre-
dialysis systolic blood pressure, haemoglobin, albumin and Kt/V, the major factor 
associating with all fatigue scores (general, mental and physical subscales) was 
depressive symptoms measured by either BDI or PHQ-9. The most powerful model 
R² = 0.43 described the association of BDI with Mental Fatigue and included dialysis 
vintage (p=0.01), diabetes (p=0.046) and haemoglobin (p= 0.030) as other significant 
factors. 
CONCLUSION: Depression scores are the strongly associated with all fatigue 
subscales General, Mental and Physical. This emphasise the strong overlap of 
depressive symptoms and fatigue in this population which complicates the diagnosis 
of depression. 
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AIMS AND HYPOTHESIS: We undertook this study in order to investigate 
whether there are distinctive characteristics of fatigue as defined by the 
Multidimensional Fatigue Inventory (MFI), which may relate more strongly to 
depressive symptomatology than other characteristics. This knowledge could lead to 
refinements of the screening tools for depression in this cohort. 
BACKGROUNDS: Depressive symptomatology is very common in patients with 
advanced kidney disease. Diagnosis of depression in these patients is complicated by 
overlapping symptoms. Fatigue is a psychosomatic syndrome that is also common in 
chronic disease, and a key area of overlap. Its prevalence ranges from 42% - 89% 
according to treatment modality and assessment instruments employed.  
METHODS: We studied 244 unselected HD patients across 3 UK renal centres. 
Inclusion criteria: being on dialysis for over 3 months, age over 18 years and 
proficiency in English. Patients were screened for fatigue using MFI, and for 
depression using Beck Depressive Inventory Version II (BDI-II). Demographic and 
clinical data were also collected. 
RESULTS: Mean age was (63.1±17.6). 64.3% were male. 71.3% were white. 
Median dialysis vintage was 31.5 (IQR 70.8) months. Mean BDI-II score was 
(12.7±10.5). 34.7% had a high BDI score (>16).Mean scores in the  different MFI 
domains were 13.2 ± 3.8 for General Fatigue, 9.5 ± 4.3 for Mental Fatigue and 14.7 ± 
4.1 for Physical Fatigue. BDI score correlated with age (rho = -0.223: p = 0.001), and 
all the fatigue scales - General (rho = 0.641: p <0.001), Mental (rho = 0.573: p < 
0.001), Physical (rho = 0.521: p < 0.001). In models adjusted for age, gender, 
ethnicity, and marital status, the best predictor of BDI-II Score was Mental Fatigue 
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accounting for 41% of the variation (adjusted R-square = 0.412: p < 0.001), followed 
by General Fatigue accounting for 38% (adjusted R-square = 0.377 : p <0.001) and 
Physical Fatigue accounting for 29% (adjusted R-square = 0.294: p< 0.001). For high 
depression scores (BDI-II ≥ 16) adjusted for the same factors Mental (Nagelkerke R-
square 0.410: p < 0.001), and General (Nagelkerke R-square 0.412: p < 0.001) had 
similar predictive power which was superior to that of Physical Fatigue (Nagelkerke 
R-square 0.372: p < 0.001). 
CONCLUSIONS:  BDI-II scores and those in all 3 MFI subscales were highly 
correlated. Adjusted scores for Mental Fatigue performed marginally better than 
General Fatigue scores in predicting BDI-II but similarly in predicting high BDI-II 
scores. Physical Fatigue scores were less predictive on both counts. It may be 
possible to adjust depression screening methodology to take more account of Mental 
Fatigue. The relationships between scores in MFI domains and diagnosed depression 
need to be studied. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
295 
 
International Congress, Royal College of Psychiatrists’, London- June 24-27 2014 
CHARACTERISTICS OF FATIGUE AND DEPRESSIVE SYMPTOMS IN 
HAEMODIALYSIS PATIENTS 
Guirguis, A.
1, 2, 3
, Friedli, K.
2
, Fineberg, N.A.,
 2, 3
, Day, C.
4
, Almond. M.
5
, 
Davenport, A.
5
, Da Silva- Gane, M
1
., Chilcot, J.
7
, Wellsted, D.
 2
, Farrington, K.
1, 2 
1
E&N Herts NHS Trust,
 2
 University of Herts, 
3
Herts Partnership University NHS 
Foundation Trust,
 4
University Hospitals Birmingham NHS Foundation Trust, 
5
Southend University Hospital NHS Foundation Trust, 
6
Royal Free London NHS 
Foundation Trust and 
7King’s College London 
AIMS AND HYPOTHESIS: We undertook this study in order to investigate 
whether there are distinctive characteristics of fatigue as defined by the 
Multidimensional Fatigue Inventory (MFI), which may relate more strongly to 
depressive symptomatology than other characteristics. This knowledge could lead to 
refinements of the screening tools for depression in this cohort. 
BACKGROUND: Depressive symptomatology is very common in patients with 
advanced kidney disease. Diagnosis of depression in these patients is complicated by 
overlapping symptoms. Fatigue is a psychosomatic syndrome that is also common in 
chronic disease, and a key area of overlap. Its prevalence ranges from 42% - 89% 
according to treatment modality and assessment instruments employed.  
METHODS: We studied 244 unselected HD patients across 3 UK renal centres. 
Inclusion criteria: being on dialysis for over 3 months, age over 18 years and 
proficiency in English. Patients were screened for fatigue using MFI, and for 
depression using Beck Depressive Inventory Version II (BDI-II). Demographic and 
clinical data were also collected. 
RESULTS: Mean age was (63.1±17.6). 64.3% were male. 71.3% were white. 
Median dialysis vintage was 31.5 (IQR 70.8) months. Mean BDI-II score was 
(12.7±10.5). 34.7% had a high BDI score (>16).Mean scores in the  different MFI 
domains were 13.2 ± 3.8 for General Fatigue, 9.5 ± 4.3 for Mental Fatigue and 14.7 ± 
4.1 for Physical Fatigue. BDI score correlated with age (rho = -0.223: p = 0.001), and 
all the fatigue scales - General (rho = 0.641: p <0.001), Mental (rho = 0.573: p < 
0.001), Physical (rho = 0.521: p < 0.001). In models adjusted for age, gender, 
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ethnicity, and marital status, the best predictor of BDI-II Score was Mental Fatigue 
accounting for 41% of the variation (adjusted R-square = 0.412: p < 0.001), followed 
by General Fatigue accounting for 38% (adjusted R-square = 0.377 : p <0.001) and 
Physical Fatigue accounting for 29% (adjusted R-square = 0.294: p< 0.001). For high 
depression scores (BDI-II ≥ 16) adjusted for the same factors Mental (Nagelkerke R-
square 0.410: p < 0.001), and General (Nagelkerke R-square 0.412: p < 0.001) had 
similar predictive power which was superior to that of Physical Fatigue (Nagelkerke 
R-square 0.372: p < 0.001) 
CONCLUSION:  BDI-II scores and those in all 3 MFI subscales were highly 
correlated. Adjusted scores for Mental Fatigue performed marginally better than 
General Fatigue scores in predicting BDI-II but similarly in predicting high BDI-II 
scores. Physical Fatigue scores were less predictive on both counts. It may be 
possible to adjust depression screening methodology to take more account of Mental 
Fatigue. The relationships between scores in MFI domains and diagnosed depression 
need to be studied.  
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Appendix 5 – Participants’ Information Sheets and 
Consent 
Participant Information Sheet 1 
FULL STUDY TITLE: A Pilot Randomised Controlled Trial of Drug Treatment for 
Depression in Patients undergoing Haemodialysis 
Short Study Title: ASSERTID (A study of Sertraline in Dialysis)  
Screening and Prevalence Phase 
We would like to invite you to take part in our research study. Before you decide, it 
is important for you to understand why the research is being done and what it will 
involve. Please take time to read the following information carefully and discuss it 
with others if you wish. Ask us if there is anything that is not clear or if you would 
like more information. The research nurse will be happy to discuss any questions you 
may have. Take time to decide whether or not you wish to take part. Thank you for 
reading this. 
WHAT IS THE RESEARCH ABOUT? 
The aim of this phase of the study is to find out how people on haemodialysis feel. In 
particular, we are interested in knowing more about the mood and feeling of 
tiredness of people on haemodialysis. The research will investigate how many people 
on haemodialysis have low mood (for example feeling sad or down) and feeling tired 
with no energy, so that we can assess whether additional care to try and help with 
low mood should routinely be offered to people on haemodialysis. The study as a 
whole will look at helping people on haemodialysis with these problems. If you are 
affected by low mood, you may be invited to take part in another phase of this study. 
WHY HAVE I BEEN INVITED? 
You have been approached about this phase of the study because you use are on 
haemodialysis. We would like to ask all patients on haemodialysis to take part to find 
out the number of patients affected by low mood. 
DO I HAVE TO TAKE PART? 
It is up to you to decide to join this phase of the study. We will describe the study 
and go through this information sheet. If you agree to take part, we will ask you to 
sign a consent form. You are free to withdraw at any time, without giving a reason. 
This will not affect the standard of care you receive. 
WHAT WILL HAPPEN TO ME IF I TAKE PART AND WHAT WILL I 
HAVE TO DO? 
If you agree to take part, you will need to answer a number of questions. This should 
take between 15 and 20 minutes. First the research nurse will approach you on a 
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dialysis day and ask you a small number of questions about your kidney disease, 
whether you have any other medical problems and whether you have ever been 
treated for depression. The research nurse will collect some of this information from 
your medical notes, in particular results of recent blood tests and blood pressure 
recordings. Secondly, the research nurse will ask you to complete two short 
questionnaires, by ticking boxes. These questionnaires are standardised 
questionnaires which are used routinely in the NHS.  
WHAT WILL HAPPEN TO ME IF I DO NOT WANT TO TAKE PART?  
It is completely your decision whether you take part in this phase of the study and 
you will not be forced into the study. If you do take part now this does not mean that 
you have to take part in later phases of the study. You are free to withdraw at any 
time. Your level of care will not be affected in any way if you decide not to 
participate.  
ARE THERE ANY POSSIBLE BENEFITS IN MY TAKING PART? 
There may not be any direct benefits for you taking part in this phase of the study. 
However, if the questions you answer seem to show you are feeling low, in 
discussion with you we will offer to refer you to someone who may be able to help. 
This might be your nephrologist, your general practitioner or a member of the mental 
health care team such as a renal counsellor or a psychiatrist to discuss what options 
are available to you. 
WHAT ARE THE POSSIBLE DISADVANTAGES AND RISKS OF TAKING 
PART? 
You will be asked some questions about your mood, using questionnaires that are 
routinely used for this purpose. Occasionally these questions can be a bit upsetting so 
it is important to remember that you do not have to answer any questions you do not 
want to. 
WILL MY TAKING PART IN THE STUDY BE KEPT CONFIDENTIAL? 
All information collected about you will be kept strictly confidential. We follow 
ethical and legal practices and all information about you will be handled in 
confidence. All data collection sheets and questionnaires will be assigned a number 
and will not have your name on, so you could not be recognised from it. The data 
collected, including the questionnaires will be stored in locked filing cabinets in the 
hospital renal unit research offices. Only authorised persons will have access. All 
data entered on the electronic database will be securely entered and accessed by 
authorised research personnel only through a password protected system. If you join 
the study, some parts of your medical records and the data collected for the study 
may be looked at by authorised persons from the University of Hertfordshire and the 
participating NHS Trusts (East and North Herts NHS Trust, University Hospital 
Birmingham NHS Foundation Trust, Royal Free Hampstead NHS Trust and 
Southend University Hospital Foundation Trust) to check that the study is being 
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carried out correctly. Sometimes regulatory authorities also need to look at the 
records. All will have a duty of confidentiality to you as a research participant and 
nothing that could reveal your identity will be disclosed by them outside the research 
site. Data will be stored for 15 years and will be destroyed after this time. 
 WHAT WILL HAPPEN IF I DON’T CARRY ON WITH THE STUDY? 
You are free to withdraw from the study at any time, simply by telling a research 
nurse your wish to do so. You do not have to give a reason. If you withdraw 
completely from the study, we would still like to use the data collected up to your 
withdrawal, but is we do, we will ensure that you cannot be identified from such 
data.  
WHAT WILL HAPPEN TO THE RESULTS OF THE STUDY? 
The results of the study will be published in medical and health journals and will be 
presented at meetings. Any research publications will not identify you individually. 
If you would like a copy of the published research, let one of the researchers know, 
and we would be delighted to send any publications describing the results of this 
research to you when they become available. 
WHO IS ORGANISING AND FUNDING THE STUDY? 
Professor Ken Farrington, a kidney doctor at the Lister Hospital in Stevenage, 
Hertfordshire is the lead investigator. He is organising the study, together with three 
other kidney doctors from different hospitals, as well as other health care 
professionals and a team of researchers. East and North Herts NHS Trust and the 
University of Hertfordshire are the sponsors of this study. The sponsors have 
received funding from the National Institute for Health Research to conduct this 
study.   
WHAT IF THERE IS A PROBLEM? 
As this phase of the study only involves answering some questions there is unlikely 
to be any problems. If you have any concern about any aspect of this study, you 
should ask to speak to the Trial Manager or the Chief Investigator, who will do their 
best to answer your questions (contact details: University of Hertfordshire, CLiCIR, 
College Lane, Hatfield, tel: 01707 286472).  If you remain unhappy and wish to 
complain about any aspect of the way you are approached or treated during the 
course of this study, you can contact your local PALS office (Patient Advice and 
Liaison Service) at your hospital. If you require independent advice about making a 
complaint or seeking compensation, you may wish to contact the Independent 
Complaints Advocacy Service (ICAS). 
Formal complaints should be addressed to: 
Insert local site PALS 
Insert local site ICAS details  
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DOES YOUR GP (GENERAL PRACTITIONER) GET INVOLVED? 
If you agree to take part in this phase of the study, we would like to inform your GP 
about your participation if you are found to have low mood.  
WHO HAS REVIEWED THE STUDY? 
All research in the NHS is looked at by an independent group of people, called a 
Research Ethics Committee, to protect your interests. This study has received ethical 
approval from the National Research Ethics Committee (Add a reference). 
FURTHER INFORMATION AND CONTACT DETAILS 
If you have any further questions about this research (general or specific), please feel 
free to speak to the Trial Manager on 01707 286472. Add local PI and research 
nurse at each site. 
THANK YOU FOR TAKING TIME TO READ THIS INFORMATION 
SHEET. 
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Participant Information Sheet 2 
FULL STUDY TITLE: A Pilot Randomised Controlled Trial of Drug Treatment for 
Depression in Patients undergoing Haemodialysis 
Short Study Title: ASSERTID (A study of Sertraline in Dialysis)  
Psychiatric Assessment and Clinical Trial Phase 
We would like to invite you to take part in our research study. Before you decide, it 
is important for you to understand why the research is being done and what it will 
involve. Please take time to read the following information carefully and discuss it 
with others if you wish. Ask us if there is anything that is not clear or if you would 
like more information. The research nurse will be happy to discuss any questions you 
may have. Take time to decide whether or not you wish to take part. Thank you for 
reading this. 
WHAT IS THE RESEARCH ABOUT? 
We realise that a significant number of patients on haemodialysis suffer from low 
mood and feeling tired with no energy, and we are keen to find out more to help 
these symptoms. We are particularly interested in looking at the use of anti-
depressant tablets in helping patients on haemodialysis who are also depressed. 
To find out if anti-depressants help patients on haemodialysis who are depressed, we 
need to do a “double blind” randomised controlled placebo trial.  
 A placebo is a medication that looks exactly the same as the study 
medication but which has no effects  
 A randomised trial means that you are allocated to either treatment 
medication or placebo by chance 
 Double blind means that neither you nor your doctor will know in which 
treatment group you are (although if your doctor needs to find out he/she can 
do so). 
 Sometimes this is simply called a clinical trial.  
There are several steps in this part of the study: 
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1. You will be seen by the trial psychiatrist at your dialysis unit who will decide 
whether they think you have symptoms of clinical depression 
2. If you are felt to be depressed you will be offered the opportunity to enter the 
next phase of the trial 
3. If you decide to take part you will be allocated, by chance, either the 
treatment medication or inactive placebo. You will have a fifty percent 
chance of receiving the anti-depressants and a fifty percent chance of 
receiving the placebo tablet. Neither you nor your doctor or research team 
will know which group you are in. 
The reason we are doing this type of clinical trial is to: 
1.  find out if the antidepressant works  
2. to see if patients can tolerate the medication without bad side effects.  
Information from this quite small study help us to design in future a much larger 
study in helping patients on haemodialysis with depression. 
WHY HAVE I BEEN INVITED? 
You already agreed to take part in an earlier phase of the study and we found out that 
you may be suffering from low mood. The research nurse should have already had a 
chat to you about your low mood and possible options for further care, including this 
study. If you expressed interest, the research nurse would have invited you to take 
part in this phase of the study. If you would rather not take part in this study, we will 
refer you back to your kidney doctor and the renal team. They will be responsible for 
further options of your care, such as referral to your general practitioner or referral to 
a mental health care professional if this is appropriate and you wish it.  
DO I HAVE TO TAKE PART? 
It is up to you to decide to join this phase of the study. We will describe the study 
and go through this information sheet. If you agree to take part, we will ask you to 
sign a consent form to see the psychiatrist. If you are diagnosed with depression after 
the interview, we will invite you take part in the clinical trial. The psychiatrist will 
repeat the information about the clinical trial to you as well as other options of care 
and ask you to sign a separate consent form. You are free to withdraw at any time, 
without giving a reason. This will not affect the standard of care you receive. 
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WHAT WILL HAPPEN TO ME IF I TAKE PART AND WHAT WILL I 
HAVE TO DO? 
If you agree to take part, you first need to sign the consent form to see a psychiatrist. 
The research nurse will arrange a mutually convenient appointment for you to see the 
psychiatrist. It will probably be on one of your dialysis days. You will be talking to 
the psychiatrist in a private room and it will take between one and one and a half 
hours. The psychiatrist will ask a number of general questions about your health as 
well as specific ones regarding your mental health. They will ask about any previous 
treatment you may have had for mental disorders. At the end of the interview, the 
psychiatrist will make a diagnosis.  
If you are diagnosed with depression, the psychiatrist will ask you to sign a second 
consent form to participate in the clinical trial. Then the psychiatrist will randomly 
put you in the anti-depressant or placebo group that is by chance. You have a fifty 
percent chance of receiving the anti-depressant and a fifty percent change of 
receiving the placebo tablet. Neither you, the psychiatrist, the other doctors nor the 
nurses will know which treatment group you are in. The psychiatrist will give you a 
prescription to give to your renal nurse. The renal nurse will collect the special study 
prescription for you. The study medication is packaged in bottles with a study label 
giving clear instructions on how to take the medicines. You will be asked to take the 
study medication once a day over the next six months. 
In addition to taking the tablets you will be asked a number of questions about 
yourself, your health and the medication by the research nurse, psychiatrist and your 
kidney doctor on a monthly basis. They will also ask you to complete a number of 
questionnaires every two months. The research nurse or doctor will also look at your 
medical records to collect or confirm some of information about your medical 
condition. We will take two additional blood tests to look at the levels of the anti-
depressant in your blood. These blood samples will be stored until the end of the 
study when they will be sent to a laboratory for analysis.  
We may also ask you to take part in an additional phase of this study which will 
involve talking to a researcher about your experiences of taking part in this study. 
We will give you more details about this phase of the study at a later stage and then 
ask you to confirm whether you wish to participate in this additional phase of the 
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study. You will not have to take part in this additional phase of the study if you do 
not want to. 
WHAT WILL HAPPEN TO ME IF I DO NOT WANT TO TAKE PART?  
It is completely your decision whether you take part in the psychiatric interview and 
the clinical trial and you will not be forced into the study. If you agree to the 
psychiatric interview, you can change your mind about taking part in the clinical 
trial.  Your level of care will not be affected in any way if you decide not to 
participate.  
If you decide to not take part or change your mind, we will offer you alternative 
options of care which may be appropriate for you should you wish it. This will 
include referral back to your kidney doctor and their team, referral to your general 
practitioner, referral to a mental health care team or referral to the renal 
counsellor/psychologist. You may be prescribed an anti-depressant through these 
alternative options of care.  
ARE THERE ANY POSSIBLE BENEFITS IN MY TAKING PART? 
Firstly, we will be able to tell you if you suffer from depression. Secondly, you will 
have the opportunity of joining the clinical trial. We cannot promise the trial will 
help you, but if you receive treatment with the anti-depressant your mood may 
improve. The information we get from this study will also help improve the 
treatment of people with end stage kidney disease and depression. You will have 
extra contacts with the nursing and medical staff including the psychiatrist 
throughout the study period of 6 months, who will monitor you carefully. 
WHAT ARE THE POSSIBLE DISADVANTAGES AND RISKS OF TAKING 
PART? 
You will be asked questions about your mood by the psychiatrist and by completing 
questionnaires. Occasionally these questions can be a bit upsetting so it is important 
to remember that you do not have to answer any questions you do not want to. 
We cannot promise the trial will help you. You do not know if you are taking the 
anti-depressant or the placebo. This means that you may feel better but you may also 
feel worse and your depression may get worse. You will have increased contact with 
the research nurses and the psychiatrist who can help you if you do get worse. Again, 
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it is important that you feel free to withdraw at any time and you do not have to give 
a reason. 
WHAT ARE THE SIDE EFFECTS OF THE TREATMENT RECEIVED? 
Along with the useful effects of the anti-depressant, most medicines can cause 
unwanted side effects although not everyone experiences them. Most side effects 
lessen as your body adjust to the new medicine. Common symptoms are tiredness, 
feeling dizzy, dry mouth, feeling sick and feeling restless. In past studies, up to 30 
per cent of people have reported feeling sick or restless, up to 24 per cent have 
reported diarrhoea, and up to 16 to 17 percent have reported dizziness, dry mouth or 
tiredness.  There are some very small risks of serious side effects (less than 1 per 
cent) such as causing rhythm problems in the heart or internal bleeding for instance 
in the stomach. Part of the objective of this study is to assess the side effects 
experienced by renal patients. 
WHAT HAPPENS WHEN THE RESEARCH STUDY STOPS? 
After six months when the clinical trial comes to an end, you will be asked to take a 
smaller dose of the study medication for one or two weeks. Then your kidney doctor 
will discuss with the study psychiatrist and together with you, decide whether to 
recommend any further care for you, including referral to another health care 
professional or starting medication again. 
WILL MY TAKING PART IN THE STUDY BE KEPT CONFIDENTIAL? 
All information collected about you will be kept strictly confidential. We follow 
ethical and legal practices and all information about you will be handled in 
confidence. All data collection sheets and questionnaires will be assigned a number 
and will not have your name on, so you could not be recognised from it. The data 
collected, including the questionnaires will be stored in locked filing cabinets on the 
renal unit. Only authorised persons will have access. All data entered on the 
electronic database will be securely entered and accessed by authorised research 
personnel only through a password protected system. If you join the study, some 
parts of your medical records and the data collected for the study may be looked at 
by authorised persons from the University of Hertfordshire, the Norwich Clinical 
Trials Unit and the participating NHS Trusts (East and North Herts NHS Trust, 
University Hospital Birmingham NHS Foundation Trust, Royal Free Hampstead 
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NHS Trust and Southend University Hospital Foundation Trust) to check that the 
study is being carried out correctly. Sometimes regulatory authorities also need to 
look at the records. All will have a duty of confidentiality to you as a research 
participant and nothing that could reveal your identity will be disclosed by them 
outside the research site. Data will be stored for 15 years and will be destroyed after 
this time. 
WHAT WILL HAPPEN IF I DON’T CARRY ON WITH THE STUDY? 
You are free to withdraw from the study at any time, simply by telling a research 
nurse, kidney doctor or psychiatrist your wishes. You do not have to give a reason. 
You can withdraw from treatment but keep in contact with us to let us know your 
progress. If you decide to withdraw from treatment you will be advised to stop taking 
the treatment gradually, over a few days, as there is a possibility that you could 
experience mild withdrawal symptoms which usually do not last. Information 
collected may still be used, but we will ensure that you cannot be identified from 
such information. The stored blood samples that can still be identified as yours will 
be destroyed if you wish.  
WHAT WILL HAPPEN TO THE RESULTS OF THE STUDY? 
The results of the study will be published in medical and health journals and will be 
presented at meetings. Any research publications will not identify you individually. 
If you would like a copy of the published research, let one of the researchers know, 
and we would be delighted to send any publications describing the results of this 
research to you when they become available. 
DOES YOUR GP (General practitioner) get involved? 
If you agree to take part in this phase of the study, we will inform your GP about 
your participation.  We will tell your GP that you are taking part in the trial and that 
you are suffering from depression. 
WHO IS ORGANISING AND FUNDING THE STUDY? 
Professor Ken Farrington, a kidney doctor at the Lister Hospital in Stevenage, 
Hertfordshire is the lead investigator. He is organising the study, together with three 
other kidney doctors from different hospitals, as well as other health care 
professionals and a team of researchers. East and North Herts NHS Trust and the 
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University of Hertfordshire are the sponsors of this study. The sponsors have 
received funding from the National Institute for Health Research to conduct this 
study.   
WHAT IF THERE IS A PROBLEM? 
We do not anticipate any major problems arising from taking the medication since 
Sertraline has been used for very many years to treat depression. However all 
medications have potential side effects. It is an important part of the study to record 
what side effects occur, and we will monitor very closely, and treat them 
appropriately. This may involve stopping the medication. Also since half of the 
patients in the study will be taking placebo rather than the active drug, it is possible 
that your depression may get worse. We think this is also unlikely to occur but are 
monitoring very closely for this too. In the event of worsening depression we may 
need to withdraw you from the study and take the advice of the study psychiatrist to 
recommend definitive treatment. If you have any concern about any aspect of this 
study, you should ask to speak to the Trial Manager or the Chief Investigator, who 
will do their best to answer your questions (contact details: University of 
Hertfordshire, CLiCIR, College Lane, Hatfield, tel: 01707 286472).  If you remain 
unhappy and wish to complain about any aspect of the way you are approached or 
treated during the course of this study, you can contact your local PALS office 
(Patient Advice and Liaison Service) at your hospital. In the unlikely event that 
something does go wrong and you are harmed during the research and this is due to 
someone’s negligence then you may have grounds for a legal action for 
compensation against your hospital, but you may have to pay your legal costs. The 
normal National Health Service complaints mechanism, PALS, will be available to 
you and you can get independent advice about making a complaint or seeking 
compensation from the Independent Complaints Advocacy Service (ICAS). 
Formal complaints should be addressed to: 
Insert local site PALS 
Insert local site ICAS details –  
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WHO HAS REVIEWED THE STUDY? 
All research in the NHS is looked at by an independent group of people, called a 
Research Ethics Committee. For clinical trials, the Medicines and Healthcare 
Products Regulatory Authority looks at the research processes. These organisations 
are here to protect your interests. This study has received ethical approval from the 
National Research Ethics Committee (Add a reference) as well as approval from the 
Medicines and Healthcare Products Regulatory Authority to run the clinical trial (add 
reference). 
FURTHER INFORMATION AND CONTACT DETAILS 
If you have any further questions about this research, please feel free to speak to the 
Trial Manager on 01707 286472. Add local PI and research nurse at each site. 
THANK YOU FOR TAKING TIME TO READ THIS INFORMATION 
SHEET. 
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Participant Information Sheet 3 
FULL STUDY TITLE: A Pilot Randomised Controlled Trial of Drug Treatment for 
Depression in Patients undergoing Haemodialysis 
Short Study Title: ASSERTID (A study of Sertraline in Dialysis)  
Patient Experience Interview Phase 
We would like to invite you to take part in our research study. Before you decide, it 
is important for you to understand why the research is being done and what it will 
involve. Please take time to read the following information carefully and discuss it 
with others if you wish. Ask us if there is anything that is not clear or if you would 
like more information. The research nurse will be happy to discuss any questions you 
may have. Take time to decide whether or not you wish to take part. Thank you for 
reading this. 
WHAT IS THE RESEARCH ABOUT? 
We are interested in listening to your views and opinions on your participation in the 
current clinical trial looking at whether taking medication help patients on 
haemodialysis and who have depression. We would like to explore what it feels like 
taking part in the clinical trial, taking the study medication and answering the 
questionnaires.  
WHY HAVE I BEEN INVITED? 
You are currently taking part in a clinical trial looking at whether taking medication 
helps patients on dialysis and who have depression. We are seeking feedback from 
patients who would like to talk to us.    
DO I HAVE TO TAKE PART? 
It is up to you to decide to join this phase of the study. We will describe the study 
and go through this information sheet. If you agree to take part, we will ask you to 
sign a consent form to see the researcher who will conduct the interview. You are 
free to withdraw at any time, without giving a reason. This will not affect the 
standard of care you receive. 
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WHAT WILL HAPPEN TO ME IF I TAKE PART AND WHAT WILL I 
HAVE TO DO? 
If you agree to take part, we will ask you to sign the consent form to see the 
researcher. The research nurse will arrange an appointment for you to see the 
researcher. It will probably be on one of your dialysis day. You will be talking to the 
researcher in a private room and it will take between half an hour and one hour. The 
researcher will ask a number of questions about your views on participating in the 
clinical trial, taking the study medication and about the questionnaires and questions 
asked by the research nurse and psychiatrist. We are interested in your opinions and 
there are no right or wrong answers. With your permission the interview will be 
audio recorded but the recordings will be deleted at the end of the study. Your 
comments will be used to make recommendations for running future and larger 
studies in patients with end stage renal disease and depression.  
WHAT WILL HAPPEN TO ME IF I DO NOT WANT TO TAKE PART?  
It is completely your decision whether you take part in the patient experience 
interview and you will not be forced to do so. Your level of care will not be affected 
in any way if you decide not to participate. 
ARE THERE ANY POSSIBLE BENEFITS IN MY TAKING PART? 
You will be able to provide feedback on how you felt participating in this clinical 
trial and able to inform the researchers about what you felt was good and what was 
bad about the whole trial.  Your feedback will help us to design future studies. 
WHAT ARE THE POSSIBLE DISADVANTAGES AND RISKS OF TAKING 
PART? 
We cannot foresee any disadvantages to taking part in this study; however it is 
important to remember that you do not have to answer any questions you do not want 
to. 
WILL MY TAKING PART IN THE STUDY BE KEPT CONFIDENTIAL? 
All information collected about you will be kept strictly confidential. We follow 
ethical and legal practices and all information about you will be handled in 
confidence. All data collected will be assigned a number and will not have your 
name on it, so you could not be recognised from it. The data collected will be stored 
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in locked filing cabinets in the hospital renal unit research office. Only authorised 
persons will have access. All data entered on the electronic database will be securely 
entered and accessed by authorised research personnel only through a password 
protected system. If you join the study, some parts of your medical records and the 
data collected for the study may be looked at by authorised persons from the 
University of Hertfordshire and the participating NHS Trusts (East and North Herts 
NHS Trust, University Hospital Birmingham NHS Foundation Trust, Royal Free 
Hampstead NHS Trust and Southend University Hospital Foundation Trust) to check 
that the study is being carried out correctly. Sometimes regulatory authorities also 
need to look at the records. All will have a duty of confidentiality to you as a 
research participant and nothing that could reveal your identity will be disclosed by 
them outside the research site. Data will be stored for 15 years and will be destroyed 
after this time. 
DOES YOUR GP (General practitioner) get involved? 
If you agreed to inform your GP about phase 2 of the study, your GP will already 
know that you are participating in the trial. We will not need to tell them specifically 
that you are participating in an interview about the clinical trial. If you did not want 
your GP to know about your participation in phase 2 of the study, we will respect 
your wishes and not tell them about this phase of the study. 
WHAT WILL HAPPEN IF I DON’T CARRY ON WITH THE STUDY? 
You are free to withdraw from the interview at any time, simply tell the qualitative 
researcher that you want to stop the interview. You do not have to give a reason. If 
you withdraw completely from the interview, we would still like to use the data 
collected before your withdrawal, but if we do, we will ensure that you cannot be 
identified from such data. 
WHAT WILL HAPPEN TO THE RESULTS OF THE STUDY? 
The results of the study will be published in medical and health journals and will be 
presented at meetings. Any research publications will not identify you individually. 
If you would like a copy of the published research, let one of the researchers know, 
and we would be delighted to send any publications describing the results of this 
research to you when they become available. 
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WHO IS ORGANISING AND FUNDING THE STUDY? 
Professor Ken Farrington, a kidney doctor at the Lister Hospital in Stevenage, 
Hertfordshire is the lead investigator. He is organising the study, together with three 
other kidney doctors from different hospitals, as well as other health care 
professionals and a team of researchers. East and North Herts NHS Trust and the 
University of Hertfordshire are the sponsors of this study. The sponsors have 
received funding from the National Institute for Health Research to conduct this 
study.   
WHAT IF THERE IS A PROBLEM? 
As this phase of the study only involves talking to the researcher and answering 
some questions there is unlikely to be any problems. If you have any concern about 
any aspect of this study, you should ask to speak to the Trial Manager or the Chief 
Investigator, who will do their best to answer your questions (contact details: 
University of Hertfordshire, CLiCIR, College Lane, Hatfield, tel: 01707 286472).  If 
you remain unhappy and wish to complain about any aspect of the way you are 
approached or treated during the course of this study, you can contact your local 
PALS office (Patient Advice and Liaison Service) at your hospital. In the unlikely 
event that something does go wrong and you are harmed during the research and this 
is due to someone’s negligence then you may have grounds for a legal action for 
compensation against your hospital, but you may have to pay your legal costs. The 
normal National Health Service complaints mechanism, PALS, will be available to 
you and you can get independent advice about making a complaint or seeking 
compensation from the Independent Complaints Advocacy Service (ICAS). 
Formal complaints should be addressed to: 
Insert local site PALS 
Insert local site ICAS details –  
WHO HAS REVIEWED THE STUDY? 
All research in the NHS is looked at by an independent group of people, called a 
Research Ethics Committee, to protect your interests. This study has received ethical 
approval from the National Research Ethics Committee (Add a reference).  
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FURTHER INFORMATION AND CONTACT DETAILS 
If you have any further questions about this research, please feel free to speak to the 
Trial Manager on 01707 286472. Add local PI and research nurse at each site. 
THANK YOU FOR TAKING TIME TO READ THIS INFORMATION 
SHEET. 
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Participant Information Sheet 
Study Title: PROGRESSION OF DEPRESSIVE SYMPTOMS IN 
HAEMODIALYSIS PATIENTS ON ANTIDEPRESSANTS 
We would like to invite you to take part in our research study. Before you decide, it 
is important for you to understand why the research is being done and what it will 
involve. Please read the following information carefully and discuss it with others if 
you wish. Ask us if there is anything that is not clear or if you would like more 
information. The research nurse will be happy to discuss any questions you may 
have. Take time to decide whether or not you wish to take part. Thank you for 
reading this. 
What is the research about? 
The aim of this study is to find out how the symptoms of low mood and depression 
change over time when taking anti-depressant medication. The research psychiatrist 
will ask you a number of questions about your mood, health and medications you are 
taking at the moment. He will also ask you to complete four short questionnaires. He 
will decide whether you have symptoms of clinical diagnosis of depression. 
We are also interested in listening to your views and experiences about anti-
depressants and the need for them. Another researcher will see you and ask you some 
questions.  
Information from this study will help us to give better advice to patients with kidney 
disease and depression.  
Why have I been invited? 
About 6 to 15 months ago, you agreed to take part in the screening phase of the 
ASSERTID study and you were taking anti-depressant medication at the time. The 
research psychiatrist would like to ask all these patients who were taking 
antidepressants at the time and find out how their mood changed over time.  This is 
why we have invited you to participate in the study.  
Do I have to take part? 
It is up to you to decide to join this study. We will describe the study to you and go 
through this information sheet. If you agree to take part appointment will be 
arranged, at a time convenient to you.  We will then ask you to sign a consent form. 
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You are free to withdraw at any time, without giving a reason. This will not affect 
the standard of care you receive. 
What will happen to me if I take part and what will I have to do? 
If you agree and consent to take part, we will arrange for you to see the research 
psychiatrist. This will probably be on one of your dialysis days. Should you prefer to 
be seen on a non-dialysis day, we will pay the full taxi fare. You will answer some 
questions and fill in four short questionnaires. There are two questionnaires on mood 
and two questionnaires about your medicines. It will take about one and half to two 
hours. He will ask you questions about your medical history, including your kidney 
disease, your psychiatric history, including your mood, and about your medication. 
He will also collect information about your antidepressant treatment and your 
medical history from your medical notes, in particular results from recent blood tests.   
He will also look at the data collected from the previous ASSSERTID study. Your 
general practitioner and nephrologist will be told of the result of the psychiatric 
assessment and with your consent we will access your medical records for the 
collection of required clinical data.  
A small proportion of participants will be asked to see another researcher. This will 
probably be on one of your dialysis days. You will see the researcher in a private 
room and it will take between half an hour and one hour. The researcher will ask a 
number of questions about your views and your beliefs about antidepressants and the 
need for them. We are interested in your opinions and there are no right or wrong 
answers. With your permission the interview will be audio recorded but the 
recordings will be deleted at the end of the study.  
Should you become distressed at any point during the assessment, we will ask you if 
you wish to stop the interview and decide with you whether any additional support 
such as counselling would be helpful. 
What will happen to me if I do not want to take part?  
It is completely your decision whether you take part and you will not be forced into 
the study. You can change your mind about taking part at any time-from the time you 
are approached till the appointment time and even during the interview if you wish. 
You will be given the researcher’s contact details to discuss this or any other any 
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points you may wish to.  Your level of care will not be affected in any way if you 
decide not to participate.  
Are there any possible benefits in my taking part? 
Firstly, we will be able to tell you if there are any improvements in your mood 
symptoms. We do this by comparing the results of the new and old score of mood 
questionnaires. We will also tell you if suffer from clinical depression. The 
information we get from this study will also help improve the treatment of people 
with end stage kidney disease and depression.  
What are the possible disadvantage and risks of taking part? 
You will be asked questions about your mood by the research psychiatrist and by 
completing questionnaires. Sometimes these questions can be a bit upsetting so it is 
important to remember that you do not have to answer any questions you do not want 
to. If this happens during the interview it can be stopped at any point and we can 
discuss whether counselling or any other psychological therapy might be helpful. 
Will my taking part in the study be kept confidential? 
All information collected about you will be kept strictly confidential. We follow 
ethical and legal practices and all information about you will be handled in 
confidence. All data collection sheets and questionnaires will be assigned a number 
and will not have your name on, so you could not be recognised from it. This number 
is the same number used from the ASSERTID study. The data from the ASSERTID 
study will also be used. The data collected, including the questionnaires will be 
stored in locked filing cabinets on the renal unit. Only authorised persons will have 
access. If you join the study, some parts of your medical records and the data 
collected for the study may be looked at by authorised persons from the University of 
Hertfordshire or your Trust (East and North Herts NHS Trust, University Hospital 
Birmingham NHS Foundation Trust, Royal Free Hampstead NHS Trust, Southend 
University Hospital Foundation Trust or Basildon and Thurrock University 
Hospitals) to check that the study is being carried out correctly. Sometimes 
regulatory authorities also need to look at the records. All will have a duty of 
confidentiality to you as a research participant and nothing that could reveal your 
identity will be disclosed by them outside the research site. Data will be stored for 3 
years and will be destroyed after this time. 
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What will happen to the results of the study? 
The results of the study will be published in medical and health journals and will be 
presented at meetings. Any research publications will not identify you individually. 
If you would like a copy of the published research, let one of the researchers know 
and we will send you any publications describing the results of this research to you 
when they become available. 
Does your GP (General Practitioner) get involved? 
If you agree to take part in this phase of the study, with your permission we will tell 
your GP about your participation and the result of the psychiatric assessment. 
What if there is a problem? 
If you have any concern about any aspect of this study, you should ask to speak to 
the Dr Guirguis chief investigator, who will do their best to answer your questions.  
Contact details: University of Hertfordshire, CLiCIR, College Lane, Hatfield, tel: 
01707 284131), or via email a.guirguis3@herts.ac.uk. 
If you remain unhappy and wish to complain about any aspect of the way you are 
approached or treated during the course of this study, you can contact your local 
PALS office (Patient Advice and Liaison Service) at your hospital.  
In the unlikely event that something does go wrong and you are harmed during the 
research and this is due to someone’s negligence then you may have grounds for a 
legal action for compensation against your hospital, but you may have to pay your 
legal costs. The normal National Health Service complaints mechanism, PALS, will 
be available to you and you can get independent advice about making a complaint. 
Formal complaints should be addressed to: Insert local site PALS Insert local site 
ICAS details  
Who has reviewed the study? 
All research in the NHS is looked at by an independent group of people, called a 
Research Ethics Committee. These organisations are here to protect your interests.  
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Further information and contact details 
If you have any further questions about this research, please feel free to speak to the 
Chief Investigator Dr Ayman Guirguis on 01707 284131. Add local nephrologist and 
research nurse at each site. 
THANK YOU FOR TAKING TIME TO READ THIS INFORMATION 
SHEET 
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Consent Form 1(ASSERTID – ICF 1– Final version 5.0 5.7.13) 
A Pilot Randomised Controlled Trial of Drug Treatment for Depression in Patients 
undergoing Haemodialysis: ASSERTID 
 (Screening and Prevalence Phase) 
Study patient identification number (PID):  
Name of Researcher: 
Please initial each statement to show you have read and provide consent for the following 
statements: 
1. I confirm that I have read the information sheet dated ... (Version ...) for the above 
study and have had the opportunity to ask questions and have had these answered 
satisfactorily.  
2. I understand that my participation is voluntary and I am free to withdraw consent at 
any time, without giving a reason, without my medical care or legal rights being 
affected. 
3. I understand that relevant sections of my medical notes and data collected during the 
study may be looked at by individuals from the research team, from the regulatory 
authorities or from the NHS Trust, where it is relevant to my taking part in this 
research. I give permission for these individuals to have access to my records.  All 
data will be handled confidentially. 
4. I agree to my GP being informed of my participation if I am found to have low mood.  
5. I agree to take part in the above study. 
 
__________________________      ____________________           ____________________ 
 
Name of Patient (printed)                             Date Signature                                      
 
 
__________________________                   ___________________                     __________________________ 
Name of Person taking consent Date                         Signature 
(printed) 
 
When completed: 1 for participant; 1 for researcher site file; 1 (original) to be kept in the medical notes. 
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Consent Form 2a (ASSERTID – ICF2a Final Version 5.0 5.7.13) 
A Pilot Randomised Controlled Trial of Drug Treatment for Depression in Patients 
undergoing Haemodialysis: ASSERTID 
 (Consent to Assessment with the Psychiatrist) 
Study patient identification number (PID):  
Name of Researcher: 
Please initial each statement to show you have read and provide consent for the following 
statements: 
1. I confirm that I have read the information sheet dated ... (Version ...) for the above 
study and have had the opportunity to ask questions and have had these answered 
satisfactorily.  
2. I understand that my participation is voluntary and I am free to withdraw consent at 
any time, without giving a reason, without my medical care or legal rights being 
affected. 
3. I understand that relevant sections of my medical notes and data collected during the 
study may be looked at by individuals from the research team, from the regulatory 
authorities or from the NHS Trust, where it is relevant to my taking part in this 
research. I give permission for these individuals to have access to my records.  All 
data will be handled confidentially. 
4. I agree to my GP being informed should I be diagnosed with depression.  
5. I agree to take part in the assessment with the psychiatrist.  
 
 
 
__________________________      ____________________           ____________________ 
 
Name of Patient (printed)                             Date Signature                                      
 
__________________________                   ___________________                     __________________________ 
Name of Person taking consent Date                         Signature 
(printed) 
  
When completed: 1 for participant; 1 for researcher site file; 1 (original) to be kept in the medical notes. 
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Consent Form 2b (ASSERTID ICF2b Final version 5.0 5.7.13) 
A Pilot Randomised Controlled Trial of Drug Treatment for Depression in Patients 
undergoing Haemodialysis: ASSERTID 
 (Trial Outcome Phase) 
Study patient identification number (PID):  
Name of Researcher:  
Please initial each statement to show you have read and provide consent for the 
following statements: 
1. I confirm that I have read the information sheet dated ... (Version ...) for the above study 
and have had the opportunity to ask questions and have had these answered 
satisfactorily.  
2. I agree to have two additional blood samples taken.  
3. I understand that my participation is voluntary and I am free to withdraw consent at any 
time, without giving a reason, without my medical care or legal rights being affected. 
4. I understand that relevant sections of my medical notes and data collected during the 
study may be looked at by individuals from the research team, from the regulatory 
authorities or from the NHS Trust, where it is relevant to my taking part in this research. 
I give permission for these individuals to have access to my records. All data will be 
handled confidentially. 
5. I agree to my GP being informed of my participation in this study.  
6. I agree to take part in the above study. 
 
__________________________      ____________________           ____________________ 
 
Name of Patient (printed)                             Date Signature                                      
 
__________________________                   ___________________                    __________________________ 
Name of Person taking consent Date                         Signature 
(printed) 
 
When completed: 1 for participant; 1 for researcher site file; 1 (original) to be kept in the medical notes. 
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Consent Form 3 (ASSERTID ICF3 Final Version 5.0 5.7.13) 
A Pilot Randomised Controlled Trial of Drug Treatment for Depression in Patients 
undergoing Haemodialysis: ASSERTID 
(Patient Experience Interview Phase) 
Study patient identification number (PID): 
Name of Researcher: 
Please initial each statement to show you have read and provide consent for the 
following statements: 
1. I confirm that I have read the information sheet dated ... (Version ...) for the above study 
and have had the opportunity to ask questions and have had these answered 
satisfactorily.  
2. I understand that my participation is voluntary and I am free to withdraw consent at any 
time, without giving a reason, without my medical care or legal rights being affected. 
3. I understand that relevant sections of my medical notes and data collected during the 
study may be looked at by individuals from the research team, from the regulatory 
authorities or from the NHS Trust, where it is relevant to my taking part in this research. 
I give permission for these individuals to have access to my records. All data will be 
handled confidentially. 
4. I agree to have my conversation audiotaped. 
5. I agree to take part in the above study. 
 
 
__________________________      ____________________           ____________________ 
Name of Patient (printed)                               Date Signature                                      
 
__________________________                   ___________________                     __________________________ 
Name of Person taking consent                      Date                         Signature 
(printed) 
 
When completed: 1 for participant; 1 for researcher site file; 1 (original) to be kept in the medical notes. 
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Consent Form 
PROGRESSION OF DEPRESSIVE SYMPTOMS IN 
HAEMODIALYSIS PATIENTS ON ANTIDEPRESSANTS 
Study patient identification number (PID):  
Name of Researcher: 
Please initial each statement to show you have read and provide consent for the following 
statements: 
6.  I confirm that I have read the information sheet for the above study and have had the 
opportunity to ask questions and have had these answered satisfactorily.  
7. I understand that my participation is voluntary and I am free to withdraw consent at 
any time, without giving a reason, without my medical care or legal rights being 
affected. 
8. I understand that relevant sections of my medical notes and data collected during the 
study may be looked at by individuals from the research team, from the regulatory 
authorities or from the NHS Trust, where it is relevant to my taking part in this 
research. I give permission for these individuals to have access to my records.  All 
data will be handled confidentially. 
9. I agree to have my data previously provided to the ASSERTID study used in this 
study 
10. I agree to my GP being informed of my particiation .  
11. I agree to take part in the above study. 
 
________________________      ____________________           ____________________ 
Name of Patient (printed)                          Date                                                      Signature                                      
 
__________________________                   ___________________                    __________________________ 
Name of Person taking consent                     Date                                                  Signature 
(printed) 
 
When completed: 1 for participant; 1 for researcher site file; 1 (original) to be kept in the medical notes. 
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Appendix 6 – Questionnaires 
 
 
 
 BDI-II 
Copyright© 1996 Aron T. Beck 
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PHQ-9 QUESTIONNIAIRE 
 
Over the last 2 weeks, how often have you been bothered by any of the following 
problems?  
(Please circle your answer) 
 
  Not at 
all 
Several 
days 
More than 
half the days 
Nearly every 
day 
1. Little interest or pleasure in doing things 
 
0 1 2 3 
2. Feeling down, depressed, or hopeless 
 
0 1 2 3 
3. Trouble falling or staying asleep, or sleeping too much 
 
0 1 2 3 
4. Feeling tired or having little energy 
 
0 1 2 3 
5. Poor appetite or overeating 
 
0 1 2 3 
6. Feeling bad about yourself – or that you are a failure 
or have let yourself or your family down 
0 1 2 3 
7. Trouble concentrating on things, such as reading the 
newspaper or watching television 
 
0 1 2 3 
8. Moving or speaking so slowly that other could have 
noticed? Or the opposite – being so fidgety or restless 
that you have been moving around a lot more than 
usual 
 
0 1 2 3 
9. Thoughts that you would be better off dead or of 
hurting yourself in some way 
 
0 1 2 3 
 
If you checked off any problems, how difficult have these problems made it for you to do 
your work, take care of things at home, or get along with other people? 
Not difficult at all Somewhat        Very   Extremely  
 difficult  difficult difficult     
 
 
Date Completed                        /                               /                                                                                                                                 
(Complete date as day, month, year i.e. 13/NOV/2008)                   
 
 
 
331 
 
MFI® MULTIDIMENSIONAL FATIGUE INVENTORY 
® E. Smets, B.Garssen, B. Bonke (2013) 
Instructions:  
By means of the following statements we would like to get an idea of how you have 
been feeling lately.  
There is, for example, the statement:  
"I FEEL RELAXED" 
If you think that this is entirely true, that indeed you have been feeling relaxed lately, 
please, place an X in the extreme left box; like this:  
yes, that is true    1 2 3 4 5 no, that is not true  
The more you disagree with the statement, the more you can place an X in the direction 
of "no, that is not true". Please do not miss out a statement and place only one X in a box 
for each statement.  
 
1 I Feel Fit.                                                       Yes, that is true        1      2      3        4        5   No, that is not true 
 
2 Physically, I feel only able to do little.     Yes, that is true        1      2      3        4     5   No, that is not true 
 
3 I feel like doing all sort of nice things.     Yes, that is true                                          1      2      3        4     5   No, that is not true 
 
4 I Feel very active.                                             Yes ,that is true        1      2      3        4     5   No, that is not true 
 
5 I Feel tired.                                                         Yes ,that is true        1      2      3        4     5   No, that is not true 
 
6 I think I do a lot in a day.                             Yes ,that is true        1      2      3        4     5   No, that is not true 
 
7 When I am doing something                    Yes ,that is true  
I can keep my thoughts on it 
       1      2      3        4     5   No, that is not true 
 
8 Physically I can take on a lot.                    Yes ,that is true        1      2      3        4     5   No, that is not true 
 
9 I dread having to do things.                         Yes ,that is true        1      2      3        4     5   No, that is not true 
 
10 I think I do very little in a day.                    Yes ,that is true        1      2      3        4     5   No, that is not true 
 
11 I can concentrate well.                                  Yes ,that is true        1      2      3        4     5   No, that is not true 
 
12 I am rested.                                                        Yes ,that is true 
 
       1      2      3        4     5   No, that is not true 
13 It took a lot of effort to                             Yes ,that is true 
concentrate on things                         
       1      2      3        4     5   No, that is not true 
14 Physically I feel I am in a bad condition. Yes ,that is true 
 
       1      2      3        4     5   No, that is not true 
15 I have a lot of plans.                                       Yes ,that is true 
 
       1      2      3        4     5   No, that is not true 
16 I tire easily.                                                   Yes ,that is true 
 
       1      2      3        4     5   No, that is not true 
17 I get little done.                                           Yes ,that is true 
 
       1      2      3        4     5   No, that is not true 
18 I don’t feel like doing anything.                 Yes ,that is true 
 
       1      2      3        4     5   No, that is not true 
19 My thoughts easily wonder.                     Yes ,that is true 
 
       1      2      3        4     5   No, that is not true 
20 Physically I feel I am in an                         Yes ,that is true 
Excellent condition.      
       1      2      3        4     5   No, that is not true 
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Your Health and Well-Being 
 
Energy/Fatigue Subscale 
 
This survey asks for your views about your health. This information will 
help keep track of how you feel and how well you are able to do your 
usual activities. 
 
For each of the following questions, please tick the one box that best 
describes your answer. 
 
These questions are about how you feel and how things have been 
with you during the past 4 weeks. For each question, please give the 
one answer that comes closest to the way you have been feeling. 
How much of the time during the past 4 weeks . . . 
(Circle One Number on Each Line) 
 
 All of 
the 
time 
Most of 
the time 
A Good 
bit of the 
time 
Some of 
the time 
A little 
of the 
time 
None 
of the 
time 
 
1. Did you feel full of life? 
 
 
 
1 
 
 
 
2 
 
 
 
3 
 
 
 
4 
 
 
 
5 
 
 
 
6 
 
2. Did you have a lot of 
energy? 
 
 
 
1 
 
 
 
2 
 
 
 
3 
 
 
 
4 
 
 
 
5 
 
 
 
6 
 
3. Did you feel worn out? 
 
 
 
1 
 
 
 
2 
 
 
 
3 
 
 
 
4 
 
 
 
5 
 
 
 
6 
 
4. Did you feel tired? 
 
 
 
1 
 
 
 
2 
 
 
 
3 
 
 
 
4 
 
 
 
5 
 
 
 
6 
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M.I.N.I. 
MINI INTERNATIONAL NEUROPSYCHIATRIC INTERVIEW 
English Version 
6.0.0 M.I.N.I. 6.0.0 (October 10, 2010) (10/10/10) 
DSM-IV 
 
© Copyright 1992-010 Sheehan DV& Lecrubier Y 
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MINI MENTAL STATE EXAMINATION 
Max points       Patient  
     score 
 
1. Orientation a. Can you tell me today’s (date)/(month)/(year)?   
   Which (day of the week) is it today? 
                                 Can you also tell me which (season) it is?               5________ 
                   
                                 b. What city/town are we in?  
   What is the (county)/(country)? 
   What (building) are we in and on what (floor)?              5 ________ 
 
2. Registration I should like to test your memory 
                                (name three common objects:e.g”apple, table, penny”) 
                                Can you repeat the words I said?                                3_________ 
                                (repeat up to 6 trials until all three are remembered) 
                                (record the number of trials needed here_________) 
 
3. Attention &  a. From 100 keep subtracting 7 and give each answer: 
Calculation            Stop after 5 answers. (93-86-79-72-65) 
                                Alternatively 
                                b. Spell the word ‘WORLD’ backwards (D_L_R_O_W)              5_________ 
 
  
4. Recall  What were the three words I asked you to say earlier?          3__________
 (skip this test if all three objects were not remembered during registration test) 
 
5. Language  
Naming   Name these objects (show a watch) (show a pencil)             2_________ 
Repeating Repeat the following: “no ifs, ands or buts”              1_________ 
 
6. Reading  (show card or write “CLOSE YOUR EYES”) 
                                Read this sentence and do what it says              1________ 
                                Now can you write a short sentence for me?             1________ 
 
7. Three Stage (Present paper) 
Command Take this paper in your left (or right) hand, 
                                Fold it in half and put it on the floor.              3________ 
 
 
8. Construction Will you copy this drawing please?                1________ 
 
Total Score__________________________________________   /30 
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 Montgomery-Åsberg Depression Rating Scale  
                                                                          (MADRS) 
 
1. Apparent sadness  
 
Representing despondency, gloom and despair (more than just ordinary transient low spirits), 
reflected in speech, facial expression, and posture. Rate by depth and inability to brighten up. 
(Please tick one) 
0. = No sadness.  □  
1. □ 
 
2. = Looks dispirited but does brighten up without difficulty.  
 
□  
3. □ 
 
4. = Appears sad and unhappy most of the time.  
 
□  
 
6. = Looks miserable all the time. Extremely despondent.  
 
□  
 
 
2. Reported sadness  
 
Representing reports of depressed mood, regardless of whether it is reflected in appearance or 
not.  
Includes low spirits, despondency or the feeling of being beyond help and without hope. (Please 
tick one) 
0. = Occasional sadness in keeping with the circumstances.  □  
1. □ 
 
2. = Sad or low but brightens up without difficulty.  
 
□  
3. □ 
 
4. = Pervasive feelings of sadness or gloominess. The mood 
is still influenced by external circumstances.  
 
□  
5. □ 
 
6. = Continuous or unvarying sadness, misery or 
despondency.  
 
□  
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3. Inner tension  
 
Representing feelings or ill-defined discomfort, edginess, inner turmoil, mental tension mounting 
to either panic, dread or anguish. Rate according to intensity, frequency, duration and the extent 
of reassurance called for. (Please tick one) 
 
0. = Placid. Only fleeting inner tension.  
 
□  
1. □ 
 
2. = Occasional feelings of edginess and ill-defined 
discomfort.  
 
□  
3. □ 
 
4. = Continuous feelings of inner tension or intermittent 
panic which the patient can only master with some difficulty.  
 
□  
5. □ 
 
6. = Unrelenting dread or anguish. Overwhelming panic.  
 
□  
        
 
4. Reduced sleep  
 
Representing the experience of reduced duration or depth of sleep compared to the subject’s own 
normal pattern when well. (Please tick one) 
 
0. = Sleeps as usual.  
 
□  
1. □ 
 
2. = Slight difficulty dropping off to sleep or slightly 
reduced, light or fitful sleep.  
 
□  
3. □ 
 
4. = Sleep reduced or broken by at least 2 hours.  
 
□  
5. □ 
 
6. = Less than 2 or 3 hours sleep.  
 
□  
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5. Reduced appetite  
 
Representing the feeling of a loss of appetite compared with when well. Rate by loss of desire for 
food or the need to force oneself to eat. (Please tick one) 
 
0. = Normal or increased appetite.  
 
□  
1. □ 
 
2. = Slightly reduced appetite.  
 
□  
3. □ 
 
4. = No appetite. Food is tasteless.  
 
□  
5. □ 
 
6. = Needs persuasion to eat at all.  
 
□  
 
 
6. Concentration difficulties  
 
Representing difficulties in collecting one’s thoughts mounting to an incapacitating lack of 
concentration. Rate according to intensity, frequency, and degree of incapacity produced. (Please 
tick one) 
 
0. = No difficulties in concentrating.  
 
□  
1. □ 
 
2. = Occasional difficulties in collecting one’s thoughts.  
 
□  
3. □ 
 
4. = Difficulties in concentrating and sustaining thought 
which reduces ability to read or hold a conversation.  
 
□  
5. □ 
 
6. = Unable to read or converse without great difficulty.  
 
□  
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7. Lassitude  
 
Representing difficulty in getting started or slowness in initiating and performing everyday 
activities. (Please tick one) 
 
0. = Hardly any difficulty in getting started. No 
sluggishness.  
 
□  
1. □ 
 
2. = Difficulties in starting activities.  
 
□  
3. 
               □ 
4 = Difficulties in starting simple routine activities, which 
are carried out with effort.  
 
□  
5. □ 
6. = Complete lassitude. Unable to do anything without 
help.  
 
□  
 
 
8. Inability to feel  
 
Representing the subjective experience of reduced interest in the surroundings, or activities that 
normally give pleasure. The ability to react with adequate emotion to circumstances or people is 
reduced. (Please tick one) 
 
0. = Normal interest in the surroundings and in other 
people.  
 
□  
1. □ 
 
2. = Reduced ability to enjoy usual interests.  
 
□  
3. □ 
4. = Loss of interest in the surroundings. Loss of feelings for 
friends and acquaintances.  
 
□  
5. □ 
6. = The experience of being emotionally paralysed, inability 
to feel anger, grief or pleasure and a complete or even 
painful failure to feel for close relatives and friends.  
 
 
 
 
 
 
□  
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9. Pessimistic thoughts  
 
Representing thoughts of guilt, inferiority, self-reproach, sinfulness, remorse and ruin. (Please 
tick one) 
 
0. = No pessimistic thoughts.  
 
□  
1. □ 
 
2. = Fluctuating ideas of failure, self-reproach or self-
depreciation.  
 
□  
3. □ 
 
4. = Persistent self-accusation, or definite but still rational 
ideas of guilt or sin. Increasingly pessimistic about the 
future.  
 
 
□  
5. □ 
 
6. = Delusions of ruin, remorse or irredeemable sin. Self-
accusations, which are absurd and unshakable.  
 
□  
 
 
10. Suicidal thoughts  
 
Representing the feeling that life is not worth living, that a natural death would be welcome, 
suicidal thoughts, and preparations for suicide. Suicide attempts should not in themselves 
influence the rating. (Please tick one) 
 
0. = Enjoys life or takes it as it comes.  
 
□  
1. □ 
 
2. = Weary of life. Only fleeting suicidal thoughts.  
 
□  
3. □ 
4. = Probably better off dead. Suicidal thoughts are 
common, and suicide is considered as a possible solution, 
but without specific plans or intension.  
 
 
□  
5. □ 
6. = Explicit plans for suicide when there is an opportunity. 
Active preparations for suicide.  
 
□  
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Clinical Global Impression Scale for Severity (CGIs) 
The rating considers the clinician’s entire experience with the disorder under investigation and the 
severity of that condition at the current time. Note that it is the severity of the particular condition 
that is rated, and not psychiatric illness generally.  
0 = not assessed 
1 = normal, not ill  
2 = borderline ill  
3 = mildly ill  
4 = moderately ill  
5 = markedly ill  
 6 = severely ill  
7 = among the most extremely ill      CGIs =  
Clinical Global Impression Scale for Improvement (CGIi) 
The rating considers the degree of change since the start of the current treatment plan. The rating 
does not consider whether the improvement is related to therapy or not. 
 
0 = not assessed 
1 = very much improved 
2 = much improved 
3 = minimally improved 
4 = unchanged 
5 = minimally worse 
 6 = much worse 
7 = very much worse      
                                                                                                                                 CGIi = 
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P4 Screener 
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The Medication Adherence Rating Scale (MARS) 
Please respond to the following statements by ticking the answer which best 
describes your behaviour or the attitude you have held toward your medication in the 
past week. 
QUESTION YES NO 
1- Do you ever forget to take your medication? 
 
  
2- Are you careless at times about taking your medicine? 
 
  
3- When you feel better, do you sometimes stop taking your medicine? 
 
  
4- Sometimes if you feel worse when you take the medicine, do you stop taking it? 
 
  
5- I take my medication only when I am sick. 
 
  
6- It is unnatural for my mind and body to be controlled by medication. 
 
  
7- My thoughts are clearer on medication. 
 
  
8- By staying on medication, I can prevent getting sick. 
 
  
9- I feel weird, like a ‘zombie’, on medication. 
 
  
10- Medication makes me feel tired and sluggish. 
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BELIEFS ABOUT MEDICINES 
QUESTIONNAIRE (BMQ) 
 
BMQ –Specific 
Your views about medicines prescribed to you. 
• I would like to ask you about your personal views about medicines prescribed for 
your depression. 
• These are statements other people have made about their antidepressant 
medication. 
• Please indicate the extent to which you agree or disagree with them by placing a 
cross in the appropriate box. 
• There are no right or wrong answers. I am interested in your personal views. 
• Please only cross one box per question. 
 
1) My health at present depends on my antidepressant medicines 
 
Strongly agree  Agree  Uncertain  Disagree       strongly disagree 
  
     
 
 
 
2) Having to take antidepressant medication worries me 
 
Strongly agree  Agree  Uncertain  Disagree       strongly disagree 
 
 
 
 
 
3) My life would be impossible without my antidepressant medication 
 
Strongly agree  Agree  Uncertain  Disagree      Strongly disagree 
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4) Without my antidepressant medication I would be very ill 
 
Strongly agree  Agree  Uncertain  Disagree      Strongly disagree 
 
 
 
 
 
5) I sometimes worry about the long term effects of my antidepressant 
medication 
 
Strongly agree  Agree  Uncertain  Disagree      Strongly disagree 
 
 
 
 
6) My antidepressant medication is mystery to me  
 
Strongly agree  Agree  Uncertain  Disagree      Strongly disagree 
 
 
 
 
7) My health in the future will depend on my antidepressant medication 
 
Strongly agree  Agree  Uncertain  Disagree      Strongly disagree 
 
 
 
 
8) My antidepressant medication disrupts my life 
 
Strongly agree  Agree  Uncertain  Disagree      Strongly disagree 
 
 
 
 
9) I sometimes worry about becoming too dependent on my antidepressant 
medication 
 
Strongly agree  Agree  uncertain  Disagree      Strongly disagree 
 
 
 
 
10) My antidepressant medication protects me from becoming worse. 
 
Strongly agree  Agree  uncertain  Disagree      Strongly disagree 
 
     
     
     
     
     
     
    
